Innovation, Sciences et Développement économique Canada
Office de la Propriété Intellectuelle du Canada

Innovation, Science and Economic Development Canada
Canadian Intellectual Property Office

CA 3072610 A1 2019/02/28

(21) 3 072 610

(12) DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION

(13) A1

(86) Date de dépôt PCT/PCT Filing Date: 2018/08/22
(87) Date publication PCT/PCT Publication Date: 2019/02/28
(85) Entrée phase nationale/National Entry: 2020/02/10
(86) N° demande PCT/PCT Application No.: US 2018/047597
(87) N° publication PCT/PCT Publication No.: 2019/040664
(30) Priorités/Priorities: 2017/08/22 (US62/548,846); 2017/10/16 (US62/572,963); 2018/03/06 (US62/639,178); 2018/03/27 (US15/937,699)

(51) Cl.Int./Int.Cl. *C12N 9/22* (2006.01), *C12N 15/55* (2006.01)

(71) Demandeur/Applicant:
SALK INSTITUTE FOR BIOLOGICAL STUDIES, US

(72) Inventeurs/Inventors:
HSU, PATRICK D., US;
KONERMANN, SILVANA, US

(74) Agent: SMART & BIGGAR LLP

(54) Titre : METHODES ET COMPOSITIONS DE CIBLAGE D'ARN
(54) Title: RNA TARGETING METHODS AND COMPOSITIONS

(57) Abrégé/Abstract:
Provided herein are CRISPR/Cas methods and compositions for targeting RNA molecules, which be used to detect, edit, or modify a target RNA.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 February 2019 (28.02.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/040664 A1

(51) International Patent Classification:
C12N 9/22 (2006.01) *C12N 15/55* (2006.01)

(21) International Application Number:
PCT/US2018/047597

(22) International Filing Date:
22 August 2018 (22.08.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/548,846	22 August 2017 (22.08.2017)	US
62/572,963	16 October 2017 (16.10.2017)	US
62/639,178	06 March 2018 (06.03.2018)	US
15/937,699	27 March 2018 (27.03.2018)	US

(71) Applicant: **SALK INSTITUTE FOR BIOLOGICAL STUDIES** [US/US]; 10010 N. Torrey Pines Road, La Jolla, CA 92037-1002 (US).

(72) Inventors: **HSU, Patrick, D.**; 10010 N. Torrey Pines Road, La Jolla, CA 92037-1002 (US). **KONERMANN, Silvana**; 10010 N. Torrey Pines Road, La Jolla, CA 92037-1002 (US).

(74) Agent: **RYBAK, Sheree**; Klarquist Sparkman, LLP, One World Trade Center, Suite 1600, 121 SW Salmon Street, Portland, OR 97204 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2019/040664 A1

(54) **Title:** RNA TARGETING METHODS AND COMPOSITIONS

(57) **Abstract:** Provided herein are CRISPR/Cas methods and compositions for targeting RNA molecules, which be used to detect, edit, or modify a target RNA.

RNA TARGETING METHODS AND COMPOSITIONS

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to US Provisional Application No. 62/548,846 filed August 22, 2017, US Provisional Application No. 62/572,963 filed October 16, 2017, US Provisional Application No. 62/639,178, filed March 6, 2018, and US Application No. 15/937,699 filed March 27, 2018, all of which are herein incorporated by reference in their entireties.

FIELD

This disclosure relates to a CRISPR/Cas system for modifying (including detecting) RNA, which utilizes novel Cas13d proteins (also referred to CasR and nCas1) and guide RNAs.

ACKNOWLEDGMENT OF GOVERNMENT SUPPORT

This invention was made with government support under 5 DP5 OD021369-02 and 5 R21 AG056811-02 awarded by The National Institutes of Health. The Government has certain rights in the invention.

BACKGROUND

Mapping of transcriptome changes in cellular function and disease has been transformed by technological advances over the last two decades, from microarrays (Schena et al., 1995) to next-generation sequencing and single cell studies (Shendure et al., 2017). However, interrogating the function of individual transcript dynamics and establishing causal linkages between observed transcriptional changes and cellular phenotype requires the ability to actively control or modulate desired transcripts.

DNA engineering technologies such as CRISPR-Cas9 (Doudna and Charpentier, 2014; Hsu et al., 2014) enable researchers to dissect the function of specific genetic elements or correct disease-causing mutations. However, simple and scalable tools to study and manipulate RNA lag significantly behind their DNA counterparts. Existing RNA interference technologies, which enable cleavage or inhibition of desired transcripts, have significant off-target effects and remain challenging engineering targets due to their key role in endogenous processes (Birmingham et al., 2006; Jackson et al., 2003). As a result, methods for studying the functional role of RNAs directly have remained limited.

One of the key restrictions in RNA engineering has been the lack of RNA-binding domains that can be easily retargeted and introduced into target cells. The MS2 RNA-binding domain, for example, recognizes an invariant 21-nucleotide (nt) RNA sequence (Peabody, 1993), therefore requiring genomic modification to tag a desired transcript. Pumilio homology domains possess modular repeats with each protein module recognizing a separate RNA base, but they can only be targeted to short 8 nt RNA sequences (Cheong and Hall, 2006). While previously characterized type II (Batra et al., 2017; O'Connell et al., 2014) and VI (Abudayyeh et al., 2016; East-Seletsky et al., 2016) CRISPR-Cas systems can be reprogrammed to

recognize 20-30 nt RNAs, their large size (~1200 amino acids, aa) makes it difficult to package into AAV for primary cell and *in vivo* delivery.

SUMMARY

This application provides bioinformatic analysis of prokaryotic genomes to identify sequence signatures of CRISPR-Cas repeat arrays and mine previously uncharacterized, compact Cas ribonucleases that can be used for RNA targeting tools. Engineered Type VI-D CRISPR effectors can be used to efficiently knockdown endogenous RNAs in human cells and manipulate alternative splicing, paving the way for RNA targeting applications and further effector domain fusions as part of a transcriptome engineering toolbox.

Provided herein are methods of modifying one or more target RNA molecules, such as a clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated (Cas) system-mediated RNA editing method. Such methods can include contacting one or more target RNA molecules with a non-naturally occurring (*e.g.*, does not naturally occur in the cell or system into which it is introduced) or engineered CRISPR-Cas system. Such a CRISPR-Cas system can include (1) at least one Cas13d protein or at least one Cas13d nucleic acid coding sequence (such as a mRNA or a vector encoding the at least one Cas13d protein) provided herein and (2) at least one CRISPR-Cas system guide nucleic acid molecule (such as a guide RNA, gRNA) that hybridizes with the one or more target RNA molecules, or at least one nucleic acid molecule encoding the gRNA. The Cas13d protein forms a complex with the gRNA, and the gRNA directs the complex to the one or more target RNA molecules and modifies (*e.g.*, cuts, detects) the one or more target RNA molecules. In some examples, the one or more target RNA molecules (or a cell containing the one or more target RNA molecules) are contacted with a complex including the at least one Cas13d protein and the at least one gRNA. In some examples, the system includes Mg^{2+}. However, in some examples, the system does not include Mg^{2+}, such as if cleavage of the target RNA is not desired.

In some examples, contacting the one or more target RNA molecules with the non-naturally occurring or engineered CRISPR-Cas system includes introducing into a cell (such as a eukaryotic or prokaryotic cell) containing the one or more target RNA molecules the non-naturally occurring or engineered CRISPR-Cas system, for example using endocytosis, a liposome, a particle, an exosome, a microvesicle, a gene gun, electroporation, a virus, or combinations thereof. In some examples, contacting the one or more target RNA molecules with the non-naturally occurring or engineered CRISPR-Cas system includes contacting a cell-free system (such as a biological or environmental sample, or a cell lysate) containing the one or more target RNA molecules with the non-naturally occurring or engineered CRISPR-Cas system (for example in a diagnostic method to detect a target RNA).

In some examples, the least one Cas13d protein (1) includes one or more HEPN domains, (2) is no more than 150 kD (such as no more than 140 kD, no more than 130 kD, no more than 120 kD, such as about 90 to 120 kD, about 100 to 120 kD or about 110 kD), (3) includes one or more mutated HEPN domains, and can process the guide RNA, but cannot cleave or cut the one or more target RNA molecules, (4) includes a

Cas13d ortholog from a prokaryotic genome or metagenome, gut metagenome, an activated sludge metagenome, an anaerobic digester metagenome, a chicken gut metagenome, a human gut metagenome, a pig gut metagenome, a bovine gut metagenome, a sheep gut metagenome, a goat gut metagenome, a capybara gut metagenome, a primate gut metagenome, a termite gut metagenome, a fecal metagenome, a genome from the Order Clostridiales, or the Family Ruminococcaceae, (5) includes a Cas13d ortholog from Ruminococcus albus, Eubacterium siraeum, a flavefaciens strain XPD3002, Ruminococcus flavefaciens FD-1, uncultured Eubacterium sp TS28-c4095, uncultured Ruminococcus sp., Ruminococcus bicirculans, or Ruminococcus sp CAG57, (6) includes at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, 296 or (7) combinations thereof (*e.g.*, combinations of any of 1 to 6). In some examples, the least one Cas13d protein has at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296 and includes at least one motif shown in SEQ ID NO: 195, 196 or 197. In some examples, the least one Cas13d protein has at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296, and includes at least one consensus sequence shown in SEQ ID NO: 288, 289, 290 or 291. In some examples, the least one Cas13d protein further includes one or more other agents (*e.g.*, is a fusion protein),

such as one or more subcellular localization signals, one or more effector domains, or combinations thereof. In some examples, the least one Cas13d protein that includes one or more HEPN domains, is no more than 1500 aa, no more than 1200 aa, no more than 1100 aa, no more than 1000 aa, such as about 800 to 1500 aa, about 800 to 1250 aa or about 850 to 950 aa.

Also provided are isolated nucleic acid molecules encoding such Cas13d proteins, such as a cDNA, genomic DNA, RNA, or mRNA. Such isolated nucleic acid molecules can be part of a vector (such as a plasmid or viral vector), and can be operably linked to a promoter or enhancer element (or both). In some examples, an isolated nucleic acid molecule encoding a Cas13d protein has at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 124, 125, 126, 127, 128, 139, 140 or 141. In some examples, an isolated nucleic acid molecule encoding at least one Cas13d protein (which can be part of a vector) includes at least one Cas13d protein coding sequence codon optimized for expression in a eukaryotic cell, such as human cell, for example a Cas13d coding sequence having at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 142, 143, 144, or 145.

In some examples, the gRNA that hybridizes with the one or more target RNA molecules in a Cas13d-mediated manner includes one or more direct repeat (DR) sequences, one or more spacer sequences, such as one or more sequences comprising an array of DR-spacer-DR-spacer. In some examples, the one or more DR sequences have at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 129, 130, 131, 132, 133, 134, 135, 136, 137, 148, 150, 151, 152, 154, 156, 157, 159, 161, 163, 165, 167, 169, 176, 178, 180, 182, 184, 186, 188, 190, 191, 192, 193, 199, 201, 203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 228, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 252, or 254. In one example, the gRNA includes additional sequences, such as an aptamer sequence (*e.g.*, MS2 stem loops).

In some examples, a plurality of gRNAs are generated from a single array, wherein each gRNA can be different, for example target different RNAs or target multiple regions of a single RNA, or combinations thereof.

Methods of targeting one or more target RNA molecules are provided. In some examples, an entire RNA is targeted. In some examples, a portion of an RNA is targeted. Targeting an RNA molecule can include one or more of cutting or nicking one or more target RNA molecules, activating one or more target RNA molecules, deactivating the one or more target RNA molecules, visualizing or detecting the one or more target RNA molecules, labeling the one or more target RNA molecules, binding the one or more target RNA molecules, editing the one or more target RNA molecules, trafficking the one or more target RNA molecules, and masking the one or more target RNA molecules. In some example, modifying one or more target RNA molecules includes one or more of an RNA base substitution, an RNA base deletion, an RNA base insertion, a break in the target RNA, methylating RNA, and demethylating RNA.

In some examples, such methods are used to treat a disease, such as a disease in a human. In such examples, the one or more target RNA molecules is associated with the disease.

Also provided are isolated proteins, including non-naturally occurring proteins. In some examples, a protein has at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296. In some examples, an isolated Cas13d protein encompassed by this disclosure includes a sequence having at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 195, 196, 197, 288, 289, 290, or 291. In some examples, an isolated protein is a Cas13d ortholog from a prokaryotic genome or metagenome, gut metagenome, an activated sludge metagenome, an anaerobic digester metagenome, a chicken gut metagenome, a human gut metagenome, a pig gut metagenome, a bovine gut metagenome, a sheep gut metagenome, a goat gut metagenome, a capybara gut metagenome, a primate gut metagenome, a termite gut metagenome, a fecal metagenome, a genome from the Order Clostridiales, or the Family Ruminococcaceae. In some examples, a Cas13d ortholog includes a Cas13d ortholog from Ruminococcus albus, Eubacterium siraeum, a Ruminococcus flavefaciens strain XPD3002, Ruminococcus flavefaciens FD-1, uncultured Eubacterium sp TS28-c4095, uncultured Ruminococcus sp., Ruminococcus bicirculans, or Ruminococcus sp CAG57. The Cas13d protein can further include one or more other agents or domains (*e.g.*, is a fusion protein), such as one or more subcellular localization signals, one or more effector domains, or combinations thereof.

Also provided are isolated guide RNA (gRNA) molecules. In some examples, an isolated gRNA includes one or more direct repeat (DR) sequences, such as an unprocessed (*e.g.*, about 36 nt) or processed DR (*e.g.*, about 30 nt). In some examples a DR has at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 129, 130, 131, 132, 133, 134, 135, 136, 137, 148, 150, 151, 152, 154, 156, 157, 159, 161, 163, 165, 167, 169, 176, 178, 180, 182, 184, 186, 188, 190, 191, 192, 193, 199, 201, 203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 228, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 252, or 254. Such a gRNA can further include one or more spacer sequences specific for (*e.g.*, is complementary to) the target RNA.

Also provided are ribonucleoprotein (RNP) complexes, which include a Cas13d protein provided herein and a gRNA provided herein.

Also provided are recombinant cells that include any Cas13d protein (or nucleic acid molecule encoding Cas13d), any gRNA, any RNP complex, or any vector, provided herein. In one example, the cell is not a bacterial cell. In one example, the cell is a bacterial cell.

Also provided are compositions that include one or more of any Cas13d protein (or nucleic acid molecule encoding Cas13d), any gRNA, any RNP complex, any isolated nucleic acid molecule, any vector, or any cell, provided herein. Such compositions can include a pharmaceutically acceptable carrier.

Also provided are kits. Such kits can include one or more of any Cas13d protein (or nucleic acid molecule encoding Cas13d), any gRNA, any RNP complex, any isolated nucleic acid molecule, any vector, any cell, or any composition provided herein. Such reagents can be combined or in separate containers.

The foregoing and other objects and features of the disclosure will become more apparent from the following detailed description, which proceeds with reference to the accompanying figures.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1B: Bioinformatic pipeline for the identification of the RNA-targeting class 2 CRISPR system Cas13d. (A) Schematic describing a computational pipeline for CRISPR system identification. A minimal definition for a putative class 2 CRISPR locus was used, requiring only a CRISPR repeat array and a nearby protein >750 aa in length. The initial search was performed on prokaryotic genome assemblies derived from NCBI Genome, and later expanded via TBLASTN of predicted Cas13d proteins against public metagenome sequences without predicted open reading frames. DR, direct repeat. (B) Phylogenetic classification and alignment of full-length Cas13d effectors and metagenomic fragments. Cas13d effectors and metagenomic Cas13d protein fragments cluster into several distinct branches, which are colored for ease of interpretation. Shading indicates residue conservation using the Blosum62 matrix. Full-length Cas13d effectors used in this study were sampled from distinct branches of the Cas13d family. Alignment of Cas13d proteins and protein fragments was performed using ClustalOmega 1.2.4 and maximum-likelihood tree building was performed with PhyML 3.2.

FIGS. 2A-2C: Type VI CRISPR-Cas13d is a family of single effector CRISPR ribonucleases. (A) Maximum-likelihood phylogenetic tree of Cas13d effectors used herein, with the full Cas13d CRISPR locus depicted along with conserved HEPN RNase domains. Grey rectangles denote CRISPR direct repeats (DRs) and blue diamonds indicate spacer sequences. (B) RNA sequencing of a heterologously expressed Cas13d locus from an uncultured *Ruminococcus sp.* sample. Mature gRNAs mapping to the CRISPR array indicate a processed 30 nt DR and a variable spacer length from 14-26 nt. Co-fold analysis of direct repeat truncation indicates a strong hairpin structure. (C) Purified *E. siraeum* Cas13d and catalytically dead Cas13d (dCas13d) protein are each sufficient to process a guide array into its two component gRNAs. Addition of EDTA does not impair gRNA processing. 'd', dCas13d(R295A, H300A, R849A, H854A).

FIGS. 3A-3D. Phylogenetic classification of RNA-targeting class 2 CRISPR effectors and sequence conservation within the Cas13d family. (A) HEPN motif conservation in Cas13d effectors used herein with conserved residues shaded according to Blosum62. The *RxxxxH* HEPN motif is highlighted. (B)

Maximum-likelihood tree of type VI CRISPR-Cas families. Average amino acid lengths of Type VI Cas13 superfamily effectors are indicated in red. Alignment of previously described class 2 CRISPR RNA-targeting proteins (Abudayyeh et al., 2017; Cox et al., 2017; East-Seletsky et al., 2017; East-Seletsky et al., 2016; Smargon et al., 2017) and Cas13d effectors was performed using MAFFT 7.38 and maximum-likelihood tree building was performed with PhyML 3.2. Branch labels and scale bar indicate substitutions per site. (C) Predicted Cas13d direct repeat RNA secondary structure. (D) Sequence logo of full length 36 nt Cas13d direct repeats.

FIGS. 4A-4C: **Purification of recombinant Cas13d protein**. EsCas13d was expressed as N-terminal His-MBP fusion and purified by successive affinity, cation exchange, and size exclusion chromatography. The His-tag was removed by TEV protease cleavage. (A) Chromatogram from Superdex 200 column for EsCas13d. (B) SDS-PAGE gel of size exclusion chromatography fractions for *E. siraeum* Cas13d. (C) SDS-PAGE gel of purified *E. siraeum* Cas13d and dCas13d (R295A, H300A, R849A, H854A mutations of predicted catalytic residues in both HEPN motifs).

FIGS. 5A-5D: Programmable RNA targeting by Cas13d *in vitro*. (A) *E. siraeum* Cas13d requires a matching guide array or mature gRNA to efficiently cleave complementary ssRNA targets. Denaturing gel depicts cleavage reactions incubated at 37°C for 1 hour. NT, non-targeting. (B) Substitution with dCas13d or addition of EDTA abrogate Cas13d-mediated RNA targeting with both the guide and array. 'd', dead Cas13d. (C) Denaturing gel depicting guide-target match dependent activation of Cas13d cleavage activity. Scrambled target RNA ('A') is fluorescently labeled, while guide-complementary activator target RNA ('B') is unlabeled. RNA cleavage activity is abolished by the individual removal of guide RNA or complementary target RNA, as well as the addition of EDTA or the catalytic inactivation of Cas13d (indicated as 'd'). (D) A model for guide and target-dependent activation of Cas13d RNase activity. The ternary Cas13d:gRNA:target RNA complex is capable of cleaving the complementary target RNA or bystander RNAs.

FIGS. 6A-6H. *In vitro* characterization of Cas13d properties. (A) Schematic showing the length and sequence of gRNA spacer truncations and spacer position relative to the complementary ssRNA target. (B) Denaturing gel depicting EsCas13d cleavage activity of target RNA with different spacer lengths. (C) Denaturing gel depicting EsCas13d cleavage reactions paired with 12 guides from Figure 3A tiling a complementary ssDNA version of the ssRNA target. (D) Denaturing gel depicting cleavage reactions using EsCas13d paired with the same 12 guides tiling a dsDNA version of the complementary target. (E) Quantification of cleavage efficiency from Figure 3A. Each PFS base is the average of 3 different spacer sequences tiling a complementary target RNA. Cleavage percentage is determined by the ratio of cleaved band intensity divided by total lane intensity. Mean is depicted ± SD with each data point representing an independent replicate. (F) Cas13d-mediated cleavage of target RNA carrying different PFS bases given an invariant spacer sequence. Quantification of Cas13d cleavage efficiency and a representative denaturing gel depicting EsCas13d cleavage activity are shown. Differences are not significant (one-way ANOVA, P=0.768). Cleavage percentage is determined as above, and mean is depicted ± SD with n = 3. (G) and (H)

Optimal temperature range for Cas13d activity. Denaturing gels depicting EsCas13d cleavage activity at temperatures ranging from 16-62°C for two different target RNAs.

FIGS. 7A-7B: Characterization of Cas13d target substrate preference. (A) Cas13d can be generalizably reprogrammed with multiple guides and does not exhibit a protospacer flanking sequence (PFS) requirement. RNA cleavage by EsCas13d and 12 guides tiling the target RNA is shown. Control lanes are from a separate gel run in parallel. (B) Cas13d preferentially cleaves uracil bases in the loop of a hairpin or a linear homopolymer repeat, which is interrupted every 5 nt by a transition mutation (X) to enable synthesis.

FIGS. 8A-8D: RNA knockdown activity screen of engineered Cas13d orthologs in human cells. (A) Schematic for mammalian expression constructs encoding for engineered Cas13d effectors and guides. NLS, nuclear localization signal. pre-gRNA, artificial unprocessed guide RNA containing a single 30 nt spacer sequence flanked by 2 full length 36 nt DRs. gRNA, predicted mature guide RNA with a single 30 nt processed DR and 22 nt spacer sequence (B) Heatmap of mCherry protein knockdown in a Cas13d ortholog activity screen in human HEK 293FT cells using pools of 4 pre-gRNAs or gRNAs. Normalized MFI, median fluorescent intensity relative to non-targeting condition. Positions in gray were not tested, with n = 3. (C) Immunocytochemistry of Cas13d showing localization and expression of engineered constructs. Scale bar, 10 μm. Blue pseudocolor, DAPI staining of nuclei. (D) Comparison of AdmCas13d (SEQ ID NO: 143) and RfxCas13d (SEQ ID NO: 280) ortholog constructs for knockdown of endogenous *B4GALNT1* mRNA reveals RfxCas13d-NLS (CasRx; SEQ ID NO: 280) to be most effective for both guide RNA architectures. Pools of 4 guides were used for targeting. NT, non-targeting. Values are mean ± SEM with n = 3.

FIGS. 9A-9H: CasRx mediates efficient and specific knockdown of diverse human coding and noncoding transcripts. (A) Multiple guide RNAs tiling a target transcript can be expressed as a single array and processed by RfxCas13d-NLS (CasRx; SEQ ID NO: 280) into individual gRNAs within the same cell. (B) Arrays of 4 guides each mediate target knockdown by CasRx in 293FT cells via transient transfection. Knockdown relative to GFP vehicle control was determined by qPCR, with n = 3. (C) Schematic of CasRx target sequences and spacer position-matched shRNAs. (D) Relative target RNA knockdown by individual position-matched shRNAs and CasRx gRNAs. NT, non-targeting. CRISPRi, dCas9-mediated CRISPR interference for transcriptional repression (n = 3) (E) Volcano plot of differential transcript levels between *B4GALNT1* targeting and non-targeting (NT) shRNAs as determined by RNA sequencing (n = 3). 542 non-specific transcript changes were identified. (F) Volcano plot of differential transcript levels between *B4GALNT1*-targeting CasRx and non-targeting (NT) guide. Targeting guide position is matched to the shRNA shown in (E). *B4GALNT1* was the only transcript exhibiting a significant change, with n = 3. (G) Summary of significant off-target transcript perturbations by matched shRNAs and CasRx guides. (H) CasRx targeting of 11 endogenous transcripts, each with 3 guides and a non-targeting (NT) guide in 293FT cells. Transcript levels are relative to GFP vehicle control, mean ± SEM with n = 3.

FIGS. 10A-10D. Comparison of engineered Cas13 superfamily effectors for targeted knockdown and splicing. (A) Relative target RNA knockdown by individual position-matched gRNAs for

CasRx, NLS-LwaCas13a-msfGFP (Abudayyeh et al., 2017) and PspCas13b-NES (Cox et al., 2017) in HEK 293FT cells. NT, non-targeting. Values are mean ± SEM with n = 3. (B) Comparison of Cas13 median knockdown efficiencies. n = 3 per guide RNA. **** indicates $P<0.0001$ according to Friedman's test. (C) Exon exclusion by catalytically inactive NLS-dCas13a-msfGFP on the bichromatic splicing reporter. Guides are position-matched to those reported in Figure 6B for CasRx. Values are mean ± SEM with n = 3. (D) Comparison of splicing modulation by NLS-dCas13a-msfGFP and CasRx. Fold change in targeted exon exclusion relative to non-targeting guide is shown. **** indicates $P<0.0001$ according to two-way ANOVA.

FIGS. 11A-11B. RNA sequencing from CasRx and shRNA targeting of *ANXA4* in human cells. (A) Volcano plots of differential transcript levels between *ANXA4* targeting and non-targeting (NT) shRNAs as determined by RNA sequencing (n = 3). 915 non-specific transcript changes were identified. (B) Volcano plot of differential transcript levels for an *ANXA4* targeting CasRx array used in FIG. 9B containing a guide position matched to the shRNA shown in (A) and a non-targeting (NT) array. *ANXA4* was the only transcript exhibiting significant downregulation with n = 3. *HIST2HBE* was the only transcript identified to exhibit significant upregulation. H2B is a dimer partner of H2AX (Du et al., 2006) which has been shown to interact with ANXA4 (Yang et al., 2010).

FIGS. 12A-12F: AAV delivery of catalytically inactive dCasRx splice effectors to manipulate alternative splicing. (A) Schematic of bichromatic exon skipping reporter. +1 and +3, reading frame. BP, intronic branch point-targeting guide. SA, splice acceptor site-overlapping guide. EX, exonic guide. SD, splice donor site-overlapping guide. AUG, start codon. UGA, stop codon. Inclusion of the second exon leads to an out-of-frame (+3), non-fluorescent translation of dsRed followed by in-frame mTagBFP2. Exclusion of the targeted exon leads to an in frame translation of dsRed (+1) followed by a stop codon. (B) Induced exon exclusion by dCasRx and an N-terminal hnRNPa1-dCasRx fusion protein targeted to pre-mRNA. The Gly-rich C-terminal domain of hnRNPa1 is used as the effector domain. Exon skipping efficiency is depicted as a relative percentage of cells carrying primarily the dsRed or BFP isoform, determined through flow cytometry. NLS, nuclear localization signal. 'A', CRISPR array carrying all 4 guides. Values are mean ± SEM with n = 3. (C) AAV design carrying dCasRx and a three-guide array with total transgene size < 4.3 kb, including AAV inverted terminal repeats (ITRs). (D) Schematic of frontotemporal dementia (FTD) disease modeling. Neurons are generated via *Neurogenin-2* (*Ngn2*) directed differentiation of patient-derived and control iPSCs followed by transduction with dCasRx or vehicle control AAV (EFS-mTagBFP2). (E) FTD is associated with SNPs in a putative intronic splice enhancer following exon 10 of the *MAPT* transcript encoding for tau. Alternative splicing of *MAPT* exon 10 results in 4R tau (by inclusion) and 3R tau (by exclusion). SNPs in the intronic splice enhancer including the indicated IVS 10 + 16 mutation result in increased exon inclusion and higher levels of 4R tau. To facilitate reduction of 4R tau levels, gRNAs contained in a dCasRx array were targeted to the exon 10 splice acceptor (g1) as well as two putative exonic splice enhancers indicated in purple (g2, g3). (F) Relative 4R/3R tau transcript ratios in differentiated neurons were assayed via qPCR at 14 days following transduction with AAV. FTD, frontotemporal dementia cells carrying IVS 10+16. Values are mean ± S.D. with n = 3. **** indicates $P < 0.0001$.

FIG. 13 is a bar graph showing RNA targeting in human cells using the disclosed methods.

FIG. 14 is a schematic drawing showing how the disclosed Cas13d and DRs can be used to achieve alternative splicing.

FIGS. 15A-15D are a series of panels showing: (A) Cas13d is converted into an active RNase complex upon binding a target matching the spacer sequence of the guide RNA. It is capable of cleaving gRNA-complementary target RNA or non-complementary bystander RNAs. (B) Cas13d target-dependent RNase activity can be converted into a detectable signal, for example through cleavage of a labeled detector RNA that is cleaved only in the presence of a target matching the spacer of the Cas13d guide RNA. In this example, the detector RNA contains a fluorophore, 'F', and a quencher 'Q', that abolishes fluorescence. Only upon bystander RNA cleavage is the fluorophore liberated from the quencher and fluorescence is generated. (C) Cas13d from *E. siraeum* produces a visible signal only in the presence of a perfectly matched target and not in the presence of different mismatched targets. (D) Cas13d from *R. flavefaciens* strain XPD3002 produces a visible signal only in the presence of a perfectly matched target and not in the presence of different mismatched targets.

FIGS. 16A-16B: (A) Alignment of 7 orthologs shows regions with high (green bars) and low (red bars) conservation. Regions selected for deletion are marked 1-10. (B) knock-down (top) and splicing (bottom) activity of full-length CasRx and CasRx deletion variants. Deletion variant 5 is shown to retain full activity, demonstrating the feasibility of deleting areas of low conservation while retaining full activity.

FIGS. 17A and 17B show targeting of ccdB in bacterial cells. (A) construct introduced into bacterial cells expressing ccdB, and (B) relative expression of ccdB under various conditions.

FIGS. 18A-18MMM show an alignment of 53 different Cas13d proteins (SEQ ID NOs: 293, 183, 189, 220, 218, 222, 229, 216, 177, 200, 139, 179, 208, 166, 185, 202, 239, 294, 249, 210, 243, 212, 175, 164, 160, 295, 296, 187, 241, 140, 162, 155, 206, 181, 231, 128, 198, 237, 233, 253, 214, 224, 127, 235, 153, 125, 245, 247, 204, 226, 3, 126, and 149, from top to bottom).

FIG. 19A is a plot showing results of screening 50 Cas13d orthologs (see Table 1) with NLS (SEQ ID NOS: 25 and 256) and NES architectures (SEQ ID NO: 287) for knockdown in human cells via mCherry reporter assay, plotted by knockdown efficiency and genetic size of effector. Only a subset of orthologs (Ga0531-NLS, Ga7274-NLS, and k87-NES, SEQ ID NOS: 235, 198, and 189, respectively show comparable activity to the CasRx variant (SEQ ID NO: 280).

FIG. 19B is a bar graph showing the knock-down of endogenous CD81 in human HEK 293FT cells by multiple Cas13d orthologs with NLS and NES subcellular localization signals. The most active orthologs from the mCherry reporter assay (see Table 1) were selected for a second round of activity screening. CD81 knockdown was assessed via cell surface flow cytometry. The CasRx variant RfxCas13d-NLS (SEQ ID NO: 280) exhibited the highest level of knock-down, with some additional orthologs exhibiting >75% knock-down on this endogenous target.

FIG. 20 is a bar graph showing a dose-response comparison of CasRx (SEQ ID NO: 280; RfxCas13d-NLS design) to PspCas13b-NES (Cox *et al.*, *Science*. 2017 Nov 24;358(6366):1019-1027) for

knock-down of endogenous CD81 protein. CasRx displays significantly higher activity at equivalent protein levels (as measured by Cas13-GFP expression), indicating a higher activity per enzyme unit and therefore a lower required dose to reach a biologically/therapeutically relevant level of knock-down. In addition, CasRx is significantly smaller than PspCas13b. The small size and high activity at lower doses makes CasRx useful for therapeutic delivery. Readout is three days after transient transfection in human HEK 293FT cells.

FIG. 21 is a bar graph showing that multiple engineered deletions of Cas13d orthologs CasRx and Ga0531 maintain knock-down activity in human HEK 293FT cells.

FIG. 22 is a bar graph showing that dCas13d variants (with mutated HEPN domains to abolish target RNA cleavage) were targeted to the slice acceptor site of our bichromatic blue-to-red splice reporter to mediate exon exclusion (as measured by reduction in mTagBFP2 expression). Even for orthologs with high levels of endogenous protein knock down (>70% CD81 protein knock down), splicing modulation can be inefficient. This underscores the uniquely advantageous combination of high knock-down and high splicing modulation activity of certain Cas13d orthologs, such as CasRx and truncated CasRx variants such as CasRx-del13. Splicing readout by flow cytometry on day 3 following transient transfection of dCas13d variants into HEK293FT cells.

FIGS. 23A-23C: RNA editing with Cas13d. (A) Schematic of dRfxCas13d-ADAR2 effector fusion and inactivated GFP reporter. (B) Targeted A to I RNA editing of a premature stop codon in an GFP reporter reactivates GFP expression. Non-targeting guide does not lead to RNA editing. (C) Quantification of Cas13d-mediated RNA editing efficiency.

SEQUENCE LISTING

The nucleic and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids, as defined in 37 C.F.R. 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand. The Sequence Listing is submitted as an ASCII text file, created on August 22, 2018, 0.99MB, which is incorporated by reference herein. In the accompanying sequence listing:

SEQ ID NO: 1 is an exemplary Cas13d sequence from Eubacterium siraeum containing a HEPN site.

SEQ ID NO: 2 is an exemplary Cas13d sequence from Eubacterium siraeum containing a mutated HEPN site.

SEQ ID NO: 3 is an exemplary Cas13d sequence from uncultured Ruminococcus sp. containing a HEPN site.

SEQ ID NO: 4 is an exemplary Cas13d sequence from uncultured Ruminococcus sp. containing a mutated HEPN site.

SEQ ID NO: 5 is an exemplary Cas13d sequence from Gut_metagenome_contig2791000549.

SEQ ID NO: 6 is an exemplary Cas13d sequence from Gut_metagenome_contig855000317.

SEQ ID NO: 7 is an exemplary Cas13d sequence from Gut_metagenome_contig3389000027.

SEQ ID NO: 8 is an exemplary Cas13d sequence from Gut_metagenome_contig8061000170.

SEQ ID NO: 9 is an exemplary Cas13d sequence from Gut_metagenome_contig1509000299.

SEQ ID NO: 10 is an exemplary Cas13d sequence from Gut_metagenome_contig9549000591.

SEQ ID NO: 11 is an exemplary Cas13d sequence from Gut_metagenome_contig71000500.

SEQ ID NO: 12 is an exemplary Cas13d sequence from human gut metagenome.

SEQ ID NO: 13 is an exemplary Cas13d sequence from Gut_metagenome_contig3915000357.

SEQ ID NO: 14 is an exemplary Cas13d sequence from Gut_metagenome_contig4719000173.

SEQ ID NO: 15 is an exemplary Cas13d sequence from Gut_metagenome_contig6929000468.

SEQ ID NO: 16 is an exemplary Cas13d sequence from Gut_metagenome_contig7367000486.

SEQ ID NO: 17 is an exemplary Cas13d sequence from Gut_metagenome_contig7930000403.

SEQ ID NO: 18 is an exemplary Cas13d sequence from Gut_metagenome_contig993000527.

SEQ ID NO: 19 is an exemplary Cas13d sequence from Gut_metagenome_contig6552000639.

SEQ ID NO: 20 is an exemplary Cas13d sequence from Gut_metagenome_contig11932000246.

SEQ ID NO: 21 is an exemplary Cas13d sequence from Gut_metagenome_contig12963000286.

SEQ ID NO: 22 is an exemplary Cas13d sequence from Gut_metagenome_contig2952000470.

SEQ ID NO: 23 is an exemplary Cas13d sequence from Gut_metagenome_contig451000394.

SEQ ID NO: 24 is an exemplary Cas13d sequence from Eubacterium_siraeum_DSM_15702.

SEQ ID NO: 25 is an exemplary Cas13d sequence from gut_metagenome_P19E0k2120140920,_c369000003.

SEQ ID NO: 26 is an exemplary Cas13d sequence from Gut_metagenome_contig7593000362.

SEQ ID NO: 27 is an exemplary Cas13d sequence from Gut_metagenome_contig12619000055.

SEQ ID NO: 28 is an exemplary Cas13d sequence from Gut_metagenome_contig1405000151.

SEQ ID NO: 29 is an exemplary Cas13d sequence from Chicken_gut_metagenome_c298474.

SEQ ID NO: 30 is an exemplary Cas13d sequence from Gut_metagenome_contig1516000227.

SEQ ID NO: 31 is an exemplary Cas13d sequence from Gut_metagenome_contig1838000319.

SEQ ID NO: 32 is an exemplary Cas13d sequence from Gut_metagenome_contig13123000268.

SEQ ID NO: 33 is an exemplary Cas13d sequence from Gut_metagenome_contig5294000434.

SEQ ID NO: 34 is an exemplary Cas13d sequence from Gut_metagenome_contig6415000192.

SEQ ID NO: 35 is an exemplary Cas13d sequence from Gut_metagenome_contig6144000300.

SEQ ID NO: 36 is an exemplary Cas13d sequence from Gut_metagenome_contig9118000041.

SEQ ID NO: 37 is an exemplary Cas13d sequence from Activated_sludge_metagenome_transcript_124486.

SEQ ID NO: 38 is an exemplary Cas13d sequence from Gut_metagenome_contig1322000437.

SEQ ID NO: 39 is an exemplary Cas13d sequence from Gut_metagenome_contig4582000531.

SEQ ID NO: 40 is an exemplary Cas13d sequence from Gut_metagenome_contig9190000283.

SEQ ID NO: 41 is an exemplary Cas13d sequence from Gut_metagenome_contig1709000510.

SEQ ID NO: 42 is an exemplary Cas13d sequence from M24_(LSQX01212483_Anaerobic_digester_metagenome) with a HEPN domain.

SEQ ID NO: 43 is an exemplary Cas13d sequence from Gut_metagenome_contig3833000494.

SEQ ID NO: 44 is an exemplary Cas13d sequence from Activated_sludge_metagenome_transcript_117355.

SEQ ID NO: 45 is an exemplary Cas13d sequence from Gut_metagenome_contig11061000330.

SEQ ID NO: 46 is an exemplary Cas13d sequence from Gut_metagenome_contig338000322 from sheep gut metagenome.

SEQ ID NO: 47 is an exemplary Cas13d sequence from human gut metagenome.

SEQ ID NO: 48 is an exemplary Cas13d sequence from Gut_metagenome_contig9530000097.

SEQ ID NO: 49 is an exemplary Cas13d sequence from Gut_metagenome_contig1750000258.

SEQ ID NO: 50 is an exemplary Cas13d sequence from Gut_metagenome_contig5377000274.

SEQ ID NO: 51 is an exemplary Cas13d sequence from gut_metagenome_P19E0k2120140920_c248000089.

SEQ ID NO: 52 is an exemplary Cas13d sequence from Gut_metagenome_contig11400000031.

SEQ ID NO: 53 is an exemplary Cas13d sequence from Gut_metagenome_contig7940000191.

SEQ ID NO: 54 is an exemplary Cas13d sequence from Gut_metagenome_contig6049000251.

SEQ ID NO: 55 is an exemplary Cas13d sequence from Gut_metagenome_contig1137000500.

SEQ ID NO: 56 is an exemplary Cas13d sequence from Gut_metagenome_contig9368000105.

SEQ ID NO: 57 is an exemplary Cas13d sequence from Gut_metagenome_contig546000275.

SEQ ID NO: 58 is an exemplary Cas13d sequence from Gut_metagenome_contig7216000573.

SEQ ID NO: 59 is an exemplary Cas13d sequence from Gut_metagenome_contig4806000409.

SEQ ID NO: 60 is an exemplary Cas13d sequence from Gut_metagenome_contig10762000480.

SEQ ID NO: 61 is an exemplary Cas13d sequence from Gut_metagenome_contig4114000374.

SEQ ID NO: 62 is an exemplary Cas13d sequence from Ruminococcus_flavefaciens_FD1.

SEQ ID NO: 63 is an exemplary Cas13d sequence from Gut_metagenome_contig7093000170.

SEQ ID NO: 64 is an exemplary Cas13d sequence from Gut_metagenome_contig11113000384.

SEQ ID NO: 65 is an exemplary Cas13d sequence from Gut_metagenome_contig6403000259.

SEQ ID NO: 66 is an exemplary Cas13d sequence from Gut_metagenome_contig6193000124.

SEQ ID NO: 67 is an exemplary Cas13d sequence from Gut_metagenome_contig721000619.

SEQ ID NO: 68 is an exemplary Cas13d sequence from Gut_metagenome_contig1666000270.

SEQ ID NO: 69 is an exemplary Cas13d sequence from Gut_metagenome_contig2002000411.

SEQ ID NO: 70 is an exemplary Cas13d sequence from Ruminococcus_albus.

SEQ ID NO: 71 is an exemplary Cas13d sequence from Gut_metagenome_contig13552000311.

SEQ ID NO: 72 is an exemplary Cas13d sequence from Gut_metagenome_contig10037000527.

SEQ ID NO: 73 is an exemplary Cas13d sequence from Gut_metagenome_contig238000329.

SEQ ID NO: 74 is an exemplary Cas13d sequence from Gut_metagenome_contig2643000492.

SEQ ID NO: 75 is an exemplary Cas13d sequence from Gut_metagenome_contig874000057.

SEQ ID NO: 76 is an exemplary Cas13d sequence from Gut_metagenome_contig4781000489.

SEQ ID NO: 77 is an exemplary Cas13d sequence from Gut_metagenome_contig12144000352.

SEQ ID NO: 78 is an exemplary Cas13d sequence from Gut_metagenome_contig5590000448.

SEQ ID NO: 79 is an exemplary Cas13d sequence from Gut_metagenome_contig9269000031.

SEQ ID NO: 80 is an exemplary Cas13d sequence from Gut_metagenome_contig8537000520.

SEQ ID NO: 81 is an exemplary Cas13d sequence from Gut_metagenome_contig1845000130.

SEQ ID NO: 82 is an exemplary Cas13d sequence from gut_metagenome_P13E0k2120140920_c3000072.

SEQ ID NO: 83 is an exemplary Cas13d sequence from gut_metagenome_P1E0k2120140920_c1000078.

SEQ ID NO: 84 is an exemplary Cas13d sequence from Gut_metagenome_contig12990000099.

SEQ ID NO: 85 is an exemplary Cas13d sequence from Gut_metagenome_contig525000349.

SEQ ID NO: 86 is an exemplary Cas13d sequence from Gut_metagenome_contig7229000302.

SEQ ID NO: 87 is an exemplary Cas13d sequence from Gut_metagenome_contig3227000343.

SEQ ID NO: 88 is an exemplary Cas13d sequence from Gut_metagenome_contig7030000469.

SEQ ID NO: 89 is an exemplary Cas13d sequence from Gut_metagenome_contig5149000068.

SEQ ID NO: 90 is an exemplary Cas13d sequence from Gut_metagenome_contig400200045.

SEQ ID NO: 91 is an exemplary Cas13d sequence from Gut_metagenome_contig10420000446.

SEQ ID NO: 92 is an exemplary Cas13d sequence from new_flavefaciens,_strain_XPD3002.

SEQ ID NO: 93 is an exemplary Cas13d sequence from M26_Gut_metagenome_contig698000307.

SEQ ID NO: 94 is an exemplary Cas13d sequence from M36_Uncultured_Eubacterium_sp_TS28_c40956.

SEQ ID NO: 95 is an exemplary Cas13d sequence from M12_gut_metagenome_P25C0k2120140920_c134000066.

SEQ ID NO: 96 is an exemplary Cas13d sequence from human gut metagenome.

SEQ ID NO: 97 is an exemplary Cas13d sequence from M10_gut_metagenome_P25C90k2120140920,_c28000041.

SEQ ID NO: 98 is an exemplary Cas13d sequence from M11_gut_metagenome_P25C7k2120140920_c4078000105.

SEQ ID NO: 99 is an exemplary Cas13d sequence from gut_metagenome_P25C0k2120140920_c32000045.

SEQ ID NO: 100 is an exemplary Cas13d sequence from M13_gut_metagenome_P23C7k2120140920_c3000067.

SEQ ID NO: 101 is an exemplary Cas13d sequence from M5_gut_metagenome_P18E90k2120140920.

SEQ ID NO: 102 is an exemplary Cas13d sequence from M21_gut_metagenome_P18E0k2120140920.

SEQ ID NO: 103 is an exemplary Cas13d sequence from M7_gut_metagenome_P38C7k2120140920_c4841000003.

SEQ ID NO: 104 is an exemplary Cas13d sequence from Ruminococcus_bicirculans.

SEQ ID NO: 105 is an exemplary Cas13d sequence.

SEQ ID NO: 106 is an exemplary Cas13d consensus sequence.

SEQ ID NO: 107 is an exemplary Cas13d sequence from M18_gut_metagenome_P22E0k2120140920_c3395000078.

SEQ ID NO: 108 is an exemplary Cas13d sequence from M17_gut_metagenome_P22E90k2120140920_c114.

SEQ ID NO: 109 is an exemplary Cas13d sequence from Ruminococcus_sp_CAG57.

SEQ ID NO: 110 is an exemplary Cas13d sequence from gut_metagenome_P11E90k2120140920_c43000123.

SEQ ID NO: 111 is an exemplary Cas13d sequence from M6_gut_metagenome_P13E90k2120140920_c7000009.

SEQ ID NO: 112 is an exemplary Cas13d sequence from M19_gut_metagenome_P17E90k2120140920.

SEQ ID NO: 113 is an exemplary Cas13d sequence from gut_metagenome_P17E0k2120140920,_c87000043.

SEQ ID NO: 114 is an exemplary human codon optimized Eubacterium siraeum Cas13d nucleic acid sequence.

SEQ ID NO: 115 is an exemplary human codon optimized Eubacterium siraeum Cas13d nucleic acid sequence with a mutant HEPN domain.

SEQ ID NO: 116 is an exemplary human codon-optimized Eubacterium siraeum Cas13d nucleic acid sequence with N-terminal NLS.

SEQ ID NO: 117 is an exemplary human codon-optimized Eubacterium siraeum Cas13d nucleic acid sequence with N- and C-terminal NLS tags.

SEQ ID NO: 118 is an exemplary human codon-optimized uncultured Ruminococcus sp. Cas13d nucleic acid sequence.

SEQ ID NO: 119 is an exemplary human codon-optimized uncultured Ruminococcus sp. Cas13d nucleic acid sequence with a mutant HEPN domain.

SEQ ID NO: 120 is an exemplary human codon-optimized uncultured Ruminococcus sp. Cas13d nucleic acid sequence with N-terminal NLS.

SEQ ID NO: 121 is an exemplary human codon-optimized uncultured Ruminococcus sp. Cas13d nucleic acid sequence with N- and C-terminal NLS tags.

SEQ ID NO: 122 is an exemplary human codon-optimized uncultured Ruminococcus flavefaciens FD1 Cas13d nucleic acid sequence.

SEQ ID NO: 123 is an exemplary human codon-optimized uncultured Ruminococcus flavefaciens FD1 Cas13d nucleic acid sequence with mutated HEPN domain.

SEQ ID NO: 124 is an exemplary Cas13d nucleic acid sequence from Ruminococcus bicirculans.

SEQ ID NO: 125 is an exemplary Cas13d nucleic acid sequence from Eubacterium siraeum.

SEQ ID NO: 126 is an exemplary Cas13d nucleic acid sequence from Ruminococcus flavefaciens FD1.

SEQ ID NO: 127 is an exemplary Cas13d nucleic acid sequence from Ruminococcus albus.

SEQ ID NO: 128 is an exemplary Cas13d nucleic acid sequence from Ruminococcus flavefaciens XPD.

SEQ ID NO: 129 is an exemplary consensus DR nucleic acid sequence for *E. siraeum* Cas13d.

SEQ ID NO: 130 is an exemplary consensus DR nucleic acid sequence for *Rum. Sp*. Cas13d.

SEQ ID NO: 131 is an exemplary consensus DR nucleic acid sequence for *Rum. Flavefaciens strain XPD3002* Cas13d and CasRx.

SEQ ID NOS: 132-137 are exemplary consensus DR nucleic acid sequences.

SEQ ID NO: 138 is an exemplary 50% consensus sequence for seven full-length Cas13d orthologues.

SEQ ID NO: 139 is an exemplary Cas13d nucleic acid sequence from Gut metagenome P1E0.

SEQ ID NO: 140 is an exemplary Cas13d nucleic acid sequence from Anaerobic digester.

SEQ ID NO: 141 is an exemplary Cas13d nucleic acid sequence from Ruminococcus sp. CAG:57.

SEQ ID NO: 142 is an exemplary human codon-optimized uncultured Gut metagenome P1E0 Cas13d nucleic acid sequence.

SEQ ID NO: 143 is an exemplary human codon-optimized Anaerobic Digester Cas13d nucleic acid sequence.

SEQ ID NO: 144 is an exemplary human codon-optimized Ruminococcus flavefaciens XPD Cas13d nucleic acid sequence.

SEQ ID NO: 145 is an exemplary human codon-optimized Ruminococcus albus Cas13d nucleic acid sequence.

SEQ ID NO: 146 is an exemplary processing of the *Ruminococcus* sp. CAG:57 CRISPR array.

SEQ ID NO: 147 is an exemplary Cas13d protein sequence from contig emb|OBVH01003037.1, human gut metagenome sequence (also found in WGS contigs emb|OBXZ01000094.1| and emb|OBJF01000033.1.

SEQ ID NO: 148 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 147).

SEQ ID NO: 149 is an exemplary Cas13d protein sequence from contig tpg|DBYI01000091.1| (Uncultivated Ruminococcus flavefaciens UBA1190 assembled from bovine gut metagenome).

SEQ ID NOS: 150-152 are exemplary consensus DR nucleic acid sequences (goes with SEQ ID NO: 149).

SEQ ID NO: 153 is an exemplary Cas13d protein sequence from contig tpg|DJXD01000002.1| (uncultivated Ruminococcus assembly, UBA7013, from sheep gut metagenome).

SEQ ID NO: 154 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 153).

SEQ ID NO: 155 is an exemplary Cas13d protein sequence from contig OGZC01000639.1 (human gut metagenome assembly).

SEQ ID NOS: 156-177 are exemplary consensus DR nucleic acid sequences (goes with SEQ ID NO: 155).

SEQ ID NO: 158 is an exemplary Cas13d protein sequence from contig emb|OHBM01000764.1 (human gut metagenome assembly).

SEQ ID NO: 159 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 158).

SEQ ID NO: 160 is an exemplary Cas13d protein sequence from contig emb|OHCP01000044.1 (human gut metagenome assembly).

SEQ ID NO: 161 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 160).

SEQ ID NO: 162 is an exemplary Cas13d protein sequence from contig emb|OGDF01008514.1| (human gut metagenome assembly).

SEQ ID NO: 163 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 162).

SEQ ID NO: 164 is an exemplary Cas13d protein sequence from contig emb|OGPN01002610.1 (human gut metagenome assembly).

SEQ ID NO: 165 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 164).

SEQ ID NO: 166 is an exemplary Cas13d protein sequence from contig NFIR01000008.1 (Eubacterium sp. An3, from chicken gut metagenome).

SEQ ID NO: 167 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 166).

SEQ ID NO: 168 is an exemplary Cas13d protein sequence from contig NFLV01000009.1 (Eubacterium sp. An11, from chicken gut metagenome).

SEQ ID NO: 169 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 168).

SEQ ID NOS: 171-174 are an exemplary Cas13d motif sequences.

SEQ ID NO: 175 is an exemplary Cas13d protein sequence from contig OJMM01002900 human gut metagenome sequence.

SEQ ID NO: 176 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 175).

SEQ ID NO: 177 is an exemplary Cas13d protein sequence from contig ODAI011611274.1 gut metagenome sequence.

SEQ ID NO: 178 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 177).

SEQ ID NO: 179 is an exemplary Cas13d protein sequence from contig OIZX01000427.1.

SEQ ID NO: 180 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 179).

SEQ ID NO: 181 is an exemplary Cas13d protein sequence from contig emb|OCVV012889144.1.

SEQ ID NO: 182 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 181).

SEQ ID NO: 183 is an exemplary Cas13d protein sequence from contig OCTW011587266.1

SEQ ID NO: 184 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 183).

SEQ ID NO: 185 is an exemplary Cas13d protein sequence from contig emb|OGNF01009141.1.

SEQ ID NO: 186 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 185).

SEQ ID NO: 187 is an exemplary Cas13d protein sequence from contig emb|OIEN01002196.1.

SEQ ID NO: 188 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 187).

SEQ ID NO: 189 is an exemplary Cas13d protein sequence from contig e-k87_11092736.

SEQ ID NOS: 190-193 are exemplary consensus DR nucleic acid sequences (goes with SEQ ID NO: 189).

SEQ ID NO: 194 is an exemplary Cas13d sequence from Gut_metagenome_contig6893000291.

SEQ ID NOS: 195-197 are exemplary Cas13d motif sequences.

SEQ ID NO: 198 is an exemplary Cas13d protein sequence from Ga0224415_10007274.

SEQ ID NO: 199 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 198).

SEQ ID NO: 200 is an exemplary Cas13d protein sequence from EMG_10003641.

SEQ ID NO: 201 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 200).

SEQ ID NO: 202 is an exemplary Cas13d protein sequence from Ga0129306_1000735.

SEQ ID NO: 203 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 202).

SEQ ID NO: 204 is an exemplary Cas13d protein sequence from Ga0129317_1008067.

SEQ ID NO: 205 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 204).

SEQ ID NO: 206 is an exemplary Cas13d protein sequence from Ga0224415_10048792.

SEQ ID NO: 207 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 206).

SEQ ID NO: 208 is an exemplary Cas13d protein sequence from 160582958 _gene49834.

SEQ ID NO: 209 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 208).

SEQ ID NO: 210 is an exemplary Cas13d protein sequence from 250twins_35838_GL0110300.

SEQ ID NO: 211 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 210).

SEQ ID NO: 212 is an exemplary Cas13d protein sequence from 250twins_36050_GL0158985.

SEQ ID NO: 213 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 212).

SEQ ID NO: 214 is an exemplary Cas13d protein sequence from 31009_GL0034153.

SEQ ID NO: 215 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 214).

SEQ ID NO: 216 is an exemplary Cas13d protein sequence from 530373_GL0023589.

SEQ ID NO: 217 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 216).

SEQ ID NO: 218 is an exemplary Cas13d protein sequence from BMZ-11B_GL0037771.

SEQ ID NO: 219 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 218).

SEQ ID NO: 220 is an exemplary Cas13d protein sequence from BMZ-11B_GL0037915.

SEQ ID NO: 221 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 220).

SEQ ID NO: 222 is an exemplary Cas13d protein sequence from BMZ-11B_GL0069617.

SEQ ID NO: 223 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 222).

SEQ ID NO: 224 is an exemplary Cas13d protein sequence from - DLF014_GL0011914.

SEQ ID NO: 225 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 224).

SEQ ID NO: 226 is an exemplary Cas13d protein sequence from EYZ-362B_GL0088915.

SEQ ID NO: 227-228 are exemplary consensus DR nucleic acid sequences (goes with SEQ ID NO: 226).

SEQ ID NO: 229 is an exemplary Cas13d protein sequence from Ga0099364_10024192.

SEQ ID NO: 230 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 229).

SEQ ID NO: 231 is an exemplary Cas13d protein sequence from Ga0187910_10006931.

SEQ ID NO: 232 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 231).

SEQ ID NO: 233 is an exemplary Cas13d protein sequence from Ga0187910_10015336.

SEQ ID NO: 234 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 233).

SEQ ID NO: 235 is an exemplary Cas13d protein sequence from Ga0187910_10040531.

SEQ ID NO: 236 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 235).

SEQ ID NO: 237 is an exemplary Cas13d protein sequence from Ga0187911_10069260.

SEQ ID NO: 238 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 237).

SEQ ID NO: 239 is an exemplary Cas13d protein sequence from MH0288_GL0082219.

SEQ ID NO: 240 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 239).

SEQ ID NO: 241 is an exemplary Cas13d protein sequence from O2.UC29-0_GL0096317.

SEQ ID NO: 242 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 241).

SEQ ID NO: 243 is an exemplary Cas13d protein sequence from PIG-014_GL0226364.

SEQ ID NO: 244 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 243).

SEQ ID NO: 245 is an exemplary Cas13d protein sequence from PIG-018_GL0023397.

SEQ ID NO: 246 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 245).

SEQ ID NO: 247 is an exemplary Cas13d protein sequence from PIG-025_GL0099734.

SEQ ID NO: 248 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 247).

SEQ ID NO: 249 is an exemplary Cas13d protein sequence from PIG-028_GL0185479.

SEQ ID NO: 250 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 249).

SEQ ID NO: 251 is an exemplary Cas13d protein sequence from - Ga0224422_10645759.

SEQ ID NO: 252 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 251).

SEQ ID NO: 253 is an exemplary Cas13d protein sequence from ODAI chimera.

SEQ ID NO: 254 is an exemplary consensus DR nucleic acid sequence (goes with SEQ ID NO: 253).

SEQ ID NO: 255 is an HEPN motif.

SEQ ID NOs: 256 and 257 are exemplary Cas13d nuclear localization signal amino acid and nucleic acid sequences, respectively.

SEQ ID NOs: 258 and 260 are exemplary SV40 large T antigen nuclear localization signal amino acid and nucleic acid sequences, respectively.

SEQ ID NO: 259 is a dCas9 target sequence.

SEQ ID NO: 261 is an artificial Eubacterium siraeum nCas1 array targeting ccdB.

SEQ ID NO: 262 is a full 36 nt direct repeat.

SEQ ID NOs: 263-266 are spacer sequences.

SEQ ID NO: 267 is an artificial uncultured Ruminoccus sp. nCas1 array targeting ccdB.

SEQ ID NO: 268 is a full 36 nt direct repeat.

SEQ ID NOs: 269-272 are spacer sequences.

SEQ ID NO: 273 is a ccdB target RNA sequence.

SEQ ID NOs: 274-277 are spacer sequences.

SEQ ID NO: 278 is a mutated Cas13d sequence, NLS-Ga_0531(trunc)-NLS-HA. This mutant has a deletion of the non-conserved N-terminus.

SEQ ID NO: 279 is a mutated Cas13d sequence, NES-Ga_0531(trunc)-NES-HA. This mutant has a deletion of the non-conserved N-terminus.

SEQ ID NO: 280 is a full-length Cas13d sequence, NLS-RfxCas13d-NLS-HA.

SEQ ID NO: 281 is a mutated Cas13d sequence, NLS-RfxCas13d(del5)-NLS-HA. This mutant has a deletion of amino acids 558-587.

SEQ ID NO: 282 is a mutated Cas13d sequence, NLS-RfxCas13d(del5.12)-NLS-HA. This mutant has a deletion of amino acids 558-587 and 953-966.

SEQ ID NO: 283 is a mutated Cas13d sequence, NLS-RfxCas13d(del5.13)-NLS-HA. This mutant has a deletion of amino acids 376-392 and 558-587.

SEQ ID NO: 284 is a mutated Cas13d sequence, NLS-RfxCas13d(del5.12+5.13)-NLS-HA. This mutant has a deletion of amino acids 376-392, 558-587, and 953-966.

SEQ ID NO: 285 is a mutated Cas13d sequence, NLS-RfxCas13d(del13)-NLS-HA. This mutant has a deletion of amino acids 376-392.

SEQ ID NO: 286 is an effector sequence used to edit expression of ADAR2. Amino acids 1 to 969 are dRfxCas13, aa 970 to 991 are an NLS sequence, and amino acids 992 to 1378 are $ADAR2_{DD}$.

SEQ ID NO: 287 is an exemplary HIV NES protein sequence.

SEQ ID NOS: 288-291 are exemplary Cas13d motif sequences.

SEQ ID NO: 292 is Cas13d ortholog sequence MH_4866.

SEQ ID NO: 293 is an exemplary Cas13d protein sequence from 037_-_emb|OIZA01000315.1|

SEQ ID NO: 294 is an exemplary Cas13d protein sequence from PIG-022_GL0026351.

SEQ ID NO: 295 is an exemplary Cas13d protein sequence from PIG-046_GL0077813.

SEQ ID NO: 296 is an exemplary Cas13d protein sequence from pig_chimera.

DETAILED DESCRIPTION

Unless otherwise noted, technical terms are used according to conventional usage. Definitions of common terms in molecular biology can be found in Benjamin Lewin, *Genes VII*, published by Oxford University Press, 1999; Kendrew *et al.* (eds.), *The Encyclopedia of Molecular Biology*, published by Blackwell Science Ltd., 1994; and Robert A. Meyers (ed.), *Molecular Biology and Biotechnology: a Comprehensive Desk Reference*, published by VCH Publishers, Inc., 1995; and other similar references.

As used herein, the singular forms "a," "an," and "the," refer to both the singular as well as plural, unless the context clearly indicates otherwise. As used herein, the term "comprises" means "includes." Thus, "comprising a nucleic acid molecule" means "including a nucleic acid molecule" without excluding other elements. It is further to be understood that any and all base sizes given for nucleic acids are approximate, and are provided for descriptive purposes, unless otherwise indicated. Although many methods and materials similar or equivalent to those described herein can be used, particular suitable methods and materials are described below. In case of conflict, the present specification, including explanations of terms, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. All references, including patent applications and patents, are herein incorporated by reference in their entireties.

In order to facilitate review of the various embodiments of the disclosure, the following explanations of specific terms are provided:

I. Terms

Administration: To provide or give a subject an agent, such as a Cas13d protein (or Cas13d coding sequence) or guide molecule (or coding sequence) disclosed herein, by any effective route. Exemplary routes of administration include, but are not limited to, injection (such as subcutaneous, intramuscular, intradermal, intraperitoneal, intratumoral, and intravenous), transdermal, intranasal, and inhalation routes.

Cas13d (also referred to as CasR, for CRISPR-associated RNase): An RNA-guided RNA endonuclease enzyme that can cut or bind RNA. Cas13d proteins include one or two HEPN domains (*e.g.*, see SEQ ID NOS: 1-3, 42, 62, 70, 82, 83, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, and 296). Native HEPN domains include the sequence RXXXXH (SEQ ID NO: 255). Cas13d proteins that include mutated HEPN domain(s), and thus cannot cut RNA, but can process

guide RNA, are also encompassed by this disclosure (*e.g.*, see SEQ ID NOS: 2 and 4). An alignment of native Cas13d proteins is shown in FIGS. 18A-18MMM. In addition, Cas13d proteins specifically recognize direct repeat sequences of gRNA having a particular secondary structure (*e.g.*, see FIGS.S2C). In one example, Cas13d proteins recognize and/or bind a DR having (1) a loop of about 4 to 8 nt, (2) a stem of 4 to 12 nt, stem formed of complementary nucleotides, which can include a small (*e.g.*, 1 or 2 bp) bulge due to a nt mismatch in the stem, and (3) a bulge or overhang formed of unpaired nt, which can be about 10 to 14 nt (*e.g.*, 5 to 7 to on either side).

In one example, the full length (non-truncated) Cas13d protein is between 870-1080 amino acids long. In one example, the Cas13d protein is derived from a genome sequence of a bacterium from the Order Clostridiales or a metagenomic sequence. In one example, the corresponding DR sequence of a Cas13d protein is located at the 5' end of the spacer sequence in the molecule that includes the Cas13d gRNA. In one example, the DR sequence in the Cas13d gRNA is truncated at the 5' end relative to the DR sequence in the unprocessed Cas13d guide array transcript (such as truncated by at least 1 nt, at least 2 nt, at least 3 nt, at least 4 nt, at least 5 nt, such as 1-3 nt, 3-6 nt, 5-7 nt, or 5-10 nt). In one example, the DR sequence in the Cas13d gRNA is truncated by 5-7 nt at the 5' end by the Cas13d protein. In one example, the Cas13d protein can cut a target RNA flanked at the 3' end of the spacer-target duplex by any of a A, U, G or C ribonucleotide and flanked at the 5' end by any of a A, U, G or C ribonucleotide.

In one example, a Cas13d protein has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296.

In one example, a Cas13d protein contains two HEPN Rnase domains which contain a RXXXXH amino acid motif (SEQ ID NO: 255; where X indicates any amino acid). In addition, a Cas13d protein can include one or more of the following amino acid motifs written in the common Prosite format:

Motif 1: L-x(5)-[FWY]-x(3)-K-[NQS]-[ILM]-[ILMV]-x(2)-N-x(2)-[FWY]-x(2)-[AG]-x(4)-[DE]-x-D (SEQ ID NO: 195)

Motif 2: [FWY]-[ILV]-x(2)-[NQS]-[ILV]-x(2)-[DNST]-x(2)-F-x-Y-x(2)-[HKR]-[FHY] (SEQ ID NO: 196)

Motif 3: Y-[CDNSV]-x(2)-R-[FWY]-x-[ADNT]-[LM]-[ST]-x(4)-[FWY] (SEQ ID NO: 197)

In one example, a Cas13d protein include one or more of the following amino acid consensus sequences, written in the common Prosite format:

L-[DE]-G-K-E-I-N-x-[LM]-x-[CST]-[ANST]-L-I-x-K-F-[DE]-[GN]-I-x-[ADS]-[FIL]-x-[DEHK]-[AILV] (SEQ ID NO: 288)

R-N-[FY]-I-[AIL]-x-N-V-[ILV]-x-[NS]-x(2)-F-x-Y-[ILV]-[AIV]-[KR]-[HY]-x(2)-[PT]-x(3)-[HKR]-x-[IL]-x(2)-N-x(2)-[ILV]-x(2)-[FY]-V-L-x(2)-[ILM]-[AGP]-[DE]-x(4)-[NQRS] (SEQ ID NO: 289)

L-x-[LM]-[ST]-[IV]-x-Y-x(3)-K-[NS]-[ILM]-V-x-[IV]-N-[AST]-R-[FY]-x(2)-[AG]-[FY]-x-[ACV]-[LV]-E-R-D-x(2)-[FL] (SEQ ID NO: 290)

P-F-[AGS]-Y-[CNV]-x-[AP]-R-[FY]-K-N-L-[ST]-x-[EN]-x-L-F-x-[DKR]-[DEN] (SEQ ID NO: 291)

Thus, in some examples, a Cas13d protein having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296 includes the motif of SEQ ID NO: 195, 196 or 197.

In addition, in some examples, a Cas13d protein having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296 and includes the consensus sequence of SEQ ID NO: 288, 289, 290, or 291.

Complementarity: The ability of a nucleic acid to form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick base pairing or other non-traditional types. A percent complementarity indicates the percentage of residues in a nucleic acid molecule which can form hydrogen bonds (*e.g.*, Watson-Crick base pairing) with a second nucleic acid sequence (*e.g.*, 5, 6, 7, 8, 9, 10 out of 10 being 50%, 60%, 70%, 80%, 90%, and 100% complementary). "Perfectly complementary" means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence. "Substantially complementary" as used herein refers to a degree of complementarity that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, or more nucleotides, or refers to two nucleic acids that hybridize under stringent conditions.

CRISPRs (**C**lustered **R**egularly **I**nter**S**paced **R**epeats): The CRISPR RNA array is a defining feature of CRISPR systems. The term "CRISPR" refers to the architecture of the array which includes constant direct repeats (DRs) interspaced with the variable spacers. In some examples, a CRISPR array includes at least a DR-spacer-DR-spacer (see **FIG. 1A**). This feature was used in the disclosed computational pipeline to identify the novel Cas13d protein family (**FIG. 1A**). In bacteria, the array is transcribed as one single transcript (containing multiple crRNA units), which is then processed by the Cas13d protein and other RNases into individual crRNAs. CRISPRs are found in approximately 40% of sequenced bacteria genomes and 90% of sequenced archaea. CRISPRs are often associated with cas genes that code for proteins related to CRISPRs (such as the Cas13d proteins provided herein). The disclosed CRISPR/Cas system can be used for RNA targeting, for example to detect a target RNA, modify a target RNA at any desired location, or cut the target RNA at any desired location.

Downregulated or knocked down: When used in reference to the expression of a molecule, such as a target RNA, refers to any process which results in a decrease in production of the target RNA, but in some examples not complete elimination of the target RNA product or target RNA function. In one example, downregulation or knock down does not result in complete elimination of detectable target RNA expression or target RNA activity. In some examples, the target RNA is a coding RNA. In some examples, the target RNA is non-coding RNA. Specific examples of RNA molecules that can be targeted for downregulation include mRNA, miRNA, rRNA, tRNA, nuclear RNA, lincRNA, circular RNA, and structural RNA. In some examples, downregulation or knock down of a target RNA includes processes that decrease translation of the target RNA and thus can decrease the presence of corresponding proteins. The disclosed CRISPR/Cas system can be used to downregulate any target RNA of interest.

Downregulation or knock down includes any detectable decrease in the target RNA. In certain examples, detectable target RNA in a cell or cell free system decreases by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% (such as a decrease of 40% to 90%, 40% to 80% or 50% to 95%) as compared to a control (such an amount of target RNA detected in a corresponding normal cell or sample). In one example, a control is a relative amount of expression in a normal cell (*e.g.*, a non-recombinant cell that does not include Cas13d or guide RNA).

Effective amount: The amount of an agent (such as the CRISPR/Cas agents provided herein) that is sufficient to effect beneficial or desired results.

A therapeutically effective amount may vary depending upon one or more of: the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The beneficial therapeutic effect can include enablement of diagnostic determinations; amelioration of a disease, symptom, disorder, or pathological condition; reducing or preventing the onset of a disease, symptom, disorder or condition; and generally counteracting a disease, symptom, disorder or pathological condition. In one embodiment, an "effective amount" is an amount sufficient to reduce symptoms of a

disease, for example by at least 10%, at least 20%, at least 50%, at least 70%, or at least 90% (as compared to no administration of the therapeutic agent).

The term also applies to a dose that will allow for expression of a Cas13d and/or gRNA herein, and that allows for targeting (*e.g.*, detection or modification) of a target RNA.

Increase or Decrease: A statistically significant positive or negative change, respectively, in quantity from a control value. An increase is a positive change, such as an increase at least 50%, at least 100%, at least 200%, at least 300%, at least 400% or at least 500% as compared to the control value. A decrease is a negative change, such as a decrease of at least 20%, at least 25%, at least 50%, at least 75%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 100% decrease as compared to a control value. In some examples the decrease is less than 100%, such as a decrease of no more than 90%, no more than 95% or no more than 99%.

Isolated: An "isolated" biological component (such as a Cas13d protein or nucleic acid, gRNA, or cell containing such) has been substantially separated, produced apart from, or purified away from other biological components in the cell or tissue of an organism in which the component occurs, such as other cells, chromosomal and extrachromosomal DNA and RNA, and proteins. Nucleic acids and proteins that have been "isolated" include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids and proteins. Isolated Cas13d proteins or nucleic acids, or cells containing such, in some examples are at least 50% pure, such as at least 75%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 100% pure.

Label: A compound or composition that is conjugated directly or indirectly to another molecule (such as a nucleic acid molecule) to facilitate detection of that molecule. Specific, non-limiting examples of labels include fluorescent and fluorogenic moieties, chromogenic moieties, haptens, affinity tags, and radioactive isotopes. The label can be directly detectable (*e.g.,* optically detectable) or indirectly detectable (for example, via interaction with one or more additional molecules that are in turn detectable).

Modulate: A change in the content of RNA. Modulation can include, but is not limited to, RNA activation (*e.g.*, upregulation), RNA repression (*e.g.*, downregulation), ribonucleotide deletion, ribonucleotide insertion, ribonucleotide chemical modification, ribonucleotide covalent or non-covalent linkage, and/or ribonucleotide substitution.

Non-naturally occurring or engineered: Terms used herein as interchangeably and indicate the involvement of the hand of man. The terms, when referring to nucleic acid molecules or polypeptides indicate that the nucleic acid molecule or the polypeptide is at least substantially free from at least one other component with which they are naturally associated in nature and as found in nature. In addition, the terms can indicate that the nucleic acid molecules or polypeptides have a sequence not found in nature.

Operably linked: A first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence (such as a coding sequence

of a Cas13d protein) if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and, where necessary to join two protein-coding regions, in the same reading frame.

Pharmaceutically acceptable carriers: The pharmaceutically acceptable carriers useful in this invention are conventional. *Remington's Pharmaceutical Sciences*, by E. W. Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of a Cas13d protein or nucleic acid molecule (or other molecules needed for modifying RNA using the disclosed CRISPR/Cas system with the disclosed Cas13d proteins).

In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle. In addition to biologically-neutral carriers, pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.

Polypeptide, peptide and protein: Refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. As used herein the term "amino acid" includes natural and/or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics.

Promoter: An array of nucleic acid control sequences which direct transcription of a nucleic acid. A promoter includes necessary nucleic acid sequences near the start site of transcription. A promoter also optionally includes distal enhancer or repressor elements. A "constitutive promoter" is a promoter that is continuously active and is not subject to regulation by external signals or molecules. In contrast, the activity of an "inducible promoter" is regulated by an external signal or molecule (for example, a transcription factor).

Recombinant or host cell: A cell that has been genetically altered, or is capable of being genetically altered by introduction of an exogenous polynucleotide, such as a recombinant plasmid or vector. Typically, a host cell is a cell in which a vector can be propagated and its nucleic acid expressed. Such cells can be eukaryotic or prokaryotic. The term also includes any progeny of the subject host cell. It is understood that all progeny may not be identical to the parental cell since there may be mutations that occur during replication. However, such progeny are included when the term "host cell" is used.

Regulatory element: A phrase that includes promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (*e.g.*, transcription termination signals, such as polyadenylation signals and poly-U sequences). Such regulatory elements are described, for example, in

Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) which is hereby incorporated by reference in its entirety. Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cells and those that direct expression of the nucleotide sequence only in certain host cells (*e.g.*, tissue-specific regulatory sequences). A tissue-specific promoter may direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (*e.g.*, liver, pancreas), or particular cell types (*e.g.*, lymphocytes). Regulatory elements may also direct expression in a temporal-dependent manner, such as in a cell-cycle dependent or developmental stage-dependent manner, which may or may not also be tissue or cell-type specific.

In some embodiments, a vector provided herein includes a pol III promoter (*e.g.*, U6 and H1 promoters), a pol II promoter (*e.g.*, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer), the SV40 promoter, the dihydrofolate reductase promoter, the β-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1α promoter), or both.

Also encompassed by the term "regulatory element" are enhancer elements, such as WPRE; CMV enhancers; the R-U5' segment in LTR of HTLV-I; SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit β-globin.

In some examples, a Cas13d coding sequence is operably linked to a promoter, enhancer element, or both.

RNA Editing: A type of genetic engineering in which a RNA molecule (or ribonucleotides of the RNA) is inserted, deleted or replaced in the genome of an organism using engineered nucleases (such as the Cas13d proteins provided herein), which create site-specific strand breaks at desired locations in the RNA. The induced breaks are repaired resulting in targeted mutations or repairs. The CRISPR/Cas methods disclosed herein, such as those that use a Cas13d, can be used to edit the sequence of one or more target RNAs, such as one associated with cancer (*e.g.*, breast cancer, colon cancer, lung cancer, prostate cancer, melanoma), infectious disease (such as HIV, hepatitis, HPV, and West Nile virus), or neurodegenerative disorder (*e.g.*, Huntington's disease or ALS). For example, RNA editing can be used to treat a disease or viral infection.

RNA insertion site: A site of the RNA that is targeted for, or has undergone, insertion of an exogenous polynucleotide. The disclosed methods include use of a disclosed Cas13d protein, which can be used to target a RNA for manipulation at a RNA insertion site.

Sequence identity/similarity: The similarity between amino acid (or nucleotide) sequences is expressed in terms of the similarity between the sequences, otherwise referred to as sequence identity. Sequence identity is frequently measured in terms of percentage identity (or similarity or homology); the higher the percentage, the more similar the two sequences are.

Methods of alignment of sequences for comparison are well known in the art. Various programs and alignment algorithms are described in: Smith and Waterman, *Adv. Appl. Math.* 2:482, 1981; Needleman and

Wunsch, *J. Mol. Biol.* 48:443, 1970; Pearson and Lipman, *Proc. Natl. Acad. Sci. U.S.A.* 85:2444, 1988; Higgins and Sharp, *Gene* 73:237, 1988; Higgins and Sharp, *CABIOS* 5:151, 1989; Corpet *et al.*, *Nucleic Acids Research* 16:10881, 1988; and Pearson and Lipman, *Proc. Natl. Acad. Sci. U.S.A.* 85:2444, 1988. Altschul *et al.*, *Nature Genet.* 6:119, 1994, presents a detailed consideration of sequence alignment methods and homology calculations.

The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul *et al.*, *J. Mol. Biol.* 215:403, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, MD) and on the internet, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn and tblastx. A description of how to determine sequence identity using this program is available on the NCBI website on the internet.

Variants of protein and nucleic acid sequences known in the art and disclosed herein are typically characterized by possession of at least about 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity counted over the full length alignment with the amino acid sequence using the NCBI Blast 2.0, gapped blastp set to default parameters. For comparisons of amino acid sequences of greater than about 30 amino acids, the Blast 2 sequences function is employed using the default BLOSUM62 matrix set to default parameters, (gap existence cost of 11, and a per residue gap cost of 1). When aligning short peptides (fewer than around 30 amino acids), the alignment should be performed using the Blast 2 sequences function, employing the PAM30 matrix set to default parameters (open gap 9, extension gap 1 penalties). Proteins with even greater similarity to the reference sequences will show increasing percentage identities when assessed by this method, such as at least 95%, at least 98%, or at least 99% sequence identity. When less than the entire sequence is being compared for sequence identity, homologs and variants will typically possess at least 80% sequence identity over short windows of 10-20 amino acids, and may possess sequence identities of at least 85% or at least 90% or at least 95% depending on their similarity to the reference sequence. Methods for determining sequence identity over such short windows are available at the NCBI website on the internet. One of skill in the art will appreciate that these sequence identity ranges are provided for guidance only; it is entirely possible that strongly significant homologs could be obtained that fall outside of the ranges provided.

Thus, in one example, a Cas13d protein has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 19, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296.

Subject: A vertebrate, such as a mammal, for example a human. Mammals include, but are not limited to, murines, simians, humans, farm animals, sport animals, and pets. In one embodiment, the subject is a non-human mammalian subject, such as a monkey or other non-human primate, mouse, rat, rabbit, pig, goat, sheep, dog, cat, horse, or cow. In some examples, the subject has a disorder (e.g., viral infection) or genetic disease that can be treated using methods provided herein. In some examples, the subject has a disorder (*e.g.*, viral infection) or genetic disease that can be diagnosed using methods provided herein. In some examples, the subject is a laboratory animal/organism, such as a zebrafish, *Xenopus*, *C. elegans*, *Drosophila*, mouse, rabbit, or rat. Tissues, cells and their progeny of a biological entity obtained *in vivo* or cultured *in vitro* are also encompassed.

Therapeutic agent: Refers to one or more molecules or compounds that confer some beneficial effect upon administration to a subject. The beneficial therapeutic effect can include enablement of diagnostic determinations; amelioration of a disease, symptom, disorder, or pathological condition; reducing or preventing the onset of a disease, symptom, disorder or condition; and generally counteracting a disease, symptom, disorder or pathological condition.

Transduced, **Transformed** and **Transfected:** A virus or vector "transduces" a cell when it transfers nucleic acid molecules into a cell. A cell is "transformed" or "transfected" by a nucleic acid transduced into the cell when the nucleic acid becomes stably replicated by the cell, either by incorporation of the nucleic acid into the cellular genome, or by episomal replication.

These terms encompasses all techniques by which a nucleic acid molecule can be introduced into such a cell, including transfection with viral vectors, transformation with plasmid vectors, and introduction of naked DNA by electroporation, lipofection, particle gun acceleration and other methods in the art. In some example the method is a chemical method (*e.g.*, calcium-phosphate transfection), physical method (*e.g.*, electroporation, microinjection, particle bombardment), fusion (*e.g.*, liposomes), receptor-mediated endocytosis (*e.g.*, DNA-protein complexes, viral envelope/capsid-DNA complexes) and biological infection by viruses such as recombinant viruses (Wolff, J. A., ed, *Gene Therapeutics*, Birkhauser, Boston, USA, 1994). Methods for the introduction of nucleic acid molecules into cells are known (*e.g.*, see U.S. Patent No. 6,110,743). These methods can be used to transduce a cell with the disclosed agents to manipulate its genome.

Transgene: An exogenous gene.

Treating, Treatment, and Therapy: Any success or indicia of success in the attenuation or amelioration of an injury, pathology or condition, including any objective or subjective parameter such as abatement, remission, diminishing of symptoms or making the condition more tolerable to the patient, slowing in the rate of degeneration or decline, making the final point of degeneration less debilitating, improving a subject's physical or mental well-being, or prolonging the length of survival. The treatment may be assessed by objective or subjective parameters; including the results of a physical examination, blood and other clinical tests, and the like. For prophylactic benefit, the disclosed compositions may be administered to a subject at risk of developing a particular disease, condition, or symptom, or to a subject

reporting one or more of the physiological symptoms of a disease, even though the disease, condition, or symptom may not have yet been manifested.

Upregulated: When used in reference to the expression of a molecule, such as a target RNA, refers to any process which results in an increase in production of the target RNA. In one example, includes direct upregulation, for example if the target RNA participates in a feedback loop with its own transcription. In one example, includes indirect upregulation, such as by knockdown of an inhibitory miRNA that leads to the activation of a target of that miRNA.

In some examples, the target RNA is a coding RNA. In some examples, the target RNA is non-coding RNA. Specific examples of RNA molecules that can be targeted for upregulation include mRNA, miRNA, rRNA, tRNA, nuclear RNA, and structural RNA. In some examples, upregulation or activation of a target RNA includes processes that increase translation of the target RNA and thus can increase the presence of corresponding proteins. The disclosed CRISPR/Cas system can be used to upregulate any target RNA of interest.

Upregulation includes any detectable increase in target RNA. In certain examples, detectable target RNA expression in a cell or cell free system (such as a cell expressing a Cas13d protein and gRNA disclosed herein) increases by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 100%, at least 200%, at least 400%, or at least 500% as compared to a control(such an amount of target RNA detected in a corresponding normal cell or sample). In one example, a control is a relative amount of expression in a normal cell (*e.g.*, a non-recombinant cell that does not include Cas13d or guide RNA).

Under conditions sufficient for: A phrase that is used to describe any environment that permits a desired activity. In one example the desired activity is expression of a Cas13d protein disclosed herein, in combination with other necessary elements, for example to modulate a target RNA.

Vector: A nucleic acid molecule into which a foreign nucleic acid molecule can be introduced without disrupting the ability of the vector to replicate and/or integrate in a host cell. Vectors include, but are not limited to, nucleic acid molecules that are single-stranded, double-stranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (*e.g.*, circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art.

A vector can include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication. A vector can also include one or more selectable marker genes and other genetic elements known in the art. An integrating vector is capable of integrating itself into a host nucleic acid. An expression vector is a vector that contains the necessary regulatory sequences to allow transcription and translation of inserted gene or genes.

One type of vector is a "plasmid," which refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques. Another type of vector is a viral vector, wherein virally-derived DNA or RNA sequences are present in the vector for packaging into a virus (*e.g.*, retroviruses, replication defective retroviruses, adenoviruses, replication

defective adenoviruses, and adeno-associated viruses). Viral vectors also include polynucleotides carried by a virus for transfection into a host cell. In some embodiments, the vector is a lentivirus (such as an integration-deficient lentiviral vector) or adeno-associated viral (AAV) vector.

Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.

Certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as "expression vectors." Common expression vectors are often in the form of plasmids. Recombinant expression vectors can comprise a nucleic acid provided herein (such as a guide RNA [which can be expressed from an RNA sequence or a RNA sequence], nucleic acid encoding a Cas13d protein) in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (*e.g.*, in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression desired, etc. A vector can be introduced into host cells to thereby produce transcripts, proteins, or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (*e.g.*, clustered regularly interspersed short palindromic repeats (CRISPR) transcripts, proteins, enzymes, mutant forms thereof, fusion proteins thereof, etc.).

II. Overview of Several Embodiments

Class 2 CRISPR-Cas systems endow microbes with diverse mechanisms for adaptive immunity. Provided herein is an analysis of prokaryotic genome and metagenome sequences to identify an uncharacterized family of RNA-guided, RNA-targeting CRISPR systems which is classified as Type VI-D. Biochemical characterization and protein engineering of seven distinct orthologs generated a ribonuclease effector derived from *Ruminococcus flavefaciens* XPD3002 (CasRx) with robust activity in human cells. CasRx-mediated knockdown exhibits high efficiency and specificity relative to RNA interference across diverse endogenous transcripts. As one of the most compact single effector Cas enzymes, CasRx can also be flexibly packaged into adeno-associated virus. Virally encoded, catalytically inactive CasRx can be targeted to cis-elements of pre-mRNA to manipulate alternative splicing, alleviating dysregulated tau isoform ratios in a neuronal model of frontotemporal dementia. The results herein present CasRx as a programmable RNA-binding module for efficient targeting of cellular RNA, enabling a general platform for transcriptome engineering and therapeutic methods.

Class 2 CRISPR systems are found throughout diverse bacterial and archaeal life. Using a minimal definition of the CRISPR locus for bioinformatic mining of prokaryotic genome and metagenome sequences, which requires only a CRISPR repeat array and a nearby protein, provided herein is the identification of an uncharacterized, remarkably compact family of RNA-targeting class 2 CRISPR systems designated as Type VI CRISPR-Cas13d.

Because CRISPR systems generally exist as a functional operon within 20 kilobases of genome sequence, even fragmented metagenome reads may be sufficient to recover useful Cas enzymes for bioengineering purposes. CRISPR genome mining strategies described herein and by others (Shmakov et al., 2015), combined with ongoing efforts to profile microbial populations via next-generation sequencing, should contribute mechanistically diverse additions to the genome engineering toolbox.

Two distinct ribonuclease properties of the Cas13d effector, which processes a CRISPR repeat array into mature guides via a HEPN domain-independent mechanism followed by guide sequence-dependent recognition of a complementary activator RNA, were biochemically characterized. This triggers HEPN-mediated RNase activity, enabling Cas13d to cleave both activator and bystander RNAs, a property shared by other RNA-targeting CRISPR systems. Cas13d additionally exhibits no apparent flanking sequence requirements and was found to be active across crRNAs tiling a target RNA, suggesting the ability to target arbitrary single-stranded RNA sequences.

A comprehensive activity reporter screen in human cells of Cas13d orthologs sampled from distinct branches of the Cas13d family revealed that NLS fusions to Cas13d from *Ruminococcus flavefaciens* strain XPD3002 (CasRx) can be engineered for programmable RNA targeting in a eukaryotic context (**FIG. 8D**). CasRx fusions knocked down a diverse set of 14 endogenous mRNAs and lncRNAs, consistently achieving >90% knockdown with favorable efficiency relative to RNA interference, dCas9-mediated CRISPR interference, and other members of the Cas13 superfamily (**FIGS. 10A-10C**). Additionally, CasRx interference is markedly more specific than spacer-matching shRNAs, with no detectable off-target changes compared with hundreds for RNA interference.

CasRx is a minimal two-component platform, including an engineered CRISPR-Cas13d effector and an associated guide RNA, and can be fully genetically encoded. Because CasRx is an orthogonally delivered protein, HEPN-inactive dCasRx can be engineered as a flexible RNA-binding module to target specific RNA elements. Importantly, because CasRx uses a distinct ribonuclease activity to process guide RNAs, dCasRx can still be paired with a repeat array for multiplexing applications. The utility of this concept is shown herein by creating a dCasRx splice effector fusion for tuning alternative splicing and resulting protein isoform ratios, applying it in a neuronal model of frontotemporal dementia.

At an average size of 930 aa, Cas13d is the smallest class 2 CRISPR effector characterized in mammalian cells. This allows CasRx effector domain fusions to be paired with a CRISPR array encoding multiple guide RNAs while remaining under the packaging size limit of the versatile adeno-associated virus (AAV) delivery vehicle (Naldini, 2015) for primary cell and *in vivo* delivery. Further, targeted AAV delivery of CasRx to specific postmitotic cell types such as neurons can mediate long-term expression of a

corrective payload that avoids permanent genetic modifications or frequent re-administration (Chiriboga et al., 2016), complementing other nucleic acid targeting technologies such as DNA nuclease editing or antisense oligonucleotides. RNA mis-splicing diseases have been estimated to account for up to 15% of genetic diseases (Hammond and Wood, 2011), highlighting the potential for engineered splice effectors capable of multiplexed targeting. The materials provided herein can be used for RNA targeting for knockdown and splicing, such as live cell labeling and genetic screens to transcript imaging, trafficking, or regulation. CRISPR-Cas13d and engineered variants such as CasRx collectively enable flexible nucleic acid engineering, transcriptome-related study, and therapeutics, expanding the genome editing toolbox beyond DNA to RNA.

Provided herein are methods of targeting (*e.g.*, modifying, detecting) one or more target RNA molecules, such as a clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated (Cas) system-mediated RNA editing method. Such methods can include contacting one or more target RNA molecules with a non-naturally occurring or engineered (*e.g.*, does not naturally occur in the cell or system into which it is introduced) CRISPR-Cas system. Thus in some examples, the disclosed CRISPR-Cas system includes a naturally occurring Cas13d protein (or coding sequence) and a naturally occurring gRNA, but is used in a system or cell in which the Cas1 protein (or coding sequence) and the gRNA are not naturally found. Furthermore, the spacer sequence within the gRNA molecule is not naturally occurring, and has been modified to be complementary to the target RNA molecule.

In some examples, a target RNA is a coding RNA. In some examples, the RNA is non-coding RNA.

The disclosed CRISPR-Cas system can include (1) at least one Cas13d protein or at least one Cas13d nucleic acid coding sequence (such as a mRNA or a vector encoding the at least one Cas13d protein) and (2) at least one CRISPR-Cas system guide nucleic acid molecule (*e.g.*, gRNA) (or at least one nucleic acid molecule encoding the gRNA) having sufficient complementary to a target RNA such that it can hybridize to a target RNA molecule. The Cas13d protein forms a complex with the gRNA, and the gRNA directs the complex to the one or more target RNA molecules. This targeting can allow the Cas13d-gRNA complex to modify or detect the one or more target RNA molecules. In some examples, the one or more target RNA molecules (or a cell containing the one or more target RNA molecules) are contacted with a complex comprising the at least one Cas13d protein and the at least one gRNA. In some examples, the system includes Mg^{2+}. However, in some examples, the system does not require Mg^{2+}, such as if cleavage of the target RNA is not desired.

In some examples, contacting the one or more target RNA molecules with the non-naturally occurring or engineered CRISPR-Cas system includes introducing into a cell (such as a eukaryotic or prokaryotic cell) containing the one or more target RNA molecules the non-naturally occurring or engineered CRISPR-Cas system, for example using endocytosis (*e.g.*, receptor-mediated endocytosis, micropinocytosis), a liposome, a particle, an exosome, a microvesicle, a gene gun, electroporation, a virus, RNP-antibody fusion (*e.g.,* by tethering a Cas13d RNP to an antibody, antibody fragment, or other targeting

moiety [such as ScFv, aptamers, DARPins, nanobodies, affibodies, etc.], the RNP can be endocytosed into the cell, The RNP could conceivably be tethered to many things other than), or combinations thereof. Thus, cells can be transformed, transduced, transfected, or otherwise contacted with appropriate nucleic acid molecules of the disclosed CRISPR-Cas system. The resulting cells are recombinant cells. In some examples, contacting the one or more target RNA molecules with the non-naturally occurring or engineered CRISPR-Cas system includes contacting a cell-free system (such as a biological or environmental sample, or a cell lysate) containing the one or more target RNA molecules the non-naturally occurring or engineered CRISPR-Cas system (for example in a diagnostic method to detect a target RNA).

In some examples, at least 2, at least 3, at least 4, at least 5, at least 10, or at least 20 different gRNAs are used. For example, such a method could include targeting at least 2, at least 3, at least 4, at least 5, at least 10, or at least 20 different target RNA molecules, targeting at least 2, at least 3, at least 4, at least 5, at least 10, or at least 20 different regions of one or more RNA molecules, or combinations thereof.

Also provided are isolated nucleic acid molecules encoding such Cas13d proteins, such as a cDNA, genomic DNA, RNA, or mDNA. Such isolated nucleic acid molecules can be part of a vector (such as a plasmid or viral vector), and can be operably linked to a promoter. In some examples, an isolated nucleic acid molecule encoding a Cas13d protein has at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 124, 125, 126, 127, 128, 139, 140 or 141; or at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 142, 143, 144, or 145. In an additional example, an isolated nucleic acid encodes a Cas13d protein having at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296.

In some examples, an isolated nucleic acid molecule encoding at least one Cas13d protein (which can be part of a vector) includes at least one Cas13d protein coding sequence that is codon optimized for expression in a eukaryotic cell, at least one Cas13d protein coding sequence codon optimized for expression in a human cell. In one example, such a Cas13d coding sequence has at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 142, 143, 144, or 145, or has at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 124, 125, 126, 127, 128, 139, 140 or 141. In an

additional example, a eukaryotic cell codon optimized nucleic acid sequence encodes a Cas13d protein having at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296.

In some examples, the gRNA that hybridizes with the one or more target RNA molecules includes one or more direct repeat (DR) sequences, one or more spacer sequences, or one or more sequences comprising DR-spacer-DR-spacer. In some examples, the one or more DR sequences have at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 129, 130, 131, 132, 133, 134, 135, 136, 137, 148, 150, 151, 152, 154, 156, 157, 159, 161, 163, 165, 167, 169, 176, 178, 180, 182, 184, 186, 188, 190, 191, 192, 193, 199, 201, 203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 228, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 252, or 254. In one example, the gRNA includes additional sequences, such as an aptamer sequence.

In some examples, a plurality of gRNAs are processed from a single array transcript, wherein each gRNA can be different, for example to target different RNAs or target multiple regions of a single RNA.

In some examples, the DRs are truncated by 1-10 nucleotides (such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides) at the 5'end, for example to be expressed as mature pre-processed guide RNAs.

Methods of targeting one or more target RNA molecules are provided. Targeting an RNA molecule can include one or more of cutting or nicking one or more target RNA molecules, activating or upregulating one or more target RNA molecules, activating or suppressing translation the one or more target RNA molecules, deactivating the one or more target RNA molecules, visualizing, labeling, or detecting the one or more target RNA molecules, binding the one or more target RNA molecules, editing the one or more target RNA molecules, trafficking the one or more target RNA molecules, and masking the one or more target RNA molecules. In some example, modifying one or more target RNA molecules includes one or more of an RNA base substitution, an RNA base deletion, an RNA base insertion, a break in the target RNA, methylating RNA, and demethylating RNA.

In some examples, such methods are used to treat a disease, such as a disease in a human. In such examples, the one or more target RNA molecules is associated with the disease.

Also provided are isolated proteins, including non-naturally occurring proteins. In some examples, a protein has at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,

14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296. In some examples, an isolated protein is a Cas13d ortholog from a prokaryotic genome or metagenome, gut metagenome, an activated sludge metagenome, an anaerobic digester metagenome, a chicken gut metagenome, a human gut metagenome, a pig gut metagenome, a bovine gut metagenome, a sheep gut metagenome, a goat gut metagenome, a capybara gut metagenome, a primate gut metagenome, a termite gut metagenome, a fecal metagenome, a genome from the Order Clostridiales, or the Family Ruminococcaceae. In some examples, a Cas13d ortholog includes a Cas13d ortholog from Ruminococcus albus, Eubacterium siraeum, a Ruminococcus flavefaciens strain XPD3002, Ruminococcus flavefaciens FD-1, uncultured Eubacterium sp TS28-c4095, uncultured Ruminococcus sp., Ruminococcus bicirculans, or Ruminococcus sp CAG57. Such proteins can include a subcellular localization signal. In some examples, such proteins include a mutation in at least one native HEPN domain.

Also provided are isolated guide RNA (gRNA) molecules. In some examples, an isolated gRNA includes one or more direct repeat (DR) sequences, such as one having at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 129, 130, 131, 132, 133, 134, 135, 136, 137, 148, 150, 151, 152, 154, 156, 157, 159, 161, 163, 165, 167, 169, 176, 178, 180, 182, 184, 186, 188, 190, 191, 192, 193, 199, 201, 203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 228, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 252, or 254. Such a gRNA can further include one or more spacer sequences specific for (*e.g.*, is complementary to) the target RNA. Such guide RNAs can further be optionally truncated by 1-10 nucleotides (such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides) at the 5'end of the DR, for example to generate pre-processed guide RNAs.

Also provided are ribonucleoprotein (RNP) complexes, which include one or more Cas13d proteins provided herein and one or more gRNAs provided herein.

Also provided are recombinant cells that include any Cas13d protein (or nucleic acid molecule encoding Cas13d), any gRNA, any RNP complex, or any vector, provided herein. In one example, the cell is not a bacterial cell. In one example, the cell is a bacterial cell.

Also provided are compositions that include one or more of any Cas13d protein (or nucleic acid molecule encoding Cas13d), any gRNA or array, any RNP complex, any isolated nucleic acid molecule, any vector, or any cell, provided herein. Such compositions can include a pharmaceutically acceptable carrier.

Also provided are kits. Such kits can include one or more of any Cas13d protein (or nucleic acid molecule encoding Cas13d), any gRNA or array, any RNP complex, any isolated nucleic acid molecule, any

vector, any cell, or any composition provided herein. Such reagents can be combined or in separate containers.

In some examples, a Cas13d protein is programmed toward its RNA target by combining the protein (or nucleic acid encoding the protein) with an engineered RNA guide (or nucleic acid encoding RNA guide) consisting of a full or partial direct repeat sequence followed by a "spacer" sequence complementary to the RNA target(s) (or variations thereof, i.e. arrays (DR-spacer-DR-spacer-DR-spacer..etc.) or pre-guide RNAs (DR-spacer-DR). Cas13d Proteins can be catalytically inactivated and transformed into RNA binding modules by mutating the conserved RNAse HEPN motif (RXXXXH). Exemplary Cas13d proteins and corresponding guides are provided herein (e.g., SEQ ID NOS: 147-170, 175-193 and SEQ ID NOS: 198-254).

A. Cas13d Proteins

Provided herein are novel Cas13d proteins, such as those as shown in in the sequence listing. SEQ ID NOS: 1, 3, 42, 62, 70, 82, 83, 92, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 292, 293, 294, 295, and 296 provide distinct full length proteins, and SEQ ID NOS: 2, 4-41, 43-61, 63-69, 71-81, 84-91, 93-113, 194, 278, 279, 280, 281, 282, 283, 284, and 285 provide Cas13d variants and fragments. Such proteins can be used in the disclosed methods, compositions, and kits.

In some examples, a Cas13d protein includes one or more (such as 1 or 2) native HEPN domains. In some examples, a Cas13d protein includes one or more mutated HEPN domains (such as mutant Cas13d protein can process the gRNA, but cannot modify the target RNA). In some examples, a Cas13d protein is no more than 150 kD, no more than 140 kD, no more than 130 kD, no more than 120 kD, such as about 90 to 120 kD, about 100 to 120 kD or about 110 kD.

In addition to the Cas13d proteins provided herein, the disclosure encompasses Cas13d orthologs from a prokaryotic genome or metagenome, gut metagenome, an activated sludge metagenome, an anaerobic digester metagenome, a chicken gut metagenome, a human gut metagenome, a pig gut metagenome, a bovine gut metagenome, a sheep gut metagenome, a goat gut metagenome, a capybara gut metagenome, a primate gut metagenome, a termite gut metagenome, a fecal metagenome, a genome from the Order Clostridiales, or the Family Ruminococcaceae, such as a Cas13d ortholog from Ruminococcus albus, Eubacterium siraeum, a Ruminococcus flavefaciens strain XPD3002, Ruminococcus flavefaciens FD-1, uncultured Eubacterium sp TS28-c4095, uncultured Ruminococcus sp., Ruminococcus bicirculans, or Ruminococcus sp CAG57.

In some examples, a Cas13d protein is at least 800 aa, at least 900 aa, or at least 1000 aa, such as 800 to 1200 aa, 850 to 1050 aa, or 860-1040 aa.

1. Variant Cas13d Sequences

Cas13d proteins, including variants of the sequences provided herein (such as variants of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296) are encompassed within this disclosure. In some examples, Cas13d proteins provided herein can contain one or more mutations, such as a single insertion, a single deletion, a single substitution, or combinations thereof. In some examples, the Cas13d protein includes at least 1, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 75, at least 100, at least 200 or at least 300 aa insertions, such as 1-20 insertions (for example at the N- or C-terminus or within the protein, such as insertion of a whole small domain), at least 1, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 75, at least 100, at least 200 or at least 300 aa deletions (such as deletion of a whole small domain), such as 1-20 deletions (for example at the N- or C-terminus or within the protein), at least 1, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30 aa substitutions, such as 1-20 substitutions, or any combination thereof (*e.g.*, single insertion together with 1-19 substitutions), but retain the ability to bind target RNA molecules complementary to the spacer sequence within the gRNA molecule and/or process an guide array RNA transcript into gRNA molecules and/or retain the ability to cleave target RNA. Exemplary Cas13 proteins with deletions in non-conserved regions are shown in SEQ ID NOS: 278, 279, 280, 281, 282, 283, 284, and 285. In some examples, the disclosure provides a variant of any disclosed Cas13d protein (such as SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296) having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acid changes, but retain the ability to bind target RNA molecules complementary to the spacer sequence within the gRNA molecule and/or process an guide array RNA transcript into gRNA molecules. In some examples, any disclosed Cas13d protein (such as SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138,

147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, or 25, or variant thereof, such as SEQ ID NO: 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296 further includes 1-8 amino acid insertions, 1-15 amino acid deletions, 1-10 amino acid substitutions, or any combination thereof (*e.g.*, 1-15, 1-4, or 1-5 amino acid deletions together with 1-10, 1-5 or 1-7 amino acid substitutions), with the retained ability to bind target RNA molecules complementary to the spacer sequence within the gRNA molecule and/or process an guide array RNA transcript into gRNA molecules. In one example, such variant peptides are produced by manipulating the nucleotide sequence encoding a peptide using standard procedures such as site-directed mutagenesis or PCR. Such variants can also be chemically synthesized.

In some examples, a Cas13d protein includes a motif shown in SEQ ID NO: 195, 196 or 197. Thus, a Cas13d protein having at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296 in some examples includes at least one motif shown in SEQ ID NO: 195, 196 or 197.

In some examples, a Cas13d protein includes a conserved sequence shown in SEQ ID NO: 288, 289, 290, or 291. Thus, a Cas13d protein having at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296 in some examples includes at least one motif shown in SEQ ID NO: 288, 289, 290, or 291.

One type of modification or mutation includes the substitution of amino acids for amino acid residues having a similar biochemical property, that is, a conservative substitution (such as 1-4, 1-8, 1-10, or 1-20 conservative substitutions). Typically, conservative substitutions have little to no impact on the activity of a resulting peptide. For example, a conservative substitution is an amino acid substitution in a Cas13d protein (such as SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,

23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296) that does not substantially affect the ability of the Cas13d protein to bind target RNA molecules complementary to the spacer sequence within the gRNA molecule and/or process an guide array RNA transcript into gRNA molecules. An alanine scan can be used to identify which amino acid residues in a Cas13d protein (such as SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296), can tolerate an amino acid substitution. In one example, the ability of a variant Cas13d protein (such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296) to modify gene expression in a CRISPR/Cas system, is not altered by more than 25%, for example not more than 20%, for example not more than 10%, when an alanine, or other conservative amino acid, is substituted for 1-4, 1-8, 1-10, or 1-20 native amino acids. Examples of amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative substitutions include: Ser for Ala; Lys for Arg; Gln or His for Asn; Glu for Asp; Ser for Cys; Asn for Gln; Asp for Glu; Pro for Gly; Asn or Gln for His; Leu or Val for Ile; Ile or Val for Leu; Arg or Gln for Lys; Leu or Ile for Met; Met, Leu or Tyr for Phe; Thr for Ser; Ser for Thr; Tyr for Trp; Trp or Phe for Tyr; and Ile or Leu for Val.

One method for identifying regions particularly amenable to insertions, substitutions or deletion is to target stretches of amino acids exhibiting low levels of conservation between orthologs. Such regions are indicated in the conservation graph of the alignment of Cas13d proteins provided in FIG. 1B. Conserved residues of Cas13d are further marked in the Cas13d protein alignment provided in Fig 18A-18MMM (indicated by symbols "." ":" or "*" below aligned conserved residues). Examples of deletions and their

functional testing are further provided in FIGS. 16A-16B. Such methods were used to generate the functional deletion variants of Cas13d are shown in SEQ ID NOS: 278, 279, 280, 281, 282, 283, 284, and 285. Such as variants can further include or changes, such as 1-30, 1 to 20, or 5 to 30, amino acid substitutions, such as conservative amino acid substitutions.

Another type of substitution can be achieved by swapping out parts of one ortholog with the homologous region of another ortholog to obtain a combined "chimeric" protein. Such a chimeric protein may combine favorable properties of multiple Cas13d orthologs.

More substantial changes can be made by using substitutions that are less conservative, *e.g.*, selecting residues that differ more significantly in their effect on maintaining: (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation; (b) the charge or hydrophobicity of the polypeptide at the target site; or (c) the bulk of the side chain. The substitutions that in general are expected to produce the greatest changes in polypeptide function are those in which: (a) a hydrophilic residue, *e.g.*, serine or threonine, is substituted for (or by) a hydrophobic residue, *e.g.*, leucine, isoleucine, phenylalanine, valine or alanine; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, *e.g.*, lysine, arginine, or histidine, is substituted for (or by) an electronegative residue, *e.g.*, glutamic acid or aspartic acid; or (d) a residue having a bulky side chain, *e.g.*, phenylalanine, is substituted for (or by) one not having a side chain, *e.g.*, glycine.

Thus, the disclosure provides Cas13d proteins having at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296 or combinations (*e.g.*, chimeras) thereof.

In one example, a Cas13d protein includes non-naturally occurring amino acids.

2. Cas13d proteins with Other Elements

A Cas13d protein (such as any of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280,

281, 282, 283, 284, 285, 292, 293, 294, 295, or 296) can include other elements or domains, for example at the N- or C-terminus (or both). The resulting protein can be referred to as a Cas13d fusion protein.

In one example, a Cas13d protein provided herein (such as a native Cas13d, a truncated Cas13d, or a Cas13d with mutated HEPN domain(s)) includes a subcellular localization signal. Exemplary subcellular localization signals include an organelle localization signal, such as a nuclear localization signal (NLS), nuclear export signal (NES), or mitochondrial localization signal. In one example, a Cas13d protein includes an NLS, such as SPKKKRKVEAS (SEQ ID NO: 256; *e.g.,* encoded by AGCCCCAAGAAgAAGAGaAAGGTGGAGGCCAGC, SEQ ID NO: 257) or GPKKKRKVAAA (SV40 large T antigen NLS, SEQ ID NO: 258; *e.g.,* encoded by ggacctaagaaaaagaggaaggtggcggccgct, SEQ ID NO: 260). Exemplary NES that can be part of a Cas13d protein include an adenovirus type 5 E1B nuclear export sequence, an HIV nuclear export sequence (*e.g.*, see SEQ ID NO: 287), a MAPK nuclear export sequence, or a PTK2 nuclear export sequence.

In some examples, the at least one Cas13d protein (such as a native Cas13d, a truncated Cas13d, or a Cas13d with mutated HEPN domain(s)) further includes one or more effector domains. Exemplary effector domains include proteins and/or enzymes, such that those can cleave RNA (*e.g.*, a PIN endonuclease domain, an NYN domain, an SMR domain from SOT1, or an RNase domain from Staphylococcal nuclease), those that can affect RNA stability (e.g., tristetraprolin (TTP) or domains from UPF1, EXOSC5, and STAU1), those that can edit a nucleotide or ribonucleotide (*e.g.*, a cytidine deaminase, PPR protein, adenosine deaminase, ADAR family protein, or APOBEC family protein), those that can activate translation (*e.g.*, eIF4E and other translation initiation factors, a domain of the yeast poly(A)-binding protein or GLD2), those that can repress translation (*e.g.*, Pumilio or FBF PUF proteins, deadenylases, CAF1, Argonaute proteins), those that can methylate RNA (*e.g.*, domains from m6A methyltransferase factors such as METTL14, METTL3, or WTAP), those that can demethylate RNA (*e.g.*, human alkylation repair homolog 5 or Alkbh5), those that can affect splicing (*e.g.*, the RS-rich domain of SRSF1, the Gly-rich domain of hnRNP A1, the alanine-rich motif of RBM4, or the proline-rich motif of DAZAP1), those that can enable affinity purification or immunoprecipitation (*e.g.*, FLAG, HA, biotin, or HALO tags), and those that can enable proximity-based protein labeling and identification (e.g., a biotin ligase (such as BirA) or a peroxidase (such as APEX2) in order to biotinylate proteins that interact with the target RNA).

In some examples, the Cas13d protein and effector module combination can constitute a transcriptional sensor. For example, the transcriptional sensor can be comprised of at least one Cas13d protein with a mutated HEPN domain (*e.g.*, SEQ ID NO: 2 or 4), at least one gRNA containing at least one spacer sequence specific for the target RNA, and an effector module such as an optionally split fluorescent protein or probe (*e.g.*, a split Venus fluorescent protein, a split GFP, a split enhanced GFP, a split mCherry, a split super-folder mCherry, and other fluorescent protein variants such as ECFP, YFP, RFP, and derivatives or fragments thereof); an optionally split luminescent protein or probe (e.g. Gaussia, Firefly, NanoLuc, or Renilla variants); an optionally split enzyme (*e.g.*, ubiquitin or TEV protease); a FRET-compatible protein pair; one or more transcription factor(s) fused to Cas13d via cleavable linkers (*e.g.*, an

artificial GAL4, zinc finger, transcriptional activator like effector (TALE), CRISPR-Cas9, CRISPR-Cpf1, or TetR-based transcription factor or an endogenous transcription factor); a split intein that trans-splices a protein to restore its function such as a transcription factor (*e.g.*, an intein from Rhodothermus marinus or DnaE); a kinase-substrate pair that activates upon phosphorylation (*e.g.,* TYK2-STAT3); one, two, or more monomers that activate upon dimerization or multimerization (*e.g.*, caspase 9); or one or more proteins that induce conformational and functional change upon interaction. In one example, the spatial proximity of two or more Cas13d proteins and gRNAs due to binding a particular transcript would activate the effector module, resulting in a detectable signal or detectable activity in the cell.

In one example, the effector domain is fused to a protein that specifically recognizes and binds an RNA aptamer, such as one that can be appended to or inserted within a gRNA molecule (*e.g.*, an MS2, PP7, Qβ, and other aptamers). This aptamer-effector domain fusion can be used to target the target RNA because the Cas13d and gRNA complex will guide the aptamer protein-effector domain in proximity to the target RNA.

In another example, the aptamer can be directly inserted into the gRNA molecule to permit detection of a target RNA, such as a fluorophore aptamer (*e.g.*, Spinach, Mango, etc.).

In some examples, the Cas13d protein (such as a native Cas13d, a truncated Cas13d, or a Cas13d with mutated HEPN domain(s)) includes a purification tag, such as an HA-tag, His-tag (such as 6-His), Myc-tag, E-tag, S-tag, calmodulin tag, FLAG-tag, GST-tag, MBP-tag, and the like. Such tags are in some examples at the N- or C-terminal end of the Cas13d protein.

In some examples, a Cas13d protein (such as a native Cas13d, a truncated Cas13d, or a Cas13d with mutated HEPN domain(s)) includes one or more subcellular localization signals, effector domains, and purification tags.

In some examples, a Cas13d protein may be split into multiple fragments, which are then expressed individually. Such fragments of Cas13d may be optionally fused to other protein domains. In one example, a Cas13d can be split into two halves, which are then fused to two parts of an inducible heterodimer pair. Upon induction of heterodimer binding, the Cas13d halves are recruited to each other to form an active protein. Such a system would allow for the inducible control of Cas13d activity. Useful heterodimer pairs include two proteins that dimerize upon light illumination or through administration of a small molecule compound, amongst others. Specific examples of heterodimer pair include but are not limited to: light inducible Magnets proteins, the light inducible iLID-SspB pair, the light inducible Cryptochrome2-CIB1 dimer and the small molecule inducible FKBP protein. In another example of a split Cas13d design, two halved of the Cas13d protein may be fused to protein trans-splicing domains. Such a design would enable the separate expression of two halves which are reconstituted into a full length protein once expressed inside a cell. An example of such transsplicing domains includes the Intein system.

One method for identifying regions particularly amenable to splitting of the protein, is to identify stretches of amino acids exhibiting low levels of conservation between orthologs. Such regions are indicated in the conservation graph of the alignment of Cas13d proteins provided in FIG. 1B. Regions of conserved

residues of Cas13d are further marked in the Cas13d protein alignment provided in Fig 18A-18MMM (indicated by symbols . : or * below aligned conserved residues).

3. Generation of Cas13d Proteins

In one example, the Cas13d protein is expressed *in vitro*, for example, in a prokaryotic cell (*e.g.*, bacteria such as *Lactobacillus*, *Lactococcus*, *Bacillus* (such as *B. subtilis*), *Escherichia* (such as *E. coli*), *Salmonella typhimurium,* and *Clostridium*), archea cell, plant or plant cell, fungal cell (*e.g.*, *Neurospora*), yeast cell (*e.g.*, *Saccharomyces or Pichia* (such as *S. cerevisiae* or *P. pastoris*), *Kluyveromyces lactis*), insect cell (*e.g.*, SF9 cells), or mammalian cells (*e.g.*, 293 cells, or immortalized mammalian myeloid and lymphoid cell lines). Once expressed, the Cas13d protein can be isolated and/or purified (e.g., using chromatography or immunological separation). In some examples, as tag on the Cas13d protein permits isolation of the protein from a culture media. Exemplary procedures include ammonium sulfate precipitation, affinity columns, column chromatography, and the like (see, generally, R. Scopes, *Protein Purification*, Springer-Verlag, N.Y., 1982). Substantially pure compositions of at least about 90 to 95% homogeneity, such as 98% to 99% homogeneity, can be used in the methods provided herein. For example, a purified preparation of a Cas13d protein can be used as an alternative to expressing the Cas13d protein from a nucleic acid molecule in the CRISPR/Cas system.

In addition to recombinant methods, Cas13d proteins disclosed herein can also be constructed in whole or in part using native chemical ligation and/or expressed protein ligation.

B. Nucleic Acid Molecules Encoding Cas13d Proteins

Nucleic acid molecules encoding a Cas13d protein are encompassed by this disclosure. Nucleic acid molecules include DNA, genomic DNA, cDNA, mRNA, and RNA sequences which encode a Cas13d peptide. Such nucleic acid molecules can include naturally occurring or non-naturally occurring nucleotides or ribonucleotides. Exemplary nucleic acid molecules that encode the novel Cas13d proteins of SEQ ID NO: 1, 3, 42, 62, 70, 82, 83, 92 and 104, are shown in SEQ ID NOS: 124-128, 139, 140, and 141. Also provided are codon optimized nucleic acid molecules that encode the novel Cas13d proteins, for example those optimized for expression in a mammalian cells, such as a human cell (SEQ ID NOS: 114-123 and 142-145). For example, SEQ ID NOS: 114, 118, and 122 provide nucleic acid molecules optimized for expression in human cells. SEQ ID NOS: 115, 119 and 123 provide nucleic acid molecules optimized for expression in human cells, and which encode for mutant HEPN sites. SEQ ID NOS: 116 and 120 provide nucleic acid molecules optimized for expression in human cells, and which includes an N-terminal nuclear localization (NLS) coding sequence (namely, SPKKKRKVEAS). SEQ ID NO: 117 and 121 provide nucleic acid molecules optimized for expression in human cells, and which include N-terminal and C-terminal NLS coding sequences (namely, SPKKKRKVEAS, SEQ ID NO: 256, and GPKKKRKVAAA SEQ ID NO: 258, respectively).

In one example, a nucleic acid sequence encodes a Cas13d protein having at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 99% or at least 99% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296. Such nucleic acid sequences can be generated based on the amino acid sequences provided herein, and the genetic code. In one example, a Cas13d nucleic acid sequence has at least 70%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 124, 125, 126, 127, 128, 139, 140 or 141. In one example, a Cas13d nucleic acid sequence is optimized for expression in mammalian cells, such as human cells, such as one having at least 70%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 142, 143, 144, or 145.

One of skill can readily construct a variety of clones containing functionally equivalent nucleic acids, such as nucleic acids which differ in sequence but which encode the same Cas13d protein sequence. Silent mutations in the coding sequence result from the degeneracy (*i.e.*, redundancy) of the genetic code, whereby more than one codon can encode the same amino acid residue. Thus, for example, leucine can be encoded by CTT, CTC, CTA, CTG, TTA, or TTG; serine can be encoded by TCT, TCC, TCA, TCG, AGT, or AGC; asparagine can be encoded by AAT or AAC; aspartic acid can be encoded by GAT or GAC; cysteine can be encoded by TGT or TGC; alanine can be encoded by GCT, GCC, GCA, or GCG; glutamine can be encoded by CAA or CAG; tyrosine can be encoded by TAT or TAC; and isoleucine can be encoded by ATT, ATC, or ATA. Tables showing the standard genetic code can be found in various sources (see, for example, Stryer, 1988, Biochemistry, 3rd Edition, W.H. 5 Freeman and Co., NY).

Based on the genetic code, nucleic acid sequences coding for any Cas13d sequence can be generated. In some examples, such a sequence is optimized for expression in a host or target cell, such as a host cell used to express the Cas13d protein or a cell in which the disclosed methods are practice (such as in a mammalian cell, such as a human cell). Codon preferences and codon usage tables for a particular species can be used to engineer isolated nucleic acid molecules encoding a Cas13d (such as one encoding a protein having at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101,

102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, or 253 that takes advantage of the codon usage preferences of that particular species). For example, the Cas13d proteins disclosed herein can be designed to have codons that are preferentially used by a particular organism of interest. In one example, a Cas13d nucleic acid sequence is optimized for expression in human cells, such as one having at least 70%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 142, 143, 144, or 145.

A nucleic acid encoding a Cas13d protein (such as one encoding a protein having at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296) can be cloned or amplified by *in vitro* methods, such as the polymerase chain reaction (PCR), the ligase chain reaction (LCR), the transcription-based amplification system (TAS), the self-sustained sequence replication system (3SR) and the Qβ replicase amplification system (QB). In addition, nucleic acids encoding a Cas13d protein (such as one encoding a protein having at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296) can be prepared by cloning techniques. Examples of appropriate cloning and sequencing techniques, and instructions sufficient to direct persons of skill through cloning are found in Sambrook *et al.* (ed.), Molecular Cloning: A Laboratory Manual 2nd ed., vol. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring, Harbor, N.Y., 1989, and Ausubel et al., (1987) in "Current Protocols in Molecular Biology," John Wiley and Sons, New York, N.Y..

Nucleic acid sequences encoding a Cas13d protein (such as one encoding a protein having at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least

99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296) can be prepared by any suitable method including, for example, cloning of appropriate sequences or by direct chemical synthesis by methods such as the phosphotriester method of Narang *et al., Meth. Enzymol.* 68:90-99, 1979; the phosphodiester method of Brown *et al., Meth. Enzymol.* 68:109-151, 1979; the diethylphosphoramidite method of Beaucage *et al., Tetra. Lett.* 22:1859-1862, 1981; the solid phase phosphoramidite triester method described by Beaucage & Caruthers, *Tetra. Letts.* 22(20):1859-1862, 1981, for example, using an automated synthesizer as described in, for example, Needham-VanDevanter *et al., Nucl. Acids Res.* 12:6159-6168, 1984; and, the solid support method of U.S. Patent No. 4,458,066. Chemical synthesis produces a single stranded oligonucleotide. This can be converted into double stranded DNA by hybridization with a complementary sequence, or by polymerization with a DNA polymerase using the single strand as a template. One of skill would recognize that while chemical synthesis of DNA is generally limited to sequences of about 100 bases, longer sequences may be obtained by the ligation of shorter sequences.

In one example, a Cas13d protein (such as a protein having at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296) is prepared by inserting the cDNA which encodes the Cas13d protein into a plasmid or vector. The insertion can be made so that the Cas13d protein is read in frame so that the Cas13d protein is produced.

The Cas13d nucleic acid coding sequence (such as one having at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181,

183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296) can be inserted into an expression vector including, but not limited to a plasmid, virus or other vehicle that can be manipulated to allow insertion or incorporation of sequences and can be expressed in either prokaryotes or eukaryotes. Hosts can include microbial, yeast, insect, plant and mammalian organisms. The vector can encode a selectable marker, such as a thymidine kinase gene or antibiotic resistance gene.

Nucleic acid sequences encoding a Cas13d protein (such as one encoding a protein having at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296) can be operatively linked to expression control sequences. An expression control sequence operatively linked to a Cas13d coding sequence is ligated such that expression of the Cas13d protein coding sequence is achieved under conditions compatible with the expression control sequences. The expression control sequences include, but are not limited to appropriate promoters, enhancers, transcription terminators, a start codon (*i.e.*, ATG) in front of a Cas13d protein-encoding gene, splicing signal for introns, maintenance of the correct reading frame of that gene to permit proper translation of mRNA, and stop codons.

In one embodiment, vectors are used for expression in yeast such as *S. cerevisiae*, *P. pastoris*, or *Kluyveromyces lactis*. Exemplary promoters for use in yeast expression systems include but are not limited to: the constitutive promoters plasma membrane H^+-ATPase (*PMA1*), glyceraldehyde-3-phosphate dehydrogenase (*GPD*), phosphoglycerate kinase-1 (*PGK1*), alcohol dehydrogenase-1 (*ADH1*), and pleiotropic drug-resistant pump (*PDR5*). In addition, many inducible promoters are of use, such as *GAL1–10* (induced by galactose), *PHO5* (induced by low extracellular inorganic phosphate), and tandem heat shock *HSE* elements (induced by temperature elevation to 37°C). Promoters that direct variable expression in response to a titratable inducer include the methionine-responsive *MET3* and *MET25* promoters and copper-dependent *CUP1* promoters. Any of these promoters may be cloned into multicopy (2μ) or single copy (*CEN*) plasmids to give an additional level of control in expression level. The plasmids can include nutritional markers (such as *URA3*, *ADE3*, *HIS1*, and others) for selection in yeast and antibiotic resistance (*AMP*) for propagation in bacteria. Plasmids for expression on *K. lactis* are known, such as pKLAC1.

Viral vectors can also be prepared that encode a Cas13d (such as one encoding a protein having at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at

least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296). Exemplary viral vectors include polyoma, SV40, adenovirus, vaccinia virus, adeno-associated virus, herpes viruses including HSV and EBV, lentivirus, Sindbis viruses, alphaviruses and retroviruses of avian, murine, and human origin. Baculovirus (Autographa californica multinuclear polyhedrosis virus; AcMNPV) vectors can be used and obtained from commercial sources. Other suitable vectors include retrovirus vectors, orthopox vectors, avipox vectors, fowlpox vectors, capripox vectors, suipox vectors, adenoviral vectors, herpes virus vectors, alpha virus vectors, baculovirus vectors, Sindbis virus vectors, vaccinia virus vectors and poliovirus vectors. Specific exemplary vectors are poxvirus vectors such as vaccinia virus, fowlpox virus and a highly attenuated vaccinia virus (MVA), adenovirus, baculovirus and the like. Pox viruses of use include orthopox, suipox, avipox, and capripox virus. Orthopox include vaccinia, ectromelia, and raccoon pox. One example of an orthopox of use is vaccinia. Avipox includes fowlpox, canary pox and pigeon pox. Capripox include goatpox and sheeppox. In one example, the suipox is swinepox. Other viral vectors that can be used include other DNA viruses such as herpes simplex virus and adenoviruses, and RNA viruses such as retroviruses and polio.

Viral vectors that encode a Cas13d protein (such as one encoding a protein having at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296) can include at least one expression control element operationally linked to the nucleic acid sequence encoding the Cas13d protein. The expression control elements control and regulate the expression of the Cas13d nucleic acid sequence. Exemplary expression control elements that can be used include, but are not limited to, lac system, operator and promoter regions of phage lambda, yeast promoters and promoters derived from polyoma, adenovirus, retrovirus or SV40. In one example the promoter is CMV, U6, CBh, CMW, Cbh, EF1a. In one example, the promoter is a cell type specific promoter, such as synapsin or GFAP, or an inducible promoter, such as a tetracycline inducible promoter. Additional operational elements include, but are not limited to, leader sequence, termination codons,

polyadenylation signals and any other sequences necessary for the appropriate transcription and subsequent translation of the nucleic acid sequence encoding the Cas13d protein in the host system. The expression vector can contain additional elements necessary for the transfer and subsequent replication of the expression vector containing the nucleic acid sequence in the host system. Examples of such elements include, but are not limited to, origins of replication and selectable markers.

In one example, the vector includes a polyA signal after the Cas13d protein coding sequence, a WPRE signal for expression in viral vectors, or combinations thereof.

In one example, the method uses direct delivery of an mRNA that encodes for a Cas13d protein.

C. Guide Nucleic Acid Molecules

The disclosure provides guide nucleic acid molecules, such as guide RNA (gRNA or crRNA, CRISPR (guide) RNA), which can be used in the methods, compositions, and kits provided herein. Such molecules can include naturally occurring or non-naturally occurring nucleotides or ribonucleotides (such as LNAs or other chemically modified nucleotides or ribonucleotides, for example to protect a guide RNA from degradation). In some examples, the guide sequence is RNA. The guide nucleic acid can include modified bases or chemical modifications (*e.g.*, see Latorre *et al.*, *Angewandte Chemie* 55:3548-50, 2016). A guide sequence directs a Cas13d protein to a target RNA, thereby targeting the RNA (*e.g.*, modifying or detecting the RNA).

Guide molecules include one or more regions referred to as spacers. A spacer has sufficient complementarity with a target RNA sequence to hybridize with the target RNA and direct sequence-specific binding of a Cas13d protein to the target RNA. Thus, the spacer is the variable portion of the guide sequence. In some examples, a spacer has 100% complementarity to a target RNA (or region of the RNA to be target), but a spacer can have less than 100% complementarity to a target RNA, such as at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% complementarity to a target RNA.

A guide sequence can also include one or more direct repeats (DRs). The DR is the constant portion of the guide, which contains strong secondary structure (**FIG. 3C**), which facilitate interaction between a Cas13d protein and the guide molecule. Each ortholog has a slightly different DR sequence (*e.g.*, SEQ ID NOS: 129, 130, 131, 132, 133, 134, 135, 136, 137, 148, 150, 151, 152, 154, 156, 157, 159, 161, 163, 165, 167, and 169). In one example, the gRNA includes at least one DR sequence having at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 129, 130, 131, 132, 133, 134, 135, 136, 137, 148, 150, 151, 152, 154, 156, 157, 159, 161, 163, 165, 167, 169, 176, 178, 180, 182, 184, 186, 188, 190, 191, 192, 193, 199, 201, 203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 228, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 252, or 254 (such as 1, 2, 3, or 4 of such DR sequences).

In one example, a guide sequence includes a constant DR on its 5'-end and a variable spacer on its 3' end. In one example includes the sequence DR-spacer-DR-spacer. In some examples, the sequence DR-

spacer is repeated two or more times, such as at least 3 times or at least 4 times. This type of sequence is called a guide array.

Guide molecules generally exist in various states of processing. In one example, an unprocessed guide RNA is 36nt of DR followed by 30-32 nt of spacer. The guide RNA is processed (truncated/modified) by Cas13d itself or other RNases into the shorter "mature" form. In some embodiments, an unprocessed guide sequence is about, or at least about 30, 35, 40, 45, 50, 55, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, or more nucleotides (nt) in length. In some embodiments, a processed guide sequence is about 44 to 60 nt (such as 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 nt). In some embodiments, an unprocessed spacer is about 28-32 nt long (such as 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 nt) while the mature (processed) spacer can be about 10 to 30 nt, 10 to 25 nt, 14 to 25 nt, 20 to 22 nt, or 14-30 nt (such as 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 nt). In some embodiments, an unprocessed DR is about 36 nt (such as 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or 41 nt), while the processed DR is about 30 nt (such as 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 nt).

The ability of a guide sequence to direct sequence-specific binding of a CRISPR complex to a target RNA may be assessed by any suitable assay. For example, the components of a CRISPR system sufficient to form a CRISPR complex, including the guide sequence to be tested, may be provided to a host cell having the corresponding target RNA molecule, such as by transfection with vectors encoding the components of the CRISPR sequence, followed by an assessment of preferential cleavage within the target sequence. Similarly, cleavage of a target RNA sequence may be evaluated in a test tube by providing the target RNA, components of a CRISPR complex, including the guide sequence to be tested and a control guide sequence different from the test guide sequence, and comparing binding or rate of cleavage at the target RNA between the test and control guide sequence reactions. Other assays are possible, and will occur to those skilled in the art.

Also provided are vectors, such as a viral vector or plasmid (*e.g.*, retrovirus, lentivirus, adenovirus, adeno-associated virus, or herpes simplex virus), that includes a guide nucleic acid molecule. Exemplary vectors are described herein. In some examples, the guide nucleic acid molecule is operably linked to a promoter or expression control element (examples of which are provided elsewhere in this application). As described elsewhere herein, such vectors can include other elements, such as a gene encoding a selectable marker, such as an antibiotic, such as puromycin, hygromycin, or a detectable marker such as GFP or other fluorophore.

In one example, a plurality of gRNAs are part of an array (which can be part of a vector, such as a viral vector or plasmid). For example, a guide array including the sequence DR-spacer-DR-spacer-DR-spacer, can include three unique unprocessed gRNAs (one for each DR-spacer sequence). Once introduced into a cell or cell-free system, the array is processed by the Cas13d protein into the three individual mature gRNAs. This allows for multiplexing, e.g. the delivery of multiple gRNAs to a cell or system to target multiple target RNAs or multiple positions within a single target RNA (or combinations thereof).

D. Vectors that encode Cas13d and Guide Nucleic Acid Molecules

The disclosure provides vectors, such as plasmids and viral vectors as described elsewhere herein, which include one or more guide molecule coding sequences (*e.g.*, to permit targeting of one or more RNA molecules), and one or more Cas13d protein coding sequences. Such vectors can be used in the methods, compositions, and kits provided herein. Such vectors can include naturally occurring or non-naturally occurring nucleotides or ribonucleotides. Such vectors can include a single promoter operably linked to the guide molecule (which can be part of an array that includes at least two different guide molecules) and the Cas13d protein coding sequence. Alternatively, the guide molecule (which can be part of an array that includes at least two different guide molecules) and the Cas13d protein coding sequence can be operably linked to different promoters. In some examples, , the guide molecule (which can be part of an array that includes at least two different guide molecules) and the Cas13d protein coding sequence are operably linked to a promoter, an enhancer, or both.

E. Recombinant Cells and Cell-Free Systems

Cells that include a non-native Cas13d protein, a non-native Cas13d protein coding sequence, a guide molecule (or coding sequence), or combinations thereof, are provided. Such recombinant cells can be used in the methods, compositions, and kits provided herein. Nucleic acid molecules encoding a Cas13d protein disclosed herein and/or nucleic acid molecules encoding a guide molecule can be introduced into cells to generate transformed (*e.g.*, recombinant) cells. In some examples, such cells are generated by introducing one or more non-native Cas13d proteins and one or more guide molecules (*e.g.*, gRNAs) into the cell, for example as a ribonucleoprotein (RNP) complex.

Similarly, cell free systems, such as those generated from lysed cells (or those that include a Cas13d RNP in a test tube or other vessel, into which *in vitro* transcribed or chemically synthesized target RNAs are added), which include a, Cas13d protein, a Cas13d protein coding sequence, a guide molecule (or coding sequence), or combinations thereof, are provided. Such cell free systems can be used in the methods, compositions, and kits provided herein. In some examples, one or more non-native Cas13d proteins and one or more guide molecules (*e.g.*, gRNAs) are added to a cell free system, for example as a RNP complex.

Thus, cells and cell-free systems containing a Cas13d protein (such as a protein having at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283,

284, 285, 292, 293, 294, 295, or 296) are disclosed. Similarly, cells and cell-free systems containing a guide molecule, such as one having at least one DR sequence having at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 129, 130, 131, 132, 133, 134, 135, 136, or 137, and in some examples also at least one spacer sequence complementary to a target RNA, are provided.

Such recombinant cells (e.g., which can be used to generate a cell-free system) can be eukaryotic or prokaryotic. Examples of such cells include, but are not limited to bacteria, archaea, plant, fungal, yeast, insect, and mammalian cells, such as *Lactobacillus*, *Lactococcus*, *Bacillus* (such as *B. subtilis*), *Escherichia* (such as *E. coli*), *Clostridium*, *Saccharomyces or Pichia* (such as *S. cerevisiae* or *P. pastoris*), *Kluyveromyces lactis*, *Salmonella typhimurium, Drosophila* cells, *C. elegans* cells, *Xenopus* cells, SF9 cells, C129 cells, 293 cells, *Neurospora*, and immortalized mammalian cell lines (*e.g.*, Hela cells, myeloid cell lines, and lymphoid cell lines).

In one example, the cell is a prokaryotic cell, such as a bacterial cell, such as *E. coli*.

In one example, the cell is a eukaryotic cell, such as a mammalian cell, such as a human cell. In one example, the cell is primary eukaryotic cell, a stem cell, a tumor/cancer cell, a circulating tumor cell (CTC), a blood cell (*e.g.*, T cell, B cell, NK cell, Tregs, etc.), hematopoietic stem cell, specialized immune cell (*e.g.*, tumor-infiltrating lymphocyte or tumor-suppressed lymphocytes), a stromal cell in the tumor microenvironment (*e.g.*, cancer-associated fibroblasts, etc.) In one example, the cell is a brain cell (*e.g.*, neurons, astrocytes, microglia, retinal ganglion cells, rods/cones, etc.) of the central or peripheral nervous system).

In one example, a cell is part of (or obtained from) a biological sample, such as a biological specimen containing genomic DNA, RNA (*e.g.*, mRNA), protein, or combinations thereof, obtained from a subject. Examples include, but are not limited to, peripheral blood, serum, plasma, urine, saliva, sputum, tissue biopsy, fine needle aspirate, surgical specimen, and autopsy material. Such cells can also be used to generate a cell free system.

In one example the cell (or cell free system) is from a tumor, such as a hematological tumor (*e.g.*, leukemias, including acute leukemias (such as acute lymphocytic leukemia, acute myelocytic leukemia, acute myelogenous leukemia and myeloblastic, promyelocytic, myelomonocytic, monocytic and erythroleukemia), chronic leukemias (such as chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, and chronic lymphocytic leukemia), polycythemia vera, lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma (including low-, intermediate-, and high-grade), multiple myeloma, Waldenström's macroglobulinemia, heavy chain disease, myelodysplastic syndrome, mantle cell lymphoma and myelodysplasia) or solid tumor (*e.g.*, sarcomas and carcinomas: fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, and other sarcomas, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, lymphoid malignancy, pancreatic cancer, breast cancer, lung cancers, ovarian cancer, prostate cancer, hepatocellular carcinoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma,

papillary carcinoma, papillary adenocarcinomas, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, Wilms' tumor, cervical cancer, testicular tumor, bladder carcinoma, and CNS tumors (such as a glioma, astrocytoma, medulloblastoma, craniopharyogioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma and retinoblastoma).

In one example the cell (or cell free system) is obtained from an environmental sample, such as a water, soil, or air sample.

F. Compositions & Kits

Compositions and kits that include a Cas13d protein, a Cas13d protein coding sequence, a guide molecule (or coding sequence), or combinations thereof, are provided. In one example, the composition or kit includes an RNP complex composed of one or more Cas13d proteins and one or more guide molecules (*e.g.*, gRNAs). In one example, the composition or kit includes a vector encoding a Cas13d protein, a guide molecule, or both. In one example, the composition or kit includes a cell, such as a bacterial cell or eukaryotic cell, that includes a non-native Cas13d protein, a non-native Cas13d protein coding sequence, a guide molecule (or coding sequence), or combinations thereof. In one example, the composition or kit includes a cell-free system that includes a non-native Cas13d protein, a non-native Cas13d protein coding sequence, a guide molecule (or coding sequence), or combinations thereof.

Such compositions can include a pharmaceutically acceptable carrier (*e.g.*, saline, water, glycerol, DMSO, or PBS). In some examples, the composition is a liquid, lyophilized powder, or cryopreserved.

In some examples, the kit includes a delivery system (*e.g.*, liposome, a particle, an exosome, a microvesicle, a viral vector, or a plasmid), and/or a label (*e.g.*, a peptide or antibody that can be conjugated either directly to a Cas13d RNP or to a particle containing the Cas13d RNP to direct cell type specific uptake/enhance endosomal escape/enable blood-brain barrier crossing etc.). In some examples, the kits further include cell culture or growth media, such as media appropriate for growing bacterial, plant, insect, or mammalian cells.

In some examples, such parts of a kit are in separate containers.

G. Targeting RNA

The disclosed Cas13d proteins (and coding sequences), and guide molecules (e.g., gRNA and coding sequences) can be used in a CRISPR/Cas system to target one or more RNA molecules, such as those present in a sample (such as a biological sample, environmental sample (*e.g.*, soil, air or water sample), and the like. In one example, the target RNA is a coding RNA. In one example, the target RNA is a nuclear RNA. In other examples, the target RNA is non-coding RNA (such as functional RNA, siRNA, microRNA, snRNA, snoRNA, piRNA, scaRNA, tRNA, rRNA, lncRNA, or lincRNA). Such RNA targeting methods can be performed *in vitro* (such as in cell culture or in a cell-free system), or *in vivo* (such as in an organism, embryo, or mammal).

The CRISPR/Cas system provided herein includes two general components: (1) a Cas13d protein or its coding sequence (whose expression can be driven by a promoter) and (2) a guide nucleic acid molecule, such as RNA (gRNA), which is specific for the target RNA (whose expression can also be driven by promoter. When introduced into cells (or to a cell free system) for example (1) as Cas13d mRNA and Cas13d gRNA, (2) as part of a single vector or plasmid or divided into multiple vectors or plasmids, (3) as separate Cas13d protein and guide molecules, or (4) as an RNP complex of the Cas13d protein and guide molecule, the guide molecule guides the Cas13d to the target RNA. If the Cas13d protein has a native HEPN domain(s) or is fused to an appropriate effector domain bearing RNase activity, the RNA can be cut. If the Cas13d protein has a mutated HEPN domain(s), a guide array can be processed into mature gRNAs, but the target RNA is not cut. Using this system, RNA sequences are easily targeted, for example edited or detected, optionally with an effector domain.

1. Introduction of Cas13d Protein Directly into a Cell

In one example, the Cas13d protein is expressed in a recombinant cell, such as *E. coli*, and purified. The resulting purified Cas13d protein, along with an appropriate guide molecule specific for the target RNA, is then introduced into a cell or organism where one or more RNAs can be targeted. In some examples, the Cas13d protein and guide nucleic acid molecule are introduced as separate components into the target cell/organism. In other examples, the purified Cas13d protein is complexed with the guide nucleic acid (*e.g.*, gRNA), and this ribonucleoprotein (RNP) complex is introduced into target cells (*e.g.*, using transfection or injection). In some examples, the Cas13d protein and guide molecule are injected into an embryo (such as a human, mouse, zebrafish, or *Xenopus* embryo).

Once the Cas13d protein and guide nucleic acid molecule are in the cell, one or more RNAs can be targeted.

2. Expression of Cas13d from Nucleic Acids

In one example, the Cas13d protein is expressed from a nucleic acid molecule in a cell containing a target RNA, for example an RNA to be detected or modified. In some such examples, the Cas13d protein is expressed from a vector, such as a viral vector or plasmid introduced into a cell or into a cell-free system. This results in the production of the Cas13d protein in the cell, organism, or system. In addition, these nucleic acid molecules can be co-expressed in the cell/organism/system with the guide nucleic acid molecule (*e.g.*, gRNA) specific for the target RNA.

In one example, multiple plasmids or vectors are used for RNA targeting. The nucleic acid molecule encoding the Cas13d can be provided for example on one vector or plasmid, and the guide nucleic acid molecule (*e.g.*, gRNA) on another plasmid or vector. Multiple plasmids or viral vectors can be mixed and introduced into cells (or a cell free system) at the same time, or separately.

In some examples, multiple nucleic acid molecules are expressed from a single vector or plasmid. For example, a single vector can include the nucleic acid molecule encoding the Cas13d, and a separate vector can include the guide molecule.

In some examples a plurality of different guide molecules (*e.g.*, gRNAs), one for each target (such as 1, 2, 3, 4, 5, or 10 different targets), are present on a single array and/or vector. In one example, the method includes delivering a plurality of gRNAs (such as at least 2, at least 3, at least 4, at least 5, at least 10, at least 20, or at least 50 different gRNAs), which are part of an array (which can be part of a vector, such as a viral vector or plasmid). Once introduced into a cell or cell-free system, the array is processed by the Cas13d protein into the individual mature gRNAs.

The nucleic acid molecules expressed from the vector can be under the control of a promoter and optionally contain selection markers (such as antibiotic resistance).

In some examples, the protein and guide molecules are expressed by an embryo (such as a zebrafish or *Xenopus* embryo). The Cas13d protein can be expressed from injected plasmid DNA, injected mRNA, or stably integrated copies into the animal genome. The gRNA can be directly injected or expressed from a vector or stably integrated copies into the animal genome.

3. Targets

One or more RNAs can be targeted by the disclosed methods, such as at least 1, at least 2, at least 3, at least 4 or at least 5 different RNAs in a cell, cell-free system, or organism, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 different RNAs. In one example, the RNA is associated with a disease such as cystic fibrosis, Huntington's disease, Tay-Sachs, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome, Duchenne muscular dystrophy, myotonic dystrophy, spinal muscular atrophy, spinocerebellar ataxia, or familial ALS. In one example, the RNA is associated with cancer (*e.g.*, a cancer of the lung, breast, colon, liver, pancreas, prostate, bone, brain, skin (*e.g.*, melanoma), or kidney). Examples of target RNAs include, but are not limited to those associated with cancer (*e.g.*, BCR-ABL, Ras, Raf, p53, BRCA1, BRCA2, CXCR4, beta-catenin, HER2, and CDK4).

In one example, the RNA is associated with viral infection, such as infection by a positive-strand RNA viruses, such as Picornaviruses (such as Aphthoviridae [for example foot-and-mouth-disease virus (FMDV)]), Cardioviridae; Enteroviridae (such as Coxsackie viruses, Echoviruses, Enteroviruses, and Polioviruses); Rhinoviridae (Rhinoviruses)); Hepataviridae (Hepatitis A viruses); Togaviruses (examples of which include rubella; alphaviruses (such as Western equine encephalitis virus, Eastern equine encephalitis virus, and Venezuelan equine encephalitis virus)); Flaviviruses (examples of which include Dengue virus, West Nile virus, and Japanese encephalitis virus); Calciviridae (which includes Norovirus and Sapovirus); or Coronaviruses (examples of which include SARS coronaviruses, such as the Urbani strain), or a negative-strand RNA virus, such as Orthomyxyoviruses (such as the influenza virus), Rhabdoviruses (such as Rabies virus), and Paramyxoviruses (examples of which include measles virus, respiratory syncytial virus, or parainfluenza viruses), or a DNA viral infection (such as infection by Herpesviruses (such as Varicella-

zoster virus, for example the Oka strain; cytomegalovirus; and Herpes simplex virus (HSV) types 1 and 2), Adenoviruses (such as Adenovirus type 1 and Adenovirus type 41), Poxviruses (such as Vaccinia virus), or Parvoviruses (such as Parvovirus B19).

In one example, the RNA is associated with a bacterial infection or property of a bacterial infection, such as bacterial resistance, persistence, or antibiotic resistance. Detection of these RNAs can be used for diagnostic methods, while editing these RNAs in cell-based or cell-free systems can be used for therapeutic methods.

4. Methods of Detecting RNA

In one example, the method of targeting an RNA results in detecting, visualizing, or labeling a target RNA. For example, by using at least one Cas13d protein with a mutated HEPN domain (*e.g.*, SEQ ID NO: 2 or 4), at least one gRNA containing at least one spacer sequence specific for the target RNA, and an effector module, the target RNA will be recognized by Cas13d but will not be cut or nicked while the effector module becomes activated. In some examples, such a method is used to detect a target RNA. Such a method can be used in a cell or cell free system to determine if a target RNA is present, such as in a tumor cell. In some examples, the cell or cell free system is obtained from a tissue sample, blood sample or saliva sample.

In one example, the method of detecting RNA comprises of a Cas13d protein fused to a fluorescent protein or other detectable label along with a gRNA containing a spacer sequence specific for the target RNA. Binding of Cas13d to the target RNA can be visualized by microscopy or other methods of imaging. In another example, RNA aptamer sequences can be appended to or inserted within the gRNA molecule, such as MS2, PP7, Qβ, and other aptamers. The introduction of proteins that specifically bind to these aptamers, e.g. the MS2 phage coat protein, fused to a fluorescent protein or other detectable label can be used to detect the target RNA because the Cas13d-gRNA-target RNA complex will be labeled via the aptamer interaction.

In another example, the method of detecting RNA is a transcriptional sensor (*e.g.*, as part of a synthetic circuit) for diagnostics or therapeutics. For example, the transcriptional sensor can be comprised of at least one Cas13d protein with a mutated HEPN domain (*e.g.*, SEQ ID NO: 2 or 4), at least one gRNA containing at least one spacer sequence specific for the target RNA, and an effector module such as an optionally split fluorescent protein or probe; an optionally split luminescent protein or probe; an optionally split enzyme that catalyzes a detectable reaction such as ubiquitin or TEV protease; a FRET-compatible protein pair; one or more transcription factor(s) fused to Cas13d via cleavable linkers; a split intein that trans-splices a protein to restore its function such as a transcription factor; a kinase-substrate pair that activates upon phosphorylation; one, two, or more monomers that activate upon dimerization or multimerization; or one or more proteins that induce conformational and functional change upon interaction. In one example, the spatial proximity of two or more Cas13d proteins and gRNAs due to binding a particular transcript would activate the effector module, resulting in a detectable signal or detectable activity in the cell.

For example, the transcriptional sensor could allow a cancer-specific transcript, inflammation-specific transcript, disease-specific transcript, or cell state-specific transcript to be detected. A synthetic circuit containing a Cas13d-based system that is able to sense particular transcripts could encode conditional logic, e.g. requiring target detection to up- or down-regulate a gene for therapeutic application.

In one example, the method results in a detectable agent being bound to the target RNA, which can be detected. For example, two separate Cas13d fusion proteins that each include part of a fluorophore (*e.g.*, GFP), and two different gRNAs with different spacer sequences that target regions of an RNA in close proximity, can be used. When the two parts bind to the target RNA in proximity, the two parts of the fluorophore form a complete fluorophore, thereby generating a detectable signal.

In one example, the method results in RNA detection, for example by triggering a response such as expression of a second gene, modification of a protein, translocation of a protein or RNA to a different location, induction of cell death via suicide gene, induction of cell proliferation, induction of a transgene that enables a secondary function, induction of a permanent change in DNA sequence to enable storing a memory of past transcriptional events, or altering the RNA to enable pulldown.

In one embodiment, two halves of a transcription factor could be linked to two separate Cas13d via a split intein system. The Cas13d proteins are provided with two different gRNAs with different spacer sequences that target regions of an RNA in close proximity. Upon binding to the target RNA in proximity, the split inteins trans-splice a reconstituted transcription factor (TF) so that it can translocate to the nucleus and turn on a target gene or cluster of target genes. In one example, the target gene could be an endogenous gene in the cell. In another example, the target gene could be a transgene expressed on a vector or introduced through genetic engineering, such as a fluorescent protein or toxin.

5. Methods of Detecting RNA in Cell-Free Systems

In one example, the method of detecting a target RNA in a cell-free system results in a detectable label or enzyme activity. For example, by using at least one Cas13d protein (*e.g.*, SEQ ID NO: 3, 42, 62, 70, 82, 83, and 92), at least one gRNA containing at least one spacer sequence specific for the target RNA, and a detectable label, the target RNA will be recognized by Cas13d. The binding of the target RNA by Cas13d triggers its RNase activity, which can lead to the cleavage of the target RNA as well as the detectable label.

In one example, the detectable label is an RNA linked to a fluorescent probe and quencher. The intact detectable RNA links the fluorescent probe and quencher, suppressing fluorescence. Upon cleavage by Cas13d of the detectable RNA, the fluorescent probe is released from the quencher and displays fluorescent activity. Such a method can be used to determine if a target RNA is present in a lysed cell sample, lysed tissue sample, blood sample, saliva sample, environmental sample (such as a water, soil, or air sample), or other lysed cell or cell-free sample. Such a method can also be used to detect a pathogen, such as a virus or bacteria, or diagnose a disease state, such as a cancer.

In one example, the detection of the target RNA aids in the diagnosis of disease and/or pathological state, or the existence of a viral or bacterial infection. For example, Cas13d-mediated detection of non-

coding RNAs such as PCA3 can be used to diagnose prostate cancer if detected in patient urine. In another example, Cas13d-mediated detection of the lncRNA-AA174084, which is a biomarker of gastric cancer, can be used to diagnose gastric cancer.

6. Methods of Editing Target RNA

In one example, the method of targeting an RNA results in editing the sequence of a target RNA. For example, by using a Cas13d protein with a non-mutated HEPN domain (*e.g.*, SEQ ID NO: 1, 3, 42, 62, 70, 82, 83, or 92), and a gRNA containing at least one a spacer sequence specific for the target RNA, the target RNA can be cut or nicked at a precise location. In some examples, such a method is used to decrease expression of a target RNA, which will decrease translation of the corresponding protein. Such a method can be used in a cell where increased expression of an RNA is not desired. In one example, the RNA is associated with a disease such as cystic fibrosis, Huntington's disease, Tay-Sachs, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome, muscular dystrophy, myotonic dystrophy, spinal muscular atrophy, spinocerebellar ataxia, or familial ALS. In another example, the RNA is associated with cancer (*e.g.*, a cancer of the lung, breast, colon, liver, pancreas, prostate, bone, brain, skin (*e.g.*, melanoma), or kidney). Examples of target RNAs include, but are not limited to those associated with cancer (*e.g.*, PD-L1, BCR-ABL, Ras, Raf, p53, BRCA1, BRCA2, CXCR4, beta-catenin, HER2, and CDK4). Editing such target RNAs can have a therapeutic effect.

In another example, the RNA is expressed in an immune cell. The target RNA could, for example, code for a protein leading to the repression of a desirable immune response, such as infiltration of a tumor. Knock-down of such an RNA could enable progression of such a desirable immune response (*e.g.*, PD1, CTLA4, LAG3, TIM3). In another example, the target RNA encodes a protein resulting in the undesirable activation of an immune response, for example in the context of an autoimmune disease such as multiple sclerosis, Crohn's disease, lupus, or rheumatoid arthritis.

In one example, targeting the target RNA allows for decreasing expression of the target protein encoded by the RNA. For example, by using a Cas13d fusion protein with a mutated HEPN domain (*e.g.*, SEQ ID NO: 2 or 4) and a translational repression domain (such as Pumilio or FBF PUF proteins, deadenylases, CAF1, Argonaute proteins, and others), and a guide RNA containing at least one spacer sequence specific for the target RNA, expression of a target RNA can be decreased.

In some examples, Cas13d can be fused to a ribonuclease (such as a PIN endonuclease domain, an NYN domain, an SMR domain from SOT1, or an RNase domain from Staphylococcal nuclease) or a domain that affects RNA stability (such as tristetraprolin or domains from UPF1, EXOSC5, and STAU1).

In another example, RNA aptamer sequences can be appended to or inserted within the gRNA molecule, such as MS2, PP7, Qβ, and other aptamers. Proteins that specifically bind to these aptamers, *e.g.* the MS2 phage coat protein, can be fused to a translational repression domain, a ribonuclease, or a domain that affects RNA stability. This aptamer-effector domain fusion can be used to target the target RNA

because the Cas13d and gRNA complex will guide the aptamer protein-effector domain in proximity to the target RNA.

Such a method can be used in a cell where increased expression of an RNA is not desired, such as when an expressed RNA is associated with a disease such as cystic fibrosis, Huntington's disease, Tay-Sachs, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome, muscular dystrophy, myotonic dystrophy, spinal muscular atrophy, spinocerebellar ataxia, or familial ALS. In another example, the target RNA is associated with cancer (*e.g.*, a cancer of the lung, breast, colon, liver, pancreas, prostate, bone, brain, skin (*e.g.*, melanoma), or kidney). Examples of target RNAs include, but are not limited to those associated with cancer (*e.g.*, PD-L1, BCR-ABL, Ras, Raf, p53, BRCA1, BRCA2, CXCR4, beta-catenin, HER2, and CDK4). Editing such target RNAs would have a therapeutic effect.

In another example, the RNA is expressed in an immune cell. The target RNA could, for example, code for a protein leading to the repression of a desirable immune response, such as infiltration of a tumor. Knock-down of such an RNA could enable progression of such a desirable immune response (*e.g.*, PD1, CTLA4, LAG3, TIM3). In another example, the target RNA could encode a protein resulting in the undesirable activation of an immune response, for example in the context of an autoimmune disease such as multiple sclerosis, Crohn's disease, lupus, or rheumatoid arthritis.

In one example, targeting the target RNA allows for activating or increasing expression of the target RNA. For example, by using a Cas13d fusion protein with a mutated HEPN domain (e.g., SEQ ID NO: 2 or 4) and a translational activation domain (such as eIF4E and other translation initiation factors, a domain of the yeast poly(A)-binding protein or GLD2), and a guide RNA containing at least one a spacer sequence specific for the target RNA, expression of a target RNA can be increased. Aptamer introduction into the gRNA with a cognate aptamer-binding protein fused to a translational activation domain can also be used. In one example, RNA aptamer sequences are appended to or inserted within the gRNA molecule, such as MS2, PP7, Qβ, and other aptamers. The introduction of proteins that specifically bind to these aptamers, e.g. the MS2 phage coat protein, fused to a translational activation domain can be used to target the target RNA because the Cas13d and gRNA complex will bring the aptamer protein-translational activation domain in proximity to the target RNA.

In some examples, such a method is used to increase the activity or expression of a target RNA, which will increase translation of the corresponding protein (if the RNA is a coding RNA). Such a method can be used in a cell where increased expression of an RNA is desired, such as a heterozygous genetic disease or disorders caused by copy number variation. Increasing translation of a desired protein product could be therapeutic in nature.

In another example, increasing the expression of a target RNA (such as Cyclin B1) can render the target cell (such as cancers) more sensitive to drugs (such as chemotherapeutic agents).

In one example, targeting the target RNA allows for one or more RNA base substitutions, RNA base edits, RNA base deletions, RNA base insertions, or combinations thereof, in the target RNA. In some examples, the Cas13d protein with a mutated HEPN domain is associated, either via direct fusion or a

gRNA-aptamer modification, an effector domain that allows base edits (such as a cytidine deaminase, PPR protein, adenosine deaminase, ADAR family protein, or APOBEC family protein). In some examples, such a method is used to modify an RNA sequence, edit an RNA mutation, or modify an RNA transcript (*e.g.*, gene therapy), for example to treat diseases such as ALS and melanoma or genetic disorders caused by undesired splice sites, such as Leber congenital amaurosis.

In one example, targeting the target RNA allows for methylating the target RNA. Some examples may use a chimeric Cas13d protein with a mutated HEPN domain (*e.g.*, SEQ ID NO: 2 or 4) associated either via direct fusion or a gRNA-aptamer modification with a methylation domain (*e.g.*, m6A), and a guide RNA containing at least one a spacer sequence specific for the target RNA. In some examples, such a method is used to combat aberrant RNA demethylation. In one example, such a method is used modify the methylation levels of pluripotency transcripts such as NANOG or KLF4 for example to decrease their stability in breast cancer cells, which can suppress the acquisition of breast cancer stem cell phenotypes that are associated with increased proliferation and cancer stem cell formation.

In one example, targeting the target RNA allows for demethylating the target RNA. Some examples can use Cas13d protein with a mutated HEPN domain (*e.g.*, SEQ ID NO: 2 or 4), a guide RNA containing at least one a spacer sequence specific for the target RNA, and a demethylation domain (e.g., human alkylation repair homolog 5 or Alkbh5). The demethylation domain can be associated either via direct fusion to the Cas13d protein or via a gRNA-aptamer modification. In some examples, such a method is used to reverse aberrant RNA methylation, for example to treat myeloid leukemia by decreasing m^6A levels.

In one example, targeting the target RNA allows for binding to the target RNA. For example, by using a Cas13d protein with a mutated HEPN domain (*e.g.*, SEQ ID NO: 2 or 4) and a guide RNA containing at least one a spacer sequence specific for the target RNA, molecules can be bound or tethered to a target RNA. In some examples, such a method is used to capture the target RNA (*e.g.*, immuno-precipitation). This can be used as part of a kit to identify the proteins interacting with a specific RNA transcript. In one example, an epitope tagged Cas13d (*e.g.*, FLAG, HA, biotin, HALO tag) can be targeted to specific target RNAs and cross-linked via fixation (e.g. with paraformaldehyde or glutaraldehyde). Immunoprecipitation of Cas13d with an epitope-recognizing antibody allows for the identification of co-immunoprecipitated proteins via Western blot or mass spectrometry.

In another example, Cas13d can be fused to a biotin ligase (such as BirA) or a peroxidase (such as APEX2) in order to biotinylate proteins that interact with the target RNA. Labeled proteins can then be pulled down with streptavidin beads followed by mass spectrometry or Western blot.

In some examples, biotinylated Cas13d could be targeted to ribosomal RNA sequences with a gRNA. Streptavidin bead-mediated pulldown can be used to deplete rRNA for RNA sequencing library preparation.

In one example, targeting the target RNA allows for masking the target RNA. For example, by using a Cas13d protein with a mutated or intact HEPN domain and a guide RNA containing at least one a spacer

sequence specific for the target RNA, a target RNA can be masked from RNA-binding proteins or RNA-binding elements such as miRNAs.

In some examples, the Cas13d can be used to mask RNA binding sites from RNA-binding proteins (RBPs). In another example, Cas13d can mask miRNA binding sites. For example, the liver-specific miR-122 forms a complex with Hepatitis C viral RNA which protects it from degradation. A HEPN-active Cas13d protein could be targeted to the miRNA-122 binding site on the viral RNA to synergistically combat HCV infections by simultaneously reversing miRNA-122-mediated protection and directly degrading HCV RNA. In some examples, such a method is used to preserve or protect the target RNA molecule, for example to protect the target RNA from degradation. For example, by targeting AU-rich elements in the 3' UTR of a target gene, a HEPN-mutated Cas13d can block binding of RNA-binding proteins such as tristetraprolin (TTR) or AUF1, which lead to degradation of the target transcript.

In one example, targeting the target RNA allows for changing splicing of the target RNA. Both the direct binding of splice acceptor and/or donor sites as well as splice effector domains can be used to manipulate splicing. For example, by using a Cas13d protein with a mutated HEPN domain (*e.g.*, SEQ ID NO: 2 or 4), a guide RNA containing at least one a spacer sequence specific for the target RNA, and optionally an effector domain that affects splicing (such as the RS-rich domain of SRSF1, the Gly-rich domain of hnRNP A1, the alanine-rich motif of RBM4, or the proline-rich motif of DAZAP1), alternative splicing of the RNA can be achieved.

In some examples, such a method is used for exon inclusion, for example to include exon 2 of acid alpha-glucosidase (GAA) to treat Pompe disease or to include exon 7 of SMN2 to treat spinal muscular atrophy (SMA). In some examples, such a method is used for exon exclusion, for example to restore the reading frame of dystrophin to treat Duchenne muscular dystrophy or to shift the splicing of the Bcl-x pre-mRNA from the antiapoptotic long isoform to the proapoptotic short isoform to treat cancer.

In some examples, the method uses the Cas13d protein with a mutated HEPN domain to mask splice acceptor or donor sites, for example to create neoantigens to make cold tumors hot. By affecting the splicing of certain target pre-mRNAs, this method can generate novel exon-exon junctions that can lead to the creation of neo-epitopes in cancer cells. This can make a cancer cell vulnerable to the immune system due to the display of unnatural antigens. In other examples, this method can be used to dynamically manipulate isoform ratios or to restore reading frame of a protein (e.g., dystrophin for Duchenne's muscular dystrophy).

In one example, targeting the target RNA allows for controlling transcript trafficking of the target RNA. For example, by using a Cas13d fusion protein with a mutated HEPN domain (*e.g.*, SEQ ID NO: 2 or 4) and a subcellular localization signal or export sequence, a guide RNA containing at least one a spacer sequence specific for the target RNA. In some examples, such a method is used to traffic the target RNA molecule to a particular organelle or cytosolic compartment, or even export the target RNA transcript, for example to endosomes for extracellular release

In another example, the method can affect RNA trafficking. For example, the zipcode binding protein ZBP1 specifically recognizes an RNA sequence 5'-CGGAC(C/A-CA-C/U) that leads to localization

of certain transcripts to the leading edge of fibroblasts. By masking or manipulating particular RNA zipcodes or regulatory sequences from recognition by regulatory protein complexes, this method can affect RNA localization or trafficking within a cell.

In one example, the target RNA is a nuclearly localized RNA. For example, by using a Cas13d protein with a non-mutated HEPN domain (*e.g.*, SEQ ID NOS: 1, 3, 42, 62, 70, 82, 83, and 92) fused to a nuclear localization signal and a guide RNA containing at least one a spacer sequence specific for the target nuclear RNA, the nuclearly localized RNA can be targeted and degraded. In some examples, such a method is used to degrade the target nuclear RNA molecule, for example to knock-down a non-coding nuclear RNA such as HOTAIR, which is associated with metastatic progression in breast cancer.

In one example, the target RNA is viral RNA or transcript of a DNA virus. For example, a Cas13d protein with a non-mutated HEPN domain (*e.g.*, SEQ ID NOS: 1, 3, 42, 62, 70, 82, 83, and 92) and a guide RNA containing at least one spacer sequence specific for the target RNA can be used. In some examples, such a method is used to treat an RNA viral infection (such as infection by a positive-strand RNA viruses, such as Picornaviruses (such as Aphthoviridae [for example foot-and-mouth-disease virus (FMDV)]), Cardioviridae; Enteroviridae (such as Coxsackie viruses, Echoviruses, Enteroviruses, and Polioviruses); Rhinoviridae (Rhinoviruses)); Hepataviridae (Hepatitis A viruses); Togaviruses (examples of which include rubella; alphaviruses (such as Western equine encephalitis virus, Eastern equine encephalitis virus, and Venezuelan equine encephalitis virus)); Flaviviruses (examples of which include Dengue virus, West Nile virus, and Japanese encephalitis virus); Calciviridae (which includes Norovirus and Sapovirus); or Coronaviruses (examples of which include SARS coronaviruses, such as the Urbani strain), or a negative-strand RNA virus, such as Orthomyxyoviruses (such as the influenza virus), Rhabdoviruses (such as Rabies virus), and Paramyxoviruses (examples of which include measles virus, respiratory syncytial virus, or parainfluenza viruses), or a DNA viral infection (such as infection by Herpesviruses (such as Varicella-zoster virus, for example the Oka strain; cytomegalovirus; and Herpes simplex virus (HSV) types 1 and 2), Adenoviruses (such as Adenovirus type 1 and Adenovirus type 41), Poxviruses (such as Vaccinia virus), or Parvoviruses (such as Parvovirus B19), for example by cutting the viral RNA or transcript of a DNA virus. Thus, such methods can be used as an RNA-based antiviral or antimicrobial.

Example 1

Materials and Methods

This example describes the materials and methods used to obtain the results shown in Examples 2 - 7.

Cell culture of Human Embryonic Kidney (HEK) cell line 293FT

Human embryonic kidney (HEK) cell line 293FT (Thermo Fisher) was maintained in DMEM (4.5 g/L glucose), supplemented with 10% FBS (GE Life Sciences) and 10 mM HEPES at 37°C with 5% CO_2. Upon reaching 80-90% confluency, cells were dissociated using TrypLE Express (Life Technologies) and passaged at a ratio of 1:2.

Cell culture of human bone osteosarcoma epithelial cell line U2OS

Human bone osteosarcoma epithelial U2OS were maintained in DMEM (4.5 g/L glucose) supplemented with 10% FBS and 10 mM HEPES at 37°C with 5% CO_2. Cells were passaged at a 1:3 ratio upon reaching 70% confluence. This cell line was not authenticated.

Maintenance of induced pluripotent stem cells and neuronal differentiation

Stable human iPSC lines containing the FTDP-17 IVS10+16 mutation or age- and sex-matched control lines were obtained from the laboratory of Fen-Biao Gao (Biswas et al., 2016). Briefly, cells obtained from one male patient with the *MAPT* IVS10 + 16 mutation and two separate lines from one male control patient were reprogrammed into hiPSCs (Almeida et al., 2012). iPSCs were transduced with lentivirus containing a doxycycline-inducible *Ngn2* cassette. Lentiviral plasmids were a gift from S. Schafer and F. Gage. iPSCs were then passaged with Accutase and plated into a Matrigel-coated 6-well plate with mTESR media containing ROCK inhibitor Y-27632 (10 μM, Cayman) at 500,000 cells per well. On day 1, media was changed with mTESR. On day 2, media was changed to mTESR containing doxycycline (2 μg/ml, Sigma) to induce *Ngn2* expression. On day 3, culture media was replaced with Neural Induction media (NIM, DMEM/F12 (Life Technologies) containing BSA (0.1 mg/ml, Sigma), apo-transferrin (0.1 mg/ml, Sigma), putrescine (16 μg/ml, Sigma), progesterone (0.0625 μg/ml, Sigma), sodium selenite (0.0104 μg/ml, Sigma), insulin (5 μg/ml, Roche), BDNF (10 ng/ml, Peprotech), SB431542 (10 μM, Cayman), LDN-193189 (0.1 μM, Sigma), laminin (2 μg/ml, Life Technologies), doxycycline (2 μg/ml, Sigma) and puromycin (Life Technologies)). NIM media was changed daily. Following 3 days of puromycin selection, immature neuronal cells were passaged with Accumax (Innovative Cell Technologies) and plated onto 96-well plates coated with poly-D-lysine and Matrigel in Neural Maturation media (NMM; 1:1 Neurobasal/DMEM (Life Technologies) containing B27 (Life Technologies), BDNF (10 ng/ml, Peprotech), N-Acetyl cysteine (Sigma), laminin (2 μg/ml, Life Technologies), dbcAMP (49 μg/ml, Sigma) and doxycycline (2 μg/ml, Sigma). Media was replaced the next day (day 7) with NMM containing AraC (2 μg/ml, Sigma) to eliminate any remaining non-differentiated cells. On day 8, AraC was removed and astrocytes were plated on top of neurons to support neuron cultures in NMM containing hbEGF (5 ng/ml, Peprotech). Cells were transduced with AAV on day 10 and assayed on day 24.

Computational pipeline for Cas13d identification

We obtained whole genome, chromosome, and scaffold-level prokaryotic genome assemblies from NCBI Genome in June 2016 and compared CRISPRfinder, PILER-CR, and CRT for identifying CRISPR repeats. The 20 kilobase flanking regions around each putative CRISPR repeat was extracted to identify nearby proteins and predicted proteins using Python. Candidate Cas proteins were required to be >750 aa in length and within 5 proteins of the repeat array, and extracted CRISPR loci were filtered out if they contained Cas genes associated with known CRISPR systems such as types I-III CRISPR. Putative effectors

were clustered into families via all-by-all BLASTp analysis followed by single-linkage hierarchical clustering where a bit score of at least 60 was required for cluster assignment. Each cluster of at least 2 proteins was subjected to BLAST search against the NCBI non-redundant (nr) protein database, requiring a bit score >200 to assign similarity. The co-occurrence of homologous proteins in each expanded cluster to a CRISPR array was analyzed and required to be >70%. Protein families were sorted by average amino acid length and multiple sequence alignment for each cluster was performed using Clustal Omega and the Geneious aligner with a Blosum62 cost matrix. The *RxxxxH* HEPN motif was identified in the Cas13d family on the basis of this alignment. TBLASTN was performed on all predicted Cas13d effectors against public metagenome whole genome shotgun sequences without predicted open reading frames (ORFs). The Cas13d family was regularly updated via monthly BLAST search on genome and metagenome databases to identify any newly deposited sequences. New full-length homologs and homologous fragments were aligned using Clustal Omega and clustered using PhyML 3.2. CRISPRDetect was used to predict the direction of direct repeats in the Cas13d array and DR fold predictions were performed using the Andronescu 2007 RNA energy model at 37°C. Sequence logos for Cas13d direct repeats were generated using Geneious 10.

Protein expression and purification

Recombinant Cas13d proteins were PCR amplified from genomic DNA extractions of cultured isolates or metagenomic samples and cloned into a pET-based vector with an N-terminal His-MBP fusion and TEV protease cleavage site. The resulting plasmids were transformed into Rosetta2(DE3) cells (Novagen), induced with 200 μM IPTG at OD_{600} 0.5, and grown for 20 hours at 18°C. Cells were then pelleted, freeze-thawed, and resuspended in Lysis Buffer (50 mM HEPES, 500 mM NaCl, 2 mM MgCl2, 20 mM Imidazole, 1% v/v Triton X-100, 1 mM DTT) supplemented with 1X protease inhibitor tablets, 1 mg/mL lysozyme, 2.5U/mL Turbo DNase (Life Technologies), and 2.5U/mL salt active nuclease (Sigma Aldrich). Lysed samples were then sonicated and clarified via centrifugation (18,000 x g for 1 hour at 4°C), filtered with 0.45 μM PVDF filter and incubated with 50 mL of Ni-NTA Superflow resin (Qiagen) per 10 L of original bacterial culture for 1 hour. The bead-lysate mixture was applied to a chromatography column, washed with 5 column volumes of Lysis Buffer, and 3 column volumes of Elution Buffer (50 mM HEPES, 500 mM NaCl, 300 mM Imidazole, 0.01% v/v Triton X-100, 10% glycerol, 1 mM DTT). The samples were then dialyzed overnight into TEV Cleavage Buffer (50 mM Tris-HCl, 250 mM KCl, 7.5% v/v glycerol, 0.2 mM TCEP, 0.8 mM DTT, TEV protease) before cation exchange (HiTrap SP, GE Life Sciences) and gel filtration (Superdex 200 16/600, GE Life Sciences). Purified, eluted protein fractions were pooled and frozen at 4 mg/mL in Protein Storage Buffer (50 mM Tris-HCl, 1M NaCl, 10% glycerol, 2 mM DTT).

Preparation of guide and target RNAs

Oligonucleotides carrying the T7 promoter and appropriate downstream sequence were synthesized (IDT) and annealed with an antisense T7 oligo for crRNAs and PCR-amplified for target and array templates. Homopolymer target RNAs were synthesized by Synthego. The oligo anneal and PCR templates

were *in vitro* transcribed with the Hiscribe T7 High Yield RNA Synthesis kit (New England Biolabs) at 31°C for 12 hours. For labeled targets, fluorescently labelled aminoallyl-UTP atto 680 (Jena Biosciences) was additionally added at 2 mM. Guide RNAs were purified with RNA-grade Agencourt AMPure XP beads (Beckman Coulter) and arrays and targets were purified with MEGAclear Transcription Clean-Up Kit (Thermo Fisher) and frozen at -80°C. For ssDNA and dsDNA targets, corresponding oligonucleotide sequences were synthesized (IDT) and either gel purified, or PCR amplified and then subsequently gel purified respectively.

Biochemical cleavage reactions

Purified EsCas13d protein and guide RNA were mixed (unless otherwise indicated) at 2:1 molar ratio in RNA Cleavage Buffer (25mM Tris pH 7.5, 15mM Tris pH 7.0, 1mM DTT, 6mM MgCl2). The reaction was prepared on ice and incubated at 37°C for 15 minutes prior to the addition of target at 1:2 molar ratio relative to EsCas13d. The reaction was subsequently incubated at 37°C for 45 minutes and quenched with 1 µL of enzyme stop solution (10 mg/mL Proteinase K, 4M Urea, 80mM EDTA, 20mM Tris pH 8.0) at 37°C for 15 minutes. The reaction was then denatured with 2X RNA loading buffer (2X: 13mM Ficoll, 8M Urea, 25 mM EDTA), at 85°C for 10 minutes, and separated on a 10% TBE-Urea gel (Life Technologies). Gels containing labeled targets were visualized on the Odyssey Imager (Li-Cor); unlabeled array or target cleavage gels were stained with SYBR Gold prior to imaging via Gel Doc EZ system (Bio-Rad).

Transient transfection of human cell lines

Engineered Cas13 coding sequences were cloned into a standardized plasmid expression backbone containing an EF1a promoter and prepared using the Nucleobond Xtra Midi EF Kit (Machery Nagel) according to the manufacturer's protocol. NLS-LwaCas13a-msfGFP and PspCas13b-NES-HIV were PCR amplified from Addgene #103854, and #103862, respectively, a gift from Feng Zhang. Cas13d pre-gRNAs and gRNAs were cloned into a minimal backbone containing a U6 promoter. shRNAs and guides for LwaCas13a were cloned into the same backbone and position matched to their corresponding guide RNA at the 3' of the target sequence. Matched gRNAs for PspCas13b were moved to the closest 5'-G nucleotide.

For transient transfection, HEK 293FT cells were plated at a density of 20,000 cells per well in a 96-well plate and transfected at >90% confluence with 200 ng of Cas13 expression plasmid and 200 ng of gRNA expression plasmid using Lipofectamine 2000 (Life Technologies) according to the manufacturer's protocol. Transfected cells were harvested 48-72 hours post-transfection for flow cytometry, gene expression analysis, or other downstream processing.

For reporter assays, HEK 293FT cells were transfected in 96-well format with 192ng of Cas13d expression plasmid, 192ng of guide expression plasmid, and 12ng of mCherry expression plasmid with Lipofectamine 2000 (Life Technologies). Cells were harvested after 48 hours and analyzed by flow cytometry.

U2OS cells were plated at a density of 20,000 cells per well in a 96-well plate and transfected at >90% confluence with 100 ng of Cas13d expression plasmid using Lipofectamine 3000 (Life Technologies) according to the manufacturer's protocol and processed for immunocytochemistry after 48h.

Flow cytometry

Cells were dissociated 48 hours post-transfection with TrypLE Express and resuspended in FACS Buffer (1X DPBS$^{-/-}$, 0.2% BSA, 2 mM EDTA). Flow cytometry was performed in 96-well plate format using a MACSQuant VYB (Miltenyi Biotec) and analyzed using FlowJo 10. RG6 was a gift from Thomas Cooper (Addgene plasmid # 80167) and modified to replace EGFP with mTagBFP2. All represented samples were assayed with three biological replicates. In the mCherry reporter assay, data is representative of at least 20,000 gated events per condition. In the splicing reporter assay, data is representative of at least 2,500 gated events per condition.

Gene expression analysis

Cells were lysed 48 hours post-transfection with DTT-supplemented RLT buffer and total RNA was extracted using RNeasy Mini Plus columns (Qiagen). 200 ng of total RNA was then reverse transcribed using random hexamer primers and Revertaid Reverse Transcriptase (Thermo Fisher) at 25°C for 10 min, 37°C for 60 min, and 95°C for 5 min followed by qPCR using 2X Taqman Fast Advanced Master Mix (Life Technologies) and Taqman probes for GAPDH and the target gene as appropriate (Life Technologies and IDT). Taqman probe and primer sets were generally selected to amplify cDNA across the Cas13 or shRNA target site position to prevent detection of cleaved transcript fragments (see Table S4 of Konermann *et al*., Cell 173:1-12, 2018, herein incorporated by reference in its entirety). qPCR was carried out in 5 μL multiplexed reactions and 384-well format using the LightCycler 480 Instrument II (Roche). Fold-change was calculated relative to GFP-transfected vehicle controls using the ddCt method. One-way or two-way ANOVA with multiple comparison correction was used to assess statistical significance of transcript changes using Prism 7.

Immunohistochemistry

For immunohistochemical analysis, U2OS cells were cultured on 96-well optically clear plates (Greiner Bio-One), transfected as previously described, then fixed in 4% PFA (Electron Microscopy Sciences) diluted in PBS (Gibco) and washed with 0.3M glycine (Sigma) in PBS to quench PFA. Samples were blocked and permeabilized in a PBS solution containing 8% donkey serum (Jackson ImmunoResearch), 8% goat serum (Cell Signaling Technologies), and 0.3% Triton-X 100 (Sigma) for one hour, followed by primary antibody incubation in 1% BSA (Fisher Bioreagents), 1% goat serum, and 0.25% Triton-X overnight at 4°C. Samples were washed 3 times with PBS containing 0.1% BSA and 0.1% Triton-X 100 before incubating with fluorophore-conjugated secondary antibodies in PBS with 0.05% Triton-X 100 and 1% BSA at room temperature for one hour. Cells were washed with PBS with 0.1% Triton-X, stained

with DAPI, and then covered with Mounting Media (Ibidi) before imaging. Primary antibody, HA-Tag 6E2 (Cell Signaling, 2367), was used at a 1:100 dilution as per manufacturer's instructions. Secondary antibodies used were goat anti-mouse IgG1-Alexa-Fluor 647 (Thermo Fisher, A21240) and Anti-Mouse IgG1 CF 633 (Sigma, SAB4600335). Confocal images were taken using a Zeiss Airyscan LSM 880 followed by image processing in Zen 2.3 (Zeiss).

Bacterial small RNA sequencing and analysis

E. coli DH5α cells were transformed with pACYC184 carrying the CRISPR-Cas13d locus derived from an uncultured *Ruminococcus sp.* strain. Cells were harvested in stationary phase, rinsed in PBS, resuspended in TRIzol (Life Technologies), transferred to Lysing Matrix B tubes containing 0.1 mm silica beads (MP Biomedicals), and homogenized on a Bead Mill 24 (Fisher Scientific) for three 30-second cycles. Total RNA was isolated by phenol-chloroform extraction, then purified using the DirectZol Miniprep Kit (Zymo Research). RNA quality was assessed on an Agilent 2200 Tapestation followed by Turbo DNase treatment (Ambion). Total RNA was treated with T4 Polynucleotide Kinase (NEB) and rRNA-depleted using the Ribo-Zero rRNA Removal Kit for bacteria (Illumina). RNA was treated with RNA 5' polyphosphatase, poly(A)-tailed with E. coli poly(A) polymerase, and ligated with 5' RNA sequencing adapters using T4 RNA ligase 1 (NEB). cDNA was generated via reverse transcription using an oligo-dT primer and M-MLV RT/RNase Block (AffinityScript, Agilent) followed by PCR amplification and barcoding. Resulting libraries were sequenced on Illumina MiSeq, demultiplexed using custom Python scripts, and aligned to the Cas13d CRISPR locus using Bowtie 2. Alignments were visualized with Geneious.

***Ngn2* lentivirus preparation**

Low passage HEK 293FT cells were transfected with Polyethylenimine Max (PEI, Polysciences) and *Ngn2* target plasmid plus pMDG.2 and psPAX2 packaging plasmids (a gift from Didier Trono, Addgene #12259 and #12260) in DMEM + 10% FBS media during plating. The following day, media was changed to serum-free chemically defined minimal medium (Ultraculture supplemented with Glutamax, Lonza). Viral supernatant was harvested 48h later, clarified through a 0.45 micron PVDF filter (Millipore) and concentrated using ultracentrifugation.

AAV preparation

Low passage HEK 293FT cells were transfected with Polyethylenimine Max (PEI, Polysciences) and AAV target plasmid plus AAV1 serotype and pAdDeltaF6 helper packaging plasmids (UPenn Vector Core) in DMEM + 10% FBS media during plating. The following day, 60% of the media was changed to chemically defined minimal medium (Ultraculture supplemented with Glutamax, Lonza). 48h later, AAV-containing supernatant was harvested and clarified through a 0.45μm PVDF filter (Millipore) and

concentrated using precipitation by polyethylene glycol (PEG virus precipitation kit #K904, Biovision) following the manufacturer's protocol.

RNA-seq library preparation and sequencing

48h after transfection, total RNA was extracted from 293FT cells using the RNeasy Plus Mini kit from Qiagen. Stranded mRNA libraries were prepared using the NEBNext II Ultra Directional RNA Library Prep Kit from New England Biolabs (Cat# E7760S) and sequenced on an Illumina NextSeq500 with 42 nt paired end reads. ~15M total reads were demultiplexed per condition.

RNA-seq analysis

Sequenced reads were quality-tested using FASTQC and aligned to the hg19 human genome using the 2.5.1b STAR aligner (Dobin et al., 2013). Mapping was carried out using default parameters (up to 10 mismatches per read, and up to 9 multi-mapping locations per read). The genome index was constructed using the gene annotation supplied with the hg19 Illumina iGenomes collection (Illumina) and sjdbOverhang value of 100. Uniquely mapped reads were quantified across all gene exons using the top-expressed isoform as proxy for gene expression with the HOMER analysis suite (Heinz et al., 2010), and differential gene expression was carried out with DESeq2 v 1.14.1 (Love et al., 2014) using triplicates to compute within-group dispersion and contrasts to compare between targeting and non-targeting conditions. Significant differentially expressed genes were defined as having a false discovery rate (FDR) <0.01 and a log2 fold change >0.75. Volcano plots were generated in R 3.3.2 using included plotting libraries and the alpha() color function from the scales 0.5.0 package.

Statistics

All values are reported as mean ± SD or mean ± SEM as indicated in the appropriate figure legends. For comparing two groups, a one-tailed student's t-test was used and statistical significance was determined using the Holm-Sidak method with alpha = 0.05. A one-way ANOVA with Tukey multiple hypothesis correction was used to assess significance between more than two groups. Two-way ANOVA was used when comparing across two factors (i.e., RNA targeting modality and guide position) and adjusted for multiple hypothesis correction by Sidak's multiple comparisons test. For comparing groups that were found to not meet the assumption of a normal distribution by a D'Agostino and Pearson normality test, the non-parametric Friedman test with Dunn's multiple comparison adjustment was performed. PRISM 7.0 was used for all statistical analysis. Sample sizes were not determined *a priori.* At least three biological replicates were used for each experiment, as indicated specifically in each figure.

Sequencing data reported herein can be found in the NCBI Gene Expression Omnibus under GEO Series accession number GSE108519.

Additional details on the materials and methods used, such as sequences can be found in Konermann *et al.*, Cell 173:1-12, 2018, herein incorporated by reference in its entirety.

Example 2

Computational identification of a Type VI-like Cas ribonuclease family

This example describes methods used to identify previously undetected or uncharacterized RNA-targeting CRISPR-Cas systems by developing a computational pipeline for class 2 CRISPR-Cas loci, which require only a single nuclease for CRISPR interference such as Cas9, Cas12a (formerly Cpf1), or Cas13a (formerly C2c2) (Makarova et al., 2015; Shmakov et al., 2015). To improve upon previous strategies for bioinformatic mining of CRISPR systems, which focus on discovering sets of conserved Cas genes involved in spacer acquisition (Shmakov et al., 2015), the minimal requirements for a CRISPR locus to be the presence of a CRISPR repeat array and a nearby effector nuclease were defined. Using the CRISPR array as a search anchor, all prokaryotic genome assemblies and scaffolds were obtained from the NCBI WGS database and adapted algorithms for *de novo* CRISPR array detection (Bland et al., 2007; Edgar, 2007; Grissa et al., 2007) to identify 21,175 putative CRISPR repeat arrays **(FIG. 1A)**.

Up to 20 kilobases (kb) of genomic DNA sequence flanking each CRISPR array was extracted to identify predicted protein-coding genes in the immediate vicinity. Candidate loci containing signature genes of known class 1 and class 2 CRISPR-Cas systems such as Cas3 or Cas9 were excluded from further analysis, except for Cas12a and Cas13a to judge the ability of the pipeline to detect and cluster these known class 2 effector families. To identify new class 2 Cas effectors, it was required that candidate proteins be >750 residues in length and within 5 protein-coding genes of the repeat array, as large proteins closely associated with CRISPR repeats are key characteristics of known single effectors. The resulting proteins were classified into 408 putative protein families using single-linkage hierarchical clustering based on homology.

To discard protein clusters that reside in close proximity to CRISPR arrays due to chance or overall abundance in the genome, additional homologous proteins to each cluster were identified from the NCBI non-redundant protein database and their proximity to a CRISPR array determined. Reasoning that true Cas genes would have a high co-occurrence rate with CRISPR repeats, >70% of the proteins for each expanded cluster were required to exist within 20 kb of a CRISPR repeat. These remaining protein families were analyzed for nuclease domains and motifs.

Among the candidates, which include the recently described Cas13b system (Smargon et al., 2017), a family of uncharacterized putative class 2 CRISPR-Cas systems encoding a candidate CRISPR-associated ribonuclease containing 2 predicted HEPN ribonuclease motifs (Anantharaman et al., 2013) were identified **(FIG. 2A)**. Importantly, they are among the smallest class 2 CRISPR effectors described to date (~930 aa). The Type VI CRISPR-Cas13 superfamily is exemplified by sequence-divergent, single-effector signature nucleases and the presence of two HEPN domains. Other than these two *RxxxxH* HEPN motifs **(FIG. 3A),** the candidate effectors have no significant sequence similarity to previously described Cas13 enzymes, so his family of putative CRISPR ribonucleases is designated as Type VI Cas13d, or Type VI-D **(FIG. 3B)**.

CRISPR-Cas13d systems are derived from gut-resident microbes, so we sought to expand the Cas13d family via alignment to metagenomic contigs from recent large-scale microbiome sequencing efforts. Comparison of Cas13d proteins against public metagenome sequences without predicted open reading frames (ORFs) identified additional full-length systems as well as multiple effector and array fragments that cluster in several distinct branches **(FIG. 1B)**. To generate full-length Cas13d ortholog proteins and loci from the different branches of the Cas13d protein family, genomic DNA samples we43 obtained from associated assemblies and performed targeted Sanger sequencing to fill in gaps due to incomplete sequencing coverage, such as for the metagenomic ortholog 'Anaerobic digester metagenome' (Adm) (Treu et al., 2016).

Cas13d CRISPR loci are largely clustered within benign, Gram-positive gut bacteria of the genus *Ruminococcus*, and exhibit a surprising diversity of CRISPR locus architectures (**FIG. 2A**). With the exception of the metagenomic AdmCas13d system, Cas13d systems lack the key spacer acquisition protein Cas1 (Yosef et al., 2012) within their CRISPR locus, highlighting the utility of a class 2 CRISPR discovery pipeline without Cas1 or Cas2 gene requirements. Cas13d direct repeats (DRs) are highly conserved in length and predicted secondary structure **(FIG. 3C)**, with a 36 nt length, an 8-10 nt stem with A/U-rich loop, and a 5′-AAAAC motif at the 3′ end of the direct repeat **(FIG. 3D)**. This conserved 5′-AAAAC motif has been shown to be specifically recognized by a type II Cas1/2 spacer acquisition complex (Wright and Doudna, 2016). In fact, Cas1 can be found in relative proximity to some Cas13d systems (within 10-30 kb for P1E0 and Rfx) while the remaining Cas13d-containing bacteria contain Cas1 elsewhere in their genomes, likely as part of another CRISPR locus.

Example 3

CRISPR-Cas13d possesses dual RNase activities

To demonstrate that the Cas13d repeat array is transcribed and processed into CRISPR guide RNAs (gRNA), the Cas13d CRISPR locus was cloned from an uncultured *Ruminococcus sp.* sample (Ur) into a bacterial expression plasmid. CRISPR systems tend to form self-contained operons with the necessary regulatory sequences for independent expression, facilitating heterologous expression in *E. coli* (Gasiunas et al., 2012). RNA sequencing (Heidrich et al., 2015) revealed processing of the array into ~52nt mature gRNAs, with a 30 nt 5′ direct repeat followed by a variable 3′ spacer that ranged from 14-26 nt in length **(FIG. 2B).**

To characterize Cas13d properties *in vitro*, *Eubacterium siraeum* Cas13d protein (EsCas13d) was purified based on its robust recombinant expression in *E. coli* **(FIGS. 4A-4C)** and found that EsCas13d was solely sufficient to process its matching CRISPR array into constituent guides without additional helper ribonucleases **(FIG. 2C, Table S1** of Konermann *et al.*, "Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors," Cell 173:1-12, 2018, herein incorporated by reference in its entirety**)**, a property shared by some class 2 CRISPR-Cas systems (East-Seletsky et al., 2016; Fonfara et al., 2016; Smargon et al., 2017). Furthermore, inactivating the positively charged catalytic residues of the HEPN

motifs (Anantharaman et al., 2013) (dCas13d: R295A, H300A, R849A, H854A) did not affect array processing, indicating a distinct RNase activity dictating gRNA biogenesis analogous to Cas13a (East-Seletsky et al., 2016; Liu et al., 2017).

Cas effector proteins typically form a binary complex with mature gRNA to generate an RNA-guided surveillance ribonucleoprotein capable of cleaving foreign nucleic acids for immune defense (van der Oost et al., 2014). To assess if Cas13d has programmable RNA targeting activity as indicated by the presence of two HEPN motifs, EsCas13d protein was paired with an array or a mature gRNA along with a cognate *in vitro*-transcribed target. Based on the RNA sequencing results, a mature gRNA containing a 30 nt direct repeat and an intermediate spacer length of 22 nt was selected (nucleotides 6-36 of SEQ ID NO: 129, followed by 22 bases complementary to the RNA target).

Cas13d was able to efficiently cleave the complementary target ssRNA with both the unprocessed array and mature gRNA in a guide-sequence dependent manner, while non-matching spacer sequences abolished Cas13d activity **(FIG. 5A).** Substitution with dCas13d or the addition of EDTA to the cleavage reaction also abolished guide-dependent RNA targeting, indicating that Cas13d targeting is HEPN- and Mg^{2+}-dependent **(FIG. 5B)**. To determine the minimal spacer length for efficient Cas13d targeting, a series of spacer truncations ranging from the unprocessed 30 nt length down to 10 nt were generated **(FIG. 6A)**. Cleavage activity dropped significantly below a 21 nt spacer length, confirming the choice of a 22 nt spacer **(FIG. 6B)**.

RNA-targeting class 2 CRISPR systems have been proposed to act as sensors of foreign RNAs (Abudayyeh et al., 2016; East-Seletsky et al., 2016), where general RNase activity of the effector nuclease is triggered by a guide-matching target. To assay for a similar property in Cas13d, RNase activity of the binary EsCas13d:gRNA complex was monitored in the presence of a matching RNA target. It was observed that EsCas13d can be activated by target RNA to cleave bystander RNA targets (**FIG. 3C**), albeit inefficiently relative to its activity on the complementary ssRNA target. Bystander cleavage is guide sequence- and HEPN-dependent, as the presence of non-matching bystander target alone was insufficient to induce cleavage while substitution of dCas13d or addition of EDTA abolished activity. These results indicate that bystander RNase activity may be a general property of RNA-targeting class 2 systems in CRISPR adaptive bacterial immunity **(FIG. 3D).**

To assess the generalizability of Cas13d reprogramming, twelve guides tiling a complementary RNA target were generated and efficient cleavage in all cases was observed (**FIG. 7A**). Cas13d was unable to cleave a ssDNA (**FIG. 6C**) or dsDNA (**FIG. 6D)** version of the ssRNA target, indicating that Cas13d is an RNA-specific nuclease. Further, RNA target cleavage did not depend on the protospacer flanking sequence (PFS) **(FIG. 7A)** in contrast to other RNA-targeting class 2 systems, which require a 3′-H (Abudayyeh et al., 2016) or a double-sided, DR-proximal 5′-D and 3′-NAN or NNA (Smargon et al., 2017). Although a slight bias against an adenine PFS was initially observed (**FIG. 6E)**, varying the target PFS base with a constant guide sequence resulted in no significant differences (P=0.768) in targeting efficiency **(FIG. 6F)**.

While DNA-targeting class 2 CRISPR systems (Gasiunas et al., 2012; Jinek et al., 2012; Zetsche et al., 2015) and some RNA-targeting class 1 systems tend to cleave at defined positions relative to the target-guide duplex (Samai et al., 2015; Zhang et al., 2016), the Cas13d cleavage pattern varies for different targets **(FIGS. 5A, 5C, 6H)** and remains remarkably similar despite the guide sequence position **(FIG. 7A)**. This indicates that Cas13d may preferentially cleave specific sequences or structurally accessible regions in the target RNA. Cas13d was tested activity on targets containing variable homopolymer repeats in the loop region of a hairpin or as a linear single-stranded repeat. EsCas13d exhibited significant preference for uracil bases in both target structures, with lower but detectable activity at all other bases **(FIG. 7B)**.

Cas enzymes are found in nearly all archaea and about half of bacteria (Hsu et al., 2014; van der Oost et al., 2014), spanning a wide range of environmental temperatures. To determine the optimal temperature range for Cas13d activity, a spectrum of cleavage temperature conditions from 16-62°C was tested and observed maximal activity in the 24-41°C range **(FIG. 6G, 6H)**. This temperature range is compatible with a wide range of prokaryotic and eukaryotic hosts, indicating Cas13d can be adapted for RNA targeting in different cells and organisms.

Example 4

Cell-based activity screen of engineered orthologs

The Cas13d nuclease was used as a flexible tool for programmable RNA targeting in mammalian cells. CRISPR orthologs from distinct bacterial species commonly exhibit variable activity (Abudayyeh et al., 2017; East-Seletsky et al., 2017), especially upon heterologous expression in human cells (Ran et al., 2015; Zetsche et al., 2017). Highly active Cas13d orthologs were identified in a eukaryotic cell-based mCherry reporter screen.

By synthesizing human codon-optimized versions of 7 orthologs from distinct branches within the Cas13d family **(FIG. 1B)**, mammalian expression plasmids carrying the catalytically active and HEPN-inactive proteins were generated . Each protein was then optionally fused to N- and C-terminal nuclear localization signals (NLS). These Cas13d effector designs were HA-tagged and paired with two distinct guide RNA architectures, either with a 30 nt spacer flanked by two direct repeat sequences to mimic an unprocessed guide RNA (pre-gRNA) or a 30 nt direct repeat with 22 nt spacer (gRNA) predicted to mimic mature guide RNAs **(FIG. 8A)**. For each guide design, four distinct spacer sequences complementary to the mCherry transcript were then pooled to minimize potential spacer-dependent variability in targeting efficiency. The ability of Cas13d to knockdown mCherry protein levels was determined in a human embryonic kidney (HEK) 293FT cell-based reporter assay.

48 hours post-transfection, flow cytometry indicated that RfxCas13d and AdmCas13d efficiently knocked down mCherry protein levels by up to 92% and 87% ($P<0.0003$), respectively, relative to a non-targeting control guide **(FIG. 8B).** In contrast, EsCas13d along with RaCas13d and RffCas13d exhibited limited activity in human cells. Furthermore, none of the HEPN-inactive Rfx-dCas13d constructs significantly affected mCherry fluorescence, indicating HEPN-dependent knockdown ($P>0.43$ for all cases).

Robust nuclear translocation of the Rfx and AdmCas13d NLS fusion constructs was observed via immunocytochemistry, while the wild-type effectors remain primarily extra-nuclear **(FIG. 8C)**.

Proceeding with RfxCas13d and AdmCas13d as lead candidates, we next compared their ability to knockdown endogenous transcripts. To determine the optimal ortholog and guide architecture, the capability of Rfx and AdmCas13d construct variants to target β-1,4-N-acetyl-galactosaminyl transferase 1 (*B4GALNT1*) transcripts was systematically assayed. In each condition, four guides containing distinct spacer sequences tiling the *B4GALNT1* transcript were pooled. The RfxCas13d-NLS fusion targeted *B4GALNT1* more efficiently than wild-type RfxCas13d and both variants of AdmCas13d, with both the gRNA and pre-gRNA mediating potent knockdown (~82%, $P<0.0001$) **(FIG. 8D)**. Cas13d-NLS from *Ruminococcus flavefaciens* strain XPD3002 was therefore selected for the remaining experiments (CasRx).

Example 5

Programmable RNA knockdown in human cells with CasRx

Because Cas13d is capable of processing its own CRISPR array, this property was leveraged for the simultaneous delivery of multiple targeting guides in a simple single-vector system **(FIG. 9A)**. Arrays encoding four spacers that each tile the transcripts of mRNAs (*B4GALNT1 and ANXA4)* or nuclear localized lncRNAs *(HOTTIP and MALAT1)* consistently facilitated robust (>90%) RNA knockdown by CasRx ($P<0.0001$) **(FIG. 9B)**.

CasRx was compared to more established technologies for transcript knockdown or repression, by comparing CasRx-mediated RNA interference to dCas9-mediated CRISPR interference (Gilbert et al., 2014; Gilbert et al., 2013) and spacer sequence-matched shRNAs via transient transfection **(FIG. 9C)**. For CRISPRi-based repression, the most potent dCas9 guide for *B4GALNT1* from previous reports was analyzed (Gilbert et al., 2014; Zalatan et al., 2015). Across 3 endogenous transcripts, CasRx outperformed shRNAs (11/11) and CRISPRi (4/4) in each case **(FIG. 9D)**, exhibiting a median knockdown of 96% compared to 65% for shRNA and 53% for CRISPRi after 48 hours. In addition, knockdown by CasRx was compared to two recently described Cas13a and Cas13b effectors (Abudayyeh et al., 2017; Cox et al., 2017) **(FIG. 10A)**. Across three genes and eight guide RNAs, CasRx mediated significantly greater transcript knockdown than both LwaCas13a-msfGFP-NLS and PspCas13b-NES (median: 97% compared to 80% and 66% respectively, $P< 0.0001$) **(FIG. 10B)**.

RNAi has been widely used to disrupt any gene of interest due to a combination of simple re-targeting principles, scalable synthesis, knockdown potency, and ease of reagent delivery. However, widespread off-target transcript silencing has been a consistent concern (Jackson et al., 2003; Sigoillot et al., 2012), possibly due to the entry of RNAi reagents into the endogenous miRNA pathway (Doench et al., 2003; Smith et al., 2017). Consistent with these reports, upon RNA sequencing of human cells transfected with a *B4GALNT1*-targeting shRNA, widespread off-target transcriptional changes relative to a non-targeting shRNA were observed (>500 significant off-target changes, $P<0.01$, **FIGS. 9E, 9G**). In contrast, transcriptome profiling of spacer-matched CasRx guide RNAs revealed no significant off-target changes

other than the targeted transcript (**FIG. 9F**). This indicates that the moderate bystander cleavage observed *in vitro* (**FIG. 5C**) may not result in observable off-target transcriptome perturbation in mammalian cells. A similar pattern was observed when targeting *ANXA4* (**FIGS. 11A-11B**), with over 900 significant off-target changes resulting from shRNA targeting compared to zero with CasRx (**FIG. 9G**).

To confirm that CasRx interference is broadly applicable, a panel of 11 additional genes with diverse roles in cancer, cell signaling, and epigenetic regulation were selected and 3 guides per gene were screened. CasRx consistently mediated high levels of transcript knockdown across genes with a median reduction of 96% (**FIG. 9H**). Each tested guide mediated at least 80% knockdown, underscoring the consistency of the CasRx system for RNA interference.

Example 6

Splice isoform engineering with dCasRx

The experiments on RNA targeting with CasRx revealed that target RNA and protein knockdown is dependent on the catalytic activity of the HEPN domains **(FIGS. 8B, 5B).** The same guide sequences mediating efficient knockdown with CasRx failed to significantly reduce mCherry levels when paired with catalytically inactive dCasRx **(FIG. 8B)**, indicating that targeting of dCasRx to the coding portion of mRNA does not necessarily perturb protein translation. This observation indicated the possibility of utilizing dCasRx for targeting of specific coding and non-coding elements within a transcript to study and manipulate RNA. To validate this concept, the utility of the dCasRx system was expanded by creating a splice effector.

Alternative splicing is generally regulated by the interaction of cis-acting elements in the pre-mRNA with positive or negative trans-acting splicing factors, which can mediate exon inclusion or exclusion (Matera and Wang, 2014; Wang et al., 2015). It was reasoned that dCasRx binding to such motifs may be sufficient for targeted isoform perturbation. For proof-of-concept, distinct splice elements were identified in a bichromatic splicing reporter containing DsRed upstream of mTagBFP2 in two different reading frames following an alternatively spliced exon (Orengo et al., 2006) (**FIG. 12A**). Inclusion or exclusion of this second exon toggles the reading frame and resulting fluorescence, facilitating quantitative readout of splicing patterns by flow cytometry . To mediate exon skipping, four guide RNAs were designed to target the intronic branchpoint nucleotide, splice acceptor site, putative exonic splice enhancer, and splice donor of exon 2.

One widespread family of negative splice factors are the highly conserved heterogeneous nuclear ribonucleoproteins (hnRNPs), which typically inhibit exon inclusion via a C-terminal, glycine-rich domain (Wang et al., 2015). The splicing reporter was targeted with dCasRx and engineered fusions to the Gly-rich C-terminal domain of hnRNPa1, one of the most abundant hnRNP family members (**FIG. 12B**).

Guide position appears to be a major determinant of the efficiency of engineered exon skipping. While each guide position mediated a significant increase in exon exclusion ($P<0.0001$ in all cases) relative to the non-targeting guide, targeting the splice acceptor resulted in the most potent exon exclusion (increase from 8% basal skipping to 65% for dCasRx alone and 75% with hnRNPa1 fusion). By comparison,

dLwaCas13a-msfGFP-NLS mediated significantly lower levels of exon skipping across all four positions (19% skipping for splice acceptor guide) (**FIGS.** 10**C** and 10**D,** $P<0.0001$).

Targeting all 4 positions simultaneously with a CRISPR array achieved higher levels of exon skipping than individual guides alone (81% for dCasRx and 85% for hnRNPa1 fusion, $P<0.006$ compared to SA guide) (**FIG. 12B**) . These results indicate that dCasRx allows for tuning of isoform ratios through varying guide placement and suggest that it can be leveraged as an efficient RNA binding module in human cells for targeting and manipulation of specific RNA elements.

Example 7

Viral delivery of dCasRx to a neuronal model of frontotemporal dementia

The Cas13d family averages 930 amino acids in length, in contrast to Cas9 (~1100 aa to ~1400 aa depending on subtype, with compact outliers such as CjCas9 or SaCas9), Cas13a (1250 aa), Cas13b (1150 aa), and Cas13c (1120 aa) (**FIG. 3B)** (Chylinski et al., 2013; Cox et al., 2017; Hsu et al., 2014; Kim et al., 2017; Shmakov et al., 2015; Smargon et al., 2017). Although adeno-associated virus (AAV) is a versatile vehicle for transgene delivery and gene therapy due to its broad range of capsid serotypes, low levels of insertional mutagenesis, and lack of apparent pathogenicity, its limited packaging capacity (~4.7kb) makes it challenging to effectively deliver many single effector CRISPR enzymes (Abudayyeh et al., 2017; Ran et al., 2015; Swiech et al., 2015). The remarkably small size of Cas13d effectors render them uniquely suited for all-in-one AAV delivery with a CRISPR array, an optional effector domain, and requisite expression or regulatory elements (**FIG. 12C**).

Frontotemporal Dementia with Parkinsonism linked to Chromosome 17 (FTDP-17) is an autosomal dominant major neurodegenerative disease caused by diverse point mutations in *MAPT,* the gene encoding for tau. Tau exists as two major isoforms in human neurons, 4R and 3R, which are distinguished by the presence or absence of tau exon 10 and thus contain 4 or 3 microtubule binding domains. The balance of these two isoforms is generally perturbed in FTDP-17 as well as other tauopathies, driving the progression of neurodegeneration (Boeve and Hutton, 2008). Some forms of FTD are caused by mutations in the intron following MAPT exon 10 which disrupt an intronic splice silencer and elevate the expression of 4R tau (Kar et al., 2005), thereby inducing pathological changes (Schoch et al., 2016).

It was reasoned that dCasRx targeted to *MAPT* exon 10 could induce exon exclusion to alleviate dysregulated 4R/3R tau ratios. Patient-derived human induced pluripotent stem cells (hiPSCs) were differentiated into cortical neurons via *Neurogenin-2* directed differentiation for 2 weeks (Zhang et al., 2013). Postmitotic neurons were then transduced with AAV1 carrying dCasRx (**FIG. 12D)** paired with a repeat array containing 3 spacers that target the exon 10 splice acceptor and two putative exonic splice enhancers (F**IG. 12E**). dCasRx-mediated exon exclusion was able to reduce the relative 4R/3R tau ratio by nearly 50% relative to a BFP vehicle control (**FIG. 12F**) and to a level similar to unaffected control neurons, demonstrating that CasRx can be exploited for transcriptional modulation in primary cell types via AAV delivery.

Example 8

RNA Targeting in Human Cells Using Cas13d

RNA can be targeted in human cells using the active Cas13d nuclease. As a proof of concept, human U-2 OS bone osteosarcoma cells were stably integrated with an mCherry reporter and transfected with plasmids encoding human codon optimized Cas13d and guide RNAs targeting the mCherry transcript **(FIG. 13).**

Cas13d proteins were also fused with N- and C-terminal NLS sequences (SPKKKRKVEAS, SEQ ID NO: 256, for the N-terminal NLS and GPKKKRKVAAA, SEQ ID NO: 258, C-terminal NLS) to understand if nuclear localization can affect mCherry knockdown (these are denoted the 2x NLS constructs). Guide RNAs were either provided in a vector with a U6 promoter operably linked to a 36 nt DR-30 nt spacer-36 nt DR sequence, which mimics the unprocessed CRISPR guide array (denoted DR36), or to a 30nt DR-22nt spacer to mimic the processed, mature gRNA (denoted gRNA). The DR36 construct is presumed to be processed by Cas13d into mature gRNAs within the cell. The spacer sequences within the DR36 or gRNA molecules were either complementary to the mCherry target RNA (on-target mCherry) or computationally optimized to avoid complementarity to mCherry or any endogenous human transcript (non-targeting mCherry).

mCherry knockdown was quantified via flow cytometry and normalized to a transfection control. The non-targeting mCherry guides do not affect mCherry protein levels via flow cytometry, presumably because the mCherry transcripts are not targeted. However, the on-target mCherry guides paired with 4 different Cas13d orthologues exhibited significant mCherry knockdown **(FIG. 13).** "XPD" refers to Ruminococcus flavefaciens XPD3002 Cas13d; "P1E0" refers to Gut metagenome P1E0 Cas13d; "AnDig" refers to Anaerobic digester gut metagenome Cas13d; "Uncultured" refers to uncultured Ruminococcus sp. Cas13d.

Example 9

in vivo RNA Targeting Using Cas13d

RNA can be targeted in mouse models of cancer. To observe which cells in the mouse are expressing EGFR, a guide RNA is designed that includes one or more spacer regions complementary to mouse EGFR and is combined with Cas13d having a mutated HEPN domain (such as SEQ ID NO: 2 or 4), and a biotin label. The gRNA and Cas13d coding sequence are cloned into a viral vector (such as a lentivirus) which is used to infect the mice by tail vein injection at a titer to insure 100% infection rates. A fluorescent streptavidin label is administered to the mice. Cells expressing EGFR are visualized and detected with the appropriate excitation frequency for the fluorescent label. Alternatively, Cas13d is delivered in its active form *in vivo* to mediate target knock-down.

Example 10

Treatment of Cancer

Human subjects with histologically confirmed stage 1, EGFR+ breast cancer can be treated with the disclosed methods. Each subject is administered a complex comprising an active Cas13d or a Cas13d protein mutated in the HEPN domain (such as SEQ ID NO: 2 or 4), a guide RNA targeting EGFR, and a toxin, after receiving lumpectomy surgery. Treated individuals are monitored for breast cancer recurrence.

Example 11

Treatment of HIV Infection

Human subjects with HIV infection can be treated with the disclosed methods. Each subject is administered a construct comprising an active Cas13d or a Cas13d protein mutated in the HEPN domain (such as SEQ ID NO: 2 or 4), a guide RNA targeting HIV Nef protein, and a toxin. Treated individuals are monitored for HIV progression.

Example 12

Treatment of Huntington's Disease

Human subjects with Huntington's Disease can be treated with the disclosed methods. Each individual is administered a construct comprising Cas13d, a guide RNA targeting the Huntington mutation. Treated individuals are monitored for disease progression.

Example 13

Alternative Splicing Using Cas13d

Cas13d splice effectors can be used for therapeutic protein restoration (for example that results from a mutation or deletion), gene knockdown via frameshift induction, tuning or restoring a desired isoform ratio, or inducing a desired dominant splice isoform (FIG. 14). Alternative splicing is generally regulated by the interaction of cis-acting elements in the pre-mRNA with positive or negative trans-acting splicing factors, which can mediate exon inclusion or exclusion. dCas13d and Cas13d, with optional fusion to positive or negative splicing factors, can be used as splicing effectors that target to said cis-acting elements in the pre-mRNA to manipulate splicing. Such elements can include exonic splicing enhancers or suppressors, intronic splicing enhancers or suppressors, splice acceptor and splice donor sites, and more generally protein- or RNA-interacting motifs or elements on that particular pre-mRNA, mRNA, or other RNA species, such as a non-coding RNA, tRNA, miRNA, and the like.

Additionally, that the effects of Cas13d-based splice effectors can be guide position-dependent. This can be exploited to perturb or discover particular motifs or sites in an RNA transcript such as protein-binding sites, via steric hindrance, blocking, recruitment, or effector-mediated interaction. For example, the interaction between non-coding RNAs and particular chromatin remodeling complexes can be perturbed.

Access of the ribosomal binding site and other elements can be blocked in a 5' or 3' UTR (or to recruit appropriate effector domains) to decrease, increase, or otherwise manipulate translation.

Targeting or tiling Cas13d guides along a pre-mRNA can be used to discover or map new cis-acting elements such as intronic or exonic splice enhancers. This has been exploited in a therapeutic context in the case of the dystrophin gene for optimal antisense oligonucleotide positioning and can also be used for optimal Cas13dpositioning. This can be also used to map, mask, or otherwise perturb RNA zipcodes or other cis-acting elements to affect trafficking and localization, chromatin remodeling, polyadenylation, RNA stability and half-life, or levels of nonsense-mediated decay.

In one example, targeting an RNA allows for changing splicing of the target RNA. Both the direct binding of splice acceptor and/or donor sites as well as splice effector domains can be used to manipulate splicing. For example, by using a dCas13d protein with a mutated HEPN domain (*e.g.*, SEQ ID NO: 2 or 4), a guide RNA containing at least one a spacer sequence specific for the target RNA, and optionally an effector domain that affects splicing (such as the RS-rich domain of SRSF1, the Gly-rich domain of hnRNPA1, the alanine-rich motif of RBM4, or the proline-rich motif of DAZAP1), alternative splicing of the RNA can be achieved.

In some examples, such a method is used for exon inclusion, for example to include exon 2 of acid alpha-glucosidase (GAA) to treat Pompe disease or to include exon 7 of SMN2 to treat spinal muscular atrophy (SMA). In some examples, such a method is used for exon exclusion, for example to restore the reading frame of dystrophin to treat Duchenne muscular dystrophy, to shift the splicing of the Bcl-x pre-mRNA from the antiapoptotic long isoform to the proapoptotic short isoform to treat cancer, to shift the splicing of the MAPT transcript to affect ratios of 3R and 4R tau, or to manipulate the splicing of the lamin A transcript in the case of Hutchinson-Gilford progeria syndrome or other genetic diseases of aging.

In some examples, the method uses a Cas13dprotein, optionally with a mutated HEPN domain, to mask splice acceptor or donor sites, for example to create neoantigens to make cold tumors hot. By affecting the splicing of certain target pre-mRNAs, this method can generate novel exon-exon junctions that can lead to the creation of neo-epitopes in cancer cells. This can make a cancer cell vulnerable to the immune system due to the display of unnatural antigens. In other examples, this method can be used to dynamically manipulate isoform ratios or to restore reading frame of a protein (*e.g.*, dystrophin for Duchenne's muscular dystrophy).

Example 14

AAV delivery of Cas13d

As described in the examples above, Cas13d can be effectively packaged into AAV to mediate expression in cell types that are not amenable to plasmid delivery or for *in vivo* delivery of Cas13d. AAV delivery of nuclease active Cas13d can be used to mediate RNA target knock-down in the cell type of interest. Due to its small size compared to other single-effector CRISPR nucleases, Cas13d can be packaged together with a guide RNA or an array containing multiple guide RNAs in a single AAV vector.

Example 15

Nucleic acid-based diagnostics with Cas13d

Cas13d enzymes can be exploited for nucleic acid-based diagnostics within the context of a cell, using cell-free lysate derived from a cell, or a cell-free system containing an engineered Cas13d enzyme and guide RNA to facilitate formation of a ribonucleoprotein complex. Said guide RNA can be provided in the form of a pre-guide RNA, a mature guide RNA, or an array containing one or more spacer sequences. The components can also be provided in the form of a DNA or RNA precursor encoding for the Cas13d enzyme and appropriate guide RNA design via an *in vitro* transcription/translation system to facilitate the generation of the necessary components. These components of the diagnostic kit comprise the "sensor" module.

Such a method can be used to determine if a target RNA is present in a test sample. Such a method can also be used to detect a pathogen, such as a virus or bacteria, or diagnose a disease state, such as a cancer (e.g., wherein the target RNA is specific for a particular microbe or disease). Such a method can also be used to test the purity or identity of an environmental sample or agricultural sample, such as seed or soil.

The "sensor" module will then be challenged with a test sample in the form of RNA. Said test sample can be, but is not limited to, a genomic DNA sample that is converted into RNA – for example via in vitro transcription - or a direct RNA sample. These samples can be extracted from biological material such as patient samples (*e.g.*, cells, tissue, blood, plasma, serum, saliva, urine, tumor biopsy, cell free DNA or RNA, exosomes, carrier vesicles or particles) and environmental samples (*e.g.*, soil, water, air, seed, or plant samples). In one embodiment to improve diagnostic sensitivity, nucleic acid molecules in the sample are amplified using amplification techniques, such as polymerase chain reaction, recombinase polymerase amplification, loop mediated isothermal amplification, nucleic acid sequence based amplification, strand displacement amplification, rolling circle amplification, ligase chain reaction, and others (e.g., those that use isothermal amplification). Said amplification techniques can optionally employ nucleic acid conversion techniques such as transcription or reverse transcription with randomized primers or targeted primers.

If the sensor module recognizes a cognate target in the test sample, it will activate an RNase activity. This RNase activity can be detected by using a detectable label. In one example, the detectable label includes an RNA linked to a fluorophore and quencher. The intact detectable RNA links the fluorophore and quencher, suppressing fluorescence. Upon cleavage by Cas13d of the detectable RNA, the fluorophore is released from the quencher and displays detectable fluorescent activity.

In another example, cleavage of the reporter RNA releases a non-fluorescent molecule, which can be converted into a visible signal (e.g., visible by eye). In one example, cleavage of the reporter RNA releases a molecule that can be detected via lateral flow. A molecule that can be detected by lateral flow is any molecule that can be bound specifically by antibodies. In one example, the Cas13d protein along with the guide RNA detecting the target and the reporter RNA conjugated to the reporter molecule can be delivered as a single system in the form of a dry test strip. Upon incubation with the test sample, Cas1Cas13d protein a3d, guide RNA and the reporter RNA are rehydrated and in the presence of the RNA target. The Cas13d

protein will cleave the reporter RNA, resulting in the migration of the reporter molecule in the test strip via lateral flow and a resulting positive test line signal by binding to antibodies localized there. Such a shelf stable dry detection system not requiring special (frozen) storage could for example prove advantageous in situations where detection of a target RNA or DNA is performed outside a centralized laboratory facility such as a doctor's office, a hospital, a pharmacy, during field work, in an agricultural setting and so forth.

Cas13d is active over a broad range of temperatures making such an application outside of a controlled laboratory environment feasible.

Example 16

Cas13d as a diagnostic for RNA or DNA transcribed into RNA *in vitro*

Cas13d is capable of converting the presence of a matched target RNA into a visible signal in a minimal diagnostic *in vitro* system. **FIGS. 15A-15D** (A) Cas13d is converted into an active RNase complex upon binding a target matching the spacer sequence of the guide RNA. It is capable of cleaving gRNA-complementary target RNA or non-complementary bystander RNAs. (B) Cas13d target-dependent RNase activity can be converted into a detectable signal, for example through cleavage of a labeled detector RNA that is cleaved only in the presence of a target matching the spacer of the Cas13d guide RNA. In this example, the detector RNA contains a fluorophore, 'F', and a quencher 'Q', that abolishes fluorescence. Only upon bystander RNA cleavage is the fluorophore liberated from the quencher and fluorescence is generated. (C) Cas13d from *E. siraeum* produces a visible signal only in the presence of a perfectly matched target and not in the presence of different mismatched targets. (D) Cas13d from *R. flavefaciens* strain XPD3002 produces a visible signal only in the presence of a perfectly matched target and not in the presence of different mismatched targets.

Thus, the system disclosed herein can be part of a lateral flow device (or other solid support), that can be used in diagnostics. The presence of an RNA or DNA sequence can be converted into a signal than can then be detected by conventional lateral flow.

Example 17

Cas13d Modifications

FIGS. 16A-16B, Cas13d is amenable to modifications including truncations of regions with low conservation among orthologs. The alignment of Cas13d orthologs in FIG. 16A shows regions with high (green bars) and low (red bars) conservation.

Example 18

Targeting Transcripts *in vivo*

The ccdB gene in bacterial cells was targeted *in vivo* using different nCas1 orthologues, *Eubacterium siraeum* nCas1 (Es_nCas1; SEQ ID NO: 1); *Eubacterium siraeum* nCas1 with mutated HEPN domains (Es_nCas1 HEPN -/-; SEQ ID NO: 2); uncultured Ruminococcus sp. nCas1 (uncul_nCas1; SEQ ID

NO: 3) and uncultured Ruminococcus sp. nCas1 with mutated HEPN domains (uncul_nCas1 HEPN -/-; SEQ ID NO: 4) (**FIG. 17A**). Chemically competent *E. coli* (strain BW25141-DE3) cells were transformed with (1) an arabinose-inducible ccdB plasmid, and (2) a second plasmid (targeting vector) carrying a compatible origin of replication, nCas1 protein coding sequence, and nCas1 guide array containing 4 spacer sequences targeting the ccdB transcript (FIG. 17A).

1. artificial Eubacterium siraeum nCas1 array targeting ccdB
    a. **GAACUACACCCGUGCAAAAAUGCAGGGGUCUAAAAC**UAACGGCUCUCUCUU UUAUAGGUGUAAACC**GAACUACACCCGUGCAAAAAUGCAGGGGUCUAAAA CCUUUAUCUGACAGCAGACGUGCACUGGCCA**GAACUACACCCGUGCAAAAA **UGCAGGGGUCUAAAAC**CAUCAUGCGCCAGCUUUCAUCCCCGAUAUG**GAACU ACACCCGUGCAAAAAUGCAGGGGUCUAAAAC**UAAUGGCGUUUUUGAUGUCA UUUUCGCGGUCCGCUGA (SEQ ID NO: 261)
        i. Full 36 nt direct repeat: **GAACUACACCCGUGCAAAAAUGCAGGGGUCUAAAAC** (SEQ ID NO: 262)
        ii. Spacer 1: UAACGGCUCUCUCUUUUAUAGGUGUAAACC (SEQ ID NO: 263)
        iii. Spacer 2: CUUUAUCUGACAGCAGACGUGCACUGGCCA (SEQ ID NO: 264)
        iv. Spacer 3: CAUCAUGCGCCAGCUUUCAUCCCCGAUAUG (SEQ ID NO: 265)
        v. Spacer 4: UAAUGGCGUUUUUGAUGUCAUUUUCGCGGUCCGCUGA (SEQ ID NO: 266)
2. artificial uncultured Ruminoccus sp. nCas1 array targeting ccdB
    a. **CUACUACACUGGUGCAAAUUUGCACUAGUCUAAAAC**UAACGGCUCUCUCUU UUAUAGGUGUAAACC**CUACUACACUGGUGCAAAUUUGCACUAGUCUAAAAC** CUUUAUCUGACAGCAGACGUGCACUGGCCA**CUACUACACUGGUGCAAAUUU GCACUAGUCUAAAAC**CAUCAUGCGCCAGCUUUCAUCCCCGAUAUG**CUACUAC ACUGGUGCAAAUUUGCACUAGUCUAAAAC**UAAUGGCGUUUUUGAUGUCAUU UUCGCGGUCCGC (SEQ ID NO: 267)
        i. Full 36 nt direct repeat: **CUACUACACUGGUGCAAAUUUGCACUAGUCUAAAAC** (SEQ ID NO: 268)
        ii. Spacer 1: UAACGGCUCUCUCUUUUAUAGGUGUAAACC (SEQ ID NO: 269)
        iii. Spacer 2: CUUUAUCUGACAGCAGACGUGCACUGGCCA (SEQ ID NO: 270)
        iv. Spacer 3: CAUCAUGCGCCAGCUUUCAUCCCCGAUAUG (SEQ ID NO: 271)
        v. Spacer 4: UAAUGGCGUUUUUGAUGUCAUUUUCGCGGUCCGCUGA (SEQ ID NO: 272)
3. Target RNA (ccdB sequence)

a. AUGCAGUUUAA**GGUUUACACCUAUAAAAGAGAGAGCCG**UUAUCGUCUGUUU GUGGAUGUACAGAGUGAUAUUAUUGACACGCCCGGGCGACGGAUGGUGAUCC CCC**UGGCCAGUGCACGUCUGCUGUCAGAUAAAG**UCUCCCGUGAACUUUACC CGGUGGUG**CAUAUCGGGGAUGAAAGCUGGCGCAUGAUG**ACCACCGAUAUG GCCAGUGUGCCGGUCUCCGUUAUCGGGGAAGAAGUGGCUGAUCUCAGCC**ACC GCGAAAAUGACAUCAAAAACGCCAUUA**ACCUGAUGUUUUGGGGAAUA (SEQ ID NO: 273)

   i. spacer 1 target: **GGUUUACACCUAUAAAAGAGAGAGCCGUUA** (SEQ ID NO: 274)

   ii. spacer 2 target: **UGGCCAGUGCACGUCUGCUGUCAGAUAAAG** (SEQ ID NO: 275)

   iii. spacer 3 target: **CAUAUCGGGGAUGAAAGCUGGCGCAUGAUG** (SEQ ID NO: 276)

   iv. spacer 4 target: **ACCGCGAAAAUGACAUCAAAAACGCCAUUA** (SEQ ID NO: 277)

   v. dCas9 target (underlined): UUAUCGUCUGUUUGUGGAUG (SEQ ID NO: 259)

The transformed bacteria were plated on 2 mM arabinose plates to induce ccdB expression and harvested after 24 hours. Total RNA was extracted with Trizol followed by random hexamer-mediated reverse transcription and Taqman probe-based qPCR.

Mutation of the two HEPN domains in each nCas1 protein demonstrate no targeting of ccdB (**FIG. 17B**, HEPN -/-), while active wild-type nCas1 proteins knock downed the expression of ccdB (**FIG. 17B**, Es_nCas1; uncul_nCas1). Because dCas9-(catalytically inactive, or "dead" Cas9)-mediated transcriptional repression through binding of the DNA sequence downstream of the transcriptional start site is a current standard in the field, we validate the assay by targeting dCas9 to the ccdB promoter to repress transcription of the ccdB gene. Taken together, this data demonstrates guide RNA-specific degradation of target transcripts *in vivo* within prokaryotic cells in a HEPN domain-dependent manner.

Example 19

Cas13d Orthologs Decrease Expression in Human Cells

Fifty different Cas13d orthologs (some of which included NLS tags SPKKKRKVEAS SEQ ID NO: 256 and GPKKKRKVAAA SEQ ID NO: 25, or two HIV NES sequences (LQLPPLERLTL, SEQ ID NO: 287, see Table 1) were tested for their ability to decrease mCherry or endogenous CD81 expression in 293 cells.

Cell culture

Human embryonic kidney (HEK) cell line 293FT (Thermo Fisher) was maintained in DMEM (4.5 g/L glucose), supplemented with 10% FBS (GE Life Sciences) and 10 mM HEPES at 37°C with 5% CO_2. Upon reaching 80-90% confluency, cells were dissociated using TrypLE Express (Life Technologies) and passaged at a ratio of 1:2.

Transient transfection of human cell lines

Cas13d orthologs were cloned into common expression backbones flanked either by two HIV NES sequences (SEQ ID NO: 287) or two SV40 NLS sequences (SPKKKRKVEAS, SEQ ID NO: 256 and GPKKKRKVAAA, SEQ ID NO: 25), and a T2A-linked EGFP. Spacers targeting CD81 were cloned into guide expression constructs in which an array of two spacers was driven by a U6 promoter.

Prior to transient transfection, HEK 293FT cells were plated at a density of 20,000 cells per well in a 96-well plate and transfected at >90% confluence with 200 ng of Cas13 expression plasmid and 200 ng of gRNA expression plasmid using Lipofectamine 2000 (Life Technologies) according to the manufacturer's protocol. Transfected cells were harvested 72 hours post-transfection for flow cytometry.

Flow cytometry

Prior to analysis by flow cytometry, 293FT cells were blocked with Human Trustain FcX Blocking Solution (Biolegend) for 10 minutes at room temperature in FACS Buffer (1X $DPBS^{-/-}$, 0.2% BSA, 2 mM EDTA). Cells were then stained for 15 minutes on ice with α-CD81-APC (1:400 for 293FTs Miltenyi Biotec) or REA293 (S) Isotype Control (Miltenyi Biotec) antibodies. Flow cytometry was performed in 96-well plate format using a MACSQuant VYB (Miltenyi Biotec) and analyzed using FlowJo 10.

As shown in Table 1, several of orthologs had significant knowndown activity (*i.e.*, a lower value for the knockdown efficiency). In Table 1, (trunc) indicates a version of the ortholog with a truncation of the non-conserved N-terminus. NES indicates orthologs with a dual HIV NES fusion (SEQ ID NO: 287) and NLS indicates orthologs with a dual SV40 NLS fusion (SEQ ID NOS: 256 and 25).

Table 1: mCherry activity screen of Cas13d orthologs in human cells.

Ortholog	Knockdown Efficiency	Standard Deviation	Seq ID No.
Ga7274-NLS	12.7	1.0	198
Rfx-NLS	18.6	2.6	280
Ur(trunc)-NLS	19.0	1.2	3
twins_985-NES	20.7	1.3	212
Ga_0531-NES	22.3	2.8	235
Ga_0531-NLS	22.6	0.5	235
k87-NES	24.7	3.1	189
twins_985-NLS	26.4	1.8	212

Ur(trunc)-NES	27.7	1.0	3
stool_9834-NLS	29.0	2.4	208
OGPN-NES	32.6	1.9	164
Ur-NLS	33.9	0.7	3
OGZC-NES	34.7	1.7	155
Ga_9260-NLS	36.5	6.6	237
NFIR-NLS	36.7	1.5	166
Ga_9260-NES	38.3	2.9	237
DJXD-NLS	39.2	3.0	153
OGZC-trunc	40.3	1.1	155
k87-NLS	41.1	4.6	189
PIG_6364-NLS	41.2	6.3	243
twins_300-NLS	42.8	5.9	210
DLF_1914-NES	44.5	10.5	224
BMZ_7771-NLS	46.4	5.9	218
PIG_3397-NES	46.9	3.2	245
Ga7274-NES	47.7	3.6	198
PIG_5479-NES	49.1	3.6	249
OCTW-NLS	50.1	10.8	183
PIG_6364-NES	50.3	2.1	243
Piggy-NES	51.6	5.4	170
OGNF-NLS	52.3	3.2	185
Ga_8792-NES	52.9	1.9	206
OJMM-NES	53.1	1.5	175
OGDF-NLS	53.6	3.4	162
GL_3589-NLS	53.7	3.5	216
Ga_5336-NLS	53.7	0.6	233
OGDF-NES	54.6	1.4	162
BMZ_7915-NES	55.7	8.0	220
OCTW-NES	55.9	10.8	183
OBVH-NLS	56.5	5.2	147
Ga8792-NLS	59.0	8.8	206
OJMM-NLS	59.1	1.6	175
BMZ_7915-NLS	59.9	9.7	220
BMZ_7771-NES	59.9	4.6	218
Rfx-NES	60.5	7.7	92

Ga_4192	62.2	5.8	229
twins_300-NES	62.4	8.4	210
DJXD-NES	63.5	8.2	153
Ga_8067-NES	63.7	10.9	204
PIG_5479-NLS	64.4	20.8	249
Ga0735-NLS	65.2	12.4	202
OGPN-NLS	66.2	6.4	164
Piggy-NLS	66.3	8.0	147
MH_4866-NLS	67.1	4.1	292
OIEN-NES	67.8	16.6	187
Ga_4192-NLS	68.7	2.2	229
Ga_0735-NES	69.2	12.0	202
OHCP-NLS	69.2	4.1	160
OIEN-NLS	69.6	7.2	187
DBYI-NLS	70.5	13.7	149
Ga5759-trunc	71.2	15.2	251
DBYI-NES	71.5	7.1	149
stool_9834-NES	72.6	3.9	208
Ga_6931-NLS	73.4	5.2	231
MH_4866-NES	76.6	3.1	292
O2UC_6317-NES	79.2	2.7	241
OGNF-NES	80.2	10.2	185
Ga_6931-NES	83.3	15.9	231
OCVV-NES	84.8	14.7	181
O2UC_6317-NLS	86.2	6.6	241
ODAI_557-NES	86.5	14.4	
Ga5759-NLS	91.1	10.3	251
ODAI1274-NLS	92.0	9.0	177
Ga_5336-NES	93.5	2.8	233
OCVV-NLS	93.5	5.6	181
GL_3589-NES	95.4	3.5	216
PIG_9734-NLS	97.1	10.6	247
EMG3641-NES	105.8	7.6	200
GL_4153-NLS	106.7	5.3	214
BMZ_9617-NES	110.0	7.8	222
EMG3641-NLS	112.6	11.3	200

Ga8067-NLS	111.4	16.1	204

The data in Table 1 were plotted as relative mCherry expression (knockdown efficiency) vs. size of the ortholog, and compared to CasRx (SEQ ID NO: 280). As shown in FIG. 19A, three orthologs (Ga0531-NLS, k87-NES, and Ga7274-NLS, SEQ ID NOS: 235, 189, and 198, respectively) show comparable activity to the CasRx variant (SEQ ID NO: 280).

The 25 most active orthologs shown in Table 1 and FIG. 19A were tested for their ability to decrease expression of an endogenous gene, CD81, in HEK293 cells. As shown in FIG. 19B, the CasRx variant RfxCas13d-NLS (SEQ ID NO: 280) exhibited the highest level of knock-down, with several additional orthologs exhibiting >75% knock-down on this endogenous target.

Analysis of the five orthologs exhibiting >70% knock-down indicated the following consensus motifs are present at a higher frequency in Cas13d orthologs with high activity in human cells compared to Cas13d orthologs with low activity (<50% knock-down). Thus, provided herein are Cas13d proteins having such a consensus motif (*e.g.*, protein sequences comprising SEQ ID NO: 288, 289, 290, or 291, as well as nucleic acids encoding such, vectors encoding such nucleic acids, and methods of using such proteins/ nucleic acids):

1. L-[DE]-G-K-E-I-N-x-[LM]-x-[CST]-[ANST]-L-I-x-K-F-[DE]-[GN]-I-x-[ADS]-[FIL]-x-[DEHK]-[AILV] (SEQ ID NO: 288)
2. R-N-[FY]-I-[AIL]-x-N-V-[ILV]-x-[NS]-x(2)-F-x-Y-[ILV]-[AIV]-[KR]-[HY]-x(2)-[PT]-x(3)-[HKR]-x-[IL]-x(2)-N-x(2)-[ILV]-x(2)-[FY]-V-L-x(2)-[ILM]-[AGP]-[DE]-x(4)-[NQRS] (SEQ ID NO: 289)
3. L-x-[LM]-[ST]-[IV]-x-Y-x(3)-K-[NS]-[ILM]-V-x-[IV]-N-[AST]-R-[FY]-x(2)-[AG]-[FY]-x-[ACV]-[LV]-E-R-D-x(2)-[FL] (SEQ ID NO: 290)
4. P-F-[AGS]-Y-[CNV]-x-[AP]-R-[FY]-K-N-L-[ST]-x-[EN]-x-L-F-x-[DKR]-[DEN] (SEQ ID NO: 291)

Example 20

Comparison of Knock-Down Activity of CasRx to PspCas13b-NES

The ability of CasRx (RfxCas13d-NLS design; SEQ ID NO: 280) knock-down endogenous CD81 protein expression in 293FT cells was compared to PspCas13b-NES (see Cox *et al.*, *Science*. 2017 Nov 24;358(6366):1019-1027). 293FT cells were cultured, transiently transfected, and three days later, CD81 expression was detected using flow cytometry, as described in Example 19.

As shown in FIG. 20, CasRx (SEQ ID NO: 280) displays significantly higher activity at equivalent protein levels (as measured by Cas13-GFP expression), indicating a higher activity per enzyme unit and therefore a lower required dose to reach a biologically/therapeutically relevant level of knock-down. In addition, CasRx is significantly smaller than PspCas13b. The small size and high activity at lower doses makes CasRx useful for therapeutic delivery.

Example 21

Effect of Deletions on Cas13d Orthologs

The effect of deletions on Cas13d orthologs was tested as follows. Briefly, amino acid (aa) deletions were engineered into two different Cas13d orthologs, Ga-531 (SEQ ID NO: 235) and RfxCas13d (SEQ ID NO: 280). The amino acid deletions were made at the N-terminus, C-terminus, or internally. Regions for truncation were chosen based on their low conservation between Cas13d orthologs (*e.g.*, see FIGS. 18A-18MMM). Up to 50 aa deletions were made in a single protein. The resulting protein sequences are shown in Table 2.

Table 2: Cas13d mutations (**Bold**= NLS/NES tag, <u>underlined</u> = inserted linker sequence; *italics* = flanking sequence)

Effector	Sequence (SEQ ID NO:)	Description
NLS-Ga_0531(trunc)-NLS-HA	MS**PKKKRK***VEASKQSKK*TFAKASGLKST LAVDNSAVMTVFGRGNEAKLDHRINAD LQSESLHPQAALKNVHAPNKQKIHFIGR MQDMNLTADHPLHSHDGERAVGADLL CAKDKLEQLYFGRTFNDNIHIQLIYQILD IQKILALHANNIIFALDNLLHKKNDELSD DFVGMGRMRATIGYDAFRNSTNQKVQE TYREFQEFVRRKELLYFGSAFYNGDTRR DEKVIYHILSLAASVRQFCFHNDYTSDD GKGFIKADWMYRLEEALPAEYKDTLDA LYLEGVEGLDQSFLKNNTVNIQILCSIFN HDDPNKIAEEYYGFLMTKEYKNMGFSIK KLRECMLELPELSGYKEDQYNSVRSKLY KLFDFIIAHYFRKHPEKGEEMVDCLRLC MTEDEKDSHYEGTAKKLVRELAYDMQ EAAEQANGSNITQMQKNEQQGKTKGMF AIRDEIRVSRKPVSYFSKVIYVMTLLLDG KEINDLLTTLINKFENIVSFEDVLRQLNV DCTFKPEFAFFGYDRCRNISGELRLINSF ARMQKPSAKAKHVMYRDALRILGLDN GMSEEALDQEVRRILQIGADGKPIKNAN KGFRNFIASNVIESSRFRYLVRYNNPHKT RMIAQNEAIVRFVLSEIPDEQIRRYYDVC RDPKLPRSSSREAQVDILTGIITDVNYRIF EDVPQSKKINKDRPDANDRMTLKKQRY QAIVSLYLTVMYLVTKNLVYYVNSRYVM AFHALERDAYLYGITNIKGDYRKLTDNL LADENYKKFGHFKNKKWRGIAEQNLRN SDVPVIKSFRNMAAHISVIRNIDLYIGDIQ KVDSYFALYHFLMQKLIQRVVPENTKG LSDQTKKYYDALEQYNTYCKDFVKAYC TPFAYVTPRYKNLTIDGLFDRNRPGEDK GSG**PKKKRKV**AAAYPYDVPDYA (SEQ ID NO: 278)	N-terminal deletion
NES-Ga_0531(tr	M**LQLPPLERL***TLGSGKQSKK*TFAKASGL KSTLAVDNSAVMTVFGRGNEAKLDHRI	N-terminal deletion

unc)-NES-HA	NADLQSESLHPQAALKNVHAPNKQKIHF IGRMQDMNLTADHPLHSHDGERAVGAD LLCAKDKLEQLYFGRTFNDNIHIQLIYQI LDIQKILALHANNIIFALDNLLHKKNDEL SDDFVGMGRMRATIGYDAFRNSTNQKV QETYREFQEFVRRKELLYFGSAFYNGDT RRDEKVIYHILSLAASVRQFCFHNDYTS DDGKGFIKADWMYRLEEALPAEYKDTL DALYLEGVEGLDQSFLKNNTVNIQILCSI FNHDDPNKIAEEYYGFLMTKEYKNMGF SIKKLRECMLELPELSGYKEDQYNSVRS KLYKLFDFIIAHYFRKHPEKGEEMVDCL RLCMTEDEKDSHYEGTAKKLVRELAYD MQEAAEQANGSNITQMQKNEQQGKTK GMFAIRDEIRVSRKPVSYFSKVIYVMTLL LDGKEINDLLTTLINKFENIVSFEDVLRQ LNVDCTFKPEFAFFGYDRCRNISGELRLI NSFARMQKPSAKAKHVMYRDALRILGL DNGMSEEALDQEVRRILQIGADGKPIKN ANKGFRNFIASNVIESSRFRYLVRYNNPH KTRMIAQNEAIVRFVLSEIPDEQIRRYYD VCRDPKLPRSSSREAQVDILTGIITDVNY RIFEDVPQSKKINKDRPDANDRMTLKKQ RYQAIVSLYLTVMYLVTKNLVYVNSRY VMAFHALERDAYLYGITNIKGDYRKLT DNLLADENYKKFGHFKNKKWRGIAEQN LRNSDVPVIKSFRNMAAHISVIRNIDLYI GDIQKVDSYFALYHFLMQKLIQRVVPEN TKGLSDQTKKYYDALEQYNTYCKDFVK AYCTPFAYVTPRYKNLTIDGLFDRNRPG EDKGSG**LQLPPLERLTL**YPYDVPDYA (SEQ ID NO: 279)	
NLS-RfxCas13d-NLS-HA	MS**PKKKRKV**EASIEKKKSFAKGMGVKS TLVSGSKVYMTTFAEGSDARLEKIVEGD SIRSVNEGEAFSAEMADKNAGYKIGNAK FSHPKGYAVVANNPLYTGPVQQDMLGL KETLEKRYFGESADGNDNICIQVIHNILD IEKILAEYITNAAYAVNNISGLDKDIIGFG KFSTVYTYDEFKDPEHHRAAFNNNDKLI NAIKAQYDEFDNFLDNPRLGYFGQAFFS KEGRNYIINYGNECYDILALLSGLRHWV VHNNEEESRISRTWLYNLDKNLDNEYIS TLNYLYDRITNELTNSFSKNSAANVNYI AETLGINPAEFAEQYFRFSIMKEQKNLGF NITKLREVMLDRKDMSEIRKNHKVFDSI RTKVYTMMDFVIYRYYIEEDAKVAAAN KSLPDNEKSLSEKDIFVINLRGSFNDDQK DALYYDEANRIWRKLENIMHNIKEFRGN KTREYKKKDAPRLPRILPAGRDVSAFSK LMYALTMFLDGKEINDLLTTLINKFDNI QSFLKVMPLIGVNAKFVEEYAFFKDSAK IADELRLIKSFARMGEPIADARRAMYIDA IRILGTNLSYDELKALADTFSLDENGNKL KKGKHGMRNFIINNVISNKRFHYLIRYG DPAHLHEIAKNEAVVKFVLGRIADIQKK QGQNGKNQIDRYYETCIGKDKGKSVSE	No Deletion

	KVDALTKIITGMNYDQFDKKRSVIEDTG RENAEREKFKKIISLYLTVIYHILKNIVNI NARYVIGFHCVERDAQLYKEKGYDINL KKLEEKGFSSVTKLCAGIDETAPDKRKD VEKEMAERAKESIDSLESANPKLYANYI KYSDEKKAEEFTRQINREKAKTALNAYL RNTKWNVIIREDLLRIDNKTCTLFRNKA VHLEVARYVHAYINDIAEVNSYFQLYH YIMQRIIMNERYEKSSGKVSEYFDAVND EKKYNDRLLKLLCVPFGYCIPRFKNLSIE ALFDRNEAAKFDKEKKKVSGNSGSG**PK KKRKV**AAAYPYDVPDYA (SEQ ID NO: 280)	
NLS- RfxCas13d (del5)- NLS-HA	MS**PKKKRKV**EASIEKKKSFAKGMGVKS TLVSGSKVYMTTFAEGSDARLEKIVEGD SIRSVNEGEAFSAEMADKNAGYKIGNAK FSHPKGYAVVANNPLYTGPVQQDMLGL KETLEKRYFGESADGNDNICIQVIHNILD IEKILAEYITNAAYAVNNISGLDKDIIGFG KFSTVYTYDEFKDPEHHRAAFNNNDKLI NAIKAQYDEFDNFLDNPRLGYFGQAFFS KEGRNYIINYGNECYDILALLSGLRHWV VHNNEEESRISRTWLYNLDKNLDNEYIS TLNYLYDRITNELTNSFSKNSAANVNYI AETLGINPAEFAEQYFRFSIMKEQKNLGF NITKLREVMLDRKDMSEIRKNHKVFDSI RTKVYTMMDFVIYRYYIEEDAKVAAAN KSLPDNEKSLSEKDIFVINLRGSFNDDQK DALYYDEANRIWRKLENIMHNIKEFRGN KTREYKKKDAPRLPRILPAGRDVSAFSK LMYALTMFLDGKEINDLLTTLINKFDNI QSFLKVMPLIGVNAKFVEEYAFFKDSAK IADELRLIKSFARMGEPIADARRAMYIDA *IRILG*GGGGSGGGGS*MRNFI*INNVISNKRF HYLIRYGDPAHLHEIAKNEAVVKFVLGR IADIQKKQGQNGKNQIDRYYETCIGKDK GKSVSEKVDALTKIITGMNYDQFDKKRS VIEDTGRENAEREKFKKIISLYLTVIYHIL KNIVNINARYVIGFHCVERDAQLYKEKG YDINLKKLEEKGFSSVTKLCAGIDETAPD KRKDVEKEMAERAKESIDSLESANPKLY ANYIKYSDEKKAEEFTRQINREKAKTAL NAYLRNTKWNVIIREDLLRIDNKTCTLF RNKAVHLEVARYVHAYINDIAEVNSYF QLYHYIMQRIIMNERYEKSSGKVSEYFD AVNDEKKYNDRLLKLLCVPFGYCIPRFK NLSIEALFDRNEAAKFDKEKKKVSGNSG SG**PKKKRKV**AAAYPYDVPDYA (SEQ ID NO: 281)	Amino acids 558-587 deleted
NLS- RfxCas13d (del5.12)- NLS-HA	MS**PKKKRKV**EASIEKKKSFAKGMGVKS TLVSGSKVYMTTFAEGSDARLEKIVEGD SIRSVNEGEAFSAEMADKNAGYKIGNAK FSHPKGYAVVANNPLYTGPVQQDMLGL KETLEKRYFGESADGNDNICIQVIHNILD IEKILAEYITNAAYAVNNISGLDKDIIGFG KFSTVYTYDEFKDPEHHRAAFNNNDKLI	Amino acids 558-587 and 953-966 deleted

	NAIKAQYDEFDNFLDNPRLGYFGQAFFS KEGRNYIINYGNECYDILALLSGLRHWV VHNNEEESRISRTWLYNLDKNLDNEYIS TLNYLYDRITNELTNSFSKNSAANVNYI AETLGINPAEFAEQYFRFSIMKEQKNLGF NITKLREVMLDRKDMSEIRKNHKVFDSI RTKVYTMMDFVIYRYYIEEDAKVAAAN KSLPDNEKSLSEKDIFVINLRGSFNDDQK DALYYDEANRIWRKLENIMHNIKEFRGN KTREYKKKDAPRLPRILPAGRDVSAFSK LMYALTMFLDGKEINDLLTTLINKFDNI QSFLKVMPLIGVNAKFVEEYAFFKDSAK IADELRLIKSFARMGEPIADARRAMYIDA *IRILG*GGGGSGGGGS*MRNFI*INNVISNKRF HYLIRYGDPAHLHEIAKNEAVVKFVLGR IADIQKKQGQNGKNQIDRYYETCIGKDK GKSVSEKVDALTKIITGMNYDQFDKKRS VIEDTGRENAEREKFKKIISLYLTVIYHIL KNIVNINARYVIGFHCVERDAQLYKEKG YDINLKKLEEKGFSSVTKLCAGIDETAPD KRKDVEKEMAERAKESIDSLESANPKLY ANYIKYSDEKKAEEFTRQINREKAKTAL NAYLRNTKWNVIIREDLLRIDNKTCTLF RNKAVHLEVARYVHAYINDIAEVNSYF QLYHYIMQRIIMNERYEKSSGKVSEYFD AVNDEKKYNDRLLKLLCVPFGYCIPRFK NLSIEAL*FDRNEGSGPK***KKRKV**AAAYPY DVPDYA (SEQ ID NO: 282)	
NLS-RfxCas13d (del5.13)-NLS-HA	M**SPKKKRKV**EASIEKKKSFAKGMGVKS TLVSGSKVYMTTFAEGSDARLEKIVEGD SIRSVNEGEAFSAEMADKNAGYKIGNAK FSHPKGYAVVANNPLYTGPVQQDMLGL KETLEKRYFGESADGNDNICIQVIHNILD IEKILAEYITNAAYAVNNISGLDKDIIGFG KFSTVYTYDEFKDPEHHRAAFNNNDKLI NAIKAQYDEFDNFLDNPRLGYFGQAFFS KEGRNYIINYGNECYDILALLSGLRHWV VHNNEEESRISRTWLYNLDKNLDNEYIS TLNYLYDRITNELTNSFSKNSAANVNYI AETLGINPAEFAEQYFRFSIMKEQKNLGF NITKLREVMLDRKDMSEIRKNHKVFDSI RTKVYTMMDFVIYRY*YIEEDSEKDI*FVIN LRGSFNDDQKDALYYDEANRIWRKLEN IMHNIKEFRGNKTREYKKKDAPRLPRILP AGRDVSAFSKLMYALTMFLDGKEINDL LTTLINKFDNIQSFLKVMPLIGVNAKFVE EYAFFKDSAKIADELRLIKSFARMGEPIA DARRAMYIDA*IRILG*GGGGSGGGGS*MRN FI*INNVISNKRFHYLIRYGDPAHLHEIAK NEAVVKFVLGRIADIQKKQGQNGKNQI DRYYETCIGKDKGKSVSEKVDALTKIIT GMNYDQFDKKRSVIEDTGRENAEREKF KKIISLYLTVIYHILKNIVNINARYVIGFH CVERDAQLYKEKGYDINLKKLEEKGFSS VTKLCAGIDETAPDKRKDVEKEMAERA KESIDSLESANPKLYANYIKYSDEKKAEE	Amino acids 376-392 and 558-587 deleted

	FTRQINREKAKTALNAYLRNTKWNVIIR EDLLRIDNKTCTLFRNKAVHLEVARYVH AYINDIAEVNSYFQLYHYIMQRIIMNERY EKSSGKVSEYFDAVNDEKKYNDRLLKL LCVPFGYCIPRFKNLSIEALFDRNEAAKF DKEKKKVSGNSGSG**PKKKRKV**AAAYP YDVPDYA (SEQ ID NO: 283)	
NLS-RfxCas13d (del5.12+5.13)-NLS-HA	MS**PKKKRKV**EASIEKKKSFAKGMGVKS TLVSGSKVYMTTFAEGSDARLEKIVEGD SIRSVNEGEAFSAEMADKNAGYKIGNAK FSHPKGYAVVANNPLYTGPVQQDMLGL KETLEKRYFGESADGNDNICIQVIHNILD IEKILAEYITNAAYAVNNISGLDKDIIGFG KFSTVYTYDEFKDPEHHRAAFNNNDKLI NAIKAQYDEFDNFLDNPRLGYFGQAFFS KEGRNYIINYGNECYDILALLSGLRHWV VHNNEEESRISRTWLYNLDKNLDNEYIS TLNYLYDRITNELTNSFSKNSAANVNYI AETLGINPAEFAEQYFRFSIMKEQKNLGF NITKLREVMLDRKDMSEIRKNHKVFDSI RTKVYTMMDFVIYRY*YIEEDSEKDI*FVIN LRGSFNDDQKDALYYDEANRIWRKLEN IMHNIKEFRGNKTREYKKKDAPRLPRILP AGRDVSAFSKLMYALTMFLDGKEINDL LTTLINKFDNIQSFLKVMPLIGVNAKFVE EYAFFKDSAKIADELRLIKSFARMGEPIA DARRAMYIDA*IRILG*<u>GGGGSGGGGS</u>*MRN FI*INNVISNKRFHYLIRYGDPAHLHEIAK NEAVVKFVLGRIADIQKKQGQNGKNQI DRYYETCIGKDKGKSVSEKVDALTKIIT GMNYDQFDKKRSVIEDTGRENAEREKF KKIISLYLTVIYHILKNIVNINARYVIGFH CVERDAQLYKEKGYDINLKKLEEKGFSS VTKLCAGIDETAPDKRKDVEKEMAERA KESIDSLESANPKLYANYIKYSDEKKAEE FTRQINREKAKTALNAYLRNTKWNVIIR EDLLRIDNKTCTLFRNKAVHLEVARYVH AYINDIAEVNSYFQLYHYIMQRIIMNERY EKSSGKVSEYFDAVNDEKKYNDRLLKL LCVPFGYCIPRFKNLSIEAL*FDRNEGSGP **K**KKRKV*AAAYPYDVPDYA (SEQ ID NO: 284)	Amino acids 376-392, 558-587, and 953-966 deleted
NLS-RfxCas13d (del13)-NLS-HA	MS**PKKKRKV**EASIEKKKSFAKGMGVKS TLVSGSKVYMTTFAEGSDARLEKIVEGD SIRSVNEGEAFSAEMADKNAGYKIGNAK FSHPKGYAVVANNPLYTGPVQQDMLGL KETLEKRYFGESADGNDNICIQVIHNILD IEKILAEYITNAAYAVNNISGLDKDIIGFG KFSTVYTYDEFKDPEHHRAAFNNNDKLI NAIKAQYDEFDNFLDNPRLGYFGQAFFS KEGRNYIINYGNECYDILALLSGLRHWV VHNNEEESRISRTWLYNLDKNLDNEYIS TLNYLYDRITNELTNSFSKNSAANVNYI AETLGINPAEFAEQYFRFSIMKEQKNLGF NITKLREVMLDRKDMSEIRKNHKVFDSI RTKVYTMMDFVIYRY*YIEEDSEKDI*FVIN	Amino acids 376-392 deleted

	LRGSFNDDQKDALYYDEANRIWRKLEN IMHNIKEFRGNKTREYKKKDAPRLPRILP AGRDVSAFSKLMYALTMFLDGKEINDL LTTLINKFDNIQSFLKVMPLIGVNAKFVE EYAFFKDSAKIADELRLIKSFARMGEPIA DARRAMYIDAIRILGTNLSYDELKALAD TFSLDENGNKLKKGKHGMRNFIINNVIS NKRFHYLIRYGDPAHLHEIAKNEAVVKF VLGRIADIQKKQGQNGKNQIDRYYETCI GKDKGKSVSEKVDALTKIITGMNYDQF DKKRSVIEDTGRENAEREKFKKIISLYLT VIYHILKNIVNINARYVIGFHCVERDAQL YKEKGYDINLKKLEEKGFSSVTKLCAGI DETAPDKRKDVEKEMAERAKESIDSLES ANPKLYANYIKYSDEKKAEEFTRQINRE KAKTALNAYLRNTKWNVIIREDLLRIDN KTCTLFRNKAVHLEVARYVHAYINDIAE VNSYFQLYHYIMQRIIMNERYEKSSGKV SEYFDAVNDEKKYNDRLLKLLCVPFGY CIPRFKNLSIEALFDRNEAAKFDKEKKK VSGNSGSG**PKKKRKV**AAAYPYDVPDY A (SEQ ID NO: 285)	

293FT cells were cultured, transiently transfected, and three days later, CD81 expression was detected using flow cytometry, as described in Example 19.

As shown in FIG. 21, Cas13d orthologs CasRx and Ga0531 containing deletions in low-conserved regions maintain knock-down activity in human HEK 293FT cells. Based on these results, similar deletions can be made to the other Cas13d orthologs provided herein using the sequence alignments provided herein.

Example 22

dCas13d Mediated Splicing

The ability of several Cas13d orthologs (native and truncated variants, see Example 21) that exhibited high levels of protein knock-down (see Examples 19-20) to direct splicing was tested as follows. Cas13d orthologs (with mutated HEPN domains to abolish target RNA cleavage) were targeted to the slice acceptor site of a bichromatic blue-to-red splice reporter to mediate exon exclusion (as measured by reduction in mTagBFP2 expression). 293FT cells were cultured, transiently transfected, and three days later, CD81 expression was detected using flow cytometry, as described in Example 19.

As shown in FIG. 22, even for orthologs with high levels of endogenous protein knock down (>70% CD81 protein knock down), splicing modulation was in some cases inefficient. However, dCasRx (SEQ ID NO: 280), dCasRx-del13 (SEQ ID NO: 285), and dGa7274 (SEQ ID NO: 198), all exhibited good splicing activity. These three sequences are comparatively closely related and share >70% sequence identity. Thus, Cas13d orthologs, such as CasRx and truncated CasRx variants such as CasRx-del13, can be used to modulate splicing.

Example 23

RNA Editing using Cas13d

This example describes the use of Cas13d to edit RNA expression in human cells.

Cell culture

Human embryonic kidney (HEK) cell line 293FT (Thermo Fisher) was maintained in DMEM (4.5 g/L glucose), supplemented with 10% FBS (GE Life Sciences) and 10 mM HEPES at 37°C with 5% CO_2. Upon reaching 80-90% confluency, cells were dissociated using TrypLE Express (Life Technologies) and passaged at a ratio of 1:2.

Cloning of dCas13d-ADAR mammalian expression constructs

As shown in FIG. 23A, dCas13b and dCas13d coding sequences were cloned into mammalian expression vectors with N- or C-terminal fusions to $ADAR2_{DD}$(T375G) as well as a C-terminal NLS or NES sequence (*e.g.,* see SEQ ID NO: 286). The EGFP reporter used to assess A-to-I RNA editing by dCas13-ADAR fusions was engineered to contain a premature stop codon (UAG) at tryptophan 57 (W57X) and was linked to mCherry by a P2A peptide linker. Guides targeting this EGFP reporter were designed with variable spacer lengths and with A-C mismatches at defined distances away from the Direct Repeat sequence (5' for RfxCas13d and 3' for PspCas13b).

Transient transfection of human cell lines

Prior to transient transfection, HEK 293FT cells were plated at a density of 20,000 cells per well in a 96-well plate and transfected at >90% confluence with 500 ng of total plasmid DNA with 40 ng of EGFP(W57X) reporter plasmid and varying molar ratios of dCas13d-ADAR vector to guide expression vector using Lipofectamine 2000 (Life Technologies) according to the manufacturer's protocol. Transfected cells were harvested 48 hours post-transfection for flow cytometry.

Flow cytometry

Cells were dissociated 48 hours post-transfection with TrypLE Express and resuspended in FACS Buffer (1X $DPBS^{-/-}$, 0.2% BSA, 2 mM EDTA). Flow cytometry was performed in 96-well plate format using a MACSQuant VYB (Miltenyi Biotec) and analyzed using FlowJo 10. Analysis is representative of BFP^+ (expressing dCas13d-ADAR-P2A-mTagBFP2) and $mCherry^+$ (expressing mCherry-P2A-EGFP(W47X)) populations, which were assessed for RNA editing by observing the % of cells expressing EGFP above baseline.

As shown in FIG. 23B, targeted A to I RNA editing of a premature stop codon using Cas13d in an GFP reporter reactivates GFP expression, while the non-targeting guide did not result in RNA editing. FIG. 23C provides quantification of Cas13d-mediated RNA editing efficiency based on the amount of dCas13d-ADAR vector transfected into the cells.

Example 24

Cas13-mediated Identification of Antisense Oligonucleotides

Discovery of effective antisense oligonucleotide (ASO)-binding sites can be a low-throughput and expensive process, due to the lack of genetic encoding, the laborious nature of ASO generation, and the frequent need for chemical modifications. The Cas13 enzymes and variants thereof, such as the Cas13d proteins and variants disclosed herein, can be used to simplify and accelerate the identification of ASO binding sites as the binding of a catalytically active or inactive Cas13/dCas13 can mimic the effect of ASO-mediated RNA cutting and/or binding.

In one example, libraries of Cas13 guide RNAs are generated, for example in well-by-well or pooled oligonucleotide format, and designed to target specific cis-elements of desired RNAs (*e.g.,* tiling the intron of pre-mRNA of a therapeutically important protein, such as dystrophin or SMN1/SMN2, or desired locations within a UTR or gene body to identify effective and site-accessible ASO binding sites). This method can be exploited for ASO lead finding, interrogation of *in vivo* RNA secondary structure, and the identification of known or novel splicing regulatory elements.

Example 25

Increasing Translation with Cas13

The Cas13d enzymes and variants disclosed herein can be used to increase translation of a target protein, by targeted manipulation of post-transcriptional regulatory processes. Cas13d-mediated inhibition (*e.g.,* via steric blocking, or other mechanisms) of upstream open reading frames (uORFs), can be used to achieve this manipulation. For example, Cas13d-mediated inhibition using the Cas13d enzymes and variants disclosed herein can serve as an alternative start site for translation of a human or mammalian gene, or translation-inhibiting motifs and elements within the UTR of a target gene. By inhibiting uORFs, decreased ribosomal competition and other mechanisms can increase in translation of a target gene from a canonical or desired start codon. Nearly half of human transcripts present uORFs (Barbosa *et al.*, *Plos Genetics* 9:e1003529, 2013), which can cause widespread reduction of protein expression. Similarly, by inactivating inhibitory elements within a 5' UTR, such as secondary structure or G-quadruplexes, translation can be increased.

This can be achieved by using a guide RNA to target Cas13d effectors, optionally fused to effector proteins that can increase translation inhibition (*e.g.,* the C-terminal domain MA3 domain of Pdcd4), to uORFs or translation-inhibitory elements. Said guide RNAs can also be delivered in a multiplexed fashion, either via multiple guide RNAs or a pre-gRNA array. Such a method can be used to increase the translation of therapeutically or biotechnologically useful proteins, such as LDLR in familial hypercholesterolemia, CFTR in cystic fibrosis, KCNJ11 in congenital hyperinsulinism, HBB in sickle cell disease, PRKAR1A, IRF6, and others (Barbosa *et al.*, *Plos Genetics* 9:e1003529, 2013; Calvo *et al., PNAS* 106:7507-12, 2009).

Example 26

Synthetic Lethal Genetic Screens with Cas13

The Cas13d enzymes and variants disclosed herein can be used in screening methods to aid in the identification of therapeutic compounds, for example by miming a lead small molecule or inhibitory RNA (RNAi). Exploiting synthetic lethal interactions, such as for a tumor suppressor or oncogene, permits identification of compounds (*e.g.*, small molecule or inhibitory RNA) that selectively inhibit cancer cells or other cells of interest. Conventional high-throughput screening for the discovery of synthetic lethal genetic interactions with chemical compounds, CRISPR-Cas9, and RNAi all have limitations including unknown or multiple target genes (for chemical compounds), pleiotropic effect on off-target genes (chemical compounds and RNAi), and inappropriate dual loss-of-function (for CRISPR-Cas9 or other nuclease-based approaches).

Methods are provided for using the Cas13d enzymes and variants disclosed herein in oncology lead-finding to address these challenges in modeling the "second hit" for pharmacologically-oriented synthetic lethality, due to 1) its specificity for targeting a known target gene or set of genes and 2) its knockdown mechanism, which more accurately reflects the inhibitory mechanism of a small molecule lead. For example, Cas13d or other Cas13 enzymes can be introduced along with cognate guide RNAs into cells that carry a particular mutation (*e.g.,* KRAS mutant lung cancer cells, BRCA-null ovarian cancer cells, and many others). Phenotypic readouts of growth inhibition or cell loss can then be performed either in an arrayed format or a guide RNA-pooled genetic screen, followed by genetic analysis to identify the genes of interest.

References

Abudayyeh (2017). RNA targeting with CRISPR-Cas13 . Nature. 550:280-4.

Abudayye *et al.,* (2016). Science *353*, aaf5573.

Almeida *et al.,* (2012). Cell Rep *2*, 789-798.

Anantharaman *et al.,* (2013) Biol Direct *8*, 15.

Batra *et al.,* (2017). Cell *170*, 899-912 e810.

Birmingham *et al.,* (2006) Nat Methods *3*, 199-204.

Biswas *et al.,* (2016) Stem Cell Reports *7*, 316-324.

Bland *et al.,* (2007). BMC Bioinformatics *8*, 209.

Boeve, B.F., and Hutton, M. (2008). Arch Neurol *65*, 460-464.

Cheong, C.G., and Hall, T.M. (2006). Proc Natl Acad Sci U S A *103*, 13635-13639.

Chiriboga *et al.,* (2016). Neurology *86*, 890-897.

Chylinski *et al.,* (2013). RNA Biol *10*, 726-737.

Cox *et al.,* (2017). Science *358*, 1019-1027.

Deltcheva *et al.,* (2011). Nature *471*, 602-607.

Dobin *et al.,* (2013). Bioinformatics *29*, 15-21.

Doench *et al.,* . (2003). Genes Dev *17*, 438-442.

Doudna, J.A., and Charpentier, E. (2014). Science *346*, 1258096.

Du *et al.,* (2006). Mol Cell Proteomics *5*, 1033-1044.

East-Seletsky *et al.,* (2017). Mol Cell *66*, 373-383 e373.

East-Seletsky *et al.,* (2016). Nature *538*, 270-273.

Edgar, R.C. (2007). BMC Bioinformatics *8*, 18.

Fonfara *et al.,* (2016). Nature *532*, 517-521.

Gasiunas *et al.,* (2012). Proc Natl Acad Sci U S A *109*, E2579-2586.

Gilbert *et al.,* (2014). Cell *159*, 647-661.

Gilbert *et al.* (2013). Cell *154*, 442-451.

Grissa, I., Vergnaud, G., and Pourcel, C. (2007). Nucleic Acids Res *35*, W52-57.

Hammond, S.M., and Wood, M.J. (2011). Trends Genet *27*, 196-205.

Heidrich *et al.,*. (2015). Methods Mol Biol *1311*, 1-21.

Heinz *et al.,* (2010). Mol Cell *38*, 576-589.

Hsu, P.D., Lander, E.S., and Zhang, F. (2014). Cell *157*, 1262-1278.

Jackson *et al.,* (2003). Nat Biotechnol *21*, 635-637.

Jinek *et al.,* (2012). Science *337*, 816-821.

Ka *et al.,* (2005) Alzheimer Dis Assoc Disord *19 Suppl 1*, S29-36.

Kim *et al.* (2017). Nat Commun *8*, 14500.

Liu *et al., (*2017). Cell *168*, 121-134 e112.

Love, M.I., Huber, W., and Anders, S. (2014). Genome Biol *15*, 550.

Makarova *et al.* (2015). Nat Rev Microbiol *13*, 722-736.

Matera, A.G., and Wang, Z. (2014). Nat Rev Mol Cell Biol *15*, 108-121.

Naldini, L. (2015). Gene therapy returns to centre stage. Nature *526*, 351-360.

O'Connell *et al.,* (2014). Nature *516*, 263-266.

Orengo, J.P., Bundman, D., and Cooper, T.A. (2006). Nucleic Acids Res *34*, e148.

Peabody, D.S. (1993). EMBO J *12*, 595-600.

Ran *et al.,* (2015). Nature *520*, 186-191.

Samai *et al.,* (2015). Cell *161*, 1164-1174.

Schena *et al.,* (1995). Science *270*, 467-470.

Schoch *et al.,* (2016). I Neuron *90*, 941-947.

Shendure *et al.,* (2017). Nature 550:345-53.

Shmakov *et al.,* (2015) Mol Cell *60*, 385-397.

Sigoillot *et al.,* (2012). Nat Methods *9*, 363-366.

Smargon *et al.,* (2017). Mol Cell *65*, 618-630 e617.

Smith *et al.,* (2017). PLoS Biol *15*, e2003213.

Swiech *et al.,* (2015). Nat Biotechnol *33*, 102-106.

Treu *et al.,* (2016). Bioresour Technol *216*, 260-266.

van der Oos *et al.,* (2014).. Nat Rev Microbiol *12*, 479-492.

Wang *et al.,* (2015). Biomed Rep *3*, 152-158.

Wright, A.V., and Doudna, J.A. (2016). Nat Struct Mol Biol *23*, 876-883.

Yang *et al.,* (2010). J Proteome Res *9*, 1402-1415.

Yosef *et al.,* (2012). Nucleic Acids Res *40*, 5569-5576.

Zalatan *et al.,* (2015). Cell *160*, 339-350.

Zetsche *et al.,*. (2015). Cell *163*, 759-771.

Zetsche, *et al.,* (2017). A Survey of Genome Editing Activity for 16 Cpf1 orthologs. bioRxiv. doi: https://doi.org/10.1101/134015

Zhang *et al.,* (2016). M Nucleic Acids Res *44*, 1789-1799.

Zhang *et al., (*2013). RNeuron *78*, 785-798.

In view of the many possible embodiments to which the principles of the disclosure may be applied, it should be recognized that the illustrated embodiments are only examples of the invention and should not be taken as limiting the scope of the invention. Rather, the scope of the invention is defined by the following claims. We therefore claim as our invention all that comes within the scope and spirit of these claims.

We claim:

1. A method of targeting one or more target RNA molecules, comprising:

contacting one or more target RNA molecules with a non-naturally occurring or engineered clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) system comprising:

at least one Cas13d protein, or a nucleic acid molecule encoding the at least one Cas13d protein; and

at least one CRISPR-Cas system guide RNA (gRNA) that hybridizes with the one or more target RNA molecules, or at least one nucleic acid molecule encoding the gRNA,

whereby the Cas13d protein forms a complex with the gRNA, wherein the gRNA directs the complex to the one or more target RNA molecules and targets the one or more target RNA molecules.

2. A CRISPR-Cas system-mediated RNA targeting method, comprising:

contacting one or more target RNA molecules with a non-naturally occurring or engineered clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated (Cas) system comprising:

at least one Cas13d protein, or a nucleic acid molecule encoding the at least one Cas13d protein; and

at least one CRISPR-Cas system gRNA that hybridizes with the one or more target RNA molecules, or at least one nucleic acid molecule encoding the gRNA,

whereby the Cas13d protein forms a complex with the gRNA, wherein the gRNA directs the complex to the one or more target RNA molecules and targets the one or more target RNA molecules.

3. The method of claim 1 or 2, wherein contacting the one or more target RNA molecules with the non-naturally occurring or engineered CRISPR-Cas system comprises introducing into a cell containing the one or more target RNA molecules the non-naturally occurring or engineered CRISPR-Cas system.

4. The method of claim 3, wherein the CRISPR-Cas system is introduced into the cell using endocytosis, a liposome, a particle, an exosome, a microvesicle, a gene gun, electroporation, a virus, or combinations thereof.

5. The method of claim 3 or 4, wherein the cell is a eukaryotic cell.

6. The method of any one of claims 1 to 5, wherein the one or more target RNA molecules or the cell are contacted with a complex comprising the at least one Cas13d protein and the at least one CRISPR-Cas system gRNA.

7. The method of any one of claims 1 to 6 wherein the least one Cas13d protein:

comprises one or more HEPN domains,

is no more than 150 kD, no more than 140 kd, no more than 130 kD, no more than 120 kD, such as about 90 to 120 kD, about 100 to 120 kD or about 110 kD,

comprises one or more mutated HEPN domains, and can process the guide RNA, but cannot cut the one or more target RNA molecules,

comprises a Cas13d ortholog from a prokaryotic genome or metagenome, gut metagenome, an activated sludge metagenome, an anaerobic digester metagenome, a chicken gut metagenome, a human gut metagenome, a pig gut metagenome, a bovine gut metagenome, a sheep gut metagenome, a goat gut metagenome, a capybara gut metagenome, a primate gut metagenome, a termite gut metagenome, a fecal metagenome, a genome from the Order Clostridiales, or the Family Ruminococcaceae,

comprises a Cas13d ortholog from Ruminococcus albus, Eubacterium siraeum, Ruminococcus flavefaciens strain XPD3002, Ruminococcus flavefaciens FD-1, uncultured Eubacterium sp TS28-c4095, uncultured Ruminococcus sp., Ruminococcus bicirculans, or Ruminococcus sp CAG57,

comprises at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296;

comprises a motif shown in SEQ ID NO: 195, 196 or 197,

comprises a consensus sequence shown in SEQ ID NO: 288, 289, 290, or 291,

comprises one or more amino acid deletions,

comprises one or more amino acid insertions,

is divided into 2 or more fragments that can reconstitute a full-length functional enzyme when co-delivered,

is modified to be a chimera of different Cas13d orthologs,

is truncated by at least 1%, such as 1 to 10%,

optionally further comprises one or more subcellular localization signals, effector domains, purification tags, affinity tags, or

combinations thereof.

8. The method of any one of claims 1 to 7, wherein the nucleic acid molecule encoding the at least one Cas13d protein comprises:

at least one Cas13d protein coding sequence that is codon optimized for expression in a eukaryotic cell;

at least one Cas13d protein coding sequence that is codon optimized for expression in a prokaryotic cell;

at least one Cas13d protein coding sequence codon optimized for expression in a human cell and comprising at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 142, 143, 144, or 145;

at least one Cas13d protein coding sequence comprising at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 124, 125, 126, 127, 128, 139, 140 or 141;

at least one Cas13d protein coding sequence encoding a protein comprising at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296;

at least one Cas13d ortholog from a prokaryotic genome or metagenome; or

at least one Cas13d ortholog from a gut metagenome, an activated sludge metagenome, an anaerobic digester metagenome, a chicken gut metagenome, a human gut metagenome, a pig gut metagenome, a bovine gut metagenome, a sheep gut metagenome, a goat gut metagenome, a capybara gut metagenome, a primate gut metagenome, a termite gut metagenome, a fecal metagenome, a genome from the Order Clostridiales, or the Family Ruminococcaceae.

9. The method of any one of claims 1 to 8, wherein the nucleic acid molecule encoding the at least one Cas13d protein comprises a promoter operably linked to the at least one Cas13d protein coding sequence, and is optionally part of a vector.

10. The method of any one of claims 1 to 9, wherein gRNA that hybridizes with the one or more target RNA molecules comprises:

a mature gRNA,

a pre-gRNA,

one or more full-length or truncated direct repeat (DR) sequences,

one or more spacer sequences,

one or more sequences comprising DR-spacer-DR-spacer,

one or more DR sequences comprising at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 129, 130, 131, 132, 133, 134, 135, 136, 137, 148, 150, 151, 152, 154, 156, 157, 159, 161, 163, 165, 167, 169, 176, 178, 180, 182, 184, 186, 188, 190, 191, 192, 193, 199, 201, 203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 228, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 252, or 254,

optionally a nucleic acid aptamer inserted into the gRNA,

or combinations thereof.

11. The method of any one of claims 1 to 10, wherein targeting one or more target RNA molecules comprises one or more of cutting the one or more target RNA molecules, nicking the one or more target RNA molecules, activating the one or more target RNA molecules, deactivating the one or more target RNA molecules, visualizing or detecting the one or more target RNA molecules, labeling the one or more target RNA molecules, binding the one or more target RNA molecules, enriching the one or more target RNA molecules, depleting the one or more target RNA molecules, editing the one or more target RNA molecules, trafficking the one or more target RNA molecules, splicing or perturbing the splicing of the one or more target RNA molecules, and masking the one or more target RNA molecules.

12. The method of any one of claims 1 to 11, wherein modifying one or more target RNA molecules comprises one or more of:

an RNA base substitution,

an RNA base deletion,

an RNA base insertion,

a break in the target RNA,

excluding an exon,

including an exon,

perturbing RNA splicing,

perturbing translation of the RNA molecule,

methylating RNA,

demethylating RNA.

13. The method of any one of claims 1 to 12, wherein the one or more target RNA molecules is a non-coding RNA.

14. The method of any one of claims 1 to 13, wherein the method treats a disease, and wherein the one or more target RNA molecules is associated with the disease.

15. The method of any one of claims 1 to 13, wherein a plurality of gRNAs are part of an array.

16. The method of any one of claims 1 to 15, wherein the method is a diagnostic method, wherein:

contacting the one or more target RNA molecules with the non-naturally occurring or engineered CRISPR-Cas system, comprises contacting the non-naturally occurring or engineered CRISPR-Cas system with a sample comprising the one or more target RNA molecules and with a separate RNA comprising a label,

optionally transcribing nucleic acid molecules present in the sample,

optionally amplifying nucleic acid molecules present in the sample, and

detecting the label, wherein detecting the label indicates the presence of one or more target RNAs in the sample.

17. The method of claim 16, wherein the sample comprises DNA, RNA, genomic DNA converted and/or amplified into RNA, biological patient sample, or environmental sample.

18. The method of claim 16 or 17, wherein

the RNA comprising a label comprises an RNA comprising a fluorophore and a quencher, and wherein detecting the label comprises detecting fluorescence emitted from the fluorophore,

the RNA comprising a label comprises an RNA comprising a fluorophore, and wherein detecting the label comprises detecting fluorescence emitted from the fluorophore, or

the RNA comprising a label comprises an RNA comprising a non-fluorescent molecule, and wherein detecting the label comprises detecting the non-fluorescent molecule.

19. The method of any one of claims 1 to 18, wherein the method is performed ex vivo, in vitro, or in a cell-free system.

20. An isolated protein, comprising:

at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72,

73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296;

a motif shown in SEQ ID NO: 195, 196, 197, 288, 289, 290, or 291,

a Cas13d ortholog from a prokaryotic genome or metagenome, gut metagenome, an activated sludge metagenome, an anaerobic digester metagenome, a chicken gut metagenome, a human gut metagenome, a pig gut metagenome, a bovine gut metagenome, a sheep gut metagenome, a goat gut metagenome, a capybara gut metagenome, a primate gut metagenome, a termite gut metagenome, a fecal metagenome, a genome from the Order Clostridiales, or the Family Ruminococcaceae, or

combinations thereof.

21. The isolated protein of claim 20, wherein Cas13d ortholog comprises a Cas13d ortholog from Ruminococcus albus, Eubacterium siraeum, Ruminococcus flavefaciens strain XPD3002, Ruminococcus flavefaciens FD-1, uncultured Eubacterium sp TS28-c4095, uncultured Ruminococcus sp., Ruminococcus bicirculans, or Ruminococcus sp CAG57.

22. The isolated protein of claim 20 or 21, further comprising a subcellular localization signal.

23. The isolated protein of any one of claims 20 to 22, wherein the protein comprises a mutation in at least one native HEPN domain.

24. An isolated guide RNA (gRNA), comprising:

one or more direct repeat (DR) sequences comprising at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 129, 130, 131, 132, 133, 134, 135, 136, 137, 148, 150, 151, 152, 154, 156, 157, 159, 161, 163, 165, 167, 169, 176, 178, 180, 182, 184, 186, 188, 190, 191, 192, 193, 199, 201, 203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 228, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 252, or 254, or a truncated version thereof.

25. The isolated gRNA of claim 24, further comprising one or more spacer sequences specific for a target RNA.

26. A ribonucleoprotein (RNP) complex comprising:

the isolated protein of any one of claims 20 to 23; and

the isolated gRNA of claim 24 or 25.

27. An isolated nucleic acid molecule encoding the protein of any one of claims 20 to 23.

28. The isolated nucleic acid molecule of claim 27, comprising:

at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 124, 125, 126, 127, 128, 139, 140 or 141;

at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 142, 143, 144, or 145; or

encoding for a protein sequence with at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 138, 147, 149, 153, 155, 158, 160, 162, 164, 166, 168, 170, 175, 177, 179, 181, 183, 185, 187, 189, 194, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 278, 279, 280, 281, 282, 283, 284, 285, 292, 293, 294, 295, or 296.

29. A recombinant vector comprising the isolated nucleic acid molecule of claim 27 or 28.

30. The recombinant vector of claim 29, wherein the recombinant vector comprises a plasmid or viral vector.

31. The recombinant vector of claim 29 or 30, wherein the isolated nucleic acid molecule of claim 27 or 28 is operably linked to a promoter.

32. The vector of any of claims 27 to 28, further comprising at least one gRNA of claim 24 or 25, at least one sequence encoding the nCas1 protein of any of claims 20 to 23, or both.

33. A non-bacterial cell comprising the isolated protein of any one of claims 20 to 23, and the isolated gRNA of claim 24 or 25, the RNP complex of claim 26, the isolated nucleic acid molecule of any one of claims 27 to 28, the vector of any one of claims 29 to 32, or combinations thereof.

34. A bacterial cell comprising the isolated protein of any one of claims 20 to 23, and the isolated gRNA of claim 24 or 25, the RNP complex of claim 26, the isolated nucleic acid molecule of any one of claims 27 to

28, the vector of any one of claims 29 to 32, or combinations thereof, wherein the isolated protein of any one of claims 20 to 23, and the isolated gRNA of claim 24 or 25, the RNP complex of claim 26, the isolated nucleic acid molecule of any one of claims 27 to 28, the vector of any one of claims 29 to 32, is not native to the bacterial cell.

35. A composition, comprising:

one or more of

the isolated protein of any one of claims 20 to 23,

the gRNA of claim 24 or 25,

the RNP complex of claim 26,

the isolated nucleic acid molecule of any one of claims 27 to 28,

the vector of any one of claims 29 to 32, and/or

the non-bacterial cell of claim 33, and/or

the bacterial cell of claim 34, and

a pharmaceutically acceptable carrier.

36. A kit, comprising:

one or more of

the isolated protein of any one of claims 20 to 23,

the gRNA of claim 24 or 25,

the RNP complex of claim 26,

the isolated nucleic acid molecule of any one of claims 27 to 28,

the vector of any one of claims 29 to 32, and/or

the non-bacterial cell of claim 33, and/or

the bacterial cell of claim 34, and/or

the composition of claim 35.

37. The kit of claim 36, further comprising a delivery system, a label, or both.

A


CRISPR effector identification
8977 proteins proximal to CRISPR array
all v. all BLASTp
single-linkage hierarchical clustering
408 clusters
cluster expansion: BLASTp each cluster against all proteins (-nr database)
sort clusters by member protein proximity to CRISPR array (>70% co-occurrence)
candidate novel single effector CRISPR proteins
expand protein family via tblastn of metagenome contigs, custom sequencing of genomic DNA fragments
Type VI Cas13d family
CRISPR effector identification system identification
Obtain bacterial and archaeal genome assemblies and scaffolds from NCBI WGS database
Identify interspaced repeat sequence locations
DR' spacer DR
0.6X DR-1X DR 23-55 bp 0.6-2.5X DR
21175 'CRISPRs'
Identify putative Cas proteins in 20kb window around CRISPRs
Eliminate candidate arrays with proteins associated with known CRISPR subtypes
11441 'CRISPRs'
cluster of Cas proteins
CRISPR array
single effector?
Extract proteins >750 aa length and ± 5 proteins from CRISPR array

FIG. 1

FIG. 1B


Signature Cas13d ortholog
P1E0
Adm
Ra
Es
Rfx
Rff
Ur
1
87
153
235
305
399
482
548
615
683
766
809
875
941
Consensus
Identity

FIG. 2A



FIG. 2B



FIG. 2C



FIG. 3A


293
303
849
859
869
Consensus
Identity
Es
Rff
Ur
Ra
P1E0 metagenome
Adm metagenome
Rfx
HEPN-1
HEPN-2

FIG. 3B


Cas13d
average Cas13d size:
~930 aa
Cas13b
Type VI-B1
Cas13b
Type VI-B2
average Cas13b size:
~1150 aa
Cas13c
average Cas13c size:
~1120 aa
Cas13a
average Cas13a size:
~1250 aa
Cas13a
1.72
0.941
0.316
0.735
1.23
1.52
0.195
0.361
1.15
1.86
2.43
0.7


Rfx
Adm
P1E0
Raa
Ur
Rff
Ss

FIG. 3C


Sequence logo of 36 nt Cas13d direct repeats
bits
5'
3'
30
20
10

FIG. 3D

FIG. 4C



FIG. 4B



FIG. 4A



FIG. 5A



FIG. 5B



FIG. 5C



FIG. 5D





FIG. 6B



FIG. 6D



FIG. 6A



FIG. 6C

WO 2019/040664 PCT/US2018/047597

CA 03072610 2020-02-10

FIG. 6E



FIG. 6F





FIG. 6G



H

FIG. 6H



FIG. 7A


ssRNA target
PFS base
5'
3'
1
2
3
4
5
6
7
8
9
10
11
12
PFS base
A
U
C
G
guide
1 2 3 4 5 6 7 8 9 10 11 12 - -
Cas13d
+ + + + + + + + + + + + + -
uncleaved –
ssRNA 1

FIG. 7B


variable base
N N
N
N N
5'
target RNA
3'
guide RNA
5'
variable base
5' - NNNNNXNNNNN - 3'
3' -
5' -
Cas13d only
Cas13d + guide
base identity
G A U C G A U C
uncleaved –
Cas13d only
Cas13d + guide
G A U C G A U C

FIG. 8A



FIG. 8B



FIG. 8C



FIG. 8D




FIG. 9C
shRNA
target RNA
CasRx
5'
3'
1
2
3


HOTTIP
NT
1
2
3
1.0
0.8
0.6
0.4
0.2


FIG. 9B
targeting array
NT array
MALAT1
HOTTIP
ANXA4
B4GALNT1
relative expression
1.0
0.8
0.6
0.4
0.2
0


ANXA4
NT
2
3
4
1.0
0.8
0.6
0.4
0.2
0


FIG. 9A
CasRx
array
processing
5'
3'


CasRx
CRISPRi
3'
5'


FIG. 9D
shRNA
CasRx
CRISPRi
B4GALNT1
NT
1
2
3
4
1.0
0.8
0.6
0.4
0.2
0
guide:
relative expression



FIG. 9G



FIG. 9H



FIG. 9E

FIG. 9F


FIG. 10B
CasRx
Cas13a-msfGFP
Cas13b
relative expression
1.0
0.8
0.6
0.4
0.2
0.0
1
2
NT
RAF1


FIG. 10A
LwaCas13a-msfGFP
PspCas13b
CasRx
relative expression
1.0
0.8
0.6
0.4
0.2
0.0
1
2
3
NT
TP53


FIG. 10D
dCasRx
dCas13a-msfGFP
fold-change in exon exclusion
12
10
8
6
4
2
0
guide
BP
SA
EX
SD


LwaCas13a-msfGFP
relative expression
1.0
0.8
0.6
0.4
0.2
0.0
1
2
3
NT
EZH2


FIG. 10C
dLwaCas13a-msfGFP
guide
–
BP
SA
EX
SD
NT
% dominant isoform
100
75
50
25
0

FIG. 11A



FIG. 11B



FIG. 12A



FIG. 12B



FIG. 12C





FIG. 12D



FIG. 12F

FIG. 12E


on-target mCherry
non-targeting mCherry
relative mCherry expression (%)
0
50
100
150
XPD -NLS gRNA
XPD 2xNLS gRNA
XPD -NLS DR36
XPD 2xNLS DR36
P1E0 -NLS gRNA
P1E0 2xNLS gRNA
P1E0 -NLS DR36
P1E0 2xNLS DR36
AnDi9 -NLS gRNA
AnDi9 2xNLS gRNA
AnDi9 -NLS DR36
AnDi9 2xNLS DR36
Uncultured -NLS gRNA
Uncultured 2xNLS gRNA
Uncultured -NLS DR36
Uncultured 2xNLS DR36

FIG. 13

FIG. 14


gene knockdown via
frameshift induction
protein restoration due to
patient mutation or deletion
targeted splice isoform
exon exclusion
exon inclusion
induce dominant
splice isoform
tune or restore
desired isoform ratio



FIG. 15B



FIG. 15D



FIG. 15A



FIG. 15C

FIG. 16A


1012
961
820
792
HEPN2
10
7
8
9
6
5
710
614
545
HEPN1
4
355
272
179
1
2
3
93
Mtb
Consensus
Identity
Rb
Rtt
Ra
Ad
P1E0
Es
Rtx

FIG. 16B


% exon exclusion
% BFP+ dsRed+ cells
EGFP
CasRx
NO
dCasRx
CasRx del 1
CasRx del 2
CasRx del 3
CasRx del 4
CasRx del 5
CasRx del 6
CasRx del 7
CasRx del 8
CasRx del 9
CasRx del 10

FIG. 17A



FIG. 17B



CA 03072610 2020-02-10

```
CLUSTAL O(1.2.4) multiple sequence alignment

037_-_emb|OIZA01000315.1|          --------------------------MAKKKRMTAKERKQNHRESL----------MK    22
emb|OCTW011587266.1|               ------------------------------------------------------------    0
k87_11092736                       ------------------------------------------------------------    0
BMZ-11B_GL0037915                  ------------------------------------------------------------    0
BMZ-11B_GL0037771                  ------------------------------------------------------------    0
BMZ-11B_GL0069617                  ------------------------------------------------------------    0
Ga0099364_10024192                 ------------------------------------------------------------    0
530373_GL0023589                   ------------------------------------------------------------    0
emb|ODAI011611274.1|               ----------------------------MKKKISLKEQRNTKKAEN----------KL    20
EMG_10003641                       ------------------------------------------------------------    0
CasR_P1E0_metageno                 ------------------------------------------------------------    0
emb|OIZX01000427.1|                ---------------------------MAKKKKTARQLREEMQQQR----------KQ    21
160582958_gene49834                ----------------------------MKNSVTFKLIQAQENKEA----------AR    20
gi|1198542314|gb|NFIR01000008.1|   ----------------------------MAKKLRPKELREKRRMAE----------KE    20
emb|OGNF01009141.1                 ------------------------------------------------------------    0
Ga0129306_1000735                  ------------------------------------------------------------    0
MH0288_GL0082219                   ----------------------------MKKMTAKERREQEKQKR----------AE    19
PIG-022_GL0026351                  ------------------------------------------------------------    0
PIG-028_GL0185479                  ------------------------------------------------------------    0
250twins_35838_GL0110300           --------------------------MGNKQRVSAQKRRENAKLCN----------QQ    22
PIG-014_GL0226364                  ------------------------------------------------------------    0
250twins_36050_GL0158985           ---------------------------MKKKHQSAAEKRQVKKLKN----------QE    21
```

FIG. 18A

```
emb|OJMM01002900.1|                -----------------------------MGKHLNAKQRKLEKKLKN-----------QQ    20
emb|OGPN01002610.1|                -----------------------------MAKKITAKQKREEKERLN-----------KQ    20
emb|OHCP01000044.1|                -----------------------------MAKKITAKQKREEKERLN-----------KQ    20
PIG-046_GL0077813                  -----------------------------MAKKITAKQRREERERQN-----------KQ    20
pig_chimera                        -----------------------------MAKKITAKQRREERERQN-----------KQ    20
emb|OIEN01002196.1|                ------------------------------------------------------------    0
O2.UC29-0_GL0096317                ------------------------------------------------------------    0
CasR_Anaerobic_dig                 ------------------------------------------------------------    0
emb|OGDF01008514.1|                ------------------------------------------------------------    0
emb|OGZC01000639.1                 -----------------------------MKKKNIRATREALKAQK-----------IK    19
Ga0224415_10048792_chimera         ------------------------------------------------------------    0
emb|OCVV012889144.1|               ------------------------------------------------------------    0
Ga0187910_10006931                 ------------------------------------------------------------    0
R._flav_XPD_                       ------------------------------------------------------------    0
Ga0224415_10007274                 ------------------------------------------------------------    0
Ga0187911_10069260                 ------------------------------------------------------------    0
Ga0187910_10015336                 -----------------------------MENVKNPKEIVKGAKVRFEIYENPKPKKQNQ    31
ODAI_chimera                       MLKKCSVCGKKFETNYQGGKPVCRNCRSNKSKPVNPKSSRKPESIDK-----------AI    49
31009_GL0034153                    ------------------------------------------------------------    0
DLF014_GL0011914_                  -----------------------------MAKKKNAKQRREEEKNRL-----------KA    20
CasR_R._albus                      --------------------------MAKKSKGMSLREKRELEKQKR-----------IQ    23
Ga0187910_10040531                 -----------------------------MAKKKKAKQRREEQEAAR-----------MN    20
tpg|DJXD01000002.1|                ------------------------------------------------------------    0
CasR_E._siraeum                    -----------------------------MGKKIHARDLREQRKTDR-----------TE    20
```

FIG. 18B

CA 03072610 2020-02-10

```
PIG-018_GL0023397                ----------------------------MAKKLSPRELREQRERER-----------QA    20
PIG-025_GL0099734                ----------------------------MAKKMNAKEQRAAIQAEK-----------NK    20
Ga0129317_1008067_chimera        ------------------------------------------------------------    0
EYZ-362B_GL0088915               ----------------------------MKKKLNIREQREAKKAAA-----------KQ    20
uncultured_Ru_sp                 --------------------------MAKKNKMKPRELREAQKKAR-----------QL    22
R._flav._FD-1                    ----------------------------MKKKMSLREKREAEKQAK-----------KA    20
tpg|DBYI01000091.1|              ----------------------------MKKKIKARDLREAKKQEK-----------LA    20

037_-_emb|OIZA01000315.1|        KADSNAEKEKAKKPVVENK-----------------PDTAISKDNKPKPNKEIKKSKAK    64
emb|OCTW011587266.1|             ----------------------------------------MKQNDRENNNKIKKSAAK    18
k87_11092736                     ------------------------------------------------MKRQKTFAK     9
BMZ-11B_GL0037915                ----------------------------------------------MAEHSKKTAAK    11
BMZ-11B_GL0037771                ------------------------------------------------MSKDKKTKAK    10
BMZ-11B_GL0069617                ------------------------------------------------MPHNKKSTIK    10
Ga0099364_10024192               ------------------------------------------------MSQSTKTKAK    10
530373_GL0023589                 ----------------------------------MKTEMKNGEVKTSAKKENCSIAK    23
emb|ODAI011611274.1|             KYQKAQAERAAAAQQTAAGAESEENPCFDVVKDT---KRKALNPLHVEIEAPSAKKSSVK    77
EMG_10003641                     ----------------------MEET-----KVT---KETTIEKQSTKRHKQKSKKTATK    30
CasR_P1E0_metageno               ------------------------------------------MEREVKKPPKKSLAK    15
emb|OIZX01000427.1|              AIQKQQEQRQ------------EKAA-----AAR---ETAAPEQPAAAPVPKRQRKSLAK    61
160582958_gene49834              KKAKDIAEQARIAKRNGVVKKEENRI-----NRI---QIEIQTQKKSNTQNAYHLKSLAK    72
gi|1198542314|gb|NFIR01000008.1| EHKKQEK----LRKEQEELRKKQEKQ-----RED---QKELEKIKKEEGGEGEKKKSGAK    68
emb|OGNF01009141.1               ----------------------------------------------MADIDKKKSSAK    12
```

FIG. 18C

CA 03072610 2020-02-10

```
Ga0129306_1000735                 ------------------------------MQK---QREQQTVTDESERKKKPLKSGAK    26
MH0288_GL0082219                  V-----------------IRGKQEAN-----RKK---AQAAATQDATAPVHHKNAKSLAK    54
PIG-022_GL0026351                 ------------------------------------------MAESYKIKSKKTRTK    15
PIG-028_GL0185479                 ------------------------------------------MSESDKIKIKSKKTRTK    17
250twins_35838_GL0110300          KARQAESQRDKIKNMNVEK-------------M-----------KNINTNDIKHTKTTAK    58
PIG-014_GL0226364                 ------------------------------------------MTKPEKKQIKQATLTK    16
250twins_36050_GL0158985          KAQKYASEPSPLQSDTAGV-------------EC--------SQKKTVVSHIASSKTLAK    60
emb|OJMM01002900.1|               KDMMYTKSTDAVSVPTLKA-------------APTKAEMSQDTAEASTLITPGTLKTKAK    67
emb|OGPN01002610.1|               KWAKQDTPVVPKSKTEEKP--------------V---AASDDKLLKTTQVKKVQTKSKAK    63
emb|OHCP01000044.1|               KWAKNDSVIIVPETKEEIK----------------------TGEIQDNNRKRSRQKSQAK    58
PIG-046_GL0077813                 KWAKKQDDATAVFECEANI-------------KP---ADSKDEDCANT--SIKRKKTQAK    62
pig_chimera                       KWAKKQADATAVFECEADI-------------KP---ADSKDEDCTNIYIKREKKKTQAK    64
emb|OIEN01002196.1|               ------------------------------------------MERQKRKMKSKSK    13
O2.UC29-0_GL0096317               ------------------------------------------MERQKRRKKSCAK    13
CasR_Anaerobic_dig                ---------------------------------------------MNNKRKTKAK    10
emb|OGDF01008514.1|               ------------------------------------MTETKPKREDIAKTPAAKSRSK    22
emb|OGZC01000639.1                KSQENEALKKQKLAEEAAQ-------------KRREELEKKNLAQWEETSAEGRRSRVK    65
Ga0224415_10048792_chimera        ---------------------------------------------MSKKENRKSYVK    12
emb|OCVV012889144.1|              ---------------------------------------------MSKNKESYAK    10
Ga0187910_10006931                ---------------------------------------------MIEKKKSYAK    10
R._flav_XPD_                      ---------------------------------------------MIEKKKSFAK    10
Ga0224415_10007274                ---------------------------------------------MIEKKKSYAK    10
Ga0187911_10069260                ------------------------------------------MSTKKRFRYSVAAK    14
Ga0187910_10015336                RFSAINVEVITDETHKEAKIQKNEFKTFDQFTKE-LQETQKVNGETKKEHITKNKHTNVK    90
```

FIG. 18D

CA 03072610 2020-02-10

```
ODAI_chimera                    EILTEKLISDCKK----------------------------NDCASECGKGRRKSKAK    79
31009_GL0034153                 ----------------------------------------MGSRGVIIMTEKRKSRAK    18
DLF014_GL0011914_               KIEKFKIKYAEQETVDKI--------------TEEIAQSDKIMRTESILVQHTKKSLAK    65
CasR_R._albus                   KAAVNSVNDTPEKTEEAN--------------------VVSVNVRTSAENKHSKKSAAK    62
Ga0187910_10040531              KIQSAVKAKAETAPA------------------------VSSAFVEKRKDKQSKKTFAK    55
tpg|DJXD01000002.1|             ------------------------------------------------MKKQKSKKTVSK    12
CasR_E._siraeum                 KFADQNKKREAERAVPKK----------------DAAVSVKSVSSVSSKKDNVTKSMAK    63
PIG-018_GL0023397               KFAKQVQEREAEKAKREK----------------QVSVSDTVGAAAAVQNENGKKSMAK    63
PIG-025_GL0099734               KIQMANAAREKQAEEARLKAEAERIEKEENKKREAELKRFKLDQETRGKLPKNERKSLAK    80
Ga0129317_1008067_chimera       ------------------------------------------------MKKQKKSLVK    10
EYZ-362B_GL0088915              IYAAKASAAQKKADETV----------------------VAAQPAGDTANSKPIKSRNK    57
uncultured_Ru_sp                KAAEINNNAAPAI----A----------------------AMPAAEVIAPAAEKKKSSVK    56
R._flav._FD-1                   AYSAASKNTDSKPAEKKA---------------------ETPKPAEIISDNSRNKTAVK    58
tpg|DBYI01000091.1|             AFSAKANTVYENEDK-------------------------NVEAFPEALNLRSIKKSMNK    55
                                                                                          *

037_-_emb|OIZA01000315.1|       LAGVKWIIKAN--DD-----VTYISSFGKGN--------NSVLEKRIIGDVSGDVN----    105
emb|OCTW011587266.1|            AVGVKSLARLS--DG-----STVVSSFGKGA--------AAELESLITGGEIRKLS----    59
k87_11092736                    RIGIKSTVAYG--QG-----KYAITTFGKGS--------KAEIAVRSADPPEETLPTESD    54
BMZ-11B_GL0037915               RVGIKSVIAHD--GG-----KLAVTTFGKKS--------AAKLAYRDGDQTPFDEEKKSE    56
BMZ-11B_GL0037771               RMGVKALLAHG--ED-----KLTMTTFGKGN--------RSKIEFTEGYHGRALETPKHF    55
BMZ-11B_GL0069617               RIGVKSAFSHG--NS-----RLTITQFGRGN--------TADIAVETDSRGRSLSLPHRV    55
Ga0099364_10024192              RMGVKSVLAHG--KDEKGHIKLAITAFGKGN--------KAELAIQTDEKGSNLAKTYKE    60
530373_GL0023589                ANGLKSTFKLA--EN-----TYYMTSFGKNN--------TADPEKNIVRMNVENIR----    64
```

FIG. 18E

```
emb|ODAI011611274.1|                ANGLKSLLLT---DG-----KTVMTSFGRGS--------EANVEKRFDETGTKTFD----   117
EMG_10003641                        MSGLKSALVIN--NH-----EMLLTSFGKGN--------NAIAEKRYILDGDIETI---N    72
CasR_P1E0_metageno                  AAGLKSTFVISPQEK-----ELAMTAFGRGN--------DALLQKRIVDGVVRDVA----    58
emb|OIZX01000427.1|                 AAGLKSNFILDPQRR-----TTVMTAFGQGS--------TAILEKQIVDRAISDLQ----   104
160582958_gene49834                 AAGVKSVFAI---GN-----DLLMTGFGPGN--------DATIEKRVFQNRAIETL----   112
gi|1198542314|gb|NFIR01000008.1|    ALGLKSTFILDRDEQ-----KMLMTSFGRGN--------KAVRDKYIIGDKVSDIDDSWE   115
emb|OGNF01009141.1                  AAGLKSTFVLE--NN-----KLLMTSFGNGN--------KAVIEKIIDEKVDSIN-----    52
Ga0129306_1000735                   AAGLKSVFVLS--EG-----KELLTSFGRGN--------EAVPEKRVTGGTIANAR---T    68
MH0288_GL0082219                    AAGLKSTFTLP--TG-----ELLMTSFGRGS--------EALIQKRIMKDVISDVQ----    95
PIG-022_GL0026351                   RAGLKSSFVN---EN-----KGLMTAFGKGN--------NAVIEKRISGNLIENVS----    55
PIG-028_GL0185479                   RAGLKSSFVS---EG-----KGLMTAFGKGN--------NAVIEKRISGDLIENVS----    57
250twins_35838_GL0110300            KLGLKSTIIAD--K------KIILTSFINEQ-----SSKTANIEKVAGFKGDTIDT--IS   103
PIG-014_GL0226364                   RMGLKSTLVFD--N------KITVTSFANSS---NSEKASAHIEKRTDFWGKTI-----M    60
250twins_36050_GL0158985            AMGLKSTLVMG--D------KLVITSFAASKAVGGAGYKSANIEKITDLQGRVI-----E   107
emb|OJMM01002900.1|                 AMGLKSTLVFD--D------KIVVTSFLNSKT--EENEKCAHIEKIADCNGQTI-----V   112
emb|OGPN01002610.1|                 AMGLKTVLSFD--D------KIAIASFVNDK-----KTKLPHIERITDKSGTTI-----H   105
emb|OHCP01000044.1|                 AMGLKAVLSFD--N------KIAIASFVSSK-----NAKSSHIERITDKEGTTI-----S   100
PIG-046_GL0077813                   AMGLKTVLGFD--N------KIAIASFTSSK-----DSKSSHIERITDPNGKTI-----R   104
pig_chimera                         AMGLKTVLGFD--N------KIAIASFMSSK-----DSKSSHIERITDPNGKTI-----R   106
emb|OIEN01002196.1|                 MAGVKSVFVIG--D------ELLMTSFGDGD--------DAVLEKDIDENGVVNDC---R    54
O2.UC29-0_GL0096317                 MAGVKSTFVID--S------DLLMTSFGERD--------KAVREKYIAQGNVKSLR---K    54
CasR_Anaerobic_dig                  AAGLKSVFFDQ--K------QAVLTTFAKGN--------NSQIEKKVVNSEVKDLR---Q    51
emb|OGDF01008514.1|                 AAGLKSTFAVN--G------SVLLTSFGRGN--------DAVPEKLITEKAVSEIN---T    63
emb|OGZC01000639.1                  AVGVKSVFVVG--D------DLYLATFGNGN--------ETVLEKKITPDGKITTF---P   106
```

FIG. 18F

```
Ga0224415_10048792_chimera          GLGLKSTLVSD--S------KVYLTTFADGS--------NAKLEKCVENNKIICIS---N    53
emb|OCVV012889144.1|                GMGLKSALVSG--S------KVYMTSFEGGN--------DAKLEKVVENSEIVSLA----    50
Ga0187910_10006931                  GMGLKSTLVSD--S------KVYMTSFGNGN--------DARLEKVVENNAISCLV---D    51
R._flav_XPD_                        GMGVKSTLVSG--S------KVYMTTFAEGS--------DARLEKIVEGDSIRSVN----    50
Ga0224415_10007274                  GMGLKSTIVSG--S------KVYMTTFGDGS--------EARLEKVVENDSIKTLH----    50
Ga0187911_10069260                  AAGLKSSLAVD--TD-----RTVMTSFGHGN--------AAILEKEIVDGEISVLN---I    56
Ga0187910_10015336                  AAGVKSVFAVD--DG-----NVLITSFGRGN--------AADIETLKSDDDKTINL---T    132
ODAI_chimera                        AAGLKSALDLG--NG-----QALITSFGKGN--------EAVPEKRVEGDKIISLR---E    121
31009_GL0034153                     ALGVKSAFLKD--D------DVIMTSFGRGN--------DAVVEKIIKNNEVQNIN---I    59
DLF014_GL0011914_                   ASGVKSVFIKD--D------EVIMTSFGRGN--------DAVVEKIIKDNNVDEK----N    105
CasR_R._albus                       ALGLKSGLVIG--D------ELYLTSFGRGN--------EAKLEKKISGDTVEKLG---I    103
Ga0187910_10040531                  ASGLKSTLAVD--N------SAVMTVFGRGN--------EAKLDHRINADLQSESL---H    96
tpg|DJXD01000002.1|                 TSGLKEALSVQ--G------TVIMTSFGKGN--------MANLSYKIPSSQKPQNL---N    53
CasR_E._siraeum                     AAGVKSVFAVG--N------TVYMTSFGRGN--------DAVLEQKIVDTSHEPLN---I    104
PIG-018_GL0023397                   AAGVKSVFAVG--D------TVYMTSFGRGN--------DAVLEKKIVDESHESLN---K    104
PIG-025_GL0099734                   AAGLKSTFAVG--T------DLYMTSFGKGN--------DAIVEKKISNKQVTQIN---T    121
Ga0129317_1008067_chimera           AAGLKSAFVVG--D------SVYLTSFGKGN--------AARLDTKINPDNSTERY---V    51
EYZ-362B_GL0088915                  AAGLKSTFVVG--D------SLYMTSFGKGN--------LSVPEYRVDTGDAYRVD---P    98
uncultured_Ru_sp                    AAGMKSILVSE--N------KMYITSFGKGN--------SAVLEYEVDNNDYNQTQ---L    97
R._flav._FD-1                       AAGLKSTIISG--D------KLYMTSFGKGN--------AAVIEQKIDINDYSFSA----    98
tpg|DBYI01000091.1|                 AAGLKSTLIDG--K------SLYLTAFGKGN--------NAVVEHMIATDDSYSLK---T    96
                                      *:*                  :: *

037_-_emb|OIZA01000315.1|           ---KDSHMYVNPKYTKKNYEIKNGF-------------------------SSGSSLVTY    136
```

FIG. 18G

```
emb|OCTW011587266.1|          ---D-KAILEITDDTQNKNAYNVKS-------------------------SRIPNLTAR    89
k87_11092736                  ATLSIHAKFAKAGRDGREFKCGDVD----------------------ETRI---HTSRS    88
BMZ-11B_GL0037915             -----LGGFNVTGVDENTVDAERGI----------------------PGEGLIEASVAN    88
BMZ-11B_GL0037771             G----KRGFEVRKIDENVDLYGDL-------------------------------EEGK    79
BMZ-11B_GL0069617             -----EKSFTVNKIDDEIDVQRS-------------------------------------    73
Ga0099364_10024192            -----RNITANKIVSEGIQTSGTI--------------------------------AGE    82
530373_GL0023589              ------NTFSATPISERIVDITGET-------------------------------------    83
emb|ODAI011611274.1|          ---RDPELFSAKPLETGYRIQRFNA-------------------S------PKDAG----    145
EMG_10003641                  ---NKNKKFDANNDSKVVVIKGISN----------------------------PNGQLTN    101
CasR_P1E0_metageno            ---GEKQQFQVQRQDESRFRLQNSR------------------------LADRTVTADD    90
emb|OIZX01000427.1|           ----PVQQFQVEPASAAKYRLKNSR------------------------VRFPNVTADD    135
160582958_gene49834           ---SSPEQYSAEFQNKQFKIKGNIK-------------------VLNHS-TQKMEEIQTE    149
gi|1198542314|gb|NFIR01000008.1|  ---NKKAALSVEVCGKSFNISKKEN------------------------DDCEPVKVNN    147
emb|OGNF01009141.1            ----EPEVFSVTPCDKKFELQPAKR------------------------GLAADSLVDN    83
Ga0129306_1000735             ---DNKEAFSAALQNKRFEVFGR-------------------------------TAGSSDD    95
MH0288_GL0082219              ---EGDPAFSVIPMPKQFEIQGRAI-------------------DVQKEGSSVPEVLTDD    133
PIG-022_GL0026351             ----NKPRFSVEFGNKEYIINDK-------------------------------KLGIVSDD    82
PIG-028_GL0185479             ----NKPRFSVEFGNKEYIINDK-------------------------------KLGIVSDD    84
250twins_35838_GL0110300      ---YTPRMFRSEINPGEIVISKGD-------------------------------DLSEFAN    131
PIG-014_GL0226364             ---QDEKMFRTDVEKQQIYIEKEFPDENNKII------------T--------QTAMFEN    97
250twins_36050_GL0158985      ---EHERMFSADVGEKNIELSKND-------------------------------CHTNVNN    135
emb|OJMM01002900.1|           ---ERPRMFNTSINAKKVDLSKDN-------------------------------DETNYPN    140
emb|OGPN01002610.1|           ---ENARMFDSSVDEQNVNIEKRMTIEEKQND------------GTFKKDEKDVKATICN    150
emb|OHCP01000044.1|           ---VNSKMFESSVNKRDINIEKRITIEEPQQD------------GTIKKEEKGVKSTTCN    145
```

FIG. 18H

```
PIG-046_GL0077813                ---EDVRMFDSNVDECSINLEKRMTVEERQKD-----------GTIKKDEKDVKSTICN   149
pig_chimera                      ---EDVRMFDSNVDECSINLEKRMTVEERQKD-----------GTIKKDEKDVKSTICN   151
emb|OIEN01002196.1|              ---N-PAAYDAVYGTDSIRVKKTN-------------------------NNIRAKVNN   83
O2.UC29-0_GL0096317              ---Q-EQAFDAQYGKEKIFVTNAD-------------------------NKLHVAINN   83
CasR_Anaerobic_dig               ---P--PAFDLELKEKTFYISGKNNINTSRENPLASASLPLSKRQRIRAERIKRAREENR   106
emb|OGDF01008514.1|              ---V-KPRFSVEKPATSYSSSF-------------------------GIKSHISATADN   93
emb|OGZC01000639.1               ---E-EETFTAKLKFAQTEPTVATSI-----------------GISNGRIVLPEISVDN   144
Ga0224415_10048792_chimera       ---D-KEAFAASIANKNVGYKIKND-------------------EKFRHPKGYDIISNN   89
emb|OCVV012889144.1|             ---E-KESFSAEIFKKNIGCKIE-N--------------------KKFKHPKRYDVIADN   85
Ga0187910_10006931               ---K-KEAFVAEITDKNAGYKII-N--------------------KKFGHPKGYDVVANN   86
R._flav_XPD_                     ---E-GEAFSAEMADKNAGYKIG-N--------------------AKFSHPKGYAVVANN   85
Ga0224415_10007274               ---E-GEAFSAEMTDNNAGYKIG-N--------------------VKFSHPNGYDVVANN   85
Ga0187911_10069260               ---E-NPAFDAVIND---KKYALTG-------------------HH-----AGVHALVDQ   85
Ga0187910_10015336               ---ETENQ----------KKYVVTN-------------------K-----RSNVKGLADN   155
ODAI_chimera                     ---G--EAFALAKEPVNHKLVLKSG----------------------RIKAEGGPVEFDG   154
31009_GL0034153                  ---D-KPVYDVVGVEKETGIINVVG-------------------TKRGINTINKKKQYAN   96
DLF014_GL0011914_                ---T-KPAYEIVDIEKNGDLIKVQ-------------------------SRRCKNIESAN   136
CasR_R._albus                    ---G---AFEVAERD--ESTLTLES----------------------GRI--KDKTARPKD   132
Ga0187910_10040531               ---PQAALKN--VHAPNKQKIHFIG-------------------RM-----QDMNLTADH   127
tpg|DJXD01000002.1|              ---SSAGLKN--VEVS-GKKIKFQG--------------------R-----HPKIATTDN   82
CasR_E._siraeum                  ---D---DPAYQLNVVTMNGYSVTG-------------------HR--G--ETVSAVTDN   135
PIG-018_GL0023397                ---A---NPAYEITDISSVNYSVEG-------------------HR--G--QSVCATADN   135
PIG-025_GL0099734                ---E-KENFTVDTDGITDTIVPVQS-------------------KR--I--ACLNTQADN   154
Ga0129317_1008067_chimera        ---SDSEKHTLKINSITDTELRLSG-------------------P------FPKQAEAKN   83
```

FIG. 18I

```
EYZ-362B_GL0088915                  ---IS-EHSELHVLGADDLAVSFSG------------------TRRMK--DVSELKADN   133
uncultured_Ru_sp                    ---SSKDNSNIQLGGVNEVNITFSS------------------KHGFE--SGVEINTSN   133
R._flav._FD-1                       ---M-KDTPSLEVDKAESKEISFSS------------------HHPFV--KNDKLTTYN   133
tpg|DBYI01000091.1|                 ---L-ENEPSLKVKAADELKVTFMS------------------RRPFV--QESELSAVN   131

037_-_emb|OIZA01000315.1|           PNK-----------PDKNSGMDALCLKPYFEIDFFG-----HIF--TDNMHIQAIYNIFD   178
emb|OCTW011587266.1|                TDK-----------LSDKSGMDDLGFKRELELEVFG-----QCF--DDSIHIQIAHAVFD   131
k87_11092736                        EYES------LISNPAESPREDYLGLKGTLERKFFG-----DEY-PKDNLRIQIIYSILD   136
BMZ-11B_GL0037915                   PVND------LIDESRKEYGQDYLMLKDQLEKVFFG-----QTF-PGDNLRIQIIYNILD   136
BMZ-11B_GL0037771                   TIEA------LLINPSEKVGEDYLKLKGTLEKRFFG-----REF-PHDNIRIQLIYNILD   127
BMZ-11B_GL0069617                   SLLG------TLLNPAENDPVDYLGLKSTLEKEFFG-----QEF-PNDSIRIQIIHNILD   121
Ga0099364_10024192                  GHAT------FLNNPAEHVGTDYLKLKETLEMEFFG-----KSF-PGDSVRIQIIHQILD   130
530373_GL0023589                    --------KKTAQVVLPACSDNQLHAKDTIEQMYFG-----KTY--TDNIHIQIAYNIMD   128
emb|ODAI011611274.1|                -----------LAYRPAGVRPDQIGAKAALEKRYFG-----KET-PGDNIHVQIAYQIQD   188
EMG_10003641                        PLFD---QSPTAIQPNRTSGNDMIGIRRMLERKYFVHNEENKEF--QDNIRIQIAYCILD   156
CasR_P1E0_metageno                  PLHR---A-ETPRRQPLGAGMDQLRRKAILEQKYFG-----RTF--DDNIHIQLIYNILD   139
emb|OIZX01000427.1|                 PLYR---R-KD---GGFVPGMDALRRKNVLEQRFFG-----KSF--ADNIHIQMIYSILD   181
160582958_gene49834                 LQD-----------NYNRPHFDLLGCKNVLEQKYFG-----RTF--SDNIHVQIAYNIMD   191
gi|1198542314|gb|NFIR01000008.1|    PVL-----------SGNKKDDDLIHCRKNLEEMYFG-----QQF--KDNIHIQLIYNILD   189
emb|OGNF01009141.1                  PLK-----------SKKTAGDDAIHSRKFLERQFFDG----NTF--NDNIHIQLIYNILD   126
Ga0129306_1000735                   PLA-----------VSRAPGQDLIGAKTALEERYFG-----RAF--ADNIHMQVIYAIQD   137
MH0288_GL0082219                    PRA-----------SQKPAGADLIGAKPALEKRYFG-----KTF--TDNIHIQLIYRILD   175
PIG-022_GL0026351                   PRE-----------SQKPVGEDGIHCKRALEERYFG-----KTF--NDNIHIQLIYSILD   124
```

FIG. 18J

```
PIG-028_GL0185479                PRE----------SQKPVGEDGIHCKRALEERYFG-----KTF--NDNIHIQLIYSILD   126
250twins_35838_GL0110300         PAN-------------FPIGRDYVKIRSALEKQYFG-----KEF-PEDNLHVQIAYNVAD   172
PIG-014_GL0226364                PAL-------------RNCGKDYIGMKNSVEKVMFG-----KEF-PNDNLHIQIAYNILD   138
250twins_36050_GL0158985         PVV-------------TNIGKDYIGLKSRLEQEFFG-----KTF-ENDNLHVQLAYNILD   176
emb|OJMM01002900.1|              PAF-------------EDCGRDYINVKSALEKRVFG-----KTY-NKDNLHVQIAYNIFD   181
emb|OGPN01002610.1|              PYF-------------KTCGKDYIGIKDVAEKYFFG-----KTF-PNENLRVQIAYNVFD   191
emb|OHCP01000044.1|              PYF-------------KVGGKDYIGIKEIAEEHFFG-----RAF-PNENLRVQIAYNIFD   186
PIG-046_GL0077813                PYS-------------NECGKDYIGIKSVAEELFFG-----RTF-PNDNLRVQIAYNIFD   190
pig_chimera                      PYS-------------NECGKDYIGIKSVAEELFFG-----RTF-PNDNLRVQIAYNIFD   192
emb|OIEN01002196.1|              PLAKSNIRSEESALFRTRVNEYKREQKDKYETLFFG-----KTF--DDNIHIQLISKILD   136
O2.UC29-0_GL0096317              PLCGNKKQSPEAQEYSRRVLEHKKAINQKYETIVFG-----KPS--NDNIHIQVVSKIMD   136
CasR_Anaerobic_dig               PYHNV-----------KRVGEDDLRAKADLEKHYFG-----KEY--SDNLKIQIIYNILD   148
emb|OGDF01008514.1|              PLAGR-----------APVGEDAIHAKEVLEQRVFG-----KTF-SDDNIHIQLIYNILD   136
emb|OGZC01000639.1               PLHTT--MQK--NTIKRSAGEDILQLKDVLENRYFD-----RSF--NDDLHIRLIYNILD   193
Ga0224415_10048792_chimera       PLLHN-----------NSVQQDMLGLKNVLEKRYFG-----KSSGGDNNLCIQIIHNIID   133
emb|OCVV012889144.1|             PLYK------------GSVRQDMLGLKETLEKRYFN-----SAD-GTDNVCIQVIHNILD   127
Ga0187910_10006931               PLYT------------GPVQQDMLGLKETLEKRYFG-----SSVSGNDNICIQVIHNILD   129
R._flav_XPD_                     PLYT------------GPVQQDMLGLKETLEKRYFG-----ESADGNDNICIQVIHNILD   128
Ga0224415_10007274               PFYT------------GPVQQDMLGLKEILERRYFG-----SSTDGNNTICIQIIHNILD   128
Ga0187911_10069260               PQN----------------RSDAVHIRGALEKKYFG-----DTF--ADNIHVQIAYNILD   122
Ga0187910_10015336               PTKV----------ESIIPGETQIGFKSILEKHFFG-----RTF--NDNIHIQIIHNILD   198
ODAI_chimera                     PQKNS-----------SMSAVRLDEYNNQIERKFFRGN---KVL--QDNIRIQIAHNIMD   198
31009_GL0034153                  TQV-----------SQKRMGMDLIQRKDKLEKVFFN-----ENF--NDNIHIQLIYNILD   138
DLF014_GL0011914_                TEL-----------PPEKIGMDLIRCKDKLEEIYFG-----RTF--NDNIHIQLIYNILD   178
```

FIG. 18K

```
CasR_R._albus                    PRHI-----T--VDTQGKFKEDMLGIRSVLEKKIFG-----KTF--DDNIHVQLAYNILD    178
Ga0187910_10040531               PLHSH--------DGERAVGADLLCAKDKLEQLYFG-----RTF--NDNIHIQLIYQILD    172
tpg|DJXD01000002.1|              PLFK------------PQPGMDLLCLKDKLEMHYFG-----KTF--DDNIHIQLIYQILD    123
CasR_E._siraeum                  PLRRFNGRKK--DEPEQSVPTDMLCLKPTLEKKFFG-----KEF--DDNIHIQLIYNILD    186
PIG-018_GL0023397                PLHHD---------GGSSVPTDMLCLKPTLERVYFG-----KTF--DDNLHIQLIYNILD    179
PIG-025_GL0099734                PLYRK--------DSENQVQPDKLLLKDTLEKVYFG-----KTF--NDTLHIQLIYNILD    199
Ga0129317_1008067_chimera        PTHK-----K--DNEQKNTRQDMLGLKSTLEKFYFG-----STF--DDNIHIQIIHNIQD    129
EYZ-362B_GL0088915               PLHSG----K--NNLVPKNGTDILGLKGILEQRYYG-----RNF--DDNVHIQIIYNILD    180
uncultured_Ru_sp                 PTHRS--------GESSPVRGDMLGLKSELEKRFFG-----KTF--DDNIHIQLIYNILD    178
R._flav._FD-1                    PLYGG----K--DNPEKPVGRDMLGLKDKLEERYFG-----CTF--NDNLHIQIIYNILD    180
tpg|DBYI01000091.1|              PLHSG----K--DKPNKSAGQDMLGLKSELEKRYFG-----KIF--DDNLHIQIIHNILD    178
                                                .   *   :            : : ::    : *

037_-_emb|OIZA01000315.1|        IEKILAKHITNIIYTVNSFDRNYNQ-----------SGNDTIGF---------DLNYRV    217
emb|OCTW011587266.1|             IQKSLAAVIPNVLYTLNNLDRSYST--------DNTSDKKDIIGN---------TLNYQH    174
k87_11092736                     IQKILGLYVEDILHFVDGLQDEP----------------EDLVGL---------GLG--D    169
BMZ-11B_GL0037915                MQKAFGLYVNDVLYAVNNLQNTGRL-------LTDDDWTSDVIGL---------ALG--K    178
BMZ-11B_GL0037771                IYKILGMNVADILYALGNMQDTE--------------LDIDMFGQ---------SLN--N    162
BMZ-11B_GL0069617                IQKILGIYINDVLYSIANLQNVE--------------TVEDCLGQ---------SLS--K    156
Ga0099364_10024192               IQKLLGIYITDIIYCINNLRDETHL-----------DHESDIVGL---------SMS--N    168
530373_GL0023589                 MKKIFGVYSNNIIYSINNLLEE--------------REGSDFLGV----------FYTEN    164
emb|ODAI011611274.1|             IEKLLAVYISNIIYAVNNVTGVSAM-------KDSKGRPVDLLGD--------YGILGEE    233
EMG_10003641                     IEKILMPHINNICFEINNMLRL-E-----------GYQEDSFMGS----------FNLYK    194
CasR_P1E0_metageno               IHKMLAVPANHIVHTLNLLGGY---------------GETDFVGM----------LPAGL    174
```

FIG. 18L

CA 03072610 2020-02-10


```
emb|OIZX01000427.1|                IHKILAAASGHIVHLLNIVNGS--------------KDRDFIGM----------LAAHV   216
160582958_gene49834                IEKLLTPYINNIIYTLNELMRD--------------NSKDDFFGCDSHFSVAYLYDELKA   237
gi|1198542314|gb|NFIR01000008.1|   IEKILAVQINNIVFILNNLLRW-S-----------GEEEFDLIGS----------LGVNH   227
emb|OGNF01009141.1                 IEKILSVHVNDIVYSVNNILSRGE-----------GMEYNDYIGT--------L---NLK   164
Ga0129306_1000735                  INKILAVHANNIVYTLNNLDRE-A-----------DPETDDFIGS--------GYLTLKN   177
MH0288_GL0082219                   IKKVLAIHANNIVYTLDNLSRR-E-----------GTEGTDFIGI--------GGLTLKN   215
PIG-022_GL0026351                  LEKILAVHSNNIVYTFDNLRRK-E-----------TDEYDDFIGY----------MSTVN   162
PIG-028_GL0185479                  LEKILAVHSNNIVYTFDNLRRK-E-----------TDEYDDFIGY----------MSTVN   164
250twins_35838_GL0110300           IKKILSVYINNIIYMFYNLARSEEYDIFYNSQSENSGRDCDVIG----------SLYYQA   222
PIG-014_GL0226364                  IKKIICPYINNVVNIFYNLGRGKLK-----------DDKNDLLG----------KQIGP-   176
250twins_36050_GL0158985           IKKILGTYVNNIIYIFYNLNRAGTG--------RDERMYDDLIG----------TLYAYK   218
emb|OJMM01002900.1|                IKKIIGAYINNIIYIFYNLGREEYD------------AKKDIIG----------TQ----   215
emb|OGPN01002610.1|                IQKILGTYVNNIIYSFYNLRRDG-K------------SDVDIIG----------SLYAFA   228
emb|OHCP01000044.1|                VQKILGTFVNNIIYSFYNLSRDEVQ------------SDNDVIG----------MLYSIS   224
PIG-046_GL0077813                  IQKIFGTYINNIIYSFYNLSRDEFQ------------SDNDVIG----------TLYMLK   228
pig_chimera                        IQKILGTYINNIIYSFYNLSRDESQ------------SDNDVIG----------TLYMLK   230
emb|OIEN01002196.1|                IEKTFSVVIGNIVYAINNLSLEQS-----------IDRPIDIFGD--------KNTQ---   174
O2.UC29-0_GL0096317                IEKTFSFVMGNIVYAINNLDPEQN-----------IDNPIDYMSN--------KART---   174
CasR_Anaerobic_dig                 INKIISPYINDIVYSMNNLARNDEY----------IDGKIDVIG----------SLSSTT   188
emb|OGDF01008514.1|                IRKILSTYANNVVFTINSMRRLDE-----------YDREQDYLG----------YLYTGN   175
emb|OGZC01000639.1                 IEKILAEYTTNAVFAIDNVSGCS----------------DDFLS----------NFSTRN   227
Ga0224415_10048792_chimera         IEKILSEYIPNVVYAFNNIAGFKDE----------HNNIIDIIGT--------QTYNSSY   175
emb|OCVV012889144.1|               IEKILAEYITNAVYSFDNIAGFG----------------EDIIGM--------GGFKPIY   163
Ga0187910_10006931                 IEKILAEYITNAAYAVNNIAGLD----------------KDIIGF--------GKFSTVY   165
```

FIG. 18M

CA 03072610 2020-02-10

```
R._flav_XPD_                    IEKILAEYITNAAYAVNNISGLD----------------KDIIGF--------GKFSTVY    164
Ga0224415_10007274              IEKILAEYITNAVYATNNIIDPD----------------NDVIGG--------KKFTSIK    164
Ga0187911_10069260              ITKILTVYANNVVYALNNLVHADDD--------T-QADELDSLG----------NFSAGT    163
Ga0187910_10015336              IKKILAVHTNNIVYALDNIHERGRE--------NSAEKPIDMIGA--------GGISTSK    242
ODAI_chimera                    IEKILAVHINNIVYSVNNLFRVQG------------NEGDDFLG----------YRGLDK    236
31009_GL0034153                 IEKILSVYVNNIVYALGNLERDNS------------DDEKDLIG----------YASTLN    176
DLF014_GL0011914_               IEKILSVYINNAVYALGNLERKEN------------DKEKDLVG----------YLSARA    216
CasR_R._albus                   VEKIMAQYVSDIVYMLHNTDKTER--------------NDNLMG----------YMSIRN    214
Ga0187910_10040531              IQKILALHANNIIFALDNLLHKKN-----------DELSDDFVGM--------GRMRATI    213
tpg|DJXD01000002.1|             IEKILAVHVNNIVFTLDNVLHPQK-----------EELTEDFIGA--------GGWRINL    164
CasR_E._siraeum                 IEKILAVYSTNAIYALNNMSADEN------------IENSDFFM----------KRTTDE    224
PIG-018_GL0023397               IEKILAIYSTNAVYALNNMIADED------------DESSDLFQ----------NMTTDY    217
PIG-025_GL0099734               IQKILTVYSVNTVYTLNNLFGKEI------------SERGDFIG----------ALSFQQ    237
Ga0129317_1008067_chimera       IAKILAAHSNNAGYALDNMLAYQG------------VEFSDMIG----------YMGTSR    167
EYZ-362B_GL0088915              IEKNLAIYVTNVVAALDHMCDETL-----------DTEHEDFIG----------YMNTMN    219
uncultured_Ru_sp                IEKILAVYVTNIVYALNNMLGVKG-----------SESHDDFIG----------YLSTNN    217
R._flav._FD-1                   IEKILAVHSANITTALDHMVDEDDE----------KYLNSDYIG----------YMNTIN    220
tpg|DBYI01000091.1|             IEKIIAVYATNITAAIDHMVDDDNE----------QYLQGDFIG----------YMNTLN    218
                                : * :     .                            . .

037_-_emb|OIZA01000315.1|       PYLEYGGGKDSNGK--------------PNKISAWKKRENFINFYN-----EAKPHLGY-    257
emb|OCTW011587266.1|            SYESFNVE-----------------------------KRGEFTEYYN-----AAKDRFSY-    200
k87_11092736                    ------------------------------------EKMQKLLS-----KALPYMGF-    185
BMZ-11B_GL0037915               ------------------------------------GRGKEIIE-----SMSDALGF-    194
```

FIG. 18N

CA 03072610 2020-02-10


```
BMZ-11B_GL0037771                  ----------------------------------P--EKAKDVVQ-----RMKPYMGF-   179
BMZ-11B_GL0069617                  ----------------------------------GQDEKLKKILN-----SITPYLGF-   175
Ga0099364_10024192                 -----------------------------------TNVNLALN-----QMRPYFGF-   184
530373_GL0023589                   SYQAMNFADAI----------IKSKLLTKNSKYLNLDMNNVWF-NK-EVSELSSFRKYV-   211
emb|ODAI011611274.1|               GLTKRLQRIPE----------Q-----------ADEEAKALQAFL-------CSERLSY-   264
EMG_10003641                       PYDAFIATTDD----------KE-----------SSRRDNFAKLM-------TSKQVRY-   225
CasR_P1E0_metageno                 PYDKLRVVKKK----------NGDT---------VDIKADIAAYA-------KRPQLAY-   207
emb|OIZX01000427.1|                LYNELNEEA----------------------------KRSIADFC-------KSPRLIY-   240
160582958_gene49834                GYSDRLKTKPN----------LS--------KNIDRIWNNFCNYMN-SDSGNTEARLAY-   277
gi|1198542314|gb|NFIR01000008.1|   TYEEFRGRNK-------------------------NYGKFSELI-------KQSQMRY-   253
emb|OGNF01009141.1                 SFETYKNNLV----------------------NKKKFDLDRVK-------KIPQLAY-   192
Ga0129306_1000735                  TFETYCDPAAL----------NER-----EREKVTVSKQHFDAFM-------QNPRLAY-   214
MH0288_GL0082219                   SYAAYCEPRTF----------FDEGKEKNIIENIEKSHGEFLEYM-------KNPRLAY-   257
PIG-022_GL0026351                  SYEEFMNPEKL----------L-PGKDQSVYDNINRSRETFLEYR-------KNPRLGY-   203
PIG-028_GL0185479                  SYEEFISPEKL----------L-PGKEQSVYDNINRSQETFLEYR-------KNPRLGY-   205
250twins_35838_GL0110300           SYRNQDANRFE----------------KD---GKKKAIDSLLD-----DTRAYYTY-   254
PIG-014_GL0226364                  ----------------------------------KSEEMVEDLLK-----NSSAYFVY-   195
250twins_36050_GL0158985           PMEAQQTYLLK----------------GDKDMRRFEEVKQLLQ-----NTSAYYVY-   253
emb|OJMM01002900.1|                ----------------------------------DSAYISKILN-----NTSAYFTY-   233
emb|OGPN01002610.1|                DFDNQLKDK----------------------PAFREAKDLLK-----NTEAYFSY-   256
emb|OHCP01000044.1|                DYDRQKET----------------------ETFLQAKSLLK-----QTEAYYAY-   251
PIG-046_GL0077813                  DFDGQKET----------------------DTFRQARALLE-----RTEAYYSY-   255
pig_chimera                        DFDGQKET----------------------DTFRQARALLE-----RTEAYYSY-   257
emb|OIEN01002196.1|                ----------------------------------GISLREDNDYLK-----TMLPRCEYL   195
```

FIG. 18O

CA 03072610 2020-02-10


```
O2.UC29-0_GL0096317                ----------------------------------------DENLK-----RVLRRCMYL    188
CasR_Anaerobic_dig                 DYSSFMSPNKD----------------LEKEKKFSFHRENYKKFVE-----ASKPYMRY-    226
emb|OGDF01008514.1|                SYERLLDIADKYAVDGEDWRNTAAGISNDFEKKQFQTINGFWDLLD-----MIEPYMCY-    229
emb|OGZC01000639.1                 QWDEFQNPEQH-----REHF----GNKDNVICSVKKQQDLFFNFFK-------NNRIGY-    270
Ga0224415_10048792_chimera         TYADFSKDKSD-----K-------------------KYIEFQKLLK-------NKRLGY-    203
emb|OCVV012889144.1|               TYKQFKEPDK-------------------------YNKKFDDILN-------NSRLGY-    189
Ga0187910_10006931                 TFDEFAEPDRH-----KERFIKDGKLDTKLINQLKNQYDEFDAFLD-------DTRFGY-    212
R._flav_XPD_                       TYDEFKDPEHH-----RAAFN----NNDKLINAIKAQYDEFDNFLD-------NPRLGY-    207
Ga0224415_10007274                 TFAQFSASD--------------------------SSNDFEQFLK-------NPRLGY-    189
Ga0187911_10069260                 SYAKSKSKSKS------------------------KQQDFVELFI-----KKKEIHGY-    192
Ga0187910_10015336                 EYEQYCSEKSD------------------------YEDNFLKQLI------NNERIAY-    270
ODAI_chimera                       NYSDFCKNKPE------------------------DKERFFNFIGKGDGKVTNPRLSY-    270
31009_GL0034153                    SYEDFINKNL-----------------------VKQNENIDKFIE------NGNRLGY-    205
DLF014_GL0011914_                  GYNKVINKAIN-------------------DEKIKDRIEDLKEFIE------NGNRLGY-    250
CasR_R._albus                      TYKTFCDTSN---------------LPDDTKQKVENQKREFDKIIK-------SGRLGY-    251
Ga0187910_10040531                 GYDAFRNSTNQ---------------------KVQETYREFQEFVR-------RKELLY-    244
tpg|DJXD01000002.1|                DYQTLRGQTN-------------------------KYDRFKNYIK-------RKELLY-    190
CasR_E._siraeum                    TFDDFEKKKES-----T-------------NSREKADFDAFEKFIG-------NYRLAY-    258
PIG-018_GL0023397                  TYDKFRGRSE------------------------RIVKSFNDFVS-------NPRLAY-    244
PIG-025_GL0099734                  TYDDYTSDSKN-------------------------KEIFEDFYS-------KRSLGY-    263
Ga0129317_1008067_chimera          TFDNYDPNHKN-------------------------NKDFFRFLK-------LPRLGY-    193
EYZ-362B_GL0088915                 SFDVFMHPSQS--------------SRADIYKKINDSRRRFENLLR-------TKRLGY-    257
uncultured_Ru_sp                   IYDVFIDPDN------S-------SLSDDKKANVRKSLSKFNALLK-------TKRLGY-    256
R._flav._FD-1                      TYDVFMDPSKN-----S-------SLSPKDRKNIDNSRAKFEKLLS-------TKRLGY-    260
```

FIG. 18P

```
tpg|DBYI01000091.1|                    TYEVFMEPSKN-----P-------RLDSNARKNIENSREKFEYLLD-------TQRLGY-    258

037_-_emb|OIZA01000315.1|              YENIFYDHG-------------------------------------------------    266
emb|OCTW011587266.1|                   FPDILCVLEKVNGKDR-----------------------------------------    216
k87_11092736                           FGSTDVFKVTKKRE-------------------------------------------    199
BMZ-11B_GL0037915                      FGSAFKPIPKKPGDKTSGKYAGGKLKER-----------------------------    222
BMZ-11B_GL0037771                      FGGIFRTQKKEDRKKDSNLSEEEKEEKKKK---------------------------    209
BMZ-11B_GL0069617                      LGAGFKQSERPKHQKNSRPDPRQKIE-------------------------------    201
Ga0099364_10024192                     FGEAFRPVGDDKVKEITLSDEVRKNIEKIIALEEQKRNPSTPRFKQENINLEIENAMGKF    244
530373_GL0023589                       YSRSYANKTSTAKKICICLQEDFHFFDYA-------------TVKKAADQFTLLKRIQRS    258
emb|ODAI011611274.1|                   FGKEFCLVRNSPKQP-------------------------------------------    279
EMG_10003641                           LGNALYSDSLSNLTKDE-----------------------------------------    242
CasR_P1E0_metageno                     LGAAFYDVTPGKSKR-------------------------------------------    222
emb|OIZX01000427.1|                    YSAAFYETLDNGK---------------------------------------------    253
160582958_gene49834                    FGELFYKPKETGDAK-----------------------------------------S    293
gi|1198542314|gb|NFIR01000008.1|       FGSTFCLFNENEERITS-------------------------------------------    270
emb|OGNF01009141.1                     FGSAFYNTPEDTSAK-----------------------------------------    207
Ga0129306_1000735                      YGNAFFRKLSKAERLARG----REIFDK----------------ESPERRQEILGSRGKN    254
MH0288_GL0082219                       YGEAFYRRLSNNERSKLGMERYERMSDA----------------QRDAFDRKYPIDFCDG    301
PIG-022_GL0026351                      FGKVFYEKVTDPKNK-----------------------------------------    218
PIG-028_GL0185479                      FGKVFYEKSTDAKDK-----------------------------------------    220
250twins_35838_GL0110300               FDGLFSVPKREDDGKI----------------------------------------    270
PIG-014_GL0226364                      FGDVFKQVKLSKEQQE-----------------------------------------    211
```

FIG. 18Q

CA 03072610 2020-02-10

250twins_36050_GL0158985	YGTLFEKVKAKSKKEQ----------	269
emb|OJMM01002900.1|	FDGVFKQITDRDSNK----------	248
emb|OGPN01002610.1|	FGDVFKKSKKGKKDE----------	271
emb|OHCP01000044.1|	FDDVFKKNKKPDKNKE----------	267
PIG-046_GL0077813	FDNVFKKIDKKKKRN----------	270
pig_chimera	FDNVFKKIDKNKKKS----------	272
emb|OIEN01002196.1|	FHNILNSDSDNNSKMN----------	211
O2.UC29-0_GL0096317	FDLGFEYAEPSPYKKS----------	204
CasR_Anaerobic_dig	YGKVFIRDVKKSKLST----------	242
emb|OGDF01008514.1|	FSEAFFCETTVKDPDS----------	245
emb|OGZC01000639.1	FGKAFFHAESE----------	281
Ga0224415_10048792_chimera	WGKAFFTGQGN----------	214
emb|OCVV012889144.1|	YGKAFFEKNDLKHNPN----------	205
Ga0187910_10006931	FGKAFFCKEGD----------	223
R._flav_XPD_	FGQAFFSKEGR----------	218
Ga0224415_10007274	LGKAFFYKDGK----------	200
Ga0187911_10069260	FGDTFAFLDKRI----------	204
Ga0187910_10015336	FGNAFFKDEGNK----------	282
ODAI_chimera	YGAAFAEKVQPT----------	282
31009_GL0034153	FGNVFYKNKNE----------	216
DLF014_GL0011914_	FGDIFFKKEEVSKNGK----------	266
CasR_R._albus	FGEAFMVNSGNS----------	263
Ga0187910_10040531	FGSAFYNGDT----------	254
tpg|DJXD01000002.1|	FGEAFYHENE----------	200

FIG. 18R

```
CasR_E._siraeum                    FADAFYVNKKNPKGK----------------------------------------------  273
PIG-018_GL0023397                  YSDAFYEKKGKG-------------------------------------------------  256
PIG-025_GL0099734                  YGHIFFKDKK---------------------------------------------------  273
Ga0129317_1008067_chimera          FGSAFYSQKG-KD------------------------------------------------  205
EYZ-362B_GL0088915                 FGFAYNPKDR---------------------------------------------------  267
uncultured_Ru_sp                   FGLEEPKTKD-NR------------------------------------------------  268
R._flav._FD-1                      FGFDYDANGKDKK------------------------------------------------  273
tpg|DBYI01000091.1|                LSLEYDKRSKDKR------------------------------------------------  271

037_-_emb|OIZA01000315.1|          --------------EPISEEKFYNYLNILNFIRNNTFHYKDN------------------  294
emb|OCTW011587266.1|               -------------YQPKSEKDAFNVLSSVNMLRNSLFHFAPKSND------------GKA  251
k87_11092736                       -------------ERAAADEHNAKVFRALGAIRQKLAHFKWK-----------------E  229
BMZ-11B_GL0037915                  ---------------DAAIAEDVAVLRVLCGLRQISAHFRSEKKG--------------E  253
BMZ-11B_GL0037771                  ----------QEELLQKDLQHNMDVARCISALRHATAHNKPATAHDK----------QDE  249
BMZ-11B_GL0069617                  ---------------DPNWAYNKSALRILSTLRNKLAHFEDS------------------  228
Ga0099364_10024192                 KSKDAFETAKKKYNRIVADETNAKTLRILGAMRQITAHFKDQ------------------  286
530373_GL0023589                   NYFFDMLCDSAGNYQ---CKNAQILLSILGNLRQESFHENRS-----------------T  298
emb|ODAI011611274.1|               ------------DKEEKRQYKLMRVLCLLGELRQFLVHGKKK---------------EKE  312
EMG_10003641                       ---------ILDGKRSKELKKYYQELCLLGMVRQSMIHSNQF------------------  275
CasR_P1E0_metageno                 ---------DAARGRVKREQDVYAILSLMSLLRQFCAHDSVRIWG------------QNT  261
emb|OIZX01000427.1|                -------------SERRSNEDIFNILALMTCLRNFSSHHSIAIKVK-----------DYS  289
160582958_gene49834                DYKTHLSNNQKEEWELKSDKEVYNIFAILCDLRHFCTHGESIT--------------PSG  339
gi|1198542314|gb|NFIR01000008.1|   ---------ENKKEWKRFEKKCYHLLAVLGMMRQATAHGDSK-----------------R  304
```

FIG. 18S

```
emb|OGNF01009141.1                ----------ITKTKIKSNEEIYYTFMLLSTARNFSAHYLDRNRAKS----SDAEDFDGT   253
Ga0129306_1000735                 KSVDDEIRALAPEWVKREERDVYSELVLMSELRQSCFHGQQK----------------N   297
MH0288_GL0082219                  ELHFREIEKLAPEYVRKSEKEIYYILAMLSELRQCVFHDSAA----------------S   344
PIG-022_GL0026351                 ---------SKKKMRLISEKEMYYIFALLGGLRQFCTHDKNR----------------A   252
PIG-028_GL0185479                 ---------NKKKMRLISEKEMYYIFALLGGLRQFCTHDKNR----------------A   254
250twins_35838_GL0110300          ----------KESEKEKAKDQNFDVLRLLSVGRQLTFHSDKSNNE---------------   305
PIG-014_GL0226364                 -KSEEEKRRIWQELWNKNFDHNKNIVNSLIKFRQMCFHQNYENSD----------KEVS   259
250twins_36050_GL0158985          --------RAKEAEIDACTAHNYDVLRLLSLMRQLCMHSVAGTAF----------KLA   309
emb|OJMM01002900.1|               -------------DREIKNSYNALVLKVLYYLRQFCMHGNTYTKR--------NEESFLS   287
emb|OGPN01002610.1|               ----------NNEDYEKNLRHNFNVLRVLSFLRQICTHAYVKCTGGAKNNGDSTKVEAES   321
emb|OHCP01000044.1|               --------GDNSKQYQENLRHNFNILRVLSFLRQICMHAEVHVSD--DEGCTRTQNYTDS   317
PIG-046_GL0077813                 --------DDYEGKRNEILRYNFNVLRVLSFLRQICAHAKVKVSS--DNDREKGGVFVDS   320
pig_chimera                       --------DDCKRERNEILRYNFNVLRVLSFLRQICAHAQVKISN--EHDREKGGGLVDS   322

emb|OIEN01002196.1|               YNKVNKGKEEKDNRNNENIEKLKKALEVIKIIRVDSFHGVDGIKGD----------QKF   260
O2.UC29-0_GL0096317               EQ---QIEQEREEREKENLETLKKALDVISVMRTDSFHGYDMCNSTS--------AIVKF   253
CasR_Anaerobic_dig                ------GKGEKIEVMYRSDEEIFTIFQILSYVRQSIMHNDI----------------GN   279
emb|OGDF01008514.1|               -------GRIVPCLEQRSDGDIYNILRILSIVRQTCMHDNA----------------SM   281
emb|OGZC01000639.1                ----------RKIVKKTEKEVYHILTLIGSLRQWITHSTEG---------------GIS   315
Ga0224415_10048792_chimera        ------------NAKVRQENQCFHIIALLISLRNWATHSNELDK-------------HTK   249
emb|OCVV012889144.1|              -----KKKRDKNPYILKYDNECYYIIALLSGLRHWNIHSHAKDD-------------LVS   247
Ga0187910_10006931                ------------KYLNKQDNERYHILALLSGLRNWVVHNNEVES-------------KID   258
R._flav_XPD_                      ------------NYIINYGNECYDILALLSGLRHWVVHNNEEES-------------RIS   253
Ga0224415_10007274                ----------RNNRQKDPIECYHLLALLCGLRNWVVHNNEEKD-------------LIK   236
Ga0187911_10069260                -------------ADADKEKQVYAMLACLGSLRQACSHYRIRYSVNG------KNVDADA   245
```

FIG. 18T

```
Ga0187910_10015336          ------------KVMRTEKEIYYILGMLNEVRNVSTHFTEEDN-----------RDWA   317
ODAI_chimera                ------------LKYREAEDIYYIICMLGEARQMFAHGND----------------DRT   313
31009_GL0034153             --------------LKDKKDIFDMLCLLGSLRQFCFHFKGAKFEGV---------EQIS   252
DLF014_GL0011914_           --------KPKKVEVLKSEKEIFDILALLGSLRQFCFHYDEAVFENEDGV---IDKEYND   315
CasR_R._albus               ------------TKLRPEKEIYHIFALMASLRQSYFHGYVKDT-----------DYQG   298
Ga0187910_10040531          --------------RRDEKVIYHILSLAASVRQFCFHNDYTSDDGK---------GFIK   290
tpg|DJXD01000002.1|         --------------RRYEEDIFAILTLLSALRQFCFHSDLSSDES----------DHVN   235
CasR_E._siraeum             -----------AKNVLREDKELYSVLTLIGKLRHWCVHSEE----------------GRA   306
PIG-018_GL0023397           ------------SKRRSEKEIYSMLAMLGKLRHWCVHSES----------------GEA   287
PIG-025_GL0099734           --------------KRSKREIYDILALIATIRQWCIHSEE-----------------DK   301
Ga0129317_1008067_chimera   ------------FEKRSDEEVYNICALMGQIRQCCFHGKQ---------------EKYQ   237
EYZ-362B_GL0088915          ----------------NQKKRLYYLMSMIGQLRQFAFHKDS----------------PFN   295
uncultured_Ru_sp            ------------VSQAYKKRVYHMLAIVGQIRQCVFHDKS----------------GAK   299
R._flav._FD-1               ------------KNEEIKKRLYHLTAFAGQLRQWSFHSAG----------------NYP   304
tpg|DBYI01000091.1|         ------------KSEEIKKRLYHLVAFAGQLRQWSFHSVE----------------GLP   302
                                                                  *     *

037_-_emb|OIZA01000315.1|   DIELYSENYS-E-----------------------EYVFINCLNEFVKNKFKNVNKN-F   328
emb|OCTW011587266.1|        RIAVFKNQFDSD-----------------------FSHITSTVNKIYSAKIAGVNEN-F   286
k87_11092736                SLAIFGANANMPI--------------RFFQGATGGRQLWNDVIAPLWKKRIERVRKS-F   274
BMZ-11B_GL0037915           SLWASDLGVEK-----------------------YFKNEM-SVVDANYKARAKKIDAN-F   288
BMZ-11B_GL0037771           YPWFKSSDIYET--------------------KIFKAGMW-SVIEADYKKKIQDVNKQ-F   287
BMZ-11B_GL0069617           -SILFCDNLKG-------------------Q--FLGSNGNW-ITIETHYDEMITRINES-F   265
Ga0099364_10024192          -ATLFMSDVELPK--------------ILK--KEFSKADW-QTVEDYYAKLVDRINEG-F   327
```

FIG. 18U

```
530373_GL0023589                    SAWMFNLEKVLT-----------------------PERKKLLTALIDSRTNHINN-HF   332
emb|ODAI011611274.1|                FAWLYRLDRQLS-----------------------QEYRKLLGEFYDAQVDKVNK-SF   346
EMG_10003641                        NSSIYTLDSSYDSTMNTAELLGKGDDSSLVALATDARVEARAILDEIYKKGVDSINN-SF   334
CasR_P1E0_metageno                  TAALYHLQALP------------------------QDMKDLLDDGWRRALGGVND-HF   294
emb|OIZX01000427.1|                 AAGLYNLRRLG------------------------PDMKKMLDTFYTEAFIQLNQ-SF   322
160582958_gene49834                 KPFPYNLEKNLF-----------------------PEAKQVLNSLFEEKAESLGAEAF   374
gi|1198542314|gb|NFIR01000008.1|    RAEIYKLGKEFDRL-----------------EARGCRPEARKELDELYKKKIHEMNQ-GF   346
emb|OGNF01009141.1                  SVIMYNLDNEELYK------------KLYNKKVHMALTGMKKVLDANFNKKVEHLNN-SF   300
Ga0129306_1000735                   SARIFRLDNDLG----------------------PGVDGARELLDRLYAEKINDLR--SF   333
MH0288_GL0082219                    RSWLYNLEKVLP-----------------------AEAMQVLDGVYSQKVAALN--NF   377
PIG-022_GL0026351                   RNWLYSLDTMLN-----------------------DDAKAVLDKYYVSTVSSLNK-HF   286
PIG-028_GL0185479                   RNWLYSLDTMLN-----------------------DDAKAVLDKYYVSTVSSLNK-HF   288
250twins_35838_GL0110300            -AYLFDLSKLTRA--------------AQDENRRQDIQSLLNILNSTCRSNLEGVNGD-F   349
PIG-014_GL0226364                   STALFNIEQFL-----------------------NKEEKASLDEIYTGAIDKVNCD-F   293
250twins_36050_GL0158985            ESALFNIEDVL-----------------------SADLKEILDEAFSGAVNKLNDG-F   343
emb|OJMM01002900.1|                 DTALYNAKEFFAK--------------------ADPQINELIDAVYADGIKTINSD-F   324
emb|OGPN01002610.1|                 LDALFNITEYFAK--------------------TAPELSKTINEIYKEGIDRINND-F   358
emb|OHCP01000044.1|                 LEALFNISKAFGK--------------------KMPELKTLIDNIYSKGINAINDE-F   354
PIG-046_GL0077813                   LDALFNISSFFDA--------------------VAPELNEVINSVYSKGIYDINDN-F   357
pig_chimera                         LDALFNISRFFDA--------------------VAPELNEVINSVYSKGIDDINDN-F   359
emb|OIEN01002196.1|                 PRSKYNLAVN-----------------------YNEEIQKTISEPFNRKVEEVQQD-F   294
O2.UC29-0_GL0096317                 PSKKFNLDQ---------------------------KGKNLIYRNAFKYKTDTIKKQ-Y   284
CasR_Anaerobic_dig                  KSSILAIEK-----------------------YPARFVGFLSDLLKTKTNDVNRM-F   312
emb|OGDF01008514.1|                 RTVMFTLGQNSVR----------------DRKNGFDELAELLDYLYDEKIDIVNRD-F   322
```

FIG. 18V

```
emb|OGZC01000639.1                RLWLYQLEDA----------------------LSREYQETMNNCYNSTIYGLQKD-F   349
Ga0224415_10048792_chimera        RTWLYKLDDTNI--------------------LNAEYVKTLNYLYDTIADELTKS-F   285
emb|OCVV012889144.1|              YRWLYNLDSI----------------------LNREYISTLNYLYDDIADELTES-F   281
Ga0187910_10006931                RKWLYNLDKN----------------------LDKEYITTLDYMYSDIADELTKS-F   292
R._flav_XPD_                      RTWLYNLDKN----------------------LDNEYISTLNYLYDRITNELTNS-F   287
Ga0224415_10007274                YTWLYNLDKY----------------------LDAEYITTLNYMYNDIGDELTDS-F   270
Ga0187911_10069260                DTWLFSSAQLDQ--------------------TDPLFSEMLNRIYSHKIKTVNQN-F   281
Ga0187910_10015336                KANLYNLSNR----------------------LKVGSKEVLNQLYKEKIDKIDANGF   352
ODAI_chimera                      KTFLYNIVGYRN--------------------GTEINSKFTAVLDGIYSKKVEELNGN-F   352
31009_GL0034153                   NSWLYNLSQ-----------------------LHNEFKSTLDSFYNEKIEDINGN-F   285
DLF014_GL0011914_                 NSWLYNLEK-----------------------LEPEFKDTLDYFYNRKINDINKG-F   348
CasR_R._albus                     TTWAYTLEDKLK--------------------GPSHEFRETIDKIFDEGFSKISKD-F   335
Ga0187910_10040531                ADWMYRLEEA----------------------LPAEYKDTLDALYLEGVEGLDQS-F   324
tpg|DJXD01000002.1|               SFWLYQLEDQ----------------------LSDEFKETLSILWEEVTERIDSE-F   269
CasR_E._siraeum                   EFWLYKLDE-----------------------LKDDFKNVLDVVYNRPVEEINNR-F   339
PIG-018_GL0023397                 EFWLYKLDS-----------------------LNGEFIDVLNTLYNRSVNEINRG-F   320
PIG-025_GL0099734                 KTWIYNAENV----------------------LDSEYLDILDDVYGGLVEKINKN-F   335
Ga0129317_1008067_chimera         LKWLYNFHNFK---------------------SNKPFLDTLDKHFDEMIDRINKN-F   272
EYZ-362B_GL0088915                RVWLYQLDEK----------------------LSKEHKDTLNYFFDQRYDEIHEN-F   329
uncultured_Ru_sp                  RFDLYSFINN----------------------IDPEYRDTLDYLVEERLKSINKD-F   333
R._flav._FD-1                     RTWLYKLDS-----------------------LDKEYLDTLDHYFDKRFNDINDD-F   337
tpg|DBYI01000091.1|               RTWIYQLDNPK----------------------LAQEYRDTLDYFFNERFDAINKD-F   337
                                                                                  :    :
```

FIG. 18W

CA 03072610 2020-02-10

037_-_emb|OIZA01000315.1|	I-SNE-KNNLYIILKAYGEDTENVEVVKKYSKELYKLSVLKTNKNLGVNVKKLRESAIEY	386
emb|OCTW011587266.1|	L-NNE-GNNLYIILKATNWD------IKKIVPQLYRFSVLKSDKNMGFNMRKLREFAVES	338
k87_11092736	L-SNS-AKNLWVLYQVFKDDTD--EKKKARARQYYHFSVLKEGKNLGFNLTKTREYFLDK	330
BMZ-11B_GL0037915	M-ATS-RANLVLLFRILNAKTK--EEKEKIAVDYYKFAIRKEGKNLGVNLKKAREILLDK	344
BMZ-11B_GL0037771	F-SKN-KVNLAILFDLLDVRDV--KQKKRISDEFYRFTIRKDGKNLGMNLVKIREIIIDR	343
BMZ-11B_GL0069617	F-NNS-RMNLKILYLVLNAATL--EDKKKITEEYYRFSILKEGKNLGVNMRKLREMMVDM	321
Ga0099364_10024192	C-KNA-ATNVHFLTELLPE-----ESKKQLTEDYFRFAILKEGKNLGVNMKRLREVMFAL	380
530373_GL0023589	I-ENS-NKNLNAIFRLFPEKS-----QADLIVEYYDFSVRKAYKNLGFSVKLLREMLLKT	385
emb|ODAI011611274.1|	L-TNS-TVNLEVLFRALKTGTD--PERKTVTQEYYQFTVRKEDGNLGFSLKTLREILLSA	402
EMG_10003641	L-SNS-INDLENLFKIYKCDSS--EKKTELIKQYYDFCIRKPQMNMGFSITTIREGMFTR	390
CasR_P1E0_metageno	L-DTN-KVNLLTLFEYYGAETK--QARVALTQDFYRFVVLKEQKNMGFSLRRLREELLKL	350
emb|OIZX01000427.1|	Q-DHN-TTNLTCLFDILNISDS--ARQKQLAEEFYRYVVFKEQKNLGFSVRKLREEMLLL	378
160582958_gene49834	G-KTAGKTDVSILLKVFEKEQASQKEQQALLKEYYDFKVQKTYKNMGFSIKKLREAIMEI	433
gi|1198542314|gb|NFIR01000008.1|	L-KNS-KSDILMLFRIYNAESK--EAKRKLAQEYYEFIMLKSYKNTGFSIKHLRETMIDK	402
emb|OGNF01009141.1	I-KNS-AKDFVILCEVLGIKSR--DEKTKFVKDYYDFVVRKNYKHLGFSVKELRELLFAN	356
Ga0129306_1000735	D-KTSASSNFRLLFNAYHADN---EKKKELAQEFYRFSVLKVSKNTGFSIRTLREKIIED	389
MH0288_GL0082219	S-KTSSKSNFRLLFNALHADTD--AQKKQIAEDFYKFSVRKTYKNIGFSIKLLRESMLDT	434
PIG-022_GL0026351	V-DNSAKKDFSIIFNALNITDI--ELKKNIAKEYYEFVCRKNFKNIGFSIKKLREYLLEK	343
PIG-028_GL0185479	V-ENSAKKDFSIIFNALNITDI--ELKKNIAKEYYEFVCRKNFKNIGFSIKKLREYLLEK	345
250twins_35838_GL0110300	V-KHA-KNNLYVLNQLYPS-----LKANDLIGEYYNFIVKKENRNIGIRLITVRELIIEH	402
PIG-014_GL0226364	N-KNS-SNNLYILEQIYCN-----D--KNLGQRYYDFVVKKSQCNLGLDTKLIRELLIRK	344
250twins_36050_GL0158985	V-QHS-GNNLYVLQQLYPN-----ETIERIAEKYYRLTVRKEDLNMGVNIKKLRELIVGQ	396
emb|OJMM01002900.1|	M-AHA-KNNMYIICEVYKN-----EAEDSLMKEYYDFVVRKEGNNLGFNTRQLREILIDK	377
emb|OGPN01002610.1|	V-TNG-KNNLYILSKVYPD-----MQRNELVKKYYQFVVCKEGNNVGINTRKLKESIISQ	411

FIG. 18X

CA 03072610 2020-02-10

emb|OHCP01000044.1|	V-KNG-KNNLYILSKVYPN-----EKREVLLREYYNFVVCKEGSNIGISTRKLKETMIAQ	407
PIG-046_GL0077813	V-KND-KNNFYILSKIYPE-----VARENLLKEYYYFVVSKEGNNIGISTKKLKEAIIAQ	410
pig_chimera	V-KNG-KNNFYILSKIYPE-----VAREDLLREYYYFVVSKEGNNIGISTKKLKEAIIVQ	412
emb|OIEN01002196.1|	Y-RNS-CVNIDFLKEIMYGSNYTDRGSDSLECSYFNFAILKQNKNMGFSITSIRECLLDL	352
O2.UC29-0_GL0096317	A-QNS-KVNINFLSYVLYGNGCTEEQKKELSREYFNFAILKQYKNLGFSITSLREQLLSL	342
CasR_Anaerobic_dig	IDNNS-QTNFWVLFSIFGL-QDHTSGADKICRNFYDFVIKADSKNLGFSLKKIRELMLDL	370
emb|OGDF01008514.1|	L-RNQ-KNNIELLSRIYGS-SADSPERDRLVQNFYDFRVLSQDKNLGFSIKKLREKLLDS	379
emb|OGZC01000639.1	E-KTN-APNLNFLAEILGK-N-----ASELAEPYFRFIITKEYKNLGFSIKTLREMLLDQ	401
Ga0224415_10048792_chimera	S-KNG-AVNVNYLAKKYNI-K---DDLPGFSEQYFRFSIMKEQKNLGFNISKLRENMLDF	339
emb|OCVV012889144.1|	S-KNS-SANVNYIAETLNI-D-----PSEFAQQYFRFSIMKEQKNMGFNVSKLREIMLDR	333
Ga0187910_10006931	S-KNS-AANVNYIAEILNI-D-----SKTFAEQYFRFSIMKEQKNLGFTLTKLRECMLDR	344
R._flav_XPD_	S-KNS-AANVNYIAETLGI-N-----PAEFAEQYFRFSIMKEQKNLGFNITKLREVMLDR	339
Ga0224415_10007274	S-KNS-AANINYIAETLGI-D-----PKTFAEQYFRFSIMKEQKNLGFNLTKLREVMLDR	322
Ga0187911_10069260	FENNR-KANFPILKKMYPE-----TTLKVLMNEYYDFSIRKGYKNFGFSIKSLREALLSP	335
Ga0187910_10015336	VNKGC-KRDFSILFKSLNL-T-TDKDKGELVVGFYDFSIRKNYKNIGFSIKTLREYMLKI	409
ODAI_chimera	I-KNS-KKDLTILFSAFGC-Q-DEASKKKLIEKYYDFIVKKTNKNMGFSVTKLREKIIEG	408
31009_GL0034153	I-EKN-KVNIQILCNDLKL------DKNKLVQDYYNFLISKNHKNMGFSIKKIREYILDI	337
DLF014_GL0011914_	I-KTN-QINLHIICDELGL-N---WDKEQVVGDYYDFLIAKKYKNIGFSIKKIREHMFDI	402
CasR_R._albus	G-KMN-KVNLQILEQMIGE-LYGSIERQNLTCDYYDFIQLKKHKYLGFSIKRLRETMLET	392
Ga0187910_10040531	L-KNN-TVNIQILCSIFNH-----DDPNKIAEEYYGFLMTKEYKNMGFSIKKLRECMLEL	377
tpg|DJXD01000002.1|	L-KTN-TVNLHILCHVFPK-----ESKETIVRAYYEFLIKKSFKNMGFSIKKLREIMLEQ	322
CasR_E._siraeum	I-ENN-KVNIQILGSVYKN-----TDIAELVRSYYEFLITKKYKNMGFSIKKLRESMLEG	392
PIG-018_GL0023397	V-DTN-KVNIQILQAVCKN-----MDLISLIKAYYEFLITKKYKNMGFSIKKLREMMLAE	373
PIG-025_GL0099734	I-KDN-KVNLILLSDILDM-K-SKDDFEELIRQYYRFIITKEQKLLGFSITKIREAMLED	391

FIG. 18Y

```
Ga0129317_1008067_chimera          I-KNN-TPDLIILSGLYPD-----MAKKELVRLFYDFTTVKEYKNMGFSVKKLREKMLES    325
EYZ-362B_GL0088915                 N-KTN-KVNLELLAEAFPS-----EDYATLANQYYDFTVFKAHKNLGFSIKKLREKLIEN    382
uncultured_Ru_sp                   I-EDN-KVNISLLIDMMKG-----YEADDIIRLYYDFIVLKSQKNLGFSIKKLREKMLDE    386
R._flav._FD-1                      V-TKN-ATNLYILKEVFPE-----ANFKDIADLYYDFIVIKSHKNMGFSIKKLREKMLEC    390
tpg|DBYI01000091.1|                I-ETN-NINLHILKEVFPA-----EDFQKLAALYYDFIVKKTFKNIGFSIKNLREQMLEC    390
                                          :.  :                    :          *.     :*  .

037_-_emb|OIZA01000315.1|          GYCPLP-----YDKEKEVAKLSSVKHKLYKTYDFVITHYLNSN----------------    424
emb|OCTW011587266.1|               KNIDL--------SRLNDKFLTNNRKKLYKVIDFIIYYHLNKVL---------------K    375
k87_11092736                       FFPIFH-----SSAPDVKRKVDTFRSKFYAILDFIIYEASVSV-----ANSGQMGKVAPW    380
BMZ-11B_GL0037915                  HYPD-----------AKNKQFDSYRGKLYTITDFIIYRMAAED----------------    376
BMZ-11B_GL0037771                  YASG-----------LRDKKHDPHRQKINVIADFLIFRALSQN----------------    375
BMZ-11B_GL0069617                  FYSE-----------IKDKQYDSYRQKIYTILDFLLFREIKDS----------------    353
Ga0099364_10024192                 FVPELT-------APETKKRYDSYRAKIYGLTDFLLFKHIHNT----------------    416
530373_GL0023589                   QQELS---------PLNDKAYDSIRSKLYTMFDFVLYKLYVD----------------N    419
emb|ODAI011611274.1|               YKH-----------EVRDKEYDSIRHKLYQLFSFALYHYYKTG---------------VG    436
EMG_10003641                       CSEANTLLLCDEGSTVKLNVHDTMKSKFYKNLDFMIYKYYKYE---------------N    434
CasR_P1E0_metageno                 PDAA----------YLTGQEYDSVRQKLYMLLDFLLCRLYAQE---------------R    384
emb|OIZX01000427.1|                PDAA----------VIADKRYDTCRSKLYNLMDFLILRVYRTG---------------R    412
160582958_gene49834                PDAA----------KFKDDLYSSLRHKLYGLFDFILVKHFLDT-------------SDSE    470
gi|1198542314|gb|NFIR01000008.1|   MDEDK-------KEKLKDDKYNPIRRKIYRIMDFMIYQYYQEP---------------EH    440
emb|OGNF01009141.1                 HDSNKYIK---EFDKISNKKFDSVRSRLNRLADYIIYDYYNK----------------N    396
Ga0129306_1000735                  HAA-----------QYRDKIYDSMRKKLFSTFDFFLWRFYEE----------------R    421
MH0288_GL0082219                   FAP-----------EYKEKSYDSVRGKLYQLVDFLIWNIYDK----------------N    466
```

FIG. 18Z

```
PIG-022_GL0026351                PEFC----------NLKEDKYNSVRSKLYRLIDFIIYLNYKDAKF----------ENDN    382
PIG-028_GL0185479                PEFR----------NLKDDKYNSVRSKLYRLIDFIIYLNYKDAKF----------KNDN    384
250twins_35838_GL0110300         NYT-----------NLKDSKYDTYRNKIYTVLNFILFREIQEN----------------    434
PIG-014_GL0226364                LSD--------EGLDINDSRYDTYRNKIYTVFGFILYYELTKN----------------    379
250twins_36050_GL0158985         YFPE--VLDKEYDLSKNGDSVVTYRSKIYTVMNYILLYYLEDH----------------    437
emb|OJMM01002900.1|              YVG-----------NLRGKKYNTFRNKLYTVLGFILVKEIKRN----------------    409
emb|OGPN01002610.1|              HPWI--TTPQD---NNKANDYESCRHKLYTIMCFILVAELDAH----------------    449
emb|OHCP01000044.1|              NMP-------------SLKEENTYRNKLYTVMNFILVRELKNC----------------    437
PIG-046_GL0077813                DMS-----------YIKSKDYDTYRNKLYTVLCFILVKELNER----------------    442
pig_chimera                      DMS-----------YIKSEDYDTYRNKLYTVLCFILVKELNER----------------    444
emb|OIEN01002196.1|              YEL-------------NFESMQNLRPRANSFCDFLIYDYYCKNE---------------    383
O2.UC29-0_GL0096317              YDI-------------DFECKRNLRSRANSFCDYVLYYRYAVQF---------------    373
CasR_Anaerobic_dig               PNA----------NMLRDHQFDTVRSKFYTLLDFIIYQHYLEE----------------    403
emb|OGDF01008514.1|              PAL----------SVVRSKKYDTMRSKIYSLIDFMIYRKFSEN----------------    412
emb|OGZC01000639.1               PDLQ--E------IRENHNVYDSIRSKLYKMIDFVLVYAYSNERK--------------    438
Ga0224415_10048792_chimera       KDMS--V------IRDDHNRYDKDRSKIYTMMDFVIYRYYIDNNN--------------    376
emb|OCVV012889144.1|             KELS--D------IRDNHRVFDSIRSKLYTMMDFVIYRYYIEEAAKTEAENRNLPENEKK    385
Ga0187910_10006931               EELS--D------IRDNHKVFDSIRSKLYTMMDFVIYRYYIEEAKKIENENKTLSDDKKK    396
R._flav_XPD_                     KDMS--E------IRKNHKVFDSIRTKVYTMMDFVIYRYYIEEDAKVAAANKSLPDNEKS    391
Ga0224415_10007274               KDMS--E------IRENHNDFDSIRAKVYTMMDFVIYRYYIEEAAKVNAANKSLPDNEKS    374
Ga0187911_10069260               QYES--LIGV---QIKDNKEYDTVRSKLYQLFDFALTRYFNQH----------------    373
Ga0187910_10015336               SNS------T---LCADTISNNAIRPKAYKLYDFIIWHYYMNK----------------    443
ODAI_chimera                     YRFR--G------NPVTGTDYDSVRHKLYRTFDFIICSYYDDH----------------    443
31009_GL0034153                  DYA----------SYIKEQGYDSVRSKLFTLIDFIIYDLYVNKE---------------    371
```

FIG. 18AA

```
DLF014_GL0011914_          YEA----------FDIKDKRFDSVRSIMYKIIDFVIYYSFIHYK----------------  436
CasR_R._albus              TPA----------ECYKAECYNSERQKLYKLIDFLIYDLYYNRK----------------  426
Ga0187910_10040531         PEL----------SGYKEDQYNSVRSKLYKLFDFIIAHYFRKH----------------  410
tpg|DJXD01000002.1|        SDL----------KSFKEDKYNSVRAKLYKLFDFIITYYYDHH----------------  355
CasR_E._siraeum            KGY-------------ADKEYDSVRNKLYQMTDFILYTGYINED---------------  423
PIG-018_GL0023397          TAYT--SNPD---DRLYDKEINSVRNKLYQMTDFIIYLEYRDN----------------  411
PIG-025_GL0099734          TV------------FKTDKKYDSIRSKLYKLIDFMMFYKYTTVDSE--------------  425
Ga0129317_1008067_chimera  EEA----------SDFRDKDYDSVRRKLYKLMDFCIYYLYYS-D----------------  358
EYZ-362B_GL0088915         --------------ALRDEKIDSFRSKLYRLIDFCLFRIYLK-D----------------  411
uncultured_Ru_sp           YG-----------FRFKDKQYDSVRSKMYKLMDFLLFCNYYRND----------------  419
R._flav._FD-1              DGA----------DRIKEQDMDSVRSKLYKLIDFCIFKYYHE-F----------------  423
tpg|DBYI01000091.1|        DEA----------EKIRSKDMNSVRSKLYKLFDFCIFYQYFI-D----------------  423

037_-_emb|OIZA01000315.1|  DKLLLEIVETLRLSK-----ND-DEKENVYKKYA---E-KLFKADDVINPIKAISKLFAE  474
emb|OCTW011587266.1|       DSFVDDFVAALRASQ-----SE-EEKEKLYAQYS---E-RLFADEGLKSAIKKAVDMISD  425
k87_11092736               KGAIDNALVKLREAP-----DE-EAKEKIYNVLA---A-SIRNDSLFL--RLKSACDKFG  428
BMZ-11B_GL0037915          GAFLEESVQKLRSTP-----SE-EEKEKVYDVLA---E-TIWNATKDD--VKKVFDIRQQ  424
BMZ-11B_GL0037771          QGIIDKTVSSLRLTK-----DE-EEKDHVYQNAA---E-LVWGMVSNC--LTPYFNDPKN  423
BMZ-11B_GL0069617          -EELETMVADLRESE-----SD-EKKEELYHDYA---E-LFWDGVKDL--IVPFFAAFDG  400
Ga0099364_10024192         -KQLEEWVAVLRETS-----NE-DAKENLYDEFA---R-TAWNTVGDS--AKQLIENMQS  463
530373_GL0023589           EEQIDQFVRKLRAST-----SN-VEKEALYQQES---E-RTWNEIRGQ--IIDNVIPFID  467
emb|ODAI011611274.1|       AERREAFVAKLRAVM-----TA-EAKQRAYADEA---A-EIWNDEGSG--IRAAFLEILE  484
EMG_10003641               PEKGEKLIEDLRSKIKGKKKED-EDKKQRYAEES---A-CILKAKRDI--IKKDLTEAAN  487
```

FIG. 18BB

```
CasR_P1E0_metageno                    ADRCEELVSALRCAL-----SD-EEKDTVYQAEA---A-ALWQALGDT--LRRKLLPLLK   432
emb|OIZX01000427.1|                   ADRCDKLPEALRAAL-----TD-EEKAVVYHKEA---L-SLWNEMRTL--ILDGLLPQMT   460
160582958_gene49834                   NLQNNDIFRQLRACR-----CE-EEKDQVYRSIA---V-KVWEKVKKK--ELNMFKQVVV   518
gi|1198542314|gb|NFIR01000008.1|      QEEAEELVRKLRNAE-----IE-AKKELAYRKEA---E-KLKKELEKI--IFNSVLPSCD   488
emb|OGNF01009141.1                    NAKVSDLVKYLRAAA-----DD-EQKKKIYLNES---INLVKSGILER--IKKILPKLNG   445
Ga0129306_1000735                     EDEAEELRACLRAAR-----SD-EEKEQIYAEAA---A-SCWPSVKPF--VESVAATLCD   469
MH0288_GL0082219                      EKMADALVAQLRAEVK---RDR-DEKSPVYDREA---A-RLWTMIREA--VAQTAKTLRA   516
PIG-022_GL0026351                     DEKIERFVSKLRKCP-----DE-ASKETVYQTES---D-IIKKSIYGS--INSIKRGMM-   429
PIG-028_GL0185479                     DEKIERFVSKLRKCP-----DE-ASKETVYQTEA---D-IIKKSISGS--INSIKRDMM-   431
250twins_35838_GL0110300              SIAIKNFREKLRSTE-----K--AEQPALYQAFA---N-KIYPMVQAK--FAKAIDLFEE   481
PIG-014_GL0226364                     ETFCQEIVAKLRRFG-----GDEIEKNKIYNEYFLRKE-AVYNQIAEK--FKQSVCWFKK   431
250twins_36050_GL0158985              DSSRESMVEALRQNR-----EGDEGKEEIYRQFA---K-KVWNGVSGL--FGVCLNLFKT   486
emb|OJMM01002900.1|                   PKIQDSFIAKLRANQ-----NGDEGKLNIYNEFA---P-KIWSVVSSK--LNSAITCFDE   458
emb|OGPN01002610.1|                   ESIRDNMVAELRANM-----DGDDGRDAIYEKYA---K-DIYHIVKDK--LLAMQKVFDE   498
emb|OHCP01000044.1|                   ATIREQMIKELRANM-----DEEEGRDRIYSKYA---K-EIYLYVKDK--LKLMLNVFKE   486
PIG-046_GL0077813                     TTIREQMVADLRANM-----NGDIGREDIYSKYA---K-IIYAQVKPR--FDGMKNVFEE   491
pig_chimera                           TTIREQMVADLRANM-----NGDIGREDIYSKYA---K-IIYAQVKPR--FDTMKSAFEE   493
emb|OIEN01002196.1|                   -SERANLVDCLRSAA-----SE-EEKKNIYFQTA---E-RVKEKFRNA--FNRISRFDAS   430
O2.UC29-0_GL0096317                   PERIVDLVDKLRCSA-----NE-KEKTNVYIEEA---N-RIKEDLRIA--FNRINNFDAK   421
CasR_Anaerobic_dig                    KSRIDNMVEKLRMTL-----KE-EEKEVLYAAEA---K-IVWNAIGAK--VINKLVPMMN   451
emb|OGDF01008514.1|                   HVAVDDFVEELRSLL-----TE-DEKESAYSRWA---ETLINDGFAQE--ILVKLLPQTD   461
emb|OGZC01000639.1                    -SKADALASNLRSAI-----TE-DAKKRIYQNEA---D-QLWTSYQEL--FKRIRGFKGA   485
Ga0224415_10048792_chimera            --DSIDFINKLRSSI-----DE-KSKEKLYNEEA---N-RLWNKLKEY--MLYIKEFNGK   422
emb|OCVV012889144.1|                  ISEKDFFVINLRGSF-----DE-NQKEKLYIEEA---K-RLWEKLKDI--MLKIKEFRGE   433
```

FIG. 18CC

CA 03072610 2020-02-10

```
Ga0187910_10006931          LSEKDIFIISLRGSF-----SE-EQKDKLYSDEA---E-RLWAKLGKL--MLEIKKFRGQ    444
R._flav_XPD_                LSEKDIFVINLRGSF-----ND-DQKDALYYDEA---N-RIWRKLENI--MHNIKEFRGN    439
Ga0224415_10007274          LSEKDIFVISLRGSF-----NE-DQKDRLYYDEA---Q-RLWSKVGKL--MLKIKKFRGK    422
Ga0187911_10069260          PDMVDAFVVELRSLA-----KDEDAKNAVYEKYA---K-AVWNDVKQP--IAVMLSYMNG    422
Ga0187910_10015336          PDKINDFVEKLRTQN-----KN-DEKIKLYYDEA---V-CLLSELGRE--IHTMTSCVHN    491
ODAI_chimera                AKEKDTLVSSLRASL-----ND-TKKENLYAGEA---K-TIAESIKDR--MDTVCRMYNK    491
31009_GL0034153             KDRIDDIVSKLRGAI-----YD-YKKDDIYKAEA---D-WVWKKLNRQ--IKALTKLLSN    419
DLF014_GL0011914_           QDEVDEIVNYLRSTL-----SE-EQKKEKYIKLA---G-NIWAEYKTQ--FNKLKDILLA    484
CasR_R._albus               PARIEEIVDKLRESV-----ND-EEKESIYSVEA---K-YVYESLSKV--LDKSLKNSVS    474
Ga0187910_10040531          PEKGEEMVDCLRLCM-----TE-DEKDSHYEGTA---K-KLVRELAYD--MQEAAEQANG    458
tpg|DJXD01000002.1|         AFEKEALVSSLRSSL-----TE-ENKEEIYIKTA---R-TLASALGAD--FKKAAADVNA    403
CasR_E._siraeum             SDRADDLVNTLRSSL-----KE-DDKTTVYCKEA---D-YLWKKYRES--IREVADALDG    471
PIG-018_GL0023397           KSIIDTLVSKLRSSV-----TD-EAKEAVYREEA---A-NLRGRLLDA--VALIAKSLNG    459
PIG-025_GL0099734           KEHADSIVEKLRATL-----SG-ESKEEIYKAEA---N-RIWNLYEDI--IMNKIEPALD    473
Ga0129317_1008067_chimera   SERNENLVSRLRESL-----TD-ENKDIIYSKEA---K-IVWNELRKK--FSTILDNVKG    406
EYZ-362B_GL0088915          PDRAEKNVRFLRSCI-----NE-QEKEQFYTQEA---N-ALKSENPGL--VNDFCMQLKD    459
uncultured_Ru_sp            IAAGESLVRKLRFSM-----TD-DEKEGIYADEA---A-KLWGKFRND--FENIADHMNG    467
R._flav._FD-1               PELSEKNVDILRAAV-----SD-TKKDNLYSDEA---A-RLWSIFKEK--FLGFCDKIVV    471
tpg|DBYI01000091.1|         EERSRENVNYLRSTL-----ND-EQKDAFYEEEG---K-RLWSENRKK--FIYFCDNINK    471
                                      **              :    *

037_-_emb|OIZA01000315.1|   KGNKLFKEK----------------------IIIKKEYIEDVSIDKNIYDFTKVIFFMTCF    513
emb|OCTW011587266.1|        TKSNIFKMK----------------------TPLDKALIENIKVNSDASDFCKLIYVFTRF    464
k87_11092736                AEQNRPVFPNELR-------------NNRDIRNVRSEWLEATQDVDAAAFVQLIAFLCNF    475
```

FIG. 18DD

```
BMZ-11B_GL0037915                  DIKNAAAQS----------------------LDDVNLDSVTVEKEKEFPVVKLLAFLCNF    462
BMZ-11B_GL0037771                  KYILKYKDA----------------------KTPGDFEDWITSKISEDDGEPFVKVLSFLCNF    464
BMZ-11B_GL0069617                  DFTVFTTEK----------------------VPADTSKEPFLSSANTEPLVKLLAFLCNF    438
Ga0099364_10024192                 YFTKKEKEIT--K------------TAQPVLSTSSIAHTSKKITQFSSFAKLLAFLCNF    508
530373_GL0023589                   SIQKQENEDKLTKR--------------IDQSIIDKAVPHFVNSRDLSYFAKVVYVVASF    513
emb|ODAI011611274.1|               AVDFGSAVKGIKARSS----------VAGDKRFAEWLEEVRIRPEGVSCFTKLMYLLTRF    534
EMG_10003641                       KDLFADLVKSNKNEKQK------------FKNEYEELLKPFMIPVKVDYFSELIYLVTRF    535
CasR_P1E0_metageno                 GKKLQDKDK-KKSDELGLSRDVLDGVLFR--------PAQQGSRANADYFCRLMHLSTWF    483
emb|OIZX01000427.1|                PENLSRLSGQKRKGELSLDDAMLKECLYE---PGPVPEDAAPEEANAEYFCRMIYLATLF    517
160582958_gene49834                IPSLSKDE----------------LKQMEMTKNTELLSSIETISTQASLFSEMIFMMTYL    562
gi|1198542314|gb|NFIR01000008.1|   RILSEMDERRNKKVNQESSDTDKEEPL-----DSEIAEGITFIKETAHSFSEMIYLLTVF    543
emb|OGNF01009141.1                 KIIGNMQPDSTI----------------TASMLHNTGKDWHPISENAHYFTKWIYTLTLF    489
Ga0129306_1000735                  VVKGR-------------TKLNKLKLSADESTLVRNAIDGVRISPRASYFTKLIYLMTLF    516
MH0288_GL0082219                   VTLSNNTPGSIKIKELALSKYDRDLVENAIDSAVDERGRRLKITDEASYFSKLIYLLTLF    576
PIG-022_GL0026351                  ---------------SVKSKYGKLELDKQTINQLKRAVDDISINTKGDYFTKLMYLISLL    474
PIG-028_GL0185479                  ---------------LVKSKYGKLELDTQTVNQLKRAVDDISINTKGDYFTKLMYLISLL    476
250twins_35838_GL0110300           QYKTKFKSEFKGGI----------------SIENMQQQNILLQTENIDYFSKYVLFLTKF    525
PIG-014_GL0226364                  EKEKKKEFSS--------------------KTKIDLRSVQKIEDQNASVFAKMVYLISRF    471
250twins_36050_GL0158985           EKRNKFRSKV--------------------ALPDVSGAAYMLSSENIDYFVKMLFFVCKF    526
emb|OJMM01002900.1|                ESLSKFKGYK--------------------DIDESLISRYGITVANTDTLVKILYFLCKF    498
emb|OGPN01002610.1|                ELVPVKVEGKNDPQ--Q---------FTHGKLGKKEIESFCLSDKNTSDIAKVVYFLCNF    547
emb|OHCP01000044.1|                EAEGIIIPGKEDPV--K---------FSHGKLDKKEIESFCLTTKNTEDITKVIYFLCKF    535
PIG-046_GL0077813                  EAKGVIVPDKEEAV--K---------FSNGALDKSEIERFCITSANTDSVAKIIYFLCKF    540
pig_chimera                        EAKDVIVPDKKKPV--K---------FSHGKLDKNEIERFCITSANTDSVAKIIYFLCKF    542
```

FIG. 18EE

emb|OIEN01002196.1|	YIKNSREKNLSGGS--SLPK-----YSFIEGFTKRSKKINDNDEKNADLFCNMLYYLAQF	483
O2.UC29-0_GL0096317	SIKLYSTKNNVDDQ--PMLP-----FEQVSK----DIKGGDAAREKADAFCDMTYYLTQF	470
CasR_Anaerobic_dig	GDALKEIKRKN----------RDRKLPQSVIATVQVNSDANVFSGLIYFLTLF	494
emb|OGDF01008514.1|	PAVIGKIKG----------KKLLNDSIAGIKLKKDASFFTKIINVLCMF	500
emb|OGZC01000639.1	QVKEYSSKN-M----------P----IPIQKQIQNILKPAEQVTYFTKLMYLLTMF	526
Ga0224415_10048792_chimera	LASRTPDRD-G----------NISEFVESLPKIHRLLPRGQKISNFSKLMYLLTMF	467
emb|OCVV012889144.1|	KVKEYK----------KEVPRIERILPQGKDISAFSKLMYMLSMF	468
Ga0187910_10006931	MTRDYK----------KSDTPTLNRILPESEDVSTFSKLMYALTMF	480
R._flav_XPD_	KTREYK----------KKDAPRLPRILPAGRDVSAFSKLMYALTMF	475
Ga0224415_10007274	DTRKYK----------NMGTPRIRRLIPEGRDISTFSKLMYALTMF	458
Ga0187911_10069260	SAIKNIKAFEL----------KPDQKELNGIMNSNALDVPHFCKLVYFLTRF	464
Ga0187910_10015336	IENTSYEITDK----------KQKEYYKMQINSLNSADKVSDFSKVIYLVTLF	534
ODAI_chimera	GEGIKHITVDR----------FIAGAGAGKLIDKCSISTECDYFCKFIYLMTLF	535
31009_GL0034153	RRIFSQDND----------ITNWNGVEFEKIGEQKLEDNADYFCKLMYFVTLF	462
DLF014_GL0011914_	NIKEFSDAKEDDV----------YYEEFKNFKFNEVGKEKLGENAEYFCKLMYLLTLF	532
CasR_R._albus	GETIKDLQKRY----------DDETANRIWDISQHSISGNVNCFCKLIYIMTLM	518
Ga0187910_10040531	SNITQMQKNEQQG----------KT-KGMFAIRDEIRVSRKPVSYFSKVIYVMTLL	503
tpg|DJXD01000002.1|	KNIRDYQKKAN----------DYRISFEDIKIGNTGIGYFSELIYMLTLL	443
CasR_E._siraeum	DNIKKLSKS----------NIEIQEDKLRKCFISYADSVSEFTKLIYLLTRF	513
PIG-018_GL0023397	VNIKKLQQN----------TLEIPDSKLENCFIKSAEKVSAFTKLNYLLTRF	501
PIG-025_GL0099734	EGVISGLKK----------NKSYDNMSIEGIVAEETANVSYFSKIIYLLAQF	515
Ga0129317_1008067_chimera	SNIKKLEN----------VKEKFISEDEFDDIKLDIDISYFSKLMYVMCYF	447
EYZ-362B_GL0088915	RYSSGSNSTENAE----------KKEDFPVFPHCHDKQKVSNVSLFAKLMYAFCLF	505
uncultured_Ru_sp	DVIKELGK----------ADMDFDEKILDSEKKNASDLLYFSKMIYMLTYF	508

FIG. 18FF

```
R._flav._FD-1                          WVTGEHEK----------------------DITSVIDKDAYRNRSNVSYFSKLMYAMCFF    509
tpg|DBYI01000091.1|                    WVKNDYSD----------------------EVAKCIDLNEFRVNSNVSYFSKLLYAMSFF    509
                                                                                .       :

037_-_emb|OIZA01000315.1|              LDGKEINDLLTNIISKLQVIEDHNNVIKFIFH------------------------NKD    548
emb|OCTW011587266.1|                   LDGKEINILLNSLIKKFQDIHSFNTTVKKLSE------------------------NNL    499
k87_11092736                           LEGKEINELVTALIKKFEGIQALIDLLRNLEGV-------------------------     508
BMZ-11B_GL0037915                      LDGKEINELLSTFVNRLENVQALIDLAKNLGET-------------------------     495
BMZ-11B_GL0037771                      LEGKEINELLTAYIHKFECIQDFLNVISSLGEN-------------------------     497
BMZ-11B_GL0069617                      WDGKEVNEVLSAYIHKFESIQAFIDVLESKELN----------------------EKV    474
Ga0099364_10024192                     WEGKEINELLSAYIHKFENIQEFINLLEKLEGK-------------------------     541
530373_GL0023589                       LDSKEINMFFDALINELENIASFNDVLEQLDM---------------------------     545
emb|ODAI011611274.1|                   LDGKEINELLTGLINKLENIQSFLDVMQQEHA---------------------------     566
EMG_10003641                           LSGKEINDLLTQLINKFENIAAFIRMYQNDQG---------------------------     567
CasR_P1E0_metageno                     MDGKEINTLLTTLISKLENIDSLRSVLESMGL---------------------------     515
emb|OIZX01000427.1|                    MDGKEINTLLTTLISKFENIAAFLQTMEQLNI---------------------------     549
160582958_gene49834                    LDGKEINLLCTSLIEKFENIASFNEVLKSPQIG---------------------------     595
gi|1198542314|gb|NFIR01000008.1|       LDGKEINILLTQLIHCFDNISSFMDTMEEENL---------------------------     575
emb|OGNF01009141.1                     MDGKEINDLVTTLINKFDNIASFIEVLKSQSV---------------------------     521
Ga0129306_1000735                      LDGKEINDLLTTLIHAFENIDSFLSVLGSERL---------------------------     548
MH0288_GL0082219                       LDGKEINDLITTLVNSFDEIDSFCCVLQKAKL---------------------------     608
PIG-022_GL0026351                      IDGKEINDLLTTLIHQFENIASFIDVMKKENI---------------------------     506
PIG-028_GL0185479                      IDGKEINDLLTTLIHQFENIASFIDVMKKENI---------------------------     508
250twins_35838_GL0110300               LDGKEINELLCALINKFDNIADLLDISKQIGT---------------------------     557
```

FIG. 18GG

```
PIG-014_GL0226364                LDGKEINELCTKLLNKFKNINELVETAKRCGE--------------------------    503
250twins_36050_GL0158985         LDGKEINELLCALINKFDNIADILDAAAQCGS--------------------------    558
emb|OJMM01002900.1|              LDGKEINELCCAMINKFDNINDLIKTAAQCGE--------------------------    530
emb|OGPN01002610.1|              LDGKEINELCCAMMNKFDGIGDLIDTAKQCGE--------------------------    579
emb|OHCP01000044.1|              LDGKEINELCCAMMNKLDGISDLIETAKQCGE--------------------------    567
PIG-046_GL0077813                LDGKEINEFCCAMMNKLDGINDLMETAEQCGA--------------------------    572
pig_chimera                      LDGKEINELCCAMMNKLDGINDLIETAEQCGA--------------------------    574
emb|OIEN01002196.1|              LDGKEINIFLTSIHNIFQNIDSFLKVMKEKGM--------------------------    515
O2.UC29-0_GL0096317              LDGKEINVFLTTLHNLFENIASFLDVMHKQNI--------------------------    502
CasR_Anaerobic_dig               LDGKEINEMVSNLITKFENIDSLLHVDREIYKSDEKDLDLEIEKLALFFKGVVRPNAKTD    554
emb|OGDF01008514.1|              QDGKEINELVSSLVNKFANIQSFVDVMRSQGI--------------------------    532
emb|OGZC01000639.1               LDGKEINDLLTTLINKFDNISSLLKTMEQLEL--------------------------    558
Ga0224415_10048792_chimera       LDGKEINDLLTTLINKFENIQGFLDIMPEINV--------------------------    499
emb|OCVV012889144.1|             LDGKEINDLFTTLINKFDNIQCFLKIMPLIGV--------------------------    500
Ga0187910_10006931               LDGKEINELLTTLINKFDNIQSMLKIMPLIGV--------------------------    512
R._flav_XPD_                     LDGKEINDLLTTLINKFDNIQSFLKVMPLIGV--------------------------    507
Ga0224415_10007274               LDGKEINDLLTTLINKFDNIQSFLKVMPLIGV--------------------------    490
Ga0187911_10069260               LDGKEINDLLTTLVNKFDNIHSFNQVLTALGL--------------------------    496
Ga0187910_10015336               LDGKEINDLLTTLINKFDNIASLLSVLEKQSG--------------------------    566
ODAI_chimera                     IDGKEINDLLTTLINKFDNIDSPSVDKAVNNQ--------------------------    567
31009_GL0034153                  LDGKEINDLLTTLINKFDNIRSFIEVMEEMSL--------------------------    494
DLF014_GL0011914_                LDGKEINDLLTTLINKFDNIRSFVELMKEENI--------------------------    564
CasR_R._albus                    LDGKEINDLLTTLVNKFDNIASFIDVMDELGL--------------------------    550
Ga0187910_10040531               LDGKEINDLLTTLINKFENIVSFEDVLRQLNV--------------------------    535
```

FIG. 18HH

```
tpg|DJXD01000002.1|              LDGKEINDLLTTLINKFDNIISFIDILKKLNL----------------------------  475
CasR_E._siraeum                  LSGKEINDLVTTLINKFDNIRSFLEIMDELGL----------------------------  545
PIG-018_GL0023397                INGKEINDLLTTLINKFDNIRSFLETMDELGL----------------------------  533
PIG-025_GL0099734                IDGKEVNDLTTTLINKFDNIRSFIDTANQIGL----------------------------  547
Ga0129317_1008067_chimera        LDGKEINDLLTTLVSKFDNIGSIIEAATQIGI----------------------------  479
EYZ-362B_GL0088915               LDGKEINELLSALLNKFDTIACMTKCTKDLGI----------------------------  537
uncultured_Ru_sp                 LDGKEINDLLTTLISKFDNIKEFLKIMKSSAVD----------------------------  541
R._flav._FD-1                    LDGKEINDLLTTLINKFDNIANQIKTAKELGI----------------------------  541
tpg|DBYI01000091.1|              LDGKEINDLLTTLINKFDNIRSFIDTANFLNI----------------------------  541
                                  ..**:* .       :  :

037_-_emb|OIZA01000315.1|        AVYKDYSDKYAIFR----------------NA---------------GKIATELEAIKSI  577
emb|OCTW011587266.1|             IINADYVDDYSLFE----------------QS---------------GTVARELMLIKSI  528
k87_11092736                     -DSIRFENEFALFN----------------DD----------KGNMAGRIARQLRLLASV  541
BMZ-11B_GL0037915                ---VNFSKNYAVFN----------------DC----------GSGAAGRIAERLRLLASI  526
BMZ-11B_GL0037771                ---VQFQPRFALFN----------------NA------------SFAQNVAVQLRILASI  526
BMZ-11B_GL0069617                VFSAKKGRNFSAFN----------------EH------------GFAGRVADQLRVLASI  506
Ga0099364_10024192               --KPQFTENYALFN----------------EA----------AGQRAGEIAQNLRILASI  573
530373_GL0023589                 --PLDYQEKYRFFE----------------RS---------------REEAAGLRFIKSI  572
emb|ODAI011611274.1|             --ETGLSDAFSFFE----------------YS---------------GEIAAELRMTRSF  593
EMG_10003641                     --KLEFTANYKMFEIDPQKDIPKDGKRVLSGS---------------AKIAYYLRTINYI  610
CasR_P1E0_metageno               --AYSFVPAYAMFD----------------HS---------------RYIAGQLRVVNNI  542
emb|OIZX01000427.1|              --EAELGPEYAMFT----------------RS---------------RAVAEQLRVINSF  576
160582958_gene49834              -YETKYTEGYAFFK----------------NA---------------DKTAKELRQVNNM  623
```

FIG. 18II

```
gi|1198542314|gb|NFIR01000008.1|    --LTKLKEDYEIFE----------------ES--------------KEISRELRIINSF    602
emb|OGNF01009141.1                  --CTHFSEERKMFI----------------DS--------------AEICSELSAMNSF    548
Ga0129306_1000735                   --ERTFDANYRIFA----------------DS--------------GVIAQELRAVNSF    575
MH0288_GL0082219                    --DRGFTEGYRFFA----------------HS--------------AEISQELRAINSF    635
PIG-022_GL0026351                   --NYEFAEKYKFFN----------------TS--------------KNIACELRTVNSF    533
PIG-028_GL0185479                   --ECEFTEKFAFFK----------------NS--------------EIIAHELRTVNSF    535
250twins_35838_GL0110300            --PVVFCADYESLN----------------DA--------------AKIAENIRLIKNI    584
PIG-014_GL0226364                   --TIEFCPEYKMFK----------------NS--------------AKLAEEMRFVQSV    530
250twins_36050_GL0158985            --SVWFVDSYRFFE----------------RS--------------RRISAQIRIVKNI    585
emb|OJMM01002900.1|                 --DIEFVKEYKLFI----------------NS--------------NDLSDQIRIVKSI    557
emb|OGPN01002610.1|                 --EVKFIEEFACLS----------------NC--------------RKITNDIRVAKSI    606
emb|OHCP01000044.1|                 --DVEFVDQFKCLS----------------KC--------------ATMSNQIRIVKNI    594
PIG-046_GL0077813                   --KIEFVDNFNVLS----------------KC--------------GTISGQIRVVKSI    599
pig_chimera                         --KVEFVDKFSVLS----------------NC--------------ETISDQIRIVKSI    601
emb|OIEN01002196.1|                 --ECKFQKDFKMFS----------------HA--------------GHVAKKIEIVISL    542
O2.UC29-0_GL0096317                 --SYDFTEQYVMFY----------------DS--------------AYIVKKLETVISV    529
CasR_Anaerobic_dig                  TGAGEISKSFSIFQ----------------SA--------------ERIIEELKFIKNV    583
emb|OGDF01008514.1|                 --DSGFTADYAMFA----------------ES--------------GRISRELHILKGI    559
emb|OGZC01000639.1                  --QTTFKEDYTFFQ----------------QS--------------SRLCKEITQLKSF    585
Ga0224415_10048792_chimera          --NAKFEPEYVFFN----------------KS--------------HEIAGELKLIKGF    526
emb|OCVV012889144.1|                --NVKFTEDYAFFN----------------KS--------------EKIADELRLIKSF    527
Ga0187910_10006931                  --NAKFSSDYAFFN----------------NS--------------EKIADELKLIKSF    539
R._flav_XPD_                        --NAKFVEEYAFFK----------------DS--------------AKIADELRLIKSF    534
Ga0224415_10007274                  --NAKFAEEYSFFN----------------NS--------------EKIADELRLIKSF    517
```

FIG. 18JJ

CA 03072610 2020-02-10


```
Ga0187911_10069260                --SASYEADYKIFE----------------DS--------------GRVVEYLREINSF    523
Ga0187910_10015336                -KKVEFVENYSFFN----------------SSNLLKEKTLNKSENYTCKIVEELREINSF    609
ODAI_chimera                      -NRVEFGDKYDMFN----------------KA--------------GEICESLRSINSF    595
31009_GL0034153                   --KCEFMEEYKFFN----------------ES--------------KDICLRLKEIHSF    521
DLF014_GL0011914_                 --ECIFDKKFAFFD----------------ES--------------KNVCSTLREINSF    591
CasR_R._albus                     --EHSFTDNYKMFA----------------DS--------------KAICLDLQFINSF    577
Ga0187910_10040531                --DCTFKPEFAFFG----------------Y-D-----------RCRNISGELRLINSF    564
tpg|DJXD01000002.1|               --EFKFKPEYADFF----------------NMT-----------NCRYTLEELRVINSI    505
CasR_E._siraeum                   --DRTFTAEYSFFE----------------GS--------------TKYLAELVELNSF    572
PIG-018_GL0023397                 --ERTFTENYRFFE----------------DS--------------QKYRDELIELNSF    560
PIG-025_GL0099734                 --ECNLLDEYQFFN----------------TS--------------DTVKKELHVIKNL    574
Ga0129317_1008067_chimera         --NIEFIDDFKFFD----------------RS--------------KDISVELNIIRNF    506
EYZ-362B_GL0088915                --YAPFSKDFNFFE----------------DS--------------EQRAEEMNLVKSI    564
uncultured_Ru_sp                  -VECELTAGYKLFN----------------DS--------------QRITNELFIVKNI    569
R._flav._FD-1                     --NTAFVKNYDFFN----------------HS--------------EKYVDELNIVKNI    568
tpg|DBYI01000091.1|               --DVKFTKDYDFFN----------------II--------------CDYAGELNIIKNI    568
                                              :                                 :     .

037_-_emb|OIZA01000315.1|         ARMENKIE--------------NAPKEPLLKDALLALGVSSNDFDEKYEKYFKTDVD---    620
emb|OCTW011587266.1|              SKMDFGLD--------------NINLSFMYDDALRTLGVSDENLPEVKREYF--------    566
k87_11092736                      GKMKPDMT---------------DAKRVLYKSALEILGAPPD--------EVS-------    571
BMZ-11B_GL0037915                 GKMDAGLD---------------SLKPLFIRFAIQILGGARIS------DEDV-------    558
BMZ-11B_GL0037771                 GKMKPDLT---------------EAKRPLYKAAIRMLCPPEK-----WEKYTS-------    559
BMZ-11B_GL0069617                 GKMKPDLE---------------GAKRALFRDAVETLGIVENSNWLNEDGTIS-------    544
```

FIG. 18KK

CA 03072614 2020-02-10


```
Ga0099364_10024192                  GKMKPDLG---------------DAKRQLYKAAIEMLGIDTE-------EYIS-------   604
530373_GL0023589                    AKMNKTRVA--------VKNDTKTVKLKQYCDAGAVLGEINAEKIKAAFGLGD-------   617
emb|ODAI011611274.1|                ARMAAADP---------------EAKRFMVVDGAKLLGFNPKDTESEDEGIIRAIYGDAC   638
EMG_10003641                        ARMESFEI---------------KSDKTAINDAISLLGYNSNEHRDEFITYTMAKHVVDK   655
CasR_P1E0_metageno                  ARMRKPAI---------------GAKREMYRAAVVLLGVDSPEAAAAITDDLLQI-----   582
emb|OIZX01000427.1|                 ALMKKPQV---------------NAKQQLYRAAVTLLGTEDPDGVTDEMLCIDP------   615
160582958_gene49834                 ARMTKPLG-------------GVNTKCVMYNEAAKILGAKPMSKAELESVFNLDNHD---   667
gi|1198542314|gb|NFIR01000008.1|    ARMTEPVP---------------KTERIMFIEAAQILGYSNGEKELEGYVDALLD-----   642
emb|OGNF01009141.1                  ARMEAPGA---------------SSKRAMFVEAARILGDNRSKEELEEYFDTL-------   586
Ga0129306_1000735                   ARMTTEPF---------------NSKLVMFEDAAQLFGMSGGLVEHAEELREYLDNK---   617
MH0288_GL0082219                    ARMTTETV---------------QGKPCMFEDAADLLGMDTDLEEVREALEAFYNKE---   677
PIG-022_GL0026351                   ARMTGFMEN------------DESTKFIMFREAADILGTSYTDDELTDHLNL--------   573
PIG-028_GL0185479                   ARMTGFMEN------------DESTKFIMFREAADILGTSYTDDELTDHLNL--------   575
250twins_35838_GL0110300            AHLRPAIQ---EAQSSKDNADAAGTPATLLIDAYNMLNTDIQL-----------------   624
PIG-014_GL0226364                   SKMKKLTK---KE--------DKSIKPQVIDDALELLGLKIEKYKKDDQGNFVLDDQ---   576
250twins_36050_GL0158985            ASKDFKKS---KKD------SDESYPEQLYLDALALLGDVISKYKQNRDGSVVIDDQ---   633
emb|OJMM01002900.1|                 SKMKPELS---KI------------GEALILDAIDILGYKINKYKYDAAGNRLVDSN---   599
emb|OGPN01002610.1|                 SKMKNKVN---ID------------NDIIYLDAIELLGRKIEKYQKDENGKILLGTD---   648
emb|OHCP01000044.1|                 SRMKKEMT---ID------------NDTIFLDALELLGRKIEKYQKDKNGDYVKDEK---   636
PIG-046_GL0077813                   SKMKKEID---VD------------NETIFLDAFELLGKRIEKYKKDDSGNVLRNDD---   641
pig_chimera                         SKMKKEIA---ID------------NDTIFLDALELLGRKIDKYKKDATGKYLKDEN---   643
emb|OIEN01002196.1|                 AKMKKTL---------------DFYNAQALKDAVTILGVSKKHQYLDMNSYLDFYMF---   584
O2.UC29-0_GL0096317                 SRMKKAL---------------DFYNGQALRDAIRVLGISERHVDMDMKEYVDKYLF---   571
CasR_Anaerobic_dig                  TRMDNEI----------------FPSEGVFLDAANVLGVRGDDFDFSNEFVGDDLHSD--   625
```

FIG. 18LL

CA 03072610 2020-02-10

```
emb|OGDF01008514.1|              ARMQHSIAGLGDVKIYGSDDKFHGVSRRVYTDAAYILGFGERSEDNDGY--VDD------   611
emb|OGZC01000639.1               ARMGNPI---------------SNLKEVMMVDAIQILGTEKSEQELQSM--ACF------   622
Ga0224415_10048792_chimera       AQMGEPA---------------ATLKLEMTADAIKILGTEKEDAELIKL--AES------   563
emb|OCVV012889144.1|             ARMGEPV---------------ANTKRVMMIDAVKILGTDLSDDELVNM--ADS------   564
Ga0187910_10006931               ARMGEPV---------------ANAKRDMMIDAIKILGTDLDDNEIKKL--ADS------   576
R._flav_XPD_                     ARMGEPI---------------ADARRAMYIDAIRILGTNLSYDELKAL--ADT------   571
Ga0224415_10007274               ARMGEPV---------------ADARRAMYIDAIRILGTDLSDDELKAL--ADS------   554
Ga0187911_10069260               ARMTVDM---------------EKIKRSAYKKALLILGSSKYSDEDLDARVDEMLGV---   565
Ga0187910_10015336               ARMTGDC----------------KIRKSAFEDASQLLGYHDKTVNNLFEVLRLKELESK-   652
ODAI_chimera                     ARMESPA---------------PAAKRTMFVDAIRMFGFADVSDNDAEKFYKENIEP-F-   638
31009_GL0034153                  ARMKRPLD-------------NKNVEKEMYKDAISILMKDSSIENSNIDVIFNTYIY---   565
DLF014_GL0011914_                ARMQKPLN-------------NVSVKREMYKDAIKILLKDTRAEEQNIDRILNEYIP---   635
CasR_R._albus                    ARMSKID--------------DEKSKRQLFRDALVILDIGNKDETWINNYLDSDIFK---   620
Ga0187910_10040531               ARMQKPS---------------AKAKHVMYRDALRILGLDNGMSEEALDQEVRRILQ---   606
tpg|DJXD01000002.1|              ARMQKPS---------------ADARKIMYRDALRILGMDNRPDEEIDRELERTM-----   545
CasR_E._siraeum                  VKSCSFD---------------INAKRTMYRDALDILGIESDKTEEDIEKMIDNILQ---   614
PIG-018_GL0023397                AKSCSFD---------------ISAKRIMYRDALDILGIQAELSEDEIGRMIDNILQ---   602
PIG-025_GL0099734                TGMGYYD---------------VSIKHQMYKDAIDILGLHDNLSDEEINQLIDTNIL-F-   617
Ga0129317_1008067_chimera        ARMQAPV---------------PNAKRAMQEDAIRILGGSEEDIFSILDDMTG-------   544
EYZ-362B_GL0088915               ARMTKPD---------------IQAKEQLFRDALDILGVEVGVSEEALQKEIH-------   602
uncultured_Ru_sp                 ASMRKPA---------------ASAKLTMFRDALTILGIDDKITDDRISGILK-------   607
R._flav._FD-1                    ARMKKPS---------------SNAKKAMYHDALTILGIPEDMDEKALDEELDLILE---   610
tpg|DBYI01000091.1|              ARMKKPS---------------PSAKKNMYRDALTILGIPTEMSDEQLDAEIDKILE---   610
```

FIG. 18MM

CA 03072610 2020-02-10


```
037_-_emb|OIZA01000315.1|      ----------------------------------------------------------  620
emb|OCTW011587266.1|           ----------------------------------------------------------  566
k87_11092736                  ----------DEWLAENILLDKSNNDYQKAK----------------------------  592
BMZ-11B_GL0037915             ----------DAYIKENILVRKDDPEKK-------------------------------  576
BMZ-11B_GL0037771             ----------DEWLEKNMLLNSEDRKNDKKK----------------------------  580
BMZ-11B_GL0069617             ----------NDWLETYVLPGDKVTEEEK-------------------------------  563
Ga0099364_10024192            ----------DEWLEPNMLLAQPPKEPKKDNEKYRKEPHKYSYEKDMETYRKKLREYEET  654
530373_GL0023589              ----------------------------------------------------------  617
emb|ODAI011611274.1|          AEYLQFSEEEK----------------------------------------------  649
EMG_10003641                  YQNTDYQKIVKDFLSANKTLDCKS----KNMQAFVSELKNAHLSENYEQREKEIYELADT  711
CasR_P1E0_metageno            ----------------------------------------------------------  582
emb|OIZX01000427.1|           ----------------------------------------------------------  615
160582958_gene49834           ----------------------------------------------------------  667
gi|1198542314|gb|NFIR01000008.1| ------------------------------------------------------  642
emb|OGNF01009141.1            ----------------------------------------------------------  586
Ga0129306_1000735             ----------------------------------------------------------  617
MH0288_GL0082219              ----------------------------------------------------------  677
PIG-022_GL0026351             ----------------------------------------------------------  573
PIG-028_GL0185479             ----------------------------------------------------------  575
250twins_35838_GL0110300      ----------------------------------------VYGEAAYEELRKDLFERKNG  644
PIG-014_GL0226364             ------------------------------------NHNVWTDEYKSYRKECFTPKNS  598
250twins_36050_GL0158985      ------------------------------------GNAVLTEQYKRFRYEFFEEIKR  655
emb|OJMM01002900.1|           ------------------------------------NKPVYSEEYCAFKKDFFETCEL  621
```

FIG. 18NN

emb|OGPN01002610.1|	----------GKRLYTQEYKYFNDMFFNA---	667
emb|OHCP01000044.1|	----------GKKVYTKDYNNFQDMFFEG---	655
PIG-046_GL0077813	----------GKVLRTKEYNNIRKMLCKK---	660
pig_chimera	----------GKYLYSKEYDDFQYMFFKD---	662
emb|OIEN01002196.1|	----------D-----	585
O2.UC29-0_GL0096317	----------D-----	572
CasR_Anaerobic_dig	----------AN-----	627
emb|OGDF01008514.1|	----------	611
emb|OGZC01000639.1	----------F-----	623
Ga0224415_10048792_chimera	----------L-----	564
emb|OCVV012889144.1|	----------F-----	565
Ga0187910_10006931	----------F-----	577
R._flav_XPD_	----------F-----	572
Ga0224415_10007274	----------F-----	555
Ga0187911_10069260	----------D-----	566
Ga0187910_10015336	----------DWKKRTDDEQQEYDRLLN-----	670
ODAI_chimera	----------IYDRNGDIED------EW-----	650
31009_GL0034153	----------	565
DLF014_GL0011914_	----------	635
CasR_R._albus	----------	620
Ga0187910_10040531	----------	606
tpg|DJXD01000002.1|	----------	545
CasR_E._siraeum	----------I-----	615
PIG-018_GL0023397	----------L-----	603

FIG. 18OO

```
PIG-025_GL0099734                    ----------------------------------------------------I-----  618
Ga0129317_1008067_chimera            ----------------------------------------------------------  544
EYZ-362B_GL0088915                   ----------------------------------------------------------  602
uncultured_Ru_sp                     ----------------------------------------------------------  607
R._flav._FD-1                        ----------------------------------------------------K-----  611
tpg|DBYI01000091.1|                  ----------------------------------------------------K-----  611

037_-_emb|OIZA01000315.1|            ----------------------------------ADKDHQKVSTFLMNNVINNSRFKY  644
emb|OCTW011587266.1|                 ----------------------------------GKTKNLSAYIRNNVLENRRFKY  588
k87_11092736                         ----------------------------------KTVNPFRNYIAKNVITSRSFYY  614
BMZ-11B_GL0037915                    ----------------------------------RSNTFRNFITNNVIKSRRFVY  597
BMZ-11B_GL0037771                    ----------------------------------KQVNPFRNFIAGNVIESRRFMY  602
BMZ-11B_GL0069617                    ----------------------------------RAIKPFRNFIANNVIESRRFMY  585
Ga0099364_10024192                   W--------------------------RSLIDYEYLMPETNPFRNFVAKQVIESRRFMY  687
530373_GL0023589                     ------------------------------KFNTEEARVDHTFRNFIINNVINSNRFNY  646
emb|ODAI011611274.1|                 --------------EAFYVQEGLYGKEREKFSPYAYFHTDTSLRNFIAKNVVESARFRY  694
EMG_10003641                         NLPAYFSEEDKEKLARYIVHSDGTYKKFLKESFYAIEELPNEGFRNFISNNVINSRRFNY  771
CasR_P1E0_metageno                   ------------------------DPETGKVRPRSDSARDTGLRNFIANNVVESRRFTY  617
emb|OIZX01000427.1|                  ------------------------VTGKMLPPNQRHHGDTGLRNFIANNVVESRRFQY  649
160582958_gene49834                  ------------------------------YTYSPSGKKIPNKNFRNFIINNVITSRRFLY  698
gi|1198542314|gb|NFIR01000008.1|     ------------------------------TKNKTNDKKKKGFVRYIWNNVIKSTRFRY  671
emb|OGNF01009141.1                   ------------------------------FDKSASKKEKGFRNFIRNNVVDSNRFKY  614
Ga0129306_1000735                    ------------------------MLDKTKLRLLPDGKVDTGFRNFIISNVTESRRFRY  652
```

FIG. 18PP

MH0288_GL0082219	----------K--MSLKWTKDGQEADTGFRNFIISNVLKSSRFRY	710
PIG-022_GL0026351	----------KKTRLNARSKADTGLRNFIISNVIKSSRFKY	604
PIG-028_GL0185479	----------KKTRLIARSKADMGLRNFIISNVIKSSRFKY	606
250twins_35838_GL0110300	T----------KY---NKKGKKVDVYDHKFRNFLINNVIKSKWFFY	677
PIG-014_GL0226364	D----------SM---NDAEKSFVAKGHQKRNFIISNVVLNKRFLY	631
250twins_36050_GL0158985	D----------ESGGIKYKKSGKPEYNHQRRNFILNNVLKSKWFFY	691
emb|OJMM01002900.1|	D----------EFGRVKYNKKGKPVINHRRRNFIINNVLSSKWFFY	657
emb|OGPN01002610.1|	----------GNHKVRNFIANNVMQSKWFFY	688
emb|OHCP01000044.1|	----------KNHRVRNFVSNNVIKSKWFSY	676
PIG-046_GL0077813	----------DRRLNFIANSIIKNKWFSY	679
pig_chimera	----------SHRVRNFISNSVIKSKWFSY	682
emb|OIEN01002196.1|	----------NRSGATGKNAGKDHNLRNFLVSNVIRSRKFNY	617
O2.UC29-0_GL0096317	----------DC----KDVKHADHNLRNFIVTNVIKSRKFNY	600
CasR_Anaerobic_dig	----------KKIINKINGTKEDRNLRNFIINNVVKSRRFQY	659
emb|OGDF01008514.1|	----------YVSSKLLGGADKNLRNFITNNVIKNRRFLY	641
emb|OGZC01000639.1	----------FRDKNGKKLNTGEHGMRNFIGNNVISNTRFQY	655
Ga0224415_10048792_chimera	----------FKDENGKLLGNKQHGMRNFIGNNVIKSKRFHY	596
emb|OCVV012889144.1|	----------FNDSEGNLLKKGKHGMRNFIINNVIENKRFHY	597
Ga0187910_10006931	----------FKDSNGKLLHKGKHGMRNFIINNVVNNKRFHY	609
R._flav_XPD_	----------SLDENGNKLKKGKHGMRNFIINNVISNKRFHY	604
Ga0224415_10007274	----------SLDENGNKLGKGKHGMRNFIINNVITNKRFHY	587
Ga0187911_10069260	----------YNQNGEKIKVRVDTGFRNFIANNVVESSRFHY	598
Ga0187910_10015336	----------KHHYFKSGKKLPDTGLRNFIINNVIESRRFNY	702
ODAI_chimera	----------KKGKLVHKKDEKKKGVYNFIATNVIESNRFQY	682

FIG. 18QQ

```
31009_GL0034153                 ---------------------------------QKDNKNAKKDFRNFIIKNVIKSNRFIY    592
DLF014_GL0011914_               ---------------------------------SKEDKGIKKDFRNFIIKNIIKSNRFMY    662
CasR_R._albus                   ----------------------------LDKEGNKLKGARHDFRNFIANNVIKSSRFKY    651
Ga0187910_10040531              ----------------------------IGADGKPIKNANKGFRNFIASNVIESSRFRY    637
tpg|DJXD01000002.1|             ----------------------------PVGADGKFIKGKQGFRNFIASNVIESSRFHY    576
CasR_E._siraeum                 ----------------------------DANGD--KKLKKNNGLRNFIASNVIDSNRFKY    645
PIG-018_GL0023397               ----------------------------DANGERISKNQRENGLRNFIASNVIDSNRFKY    635
PIG-025_GL0099734               ----------------------------GADGKPVKMAKGKRGFRNFIISNVLKSSRFRY    650
Ga0129317_1008067_chimera       ----------------------------YDKSGKKLAQSKKGFRNFIINNVVESSRFKY    575
EYZ-362B_GL0088915              ---------------------------------QYFQKGAKHDFRNFIINNVINSTRFIY    629
uncultured_Ru_sp                ---------------------------------LKEKGKGIHGLRNFITNNVIESSRFVY    634
R._flav._FD-1                   ----------------------------KTDPVTGKPLKGKNPLRNFIANNVIENSRFIY    643
tpg|DBYI01000091.1|             ----------------------------KINPVTGKTEKGKNPFRNFIANNVIENKRFIY    643
                                                                ::  .:  .  * *

037_-_emb|OIZA01000315.1|       VVKYINPADINGLAKNRYLVKFVLSKIPE--E----------QIDSYYKLFSNEEE----    688
emb|OCTW011587266.1|            VIKYIHPSDVQKIACNKAIAGFVLNRMPD--T----------QIKRYYDSLINKGA----    632
k87_11092736                    LVRYAKPTAVRKLMSNPKIVRYVLKRLPE------------KQVASYYSAIWTQSES---    659
BMZ-11B_GL0037915               LVRYTKADAVRAVMKNGKIVRYVLARIPE------------TQVDSYYKSVVDSSD----    641
BMZ-11B_GL0037771               LVRYSKPKAVRAIMQNRSIVNYVLHRLPS------------EQIKTYSRVFPEDF-----    645
BMZ-11B_GL0069617               LARYAKPKSVRELMKHEEIIRYVLTRLPE------------KQIDTYFSNISEGDE----    629
Ga0099364_10024192              LVRYTKPKTVRALMSNRAIVHYVLSRIAD--I--QDHHMTESQIDRYYQNLPQYNEQ---    740
530373_GL0023589                VMRFMNPKSARRIMQCESLVAFSLKDIPD--T----------QIERYCKSVNIPFDS---    691
emb|ODAI011611274.1|            VIRYVSPEIARKYARQEALVRFALHRVPL--L----------QLRRYYQSCCGPKKD---    739
```

FIG. 18RR

CA 03072610 2020-02-10


```
EMG_10003641                          IMRFCNPEKIANIGKNKVLISFALSSLAEKTD----------MIAKYYRVFCDRID----   817
CasR_P1E0_metageno                    LLRYMTPEQARVLAQNEKLIAFVLSTVPD--T----------QLERYCRTCGREDI----   661
emb|OIZX01000427.1|                   LIRYSDPAQLHQLASNKKLVRFVLSSIPD--T----------QINRYYETCGQTRL----   693
160582958_gene49834                   LIRYGNPEKIRKIAINPSIISFVLKQIPD--E----------QIKRYYPPCIGKRT----   742
gi|1198542314|gb|NFIR01000008.1|      LVRYADPKKVRAFAANKKVVAFVLKDIPD--D----------QIRAYYNSCFRQNSDSSS   719
emb|OGNF01009141.1                    LTRYTDTSSVKAFSNNKALVKFAIKDIPQ--E----------QILRYYNSCFGASER---   659
Ga0129306_1000735                     LVRYCEPRAVRDYMSCRPLIRLTLRDMPD--T----------ILRRYYEQSVGAAT----   696
MH0288_GL0082219                      VVRYGNPKKLREVMQNEAVVKFVLNDLPE--E----------QINRYSENILGLDA----   754
PIG-022_GL0026351                     LIRYSNPKKVKAIAENKKLVRFVLDKIPD--P----------QIIRYCNTCGF-KV----   647
PIG-028_GL0185479                     LIRYSNPKKVKAIAENKKLVSFVLDKIPD--T----------QIIRYCNTCGF-KV----   649
250twins_35838_GL0110300              IAKYVKPADCAKMMSNKKMIEFALRDLPE--T----------QIKRYYYTITGNEA----   721
PIG-014_GL0226364                     VAKYGSPTACNQMMKNQKIVRMALESISE--D----------QLRKYARRVYDNKEH---   676
250twins_36050_GL0158985              VVKYNRPSSCRELMKNKEILRFVLRDIPD--S----------QVRRYFKAVQGEEA----   735
emb|OJMM01002900.1|                   VAKYNRPSECQKFMKSKKLIALVLKDVPE--T----------QIARYYQSVTGGRT----   701
emb|OGPN01002610.1|                   VVRYNKPAECQIIMRNKTLVKFTLDDLPD--M----------QIQRYYSSVFGDNN----   732
emb|OHCP01000044.1|                   VVRYNKPAECQALMRNSKLVKFALDELPD--S----------QIEKYYISVFGEKS----   720
PIG-046_GL0077813                     IVRYNQPSECQAIMKNKTLVKFALDELPD--L----------QIQRYFVALYGDED----   723
pig_chimera                           IVRYNQPSECRAIMKNKTLVKFALDELPD--L----------QIQRYFVALYGDED----   726
emb|OIEN01002196.1|                   LSRYSNLAEVKKLAQNPSLVQFVLSRIEP--S----------LICRYYESSQGIS-----   660
O2.UC29-0_GL0096317                   LARYSDMATVSKLSKNKEVVKFVLKRVDP--K----------QIERYYRSVCDVR-----   643
CasR_Anaerobic_dig                    IARHMNTHYVKQLANNETLNRFVLNKMGD--A---------KIINRYYESISGNT-----   703
emb|OGDF01008514.1|                   TVRYMNPKRAKKLVQNDALVVLALSGIPE--T----------QIDRYYKSCIEKR-----   684
emb|OGZC01000639.1                    LIRYGNPQKLHTLSQNETVVRFVLSRIAK--NQRVQGMNGKNQIDRYYETCGGTN-----   708
Ga0224415_10048792_chimera            LIRYGDPAHLHKIATNKNVVRFVLGRIAD--MQKKQGQKGKNQIDRYYEVCVGNK-----   649
```

FIG. 18SS

```
emb|OCVV012889144.1|          LIRYGDPAHLHEIAKNEAVVRFVLGRIAD--IQKKQGKDGKNQIDRYYEICVGKD-----  650
Ga0187910_10006931            IIRYGDPAHLHEIAKNEVVVRFVLGRIAD--IQKKQGKGGKNQIDRYYEICIGNG-----  662
R._flav_XPD_                  LIRYGDPAHLHEIAKNEAVVKFVLGRIAD--IQKKQGQNGKNQIDRYYETCIGKD-----  657
Ga0224415_10007274            LIRYGNPVHLHEIAKNEAVVKFVLGRIAD--IQKKQGQNGKNQIDRYYETCIGKD-----  640
Ga0187911_10069260            LIRYCHPRKIRNLAGNAALIEYQLRRLPE--L----------QILRYYEACTEPIK----  642
Ga0187910_10015336            IVRYADPKKIRKCTENNELLKFAFKDVPD--S----------QVDRYYNICVTNK-----  745
ODAI_chimera                  LVRYANTEKIAALARNETIVRFVIKKLPA--A----------QIVRYYIACNRIREN---  727
31009_GL0034153               LIKYSNPTNVRKFASNTNVIKFVLGTLPD--K----------QLERYYKSCGLSD-----  635
DLF014_GL0011914_             LVKYSNPTDVRNLASNRNVVKFVLNAIPD--T----------QIDRYYKSCIQHY-----  705
CasR_R._albus                 LVKYSSADGMIKLKTNEKLIGFVLDKLPE--T----------QIDRYYESCGLD------  693
Ga0187910_10040531            LVRYNNPHKTRMIAQNEAIVRFVLSEIPD--E----------QIRRYYDVCRDPK-----  680
tpg|DJXD01000002.1|           LVRYNNPHKTRTLVKNPNVVKFVLEGIPE--T----------QIKRYFDVCKGQE-----  619
CasR_E._siraeum               LVRYGNPKKIRETAKCKPAVRFVLNEIPD--A----------QIERYYEACCPKN-----  688
PIG-018_GL0023397             LVRYGNPKKIRETAKCPPAVKFVLDGIPD--S----------QIERYYNSCFPED-----  678
PIG-025_GL0099734             LVKYCNPKKIRKIANNEKIVKFVLGRITE--T----------QIERYYYSCNPELK----  694
Ga0129317_1008067_chimera     IVRYSNPQKIRKLANNSVVVGFVLGKLPD--A----------QIESYFNSCLPN------  617
EYZ-362B_GL0088915            VIKFCNPKTAGQIIRNENILRFVLQRMPQ--E----------QIERYYHACTKN------  671
uncultured_Ru_sp              LIKYANAQKIREVAKNEKVVMFVLGGIPD--T----------QIERYYKSCVEFP-----  677
R._flav._FD-1                 LIKFCNPENVRKIVNNTKVTEFVLKRIPD--A----------QIERYYKSCTDS------  685
tpg|DBYI01000091.1|           VIKFCNPKNVRKLVNNTKVTEFVLKRMPE--T----------QIDRYFESCIEG------  685
                                :.                  :  :               :  *

037_-_emb|OIZA01000315.1|     ---------------PSCEEKIKLLTKKISKLNFQTLFENNK-----------------  715
emb|OCTW011587266.1|          ---------------TDIQAQAKALLDCITGISFDAIKDDKHLHKS-----------KE  665
```

FIG. 18TT

```
k87_11092736                          ----------NSNEMVKLIEMIDRLTTEIAGFSFAVLKDKKDSIVSA----------SR    698
BMZ-11B_GL0037915                     ----------AGNGKPIKEKIKALAEKLGEFSFDLIAENRDGIIDNA----------KL    680
BMZ-11B_GL0037771                     ---------------SDTEAEIDFLVNKLSEFSFETFISNQQTILNNS------KRGFSP    684
BMZ-11B_GL0069617                     ---------------SEISRKIDTLTKALTGFSFNSLFINRDKIVENT----------KL    664
Ga0099364_10024192                    ----------QHKNVSLETKIDALADYLCKYTFEKNVLKQKNGIV-L----------NT    778
530373_GL0023589                      ------------ANPNYAHMKEQLTYKLLQVQFCNFSKVSNSSHQ--------------    724
emb|ODAI011611274.1|                  ---------------PDAAECVDFLAGVVNRVDFANFTDVRTGDSSK------------    771
EMG_10003641                          ----------------DQKTMEDYLVNKLTKISYTEFLNVNQKANAE------------    848
CasR_P1E0_metageno                    ---------------TGRPAQIRYLTAQIMGVRYESFTDVEQRGRG--------------    692
emb|OIZX01000427.1|                   ---------------AGRAAKVEFLTDMIAAIRFDQFRDVNQKERG--------------    724
160582958_gene49834                   ---------------DDVTLMRDELGKMLQSVNFEQFSRVNNKQNAK------------    774
gi|1198542314|gb|NFIR01000008.1|      NNSNASWDADSNKRDISVSDMRKALTEKITGLNFGDFEEESKKGIR--------------    765
emb|OGNF01009141.1                    ---------------YYNDGMSDKLVEAIGKINLMQFNGVIQQADRN---------MLPE    695
Ga0129306_1000735                     ---------------VDRERILDTLADKLLSLRFTDFENVNQRANAE------------    728
MH0288_GL0082219                      ---------------AAKEKKVSELARFLRALSLEDFRDVEQSANAA------------    786
PIG-022_GL0026351                     ---------------GERQENINTLAKAITNFSFSAFEKVKQSANVE---------N---    680
PIG-028_GL0185479                     ---------------GKRQENINTLAEAITYFSFSNFEKVKQSANVE---------N---    682
250twins_35838_GL0110300              --------------LGDAESLKGVIIEQLHAFSIKNTLLSIKNM--G---------EGEY    756
PIG-014_GL0226364                     ------------FQNQTADEIRENLAKKLKNFNIGAELKTVGNL------------SEKD    712
250twins_36050_GL0158985              --------------YASAEAMRTRLVDALSQFSVTACLDEVGGM--T---------DKEF    770
emb|OJMM01002900.1|                   --------------QANSEAMRMTLIKLLHEFSIKNVLSDVGTM--T---------ASEN    736
emb|OGPN01002610.1|                   --------------MPAVDEMRKRLLDKINQFSVRGFLDELDEIVLM---------SDEE    769
emb|OHCP01000044.1|                   --------------SSSNEEMRRELLKKLCDFSVRGFLDEIVLL--S---------EDEM    755
PIG-046_GL0077813                     --------------LPSYGEMRKILLKKLHDFSIRDFDEEIGSL--F---------D-EM    757
```

FIG. 18UU

pig_chimera	----------LPSYGEMRKILLKKLHDFSIKGFLDEIVLL--S---------DLDM	761
emb|OIEN01002196.1|	----------SEGITIDEQIKKLTGIIVDMNIDSFENINNGEIGMR------Y---SK	699
O2.UC29-0_GL0096317	----------NISAEDEIEKLVDIIYNFNIDELEQVNNAEIGTG------HSGRKV	683
CasR_Anaerobic_dig	----------PNIEVRSQIDYLVKRLRSFSFEDLNDVKQKVRPG----------	737
emb|OGDF01008514.1|	----------SFNPDLNEKIAALSEMITTLKIDDFEDVKQNPEKNA---------NYE	723
emb|OGZC01000639.1	----------SWSVSEEEKINFLCKILTNMSYDQFQDVKQSGAEI----------	743
Ga0224415_10048792_chimera	----------DIKKTIEEKIDALTDIIVNMNYDQFEKKKAVIENQ---NRGKTFEEKN	694
emb|OCVV012889144.1|	----------RGKTVSQKLDELTKIIVNMNYDQFEQKKEIIENTRTKTKYMRYDEEQ	697
Ga0187910_10006931	----------YGKSVSEKIDALTKVIINMNYDQFEAKRKVIENT----------	696
R._flav_XPD_	----------KGKSVSEKVDALTKIITGMNYDQFDKKRSVIEDT----------	691
Ga0224415_10007274	----------SSKSVAEKVNALTKIITGMNYDQFDSRRNVIENT----------	674
Ga0187911_10069260	----------RTARTMDEKIGTLIDLIVKMDFSQFEDVQQNDRVRV-----FSDAEKK	685
Ga0187910_10015336	----------ITNATREEKIERLVDIIKSMNLSKVATVKQRDKQ----------	779
ODAI_chimera	----------INSNVLTSDDMAESLVKLVTGMDFGKIKGVRNDDR----------	762
31009_GL0034153	----------GIGKTEWVRELSEIITGIDYSDFLNVKQRAKS----------	667
DLF014_GL0011914_	----------SNEVDKETQIQELTDIITGIDYLDFLDVRQSYR----------	738
CasR_R._albus	----------NAVVDKKVRIEKLSGLIRDMKFDDFSGVKTSNKA----------	727
Ga0187910_10040531	----------LPRSSSREAQVDILTGIITDVNYRIFEDVPQSKKINK-----DRPD---	721
tpg|DJXD01000002.1|	----------IPPTSDKSAQIDVLARIISSVDYKIFEDVPQSAKINK-----DDPS---	660
CasR_E._siraeum	----------TALCSANKRREKLADMIAEIKFENFSDAGNYQKANV-----TS-----	726
PIG-018_GL0023397	----------TAICSADKKRRELAEMISNISFDWFKDAGNVQRVNA-----ED-----	716
PIG-025_GL0099734	----------RAAYPGREAAIDDLTKIIINMKFDDFKNVKQSANV-------ED-----	731
Ga0129317_1008067_chimera	----------RVYSTPDKARESLRDMLHNISFNDFADVKQDDRR-------A------	652
EYZ-362B_GL0088915	----------PSLCTHDEKIQCLSNIIMEVRYKKFCNVAQKSRD-------T------	706

FIG. 18VV

CA 03072610 2020-02-10

```
uncultured_Ru_sp                    ----------DMNSSLGVKRSELARMIKNISFDDFKNVKQQAKG----------    711
R._flav._FD-1                       ----------EMNPPTEKKITELAGKLKDMNFGNFRNVRQSAK----------    718
tpg|DBYI01000091.1|                 ----------NLNPTTEKKIEKLAEMIKNIKFEEFRNVKQKVRD-------N------    720
                                                                 :    :

037_-_emb|OIZA01000315.1|           ---IPNVEKERKKAIITLYFTIVYILVKNLVNINGLYTLALYFVERDGFFYKQICEKKLI    772
emb|OCTW011587266.1|                KSPQRSADRERKKAMLTLYYTIVYIFVKQMLHINSLYTIGFFYLERDQRFIYSRAKKEN-    724
k87_11092736                        ESRAVNLEVERLKKLTTLYMSIAYIAVKSLVKVNARYFIAYSALERDLYFFNEKYGEEFR    758
BMZ-11B_GL0037915                   DEEKKNVEIERLKAVTGLYLTVAFIAIKNLVKANARYYIAYSAFERDSELLKEKLGEEEF    740
BMZ-11B_GL0037771                   NRRETAEEIERLKAITGLYLSVAYIAIKNIVKANARYYIAFAVFERDKELVKAKDAR---    741
BMZ-11B_GL0069617                   DTSNKNVKIERLKALTGLYLTVAFVAVKNLVKANARYFIAFSAFERDYGFMKSHDPD--V    722
Ga0099364_10024192                  KSATKNVEIEHLKALTGLYLTVAYIAVKNLVKANARYYIAFSIFERDYALFEKKLGKDTL    838
530373_GL0023589                    -----AVEKERLKALVGLYLSVLYRIVKSIVRINTSYTIAFAAYERDCVILNRKMGKNLY    779
emb|ODAI011611274.1|                ---SEQEKKQKYQAIVGLYLTVVYWIVKNLVNVNSRYVMAFHILERDTVLLEGKRLFVGG    828
EMG_10003641                        ----KNKEKDRSQKLIGLYITLLYEIVKNLVNINSRYNIAFQRCDNDSIMILQGQYDER-    903
CasR_P1E0_metageno                  ----DNPKKERYKALIGLYLTVLYLAVKNMVNCNARYVIAFYCRDRDTALYQKEVCWYDL    748
emb|OIZX01000427.1|                 ----ANTQKERYKAMLGLYQTVLYLAVKNLVNINARYVMAFHCVERDMFLYDGELTDPKG    780
160582958_gene49834                 --QNPNGEKARLQACVRLYLTVPYLFIKNMVNINARYVLAFHCLERDHALCFNSRKLN--    830
gi|1198542314|gb|NFIR01000008.1|    -------KEESDKNIIRLYLTVLYLVQKNLIYVNSRYFLAFHCAERDEMLYNGETIDNNK    818
emb|OGNF01009141.1                  EKKKANAQKEKYKSIIRLYLTVCYLFFKNLVYVNSRYYSAFYNLEKDRSLFEINGELKPT    755
Ga0129306_1000735                   ----RNREKQKMMGIISLYLNVAYQIVKNLVYVNARYTMAYHCAERDTELLLNAAGEGNL    784
MH0288_GL0082219                    ----RNARKARYQGAMSLYLNVIYQIIKNMVYINSRYTLAFAKYEHDASLLLDNWVYDPY    842
PIG-022_GL0026351                   -DTPDAIDKAQKQGLISLYLTVLYLFIKNMVYVNSRYVLAFHCLERDSQLLKITSGYN--    737
PIG-028_GL0185479                   -DTPDAIDKAQKQGLISLYLTVLYLFIKNMVYVNSRYVLAFHCLERDSQLLKITSGYN--    739
```

FIG. 18WW

250twins_35838_GL0110300	KIQQIGSSKEKLKAIVNLYLTVAYLLTKSLVKVNIRFSIAFGCLERDLVLQKKS------	810
PIG-014_GL0226364	FRSSKNALKDKSKSLIGLYLTVAYLITKNMIKINTRFSIAFGAYERDMEFLLQQ------	766
250twins_36050_GL0158985	ASQRAVDSKEKLRAIIRLYLTVAYLITKSMVKVNTRFSIAFSVLERDYYLLIDG------	824
emb|OJMM01002900.1|	KRQIENSRKERMKAIVKLYLTVVYLIAKSLVKVNTRFSIAFSAYERDVSLLADENELIA-	795
emb|OGPN01002610.1|	SKRNKSSEKEQKKSLIRLYLTIAYLITKSMVKINTRFSIACAMYERDYALLCQS------	823
emb|OHCP01000044.1|	KQKDKFSEKEKKKSLIRLYLTIVYLITKSMVKINTRFSIACATYERDYILLCQS------	809
PIG-046_GL0077813	KRKDKFCESDRKKCLFRLYLTIAYLITKSMVKINTRFSIACATYERDYALLCAS------	811
pig_chimera	ESQDKYCEKEQKKSLFRLYLTIAYLITKSMVKINTRFSIACATYERDYALLCAS------	815
emb|OIEN01002196.1|	ATPQSIERRNQMRVCVGLYLNVLYQIEKNLMNVNARYVLAFAFAERDALMLNFTLEECK-	758
O2.UC29-0_GL0096317	ASKRSVQERNQARACVSLYLNVLYQIVKNLMNVNSRYSIAFAMTERDMIVEGKGIEAIET	743
CasR_Anaerobic_dig	--TNESIEKEKKKALVGLCLTIQYLVYKNLVNINARYTTAFYCLERDSKLKGFGVDVWR-	794
emb|OGDF01008514.1|	AKKNQRISKERYKACIGLYLTVLYLICKNLVKINARYSIAIGCLERDTQLHGVDFKGAA-	782
emb|OGZC01000639.1	-TAEEKRKKERYKAIISLYLTVLYQLIKNLVNINARYIIAFHCLERDAILYSSKFNTSIN	802
Ga0224415_10048792_chimera	KYKRDNAEREKFKKIISLYLTVIYHILKNIVNVNSRYILGFHCLERDKQLYIEKYNKD--	752
emb|OCVV012889144.1|	KLRKDNAEREKFKKIISLYLTVLYYVVKNIVNINSRYVIGFHCLERDAQLYSEKYNKE--	755
Ga0187910_10006931	--GRDNAEREKYKKIISLYLTVIYQILKNLVNVNSRYVIGFHCVERDAQLYKEKGYDINT	754
R._flav_XPD_	--GRENAEREKFKKIISLYLTVIYHILKNIVNINARYVIGFHCVERDAQLYKEKGYDINL	749
Ga0224415_10007274	--GAGNAEREKYKKIISLYLTVIYHILKNIVNINSRYVIGFHCVERDAQLYKEKGYDINL	732
Ga0187911_10069260	EKIRKMREKQRYQSIISLYLTMLYLIVKNLVNINARYVMAFQAWERDNYLLLQLSGKE--	743
Ga0187910_10015336	----DNVEKQKQLAIMSLYLNILYQIAKNLVYVNSRYVMAFHSLERDSQMLFDAYYDV--	833
ODAI_chimera	-----SGDKEMKKAIVTLYLTILYHLTKNLVYVNSRYFMAFHCLERDMNLFGEGQKQALR	817
31009_GL0034153	--KEEKEDKAKKQAIVTLYLTILYILTKNLVNVNSRYVIAVHCIERDSELYKTELYEKLK	725
DLF014_GL0011914_	-----NEDKSKKQAVVTLYLTILYILTKNLVNVNSRYVIALHCLERDSKLYGYTKLSKKN	793
CasR_R._albus	-GDNDKQDKAKYQAIISLYLMVLYQIVKNMIYVNSRYVIAFHCLERDFGMYGKDFGKY--	784

FIG. 18XX

```
Ga0187910_10040531                ANDRMTLKKQRYQAIVSLYLTVMYLVTKNLVYVNSRYVMAFHALERDAYLYGITNI----   777
tpg|DJXD01000002.1|               RNFSDALKKQRYQAIVSLYLTVMYLITKNLVYVNSRYVIAFHCLERDAFLHGVTLPKM--   718
CasR_E._siraeum                   -RTSEAEIKRKNQAIIRLYLTVMYIMLKNLVNVNARYVIAFHCVERDTKLYAESGLEVG-   784
PIG-018_GL0023397                 -KSRNAEIKRKNQAIIRLYLTVMYLMLKNLVNVNSRYVIGFHCVERDAKLYKLSGLTIE-   774
PIG-025_GL0099734                 -SSKEAQEKMKYQTIISLYLTVCYHLVKNLVNINARYAMAFHSLERDARLYGIYGSEKDY   790
Ga0129317_1008067_chimera         -TPEEKVEKERYKAIIGLYLTVMYHLVKNLVYVNSRYVMAFHCLERDAMHYDVS------   705
EYZ-362B_GL0088915                ---TKQMEKERFKAIIRLYLTAIYLVVKNLVNVNARYVLAFHCLERDADLFGLQIKQTLP   763
uncultured_Ru_sp                  ---RENVAKERAKAVIGLYLTVMYLLVKNLVNVNARYVIAIHCLERDFGLYKEIIPEL-A   767
R._flav._FD-1                     ----ENMEKERFKAVIGLYLTVVYRVVKNLVDVNSRYIMAFHSLERDSQLYNVS------   768
tpg|DBYI01000091.1|               --SQEAVEKERFKAIIGLYLTVIYLLVKNLVNVNSRYVMAFHCLERDAKLYGVQ------   772
                                                *     :   *.::  *  :  .    :.*

037_-_emb|OIZA01000315.1|         ---------------ETLKKKDKKQLYNDDDYLLLPEIFSGSKYRE--------------   803
emb|OCTW011587266.1|              --------------------KNPSKNSYLNDFRSVTAYFIPSEIMKRIEKNE--------   756
k87_11092736                      ----------LHFIP-----YELNGKTCQFEYLAILKYYLARDEETLKRKCEICEEIKVG   803
BMZ-11B_GL0037915                 ----------YKLCIEFKN---KKGETGYNNAFALLKYYIDRDEDIWRKEEATHRGRDEN   787
BMZ-11B_GL0037771                 --------------------IQTTIPNTKFTNYFCLTQYYLDRDEEKKFPGDPRDKEAFFE   782
BMZ-11B_GL0069617                 ----------AQSCLAYEEIMDGKSKTKYNEIYALTEYYLKKEEENDYHPEPGQPFDKEA   772
Ga0099364_10024192                ----------EKYVKPFKYIDKGEEKEGKNNFFALTEYLLDKDNSLRYQWNNDLSDEENK   888
530373_GL0023589                  GL--------------------------KTDPMGITNDFMHMPTVAPSNPH---------   804
emb|ODAI011611274.1|              MK--------------------------AEDPFLLTDGYVSRQDAYVRK-----------   851
EMG_10003641                      ----------------------------AVQESKLTKKFISNQK----------------   919
CasR_P1E0_metageno                EE-----------------DKKSGKQRQVEDYTALTRYFVSQGY----------------   775
emb|OIZX01000427.1|               ES-------------VSAFLAVNGKKGVQPQYLLLTQLFIRRDY----------------   811
```

FIG. 18YY

CA 03072610 2020-02-10


```
160582958_gene49834                ----------------------------DDSYNEMANKFQMVRKAKKEQYEKEYKCK---   859
gi|1198542314|gb|NFIR01000008.1|   EK-------------------------GSEKDWRKFAKQFIMEHS---------------   838
emb|OGNF01009141.1                 GK-------------------------FDEGHYTGLVKLFIDNGW---------------   775
Ga0129306_1000735                  LRRDRSWPARLHLPRRALARRRDRVEVMERDVARGPEAYNRDEWLG-------------   830
MH0288_GL0082219                   ----------------------------KTVFSDLTEDSLQKGK---------------   858
PIG-022_GL0026351                  ----------------------------NSSYNNLTNYFIDNKY---------------   753
PIG-028_GL0185479                  ----------------------------NLSYNNLTNHFIEKEY---------------   755
250twins_35838_GL0110300           ----------------------------EKKFDAIINEILLEDDKIRKECDKERAQAKTL   842
PIG-014_GL0226364                  ----------------------KKEKGKRFDWLALTQKFLSEDKNYYFEHDLRRKEINKI   804
250twins_36050_GL0158985           --------------------KKKSSDYTGEDMLALTRKFVGEDAGLYREWKEKNAEAKDK   864
emb|OJMM01002900.1|                -----------------LANNEDDKWKKGNYVFALTKHFWDNDEPYFDKYNNALQQIRSI   838
emb|OGPN01002610.1|                -------------------EMKGGPWDGGAQALAVTRKFLNHDREVFDRYCAREAEIARL   864
emb|OHCP01000044.1|                -------------------EKAERAWEKGATAFALTRKFLNHDKPTFEQYYTREREISAM   850
PIG-046_GL0077813                  -------------------NKQERAWSSGATALALTRKFLNQDKLIFEKHYAREGEISKL   852
pig_chimera                        -------------------NKQERAWSSGATALALTRRFLNQDKLIFEKHYAREGEISKL   856
emb|OIEN01002196.1|                --------------------KNKKRSSGGFSFIEMTQFFIDKKLFKVAT-----------   787
O2.UC29-0_GL0096317                FKDDP-----------DAGKKSKKQIAYRTKYIALTEEYLDKGYIKCAT-----------   781
CasR_Anaerobic_dig                 ----------------------------DFESYTALTNHFIKEGY---------------   811
emb|OGDF01008514.1|                --------------------------------YMTRDVFIAKGWI---------------   795
emb|OGZC01000639.1                 ----------------------------LKKRYTALTEMILGYETDEKAR-----------   824
Ga0224415_10048792_chimera         ----------------------------KLDGFVALTKFCLGDEERFEDL--------KAK   777
emb|OCVV012889144.1|               ----------------------------IDKKISSLTKFCLGESDEKKLK---------AL   779
Ga0187910_10006931                 ------------------------NNLESKGFTSVTKLCVGIADDDPVKYKNVEIELKER   790
R._flav_XPD_                       ------------------------KKLEEKGFSSVTKLCAGIDETAPDKRKDVEKEMAER   785
```

FIG. 18ZZ

CA 03072610 2020-02-10


```
Ga0224415_10007274                -----------------------KKLKDKGFTSVTKLCAGIDEECK----DVEKEMTER    764
Ga0187911_10069260                --------------------------AEAEYLNLTRHFIEPLDGAKP-----------    764
Ga0187910_10015336                ---------------------------KRGYCDLSTVLLFGVDDLQNRNRGSYKYLRDN    865
ODAI_chimera                      NTGDY----------PADN--ADLRRRDIKYCVLTKAHIKQEEVKSRRND---------    855
31009_GL0034153                   PEQPE----------KLYKIKPDKPLQPAQYFLFTKYLLQNDFFGE------------    761
DLF014_GL0011914_                 --------------------NKKLEKIKPPKYHELTKYFIDNRYFDRK-----------    821
CasR_R._albus                     ---------------------------YQGCRKLTDHFIEEKYMKE------------    803
Ga0187910_10040531                ---------------------------KGDYRKLTDNLLADENYKKF-----------    797
tpg|DJXD01000002.1|               -------------------------NKKIVYSQLTTHLLTDKNYTTY-----------    740
CasR_E._siraeum                   -------------------------NIEKNKTNLTMAVMGVKLENG----IIKT-----    809
PIG-018_GL0023397                 ------------------------GNTDKNRTLLTATILGITSADRAPSGEIVA-----    804
PIG-025_GL0099734                 V------------------------EKLKKEQAVLVEKLLSDGPETAG-----------    814
Ga0129317_1008067_chimera         ---------------------------LDNYRDLIRHLISEGDSSCN-----------    725
EYZ-362B_GL0088915                D------------------------RKKKSDYLKLAVDQCGDNPENKP-----------    787
uncultured_Ru_sp                  S------------------------KNLKNDYRILSQTLCELCDKSPN-----------    791
R._flav._FD-1                     ---------------------------VDNDYLALTDTLVKEGDNSRS-----------    789
tpg|DBYI01000091.1|               -------------------------NIGGDYLALTAKLCAEGDDYGKKLSEAKQ-----    801


037_-_emb|OIZA01000315.1|         ------------------------------------------------------------    803
emb|OCTW011587266.1|              ------------------------------------------------------------    756
k87_11092736                      CEKHKKNANPPYEYDQEWIDKKKALNSE--RKACERRLHF-----------------STH    844
BMZ-11B_GL0037915                 GKLDYDPDP-----------------------------------------------    796
BMZ-11B_GL0037771                 ---------HL---------------------------------------------    784
```

FIG. 18AAA

BMZ-11B_GL0069617	CRKHLD----------	778
Ga0099364_10024192	QALRKHLDKKE----------	899
530373_GL0023589	----------	804
emb|ODAI011611274.1|	----------	851
EMG_10003641	----------	919
CasR_P1E0_metageno	----------	775
emb|OIZX01000427.1|	----------	811
160582958_gene49834	----------	859
gi|1198542314|gb|NFIR01000008.1|	----------	838
emb|OGNF01009141.1	----------	775
Ga0129306_1000735	----------	830
MH0288_GL0082219	----------	858
PIG-022_GL0026351	----------	753
PIG-028_GL0185479	----------	755
250twins_35838_GL0110300	P----------RELAQE	849
PIG-014_GL0226364	SD----------RDERKK	812
250twins_36050_GL0158985	YF----------DKAERK	872
emb|OJMM01002900.1|	V----------DPNERR	845
emb|OGPN01002610.1|	P----------S-EERK	870
emb|OHCP01000044.1|	P----------Q-EKRK	856
PIG-046_GL0077813	P----------K-EERK	858
pig_chimera	P----------K-EERK	862
emb|OIEN01002196.1|	----------EA	789
O2.UC29-0_GL0096317	----------ER	783

FIG. 18BBB

```
CasR_Anaerobic_dig                  ------------------------------------------------------------  811
emb|OGDF01008514.1|                 ------------------------------------------------------------  795
emb|OGZC01000639.1                  ---------------------------------------------RKD--------TR  829
Ga0224415_10048792_chimera          AQASI------------------QALETANPKLYAKYMNYSDEEKKEEFK--------KQ  811
emb|OCVV012889144.1|                AKKSL------------------EELKTTNSKLYENYIKYSDERKAEEAK--------RQ  813
Ga0187910_10006931                  ALASF------------------DALEKENPELYEKYNMYSEKQKEAELE--------KQ  824
R._flav_XPD_                        AKESI------------------DSLESANPKLYANYIKYSDEKKAEEFT--------RQ  819
Ga0224415_10007274                  AKASF------------------AALETANPKLYATYINYSDEEKNAELR--------KQ  798
Ga0187911_10069260                  ------------------------------------------------------------  764
Ga0187910_10015336                  RRSNKDVIETFGDFKGKVSKVVEKKNQGLTNEIYDSLCNVAGTTKTEVQNEIKSILKSNG  925
ODAI_chimera                        ------------------------------------------------------------  855
31009_GL0034153                     ------------------------------------------------------------  761
DLF014_GL0011914_                   ------------------------------------------------------------  821
CasR_R._albus                       ------------------------------------------------------------  803
Ga0187910_10040531                  ------------------------------------------------------------  797
tpg|DJXD01000002.1|                 ------------------------------------------------------------  740
CasR_E._siraeum                     ---------------------------------------------------EF----  811
PIG-018_GL0023397                   ---------------------------------------------------DC----  806
PIG-025_GL0099734                   ------------------------------------------------------------  814
Ga0129317_1008067_chimera           ------------------------------------------------------------  725
EYZ-362B_GL0088915                  ------------------------------------------------------------  787
uncultured_Ru_sp                    ------------------------------------------------------------  791
R._flav._FD-1                       ------------------------------------------------------------  789
tpg|DBYI01000091.1|                 ---------------------------------------------------NI----  803
```

FIG. 18CCC

```
037_-_emb|OIZA01000315.1|          --------------------ET--KNLKLPKEKDRDIMKKYLPNDKDREEYNKFFKQYRN    841
emb|OCTW011587266.1|               -------NKGFLEDFEALWNSC--GKTSRLRKEDVLLYARYISPDHALKNYKMILNSYRN    807
k87_11092736                       WAQYATKRDENMAKHPQKWYDILASHYDELLAL---------------QATGWLATQARN    889
BMZ-11B_GL0037915                  ---------RRKHYPKRRWLNILKDNLAEMERI---------------DPTGMLAAQMRN    832
BMZ-11B_GL0037771                  --------RKTKRHFSKQWREWLNEKIADAKSS---------------QATGLLLREARN    821
BMZ-11B_GL0069617                  ---------SIRRHFTKKWRDIFRKEIDEAVKI---------------HFTGYLGVWARN    814
Ga0099364_10024192                 --------IRSQRHFSQYWLDIFARQIENAKKT---------------SESGYLLTAARN    936
530373_GL0023589                   ------NDFINETKLSKRVCALVNKNRTL--------------------CTNRTYQVYRN    838
emb|ODAI011611274.1|               -------RIGENKRANRHGLNCVLENRNALGS-D----------PASTDAAASLIWSYRN    893
EMG_10003641                       --------------LNSYSCRYLTHNISQLD-----------------RCNDFIRQYRN    947
CasR_P1E0_metageno                 --------------LNRHACGYLRSNMNG--------------------ISNSLLTAYRN    801
emb|OIZX01000427.1|                --------------LKRSACEQIQHNMEN--------------------ISDRLLREYRN    837
160582958_gene49834                -KQETGTAHTKKIEKLNQQIAYIDKDIKN--------------------MHSYTCRNYRN    898
gi|1198542314|gb|NFIR01000008.1|   --------------PKKKVKDYLAKNFEY--------------------SNKWSLKEFRN    864
emb|OGNF01009141.1                 --------------INPRASAYLTVNLAN--------------------SDETAIRTFRN    801
Ga0129306_1000735                  --------LVRTLRREKRVCDNLHNNYAYLCGAD----------AEPGDASLSLLFVYRN    872
MH0288_GL0082219                   --------------LNRRAAKYLQTNLEH--------------------SDNTLIRQYRN    884
PIG-022_GL0026351                  --------------LNPHASRYLKVNISN--------------------ADEWSIVKFRN    779
PIG-028_GL0185479                  --------------LNSHARNYLRVNISN--------------------SDEWSIVKFRN    781
250twins_35838_GL0110300           RFAQIKRRESGCYFKSYHVYDYLSKNSNEFKQ----------------NHIDFAVTSYRN    893
PIG-014_GL0226364                  QHRENDKYYDSCMHFSRHSFEYISKNFAEVQSH---------------PDPLKLFIKYRN    857
250twins_36050_GL0158985           KVLRQNDKMIRKMHFTPHSLNYVQKNLESVQS----------------NGLAAVIKEYRN    916
```

FIG. 18DDD

emb|OJMM01002900.1|	LAYRANDKVVKHTHFNLHSYKYVKHNYEEISK----------ASKIITAYRN	887
emb|OGPN01002610.1|	PLRKANDKLLKQTHYTNHSYTYIVNNLNSFTDIDYCAKDVGLPAPNDKNDNASILGEMRN	930
emb|OHCP01000044.1|	ELRKENDQLLKKTHYSKHAYCYIVDNVNNLTGAVANDNGRGLPCLSEKNDNANLFLEMRN	916
PIG-046_GL0077813	AMRKVNDQLLKQTHFSKHSYCYIVDNVNRLTGGECRTDKRVLPVLNEKNDNAGILSDFRK	918
pig_chimera	AMRKVNDQLLKRTHFSKHSYCYIVDNVNRLTGGECRTDKRVLPVLNEKNDNAGILLDFRK	922
emb|OIEN01002196.1|	IKKNVLKYNGNPESLNHIPGEYICKNMEGYHEN----------TVRNFRN	829
O2.UC29-0_GL0096317	IKENIKKYGGDPKSIDHIPGEYIKKNLEGYCAG----------STNTFRN	823
CasR_Anaerobic_dig	----------LPVRKAEILRANLKHLDCED----------GFKYYRN	838
emb|OGDF01008514.1|	----------NPKKPTVKSIKEQYAFLTPY----------IFTTYRN	822
emb|OGZC01000639.1	TVYEKAEAAKNRHLKNVKWNCKTRENLENA----------DKNAIVAFRN	869
Ga0224415_10048792_chimera	LNRERVKNARNAYLKNIKNYIMIRLQLRDQTDS----------SGYLCGEFRD	854
emb|OCVV012889144.1|	INRERAKTAMNAHLRNTKWNDIMYGQLKDLADS----------KSRICSEFRN	856
Ga0187910_10006931	INREKAKTALNAHLRNTKWNVIIRENIRNT----------EKDACKQFRN	864
R._flav_XPD_	INREKAKTALNAYLRNTKWNVIIREDLLRI----------DNKTCTLFRN	859
Ga0224415_10007274	INREKAKTALNAHLRNTKWNVIIREDLLRR----------DNKACKIFRN	838
Ga0187911_10069260	----------YLKKRPVEYLKKDMAMVGNS----------SIRHFRN	791
Ga0187910_10015336	LDESASSYLSHKLVNKVHSYKYLKQNLDCADNT----------MINQFRN	965
ODAI_chimera	---TDSKSQQKAKSRRRRWCLLLKEDIDKLNGC----------ESLRILYRN	894
31009_GL0034153	----------YTSKKNQYIQKNMKIYSKI----------NKNFNVFVRYRN	792
DLF014_GL0011914_	-----KKNKKYGEYTSKKISTYIETNMKNFIGCE-----QFRTPERYRDTQIDMFVKYRN	871
CasR_R._albus	----------GKLGCNKKVGRYLKNNISCCTDG----------LINTYRN	833
Ga0187910_10040531	-------GH----FKNKKWRGIAEQNLRNSDVP----------VIKSFRN	826
tpg|DJXD01000002.1|	-------GHLKNQKGHRKWYVLVKNNLQNSDIT----------AVSSFRN	773
CasR_E._siraeum	DKSF-AENAANRYLRNARWYKLILDNLKKSERA----------VVNEFRN	850

FIG. 18EEE

```
PIG-018_GL0023397                  DLGR-AETAANRHLRKKRWYVQIFNNLKQADRN--------------------VINEFRN   845
PIG-025_GL0099734                  ----------NLHLRSKKWNRLMRVNLENYSAA--------------------ASQNFRN   844
Ga0129317_1008067_chimera          ----------HFISHNRRMRDCIEENVKNSEQLI--------------FGKEDAVIRFRN   761
EYZ-362B_GL0088915                 ---------KGYLARNKRLCQCVREDIDNAKHL------------------NGDITDYRN   820
uncultured_Ru_sp                   ----------LFLKKNERLRKCVEVDINNADSS--------------------MTRKYRN   821
R._flav._FD-1                      ----------RYLAGNKRLRDCVKQDIDNAKKWF-------------VSDKYNSITKYRN   826
tpg|DBYI01000091.1|                NQDKVQMPKNYFLARNKRWREAIEQDIDNAKKWF-------------IGEKFNNVKNYRN   850
                                                          .                                *.

037_-_emb|OIZA01000315.1|          NIVHLKIIA-KLSEL---TKNIDK-----------DINSYFDIYHYCTQRVMFDYCKKNN   886
emb|OCTW011587266.1|               KIAHINVIM-SAGKY---TGGIK------------RMDSYFSVFQHLVQCDILSNPNNKG   851
k87_11092736                       DAEHLNPVN-EFDVY---IEDLRRYPEGTPKNKDYHIGSYFEIYHYIRQRAYLEEVLAKR   945
BMZ-11B_GL0037915                  DAMHLNAMF-KIAKF---VGDFRK---G----SSHEMRSYFELFHFLEQKTLLDSKEDFV   881
BMZ-11B_GL0037771                  DVEHLNVLR-AIPDY---IQDFRH---GEKG--ETAMNSYFELYHYLMQRLMLKNTELDL   872
BMZ-11B_GL0069617                  QSAHLNVLTQALPQF---IGQFAR---NSKTGKTARMTSYFQLYHYLLQRLLCEDLNFDV   868
Ga0099364_10024192                 CALHLNVLT-ALPEF---VGEFRK---T-----GDKMTSYFELYHFLLQKLMLAEAGLNL   984
530373_GL0023589                   IIMHLNAVS-AFPQY---LEGLK------------VVHSYFDLYHYTVMMLLHRQNEKE-   881
emb|ODAI011611274.1|               AAAHLTAVA-AAQEY---VSELR------------EIHSYFEVYHYAMQRYLKSGAEFA-   936
EMG_10003641                       KVAHLEVVS-NIDEY---LSGIK------------HIESYYALYHYLMQKCLLKNYRIE-   990
CasR_P1E0_metageno                 AVDHLNAIP-PLGSL---CRDIG------------RVDSYFALYHYAVQQYLNGRYYRK-   844
emb|OIZX01000427.1|                AVAHLNVIA-HLADY---SADMR------------EITSYYGLYHYLMQRHLFKRHAWQI   881
160582958_gene49834                LVAHLNVVS-KLQNYVSELPNDY------------QITSYFSFYHYCMQLGLMEKVSSK-   944
gi|1198542314|gb|NFIR01000008.1|   SVQHLNVIR-DAHKYIKYINDNK------------DVQSYFALYHYLVQRYISERAANRT   911
emb|OGNF01009141.1                 TAEHLEALR-NADKY---LNDLK------------QFDSYFEIYHYITQRNIKEKCEML-   844
```

FIG. 18FFF

CA 03072610 2020-02-10

Ga0129306_1000735	KAAHLSVLN-KGGRL---SGDLK----------EAKSWFYVYHFLMQRVLEEEFRNT-	915
MH0288_GL0082219	SVAHLNAVR-NMNLY---IGDLR----------EITSYFGIYHYIMQRDLITRCQKV-	927
PIG-022_GL0026351	GTAHLNSVR-NIDTC---IEGLK----------DFKSYFEIYAYTVQKSIKKYFDAEF	823
PIG-028_GL0185479	GVAHLNSVR-NIDTS---IKGLR----------EFKSYFEIYAYTVQKSIKNYYDAES	825
250twins_35838_GL0110300	NVEHLNVVH-CMTKY---FSEVK----------DVKSYYGVYCYIMQRMLCDELIIKN	937
PIG-014_GL0226364	NVMHLNIIR-DLNDY---LPDFKR---G---KAFEKTDTFYDLYCYCLQKMLLSEVD---	904
250twins_36050_GL0158985	AVAHLNIIN-RLDEY---IGSAR----------ADSYYSLYCYCLQMYLSKNFSVG-	958
emb|OJMM01002900.1|	NVQHLNVMN-SITKY---LGDIS----------EVTSYYSLYCYTLQRLLLDDNNND-	930
emb|OGPN01002610.1|	DIAHLNIVH-DMVKY---IEELK----------DISSYYAFYCYVLQRRLVGKDPNC-	973
emb|OHCP01000044.1|	KIVHLNVVH-DMVKY---INEIK----------NITSYYAFFCYVLQRMIIGNNSNE-	959
PIG-046_GL0077813	TIAHLNVVH-KMVDY---VAEIK----------GITSYYAFFCYVLQRMPVGNKN-E-	960
pig_chimera	TIAHLNVVH-KMVDY---VDEIK----------GITSYYAFFCYVLQRMLVGNNLNE-	965
emb|OIEN01002196.1|	MVAHLTAVA-RVPLY---ISEVT----------QIDSYYALYHYCMQMNILQGIEQSG	873
O2.UC29-0_GL0096317	AVAHLALMA-RVSEY---ASDIK----------NVNSYFSLYHYCMQKHILYCARRFN	867
CasR_Anaerobic_dig	QVTHLNAIR-VAYKY---INEIK----------SVHSYFALYHYIMQRHLYDSLQAKA	882
emb|OGDF01008514.1|	MIAHLAAVT-NAYKY---IPQMD----------RFKSWFHLYHTVIQHSLIQQYEYDR	866
emb|OGZC01000639.1	IVAHLWIIR-DADRF---ITGMG----------AMKRYFDCYHYLLQRELGYILEKSN	913
Ga0224415_10048792_chimera	KVAHLEVAR-HAHEY---IGNIK----------EVNSYFQLYHYIMQCRLYDVLKNNT	898
emb|OCVV012889144.1|	KAAHLEVAR-YAHMY---INDIS----------EVKSYFRLYHYIMQRRIIDVIENNP	900
Ga0187910_10006931	KADHLEVAR-YAYKY---INDIS----------EVNSYFQLYHYIMQRIIIDSSGN--	906
R._flav_XPD_	KAVHLEVAR-YVHAY---INDIA----------EVNSYFQLYHYIMQRIIMNERYE--	901
Ga0224415_10007274	KVAHLEAIR-YAHLY---INDIA----------EVNSYFQFYHYIMQRRIMAERYD--	880
Ga0187911_10069260	ATVHLNVIM-EAHRY---TKDIK----------YIGSYYALYHYILQRHLLDKIEEDS	835
Ga0187910_10015336	NVAHLNTIR-NMDG----IENVT----------GITSYFQIYHYLMQKALYKEFKKCR	1008

FIG. 18GGG

```
ODAI_chimera                    AVAHLNIPR-NAIDY---IGGIK-----------KADSYFAIYHYMMQQYLSKKHGLP-    937
31009_GL0034153                 NIAHLNSIK-NATKY---VNDIG-----------TFTSYFQLYHYIMQCDLKDWVKKEV    836
DLF014_GL0011914_               SIAHLNAVR-KASKY---INDIR-----------GFDTYFELYHYIMQRDLKDILEKIA    915
CasR_R._albus                   QVDHFAVVR-KIGNY---AAYIK-----------SIGSWFELYHYVIQRIVFDEYRFAL    877
Ga0187910_10040531              MAAHISVIR-NIDLY---IGDIQ-----------KVDSYFALYHFLMQKLIQRVVPENT    870
tpg|DJXD01000002.1|             IVAHISVVR-NSNEY---ISGIG-----------ELHSYFELYHYLVQSMIAKNNWYDT    817
CasR_E._siraeum                 TVCHLNAIR-NININ---IKEIK-----------EVENYFALYHYLIQKHLENRFADKK    894
PIG-018_GL0023397               SVCHLNAIR-NINTN---IEGIG-----------FVKNYFALYHYLIQRHISSKRIS--    887
PIG-025_GL0099734               AVAHLNPIR-NADVL---IEGIE-----------NITSYFDIYHYIVQRSVLNRTNKT-    887
Ga0129317_1008067_chimera       NVAHLSAIR-NANEY---IGDIR-----------EITSYFALYHYLMQRKLIDDCKVN-    804
EYZ-362B_GL0088915              CVAHLNVVR-NCDQY---LENID-----------TVHSYFSLYQYLVQHYLLKRFEKDK    864
uncultured_Ru_sp                CIAHLTVVR-ELKEY---IGDIC-----------TVDSYFSIYHYVMQRCITKRENDTK    865
R._flav._FD-1                   NVAHLTAVR-NCAEF---IGDIT-----------KIDSYFALYHYLIQRQLAKGLDHER    870
tpg|DBYI01000091.1|             NVAHLTAIR-NCAEF---IGEIT-----------KIDSYFALYHYLIQRQLAGRLDPNH    894
                                   *:                                  ::  :

037_-_emb|OIZA01000315.1|       NVVLA-----------------------KMKDLAHIKSDCDEFSSKHTYPYSSAVLRFM    922
emb|OCTW011587266.1|            KCFES-----------------------ESL--KPLLL-DMKFDGTDEKLYSKRLTRAL    884
k87_11092736                    KEYRD---------------------SGSFTDEQLDK-LQKILDDIRARGSYDKNLLKLE    983
BMZ-11B_GL0037915               QGMRE---------------------S----------------YGDRIRVEPCVDLIKYL    904
BMZ-11B_GL0037771               S-HWS---------------------G----------------WIMRSGRPDRDLIQIA    893
BMZ-11B_GL0069617               PEEWK---------------------N----------------KIQETGLPCNDLIHIC    890
Ga0099364_10024192              D-EYR---------------------E----------------RIDTYQTACKDLINIT   1005
530373_GL0023589                ---------------KKRNEKEKKQNEKENNMILSTA-ALEKYDMVRKYQSANKDFIYAI    925
```

FIG. 18HHH

CA 03072610 2020-02-10

```
emb|ODAI011611274.1|                    ------------------------ELVSKNGPASGK-IAAWANAVDRCHSFCKDWLWLL    970
EMG_10003641                            ---------------------------DHSQNEYKN-LNDFSSKLDKHGTYVKDFVKAL    1021
CasR_P1E0_metageno                      ---------------------------------TPR-EQELFAAMAQHRTWCSDLVKAL    869
emb|OIZX01000427.1|                     RQPERP--------------TEEEQKLIEQEQKQLAW-EKALFDKTLQYHSYNKDLVKAL    926
160582958_gene49834                     ---------------NIPLVESLKNEANDAQSYSAKK-TLEYFDLIEKNRTYCKDFLKAL    988
gi|1198542314|gb|NFIR01000008.1|        ---------------------------DKESLSEGR-LQYYLSQVKEYRTYCKDFVKAL    942
emb|OGNF01009141.1                      ---------------------------------KEQ-TVKYNNDLLKYHGYSKDFVKAL    869
Ga0129306_1000735                       -------------------------------QALPER-LRELLMMAERYRGCSKDLIKVL    943
MH0288_GL0082219                        -------------------------------KMKNPV-VVGYFDKVRTYRTCCKDLVKAL    955
PIG-022_GL0026351                       SEDRNIEDGKISLCNGVYIHERQKNGKPKITVKINPK-TIEYMESVDKYGSYTKDFVKAL    882
PIG-028_GL0185479                       P-----------------------------VQINPK-TIEYMESVDKYGSYTKDFVKAL    854
250twins_35838_GL0110300                QDKPD---------------------------VRQT-FEEYNRLLKDHGTYSKNLMWLL    968
PIG-014_GL0226364                       ---------------------------------G-FSAINENIDKYCTASKDFMNLL    927
250twins_36050_GL0158985                ---------------------------------Y-LINVQKQLEEHHTYMKDLMWLL    981
emb|OJMM01002900.1|                     ---------------------------------K-FASIKGNLRKFGIYNKDFMWLL    953
emb|OGPN01002610.1|                     --------------------------------QNKF-KAKYAKELNDYGTYNKNLMWML    999
emb|OHCP01000044.1|                     --------------------------------QNKF-KAKYSKTLQEFGTYSKDLMWVL    985
PIG-046_GL0077813                       --------------------------------KNAL-KEKYSETAKSYGTYSKDFMWLI    986
pig_chimera                             --------------------------------KNAI-KEKYSATVKSFGTYSKDFMWLI    991
emb|OIEN01002196.1|                     KIL-----------------------------DNIK-LKNALENARVHRTYSKDAVKYL    902
O2.UC29-0_GL0096317                     KQ-----------------------------GNEK-MAAALNDAEIHRSYSKDAVKFL    895
CasR_Anaerobic_dig                      KDS----------------------------SGF-VIDALKKSFEHKIYSKDLLHVL    910
emb|OGDF01008514.1|                     DYGRK-----------------------GAPVVSER-VLQLLEQCREHSNYSRDLLHIL    901
emb|OGZC01000639.1                      ----Q----------------------------GSEY-TKKSLEKVQQYHSYCKDFLHML    940
```

FIG. 18III

```
Ga0224415_10048792_chimera      KAEAM--------------------------VKGK-AKEYFEALEKEGTYNDKLLKIA    929
emb|OCVV012889144.1|            K--AK--------------------------YEGK-VKVYFEDVKKNKKYNKNLLKLM    929
Ga0187910_10006931              ----N--------------------------ANGM-IKKYYESVISDKKYNDRLLKLL    933
R._flav_XPD_                    ----K--------------------------SSGK-VSEYFDAVNDEKKYNDRLLKLL    928
Ga0224415_10007274              ----K--------------------------SSGK-VREYFDAVNNEKKYNDRLLKLL    907
Ga0187911_10069260              YAEKT------------------------------VS-EKLWESQISQYGTYSKDFVKAL    864
Ga0187910_10015336              ENAVRKWIPYITENAEPKYVYWNKKEQQEVEVSFNPKIFGYMENIKNHSNTYCKDFVKAL    1068
ODAI_chimera                    ----------------------------------------EGLGCTHGVYCKDLVKAL    955
31009_GL0034153                 EEKKI--------------------------SDKY-YNYLEKYYKNNNIYLKDFVKAI    867
DLF014_GL0011914_               EGAAKET--------------------EEGQKQDEL-LKTYFDNLDKYGTYVKDFVKAL    953
CasR_R._albus                   N-----------------------------NT-ESNYKNSIIKHHTYCKDMVKAL    902
Ga0187910_10040531              KGL----------------------------SDQ-TKKYYDALEQYNTYCKDFVKAY    898
tpg|DJXD01000002.1|             S-H----------------------------QPK-TAEYLNNLKKHHTYCKDFVKAY    844
CasR_E._siraeum                 VE-----------------------------RD-TGDFISKLEEHKTYCKDFVKAY    920
PIG-018_GL0023397               FN-----------------------------SF-SAEYISNLEKYHTPSEYFIKAY    913
PIG-025_GL0099734               ------------------------------PK-MKEYEELINKYHTYNKDFVKAL    911
Ga0129317_1008067_chimera       ------------------------------DT-AHKYFEQLTKYKTYVMDMVKAL    828
EYZ-362B_GL0088915              YRCK---------------------------DDL-AIHYYSQVKQYRSYVKDLVKAL    893
uncultured_Ru_sp                QEE------------------------------KIKYEDDLLKNHGYTKDFVKAL    890
R._flav._FD-1                   SGF------------------------------DR-NYPQYAPLFKWHTYVKDVVKAL    897
tpg|DBYI01000091.1|             PGF------------------------------EK-NYPQYAPLFKWNTYVKDMVKAL    921


037_-_emb|OIZA01000315.1|       NLPFAYNVPRFKNLSYKKFFDKQ-----------------------------------    945
```

FIG. 18JJJ

```
emb|OCTW011587266.1|                NIPFGYNVPRYKNLTFEKIYLKSSINE--------------------------------    911
k87_11092736                        YLPFAYNLPRYKNLTTEALFDDDSVSGKKRVAEWREREKTREAEREQRRQR--------    1034
BMZ-11B_GL0037915                   YITLGYSLPRYKTMTVSGLFDPDSEDAKERAKGKRA----------------------    940
BMZ-11B_GL0037771                   FVSLAYNLPRYRNLTKEHHFDDTVLQKIREKESLD-----------------------    928
BMZ-11B_GL0069617                   FVPLGYNLPRYKNLTIECLFDEDSVSAKEGKKA-------------------------    923
Ga0099364_10024192                  YVSLGYNLPRYKNLTCEPLFDEESATGKERQTRLDEKSKEKKQRKGGQK----------    1054
530373_GL0023589                    NSPLAYNAARYINLSCRTKFEEGFGK--------------------------------    951
emb|ODAI011611274.1|                NVPFAYNPARYKNLSIANLFDKNEAAPVTEDASEQKEDE--------------------    1009
EMG_10003641                        NVPFGYNLPRYKNLSIDELFDRNKLKTGGTIEMKGE----------------------    1057
CasR_P1E0_metageno                  NTPFGYNLARYKNLSIDGLFDREGDHVVREDGEKPAE----------------------    906
emb|OIZX01000427.1|                 NAPFGYNLARYKNLSIEPLFSKEAAPAAEIKATHA-----------------------    961
160582958_gene49834                 NAPFSYNLPRFKNLSIEALFDKNIVYEQADLKKE------------------------    1022
gi|1198542314|gb|NFIR01000008.1|    NVPFAYNLPRYKNLSIDELFDRNNYLPNKAKKWIPEKKENGEYVMEDCGNKDAGQVENA    1001
emb|OGNF01009141.1                  CVPFGYNLPRFKNLSIDALFDKNDKREKLKKGFED-----------------------    904
Ga0129306_1000735                   NLTFAYNLPRYKNLSIDGRFDKNHPDPSDE----------------------------    973
MH0288_GL0082219                    NITFGYNLPRYKNLSIEGLFDKNRPGDKKESALIAE----------------------    991
PIG-022_GL0026351                   NTPFGYCLARYKNLSIEPLFDRNTVYNKEDVTEEFSVNSKEQ-----------------    924
PIG-028_GL0185479                   NTPFGYCLARYKNLSIEPLFDRNTVYNKKDVKEEFAVNSK------------------    894
250twins_35838_GL0110300            NFPFAYNLARYKNLSNEDLFNAKNNDQKSK----------------------------    998
PIG-014_GL0226364                   NIIFAYNVPRYKNLSNKELFYRLDSEQ-------------------------------    954
250twins_36050_GL0158985            NIPFAYNLARYKNLSNEKLFYDEEAAAEKADKAENERGE-------------------    1020
emb|OJMM01002900.1|                 NIPFAYNLPRYKNLSNEEIFYDELQK--------------------------------    979
emb|OGPN01002610.1|                 NLPFAYNLPRYKNLSSEFLFYDMEYNKKDDE---------------------------    1030
emb|OHCP01000044.1|                 NLPFAYNLPRYKNLSNEQLFYDEEERMEKIVGRKNDSR--------------------    1023
```

FIG. 18KKK

CA 03072610 2020-02-10

PIG-046_GL0077813	NLPFAYNLPRYKNLSNEQLFYDEEERNETEGQIDRL----------	1022
pig_chimera	NLPFAYNLPRYKNLSNEQLFYDEEERNETEEQIDRL----------	1027
emb|OIEN01002196.1|	CLPFAYNISRYKALTIKDLFDWTEYSCKKDE----------	933
O2.UC29-0_GL0096317	CLPFAYNLPRYKALTVEGLFDWNEYGQDDD----------	925
CasR_Anaerobic_dig	HSPFGYNTARYKNLSIEALFDKNESRPEVNPLSTND----------	946
emb|OGDF01008514.1|	NLPFGYNLPRYLNLSSEKYFDANAI----------	926
emb|OGZC01000639.1	CLPFAYCIPRYKNLSIAELFDRHEPEAEPKEEASSVNNSQFITT----------	984
Ga0224415_10048792_chimera	CVPFGYCIPRYKNLSMEELFDMNEEKKFKKKAPENT----------	965
emb|OCVV012889144.1|	CVPFGYCIPRFKNLSIEQMFDMNETDNSDKKKEK----------	963
Ga0187910_10006931	CVPFGYCIPRFKNLSIEALFDKNEAAKYDKIKKKVAVR----------	971
R._flav_XPD_	CVPFGYCIPRFKNLSIEALFDRNEAAKFDKEKKKVSGNS----------	967
Ga0224415_10007274	CVPFGYCIPRFKNLSIEALFDMNEAVKFDKEKK----------	940
Ga0187911_10069260	CCPFGYNLPRFKNLSIEQLFDRNESKEITDATAPRQ----------	900
Ga0187910_10015336	CAPFAYNLPRFKNLSIEELFDMHELSEEPKESMKLTD----------	1105
ODAI_chimera	NAPFGYNLPRFKNLSVEALFDMNEEPAPEGKERSKNADGCN----------	996
31009_GL0034153	NVPFAYNYSRFKNLSIDKLFDKNDPRKKKWIVIFNF----------	903
DLF014_GL0011914_	NIPFAYNYPRYKNLSIDELFDKNNTRKTIKIQDKKLEERT----------	993
CasR_R._albus	NTPFGYDLPRYKNLSIGDLFDRNNYLNKTKESIDANSSIDSQ----------	944
Ga0187910_10040531	CTPFAYVTPRYKNLTIDGLFDRNRPGEDK----------	927
tpg|DJXD01000002.1|	CIPFGYVVPRYKNLTINELFDRNNPNPEPKEEV----------	877
CasR_E._siraeum	CTPFGYNLVRYKNLTIDGLFDKNYPGKDDSDEQK----------	954
PIG-018_GL0023397	CTPFAYNLVRYKNLTIDGLFDRNAPSEK----------	941
PIG-025_GL0099734	CAPFGYNVVRFKALTIYEMFDRNYPEEKRAEEARKSC----------	948
Ga0129317_1008067_chimera	CSPFGYNLPRFKNLSIEGKFDMHESK----------	854

FIG. 18LLL

```
EYZ-362B_GL0088915                NAPFGYNIPRFKNLTVEQLFDRNADPETITA---------------------------     924
uncultured_Ru_sp                  NSPFGYNIPRFKNLSIEQLFDRNEYLTEK-----------------------------     919
R._flav._FD-1                     NAPFGYNIPRFKNLSIDALFDRNEIKKNDGEKKSDD----------------------     933
tpg|DBYI01000091.1|               NSPFGYNIPRFKDLSIDALFDRNEMKEETDDEKKIQT----------------------     958
                                     :.*   *:  ::    :
```

FIG. 18MMM

FIG. 19A


KD. vs size
120
100
80
60
40
20
0
relative (%) mCherry expression
800
900
1000
1100
Size (aa)
Ga0531-NLS
CasRx
k87-NES
Ga7274-NLS

FIG. 19B


125
100
75
50
25
0
relative CD81 expression
EGFP
Rfx-NLS
stool_9834-NLS
k87-NLS
k87-NES
Adm-NLS
DJXD-NLS
Ga_7274-NLS
twins_985-NES
Ga_0531 (trunc)-NLS
twins_985-NLS
Ga_0531-NES
Ga_0531-NLS
Rsp-NLS
Rsp-Trunc-NES
NFIR-NLS
Ga_9260-NES
Rsp-trunc-NLS
NFIR-NES
PIG_6364-NES
DLF_1914-NES
PIG_6364-NLS
OGZC-NES
twins_300-NLS
OGZC-NLS-trunc
OGPN-NES
Cas13d ortholog

FIG. 20



FIG. 21


relative CD81 expression (GFP High Cells)
1.2
1.0
0.8
0.6
0.4
0.2
0.0
GFP
CasRx
CasRx del5
CasRx del13
CasRx del5.12
CasRx del5.13
CasRx del5.12+13
Rfx-NES
Ga0531-NLS
Ga0531-NES
Ga0531-NLS(trunc)
Ga0531-NES(trunc)
Cas13d ortholog

FIG. 22


% Blue relative to NTG
1.2
1.0
0.8
0.6
0.4
0.2
0.0
GFP
dCasRx
dCasRx-del13
dGa7274
dAdm
dDJXD
dK87
dStool_9834
dStool_9834(truncated)
dTwins_985
dTwins_985(truncated)
dGa0531
dGa0531(truncated)



FIG. 23A



FIG. 23B

FIG. 23C